# ESC Guidelines: Cardiomyopathies (2023)

**Source**: `2023_Cardiomyopathies.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 124

---

## Table of Contents

- [2023 ESC Guidelines for the management of cardiomyopathies](#2023-esc-guidelines-for-the-management-of-cardiomy) *(p. 1)*
  - [1. Preamble](#1-preamble) *(p. 7)*
  - [2. Introduction](#2-introduction) *(p. 9)*
  - [3. Phenotypic approach to cardiomyopathies](#3-phenotypic-approach-to-cardiomyopathies) *(p. 9)*
    - [3.1. Definitions](#31-definitions) *(p. 12)*
    - [3.2. Cardiomyopathy phenotypes](#32-cardiomyopathy-phenotypes) *(p. 12)*
      - [3.2.1. Hypertrophic cardiomyopathy](#321-hypertrophic-cardiomyopathy) *(p. 12)*
      - [3.2.2. Dilated cardiomyopathy](#322-dilated-cardiomyopathy) *(p. 12)*
      - [3.2.3. Non-dilated left ventricular cardiomyopathy](#323-non-dilated-left-ventricular-cardiomyopathy) *(p. 12)*
      - [3.2.4. Arrhythmogenic right ventricular cardiomyopathy](#324-arrhythmogenic-right-ventricular-cardiomyopath) *(p. 14)*
      - [3.2.5. Restrictive cardiomyopathy](#325-restrictive-cardiomyopathy) *(p. 15)*
    - [3.3. Other traits and syndromes associated with cardiomyopathy phenotypes](#33-other-traits-and-syndromes-associated-with-card) *(p. 15)*
      - [3.3.1. Left ventricular hypertrabeculation (left ventricular non-compaction)](#331-left-ventricular-hypertrabeculation-(left-vent) *(p. 15)*
      - [3.3.2. Takotsubo syndrome](#332-takotsubo-syndrome) *(p. 15)*
  - [4. Epidemiology](#4-epidemiology) *(p. 15)*
    - [4.1. Special populations](#41-special-populations) *(p. 16)*
  - [5. Integrated patient management](#5-integrated-patient-management) *(p. 16)*
    - [5.1. Multidisciplinary cardiomyopathy teams](#51-multidisciplinary-cardiomyopathy-teams) *(p. 16)*
    - [5.2. Co-ordination between different levels of care](#52-co-ordination-between-different-levels-of-care) *(p. 16)*
  - [6. The patient pathway](#6-the-patient-pathway) *(p. 17)*
    - [6.1. Clinical presentation](#61-clinical-presentation) *(p. 18)*
    - [6.2. Initial work-up](#62-initial-work-up) *(p. 18)*
    - [6.3. Systematic approach to diagnosis of cardiomyopathy](#63-systematic-approach-to-diagnosis-of-cardiomyopa) *(p. 18)*
    - [6.4. History and physical examination](#64-history-and-physical-examination) *(p. 18)*
    - [6.5. Resting and ambulatory electrocardiography](#65-resting-and-ambulatory-electrocardiography) *(p. 19)*
    - [6.6. Laboratory tests](#66-laboratory-tests) *(p. 22)*
    - [6.7. Multimodality imaging](#67-multimodality-imaging) *(p. 22)*
      - [6.7.1. General considerations](#671-general-considerations) *(p. 22)*
      - [6.7.2. Echocardiography](#672-echocardiography) *(p. 22)*
      - [6.7.3. Cardiac magnetic resonance](#673-cardiac-magnetic-resonance) *(p. 23)*
        - [6.7.3.1. Special considerations](#6731-special-considerations) *(p. 23)*
      - [6.7.4. Computed tomography and nuclear medicine techniques](#674-computed-tomography-and-nuclear-medicine-techn) *(p. 26)*
      - [6.7.5. Endomyocardial biopsy](#675-endomyocardial-biopsy) *(p. 26)*
    - [6.8. Genetic testing and counselling](#68-genetic-testing-and-counselling) *(p. 27)*
      - [6.8.1. Genetic architecture](#681-genetic-architecture) *(p. 27)*
      - [6.8.2. Genetic testing](#682-genetic-testing) *(p. 27)*
        - [6.8.2.1. Non-Mendelian cardiomyopathies and implications for genetic testing](#6821-non-mendelian-cardiomyopathies-and-implicatio) *(p. 32)*
        - [6.8.2.2. Genetic test reports and variant interpretation](#6822-genetic-test-reports-and-variant-interpretati) *(p. 32)*
      - [6.8.3. Genetic counselling](#683-genetic-counselling) *(p. 32)*
        - [6.8.3.1. Genetic counselling in children](#6831-genetic-counselling-in-children) *(p. 32)*
        - [6.8.3.2. Pre- and post-test genetic counselling (proband)](#6832-pre--and-post-test-genetic-counselling-(proba) *(p. 33)*
        - [6.8.3.3. Genetic counselling for cascade testing](#6833-genetic-counselling-for-cascade-testing) *(p. 33)*
        - [6.8.3.4. Pre-natal or pre-implantation genetic diagnosis](#6834-pre-natal-or-pre-implantation-genetic-diagnos) *(p. 34)*
    - [6.9. Diagnostic approach to paediatric patients](#69-diagnostic-approach-to-paediatric-patients) *(p. 35)*
      - [6.9.1. Infantile and early childhood-onset cardiomyopathy](#691-infantile-and-early-childhood-onset-cardiomyop) *(p. 36)*
    - [6.10. General principles in the management of patients with cardiomyopathy](#610-general-principles-in-the-management-of-patien) *(p. 37)*
      - [6.10.1. Assessment of symptoms](#6101-assessment-of-symptoms) *(p. 37)*
      - [6.10.2. Heart failure management](#6102-heart-failure-management) *(p. 37)*
        - [6.10.2.1. Preventive heart failure medical therapy of asymptomatic carriers/early disease expression](#61021-preventive-heart-failure-medical-therapy-of-) *(p. 38)*
        - [6.10.2.2. Cardiac transplantation](#61022-cardiac-transplantation) *(p. 38)*
        - [6.10.2.3. Left ventricular assist devices](#61023-left-ventricular-assist-devices) *(p. 38)*
      - [6.10.3. Management of atrial arrhythmias](#6103-management-of-atrial-arrhythmias) *(p. 39)*
        - [6.10.3.1. Anticoagulation](#61031-anticoagulation) *(p. 39)*
        - [6.10.3.2. Rate control](#61032-rate-control) *(p. 39)*
        - [6.10.3.3. Rhythm control](#61033-rhythm-control) *(p. 41)*
        - [6.10.3.4. Comorbidities and risk factor management](#61034-comorbidities-and-risk-factor-management) *(p. 41)*
      - [6.10.4. Management of ventricular arrhythmias](#6104-management-of-ventricular-arrhythmias) *(p. 42)*
      - [6.10.5. Device therapy: implantable cardioverter defibrillator](#6105-device-therapy:-implantable-cardioverter-defi) *(p. 42)*
      - [6.10.6. Routine follow-up of patients with cardiomyopathy](#6106-routine-follow-up-of-patients-with-cardiomyop) *(p. 44)*
    - [6.11. Family screening and follow-up evaluation of relatives](#611-family-screening-and-follow-up-evaluation-of-r) *(p. 44)*
      - [6.11.1. Special considerations in family screening](#6111-special-considerations-in-family-screening) *(p. 45)*
    - [6.12. Psychological support in cardiomyopathy patients and family members](#612-psychological-support-in-cardiomyopathy-patien) *(p. 46)*
    - [6.13. The patient pathway](#613-the-patient-pathway) *(p. 47)*
  - [7. Specific cardiomyopathy phenotypes](#7-specific-cardiomyopathy-phenotypes) *(p. 47)*
    - [7.1. Hypertrophic cardiomyopathy](#71-hypertrophic-cardiomyopathy) *(p. 47)*
      - [7.1.1. Diagnosis](#711-diagnosis) *(p. 47)*
        - [7.1.1.1. Diagnostic criteria](#7111-diagnostic-criteria) *(p. 47)*
        - [7.1.1.2. Diagnostic work-up](#7112-diagnostic-work-up) *(p. 47)*
        - [7.1.1.3. Echocardiography](#7113-echocardiography) *(p. 47)*
        - [7.1.1.4. Cardiac magnetic resonance](#7114-cardiac-magnetic-resonance) *(p. 48)*
        - [7.1.1.5. Nuclear imaging](#7115-nuclear-imaging) *(p. 49)*
      - [7.1.2. Genetic testing and family screening](#712-genetic-testing-and-family-screening) *(p. 49)*
      - [7.1.3. Assessment of symptoms](#713-assessment-of-symptoms) *(p. 50)*
      - [7.1.4. Management of symptoms and complications](#714-management-of-symptoms-and-complications) *(p. 50)*
        - [7.1.4.1. Management of left ventricular outflow tract obstruction](#7141-management-of-left-ventricular-outflow-tract-) *(p. 51)*
          - [7.1.4.1.1. General measures](#71411-general-measures) *(p. 51)*
          - [7.1.4.1.2. Drug therapy](#71412-drug-therapy) *(p. 51)*
          - [7.1.4.1.3. Invasive treatment of left ventricular outflow tract (septal reduction therapy)](#71413-invasive-treatment-of-left-ventricular-outfl) *(p. 53)*
        - [7.1.4.2. Management of symptoms in patients without left ventricular outflow tract obstruction](#7142-management-of-symptoms-in-patients-without-le) *(p. 55)*
          - [7.1.4.2.1. Heart failure and chest pain](#71421-heart-failure-and-chest-pain) *(p. 55)*
          - [7.1.4.2.2. Cardiac resynchronization therapy](#71422-cardiac-resynchronization-therapy) *(p. 55)*
      - [7.1.5. Sudden cardiac death prevention in hypertrophic cardiomyopathy](#715-sudden-cardiac-death-prevention-in-hypertrophi) *(p. 56)*
        - [7.1.5.1. Left ventricular apical aneurysms](#7151-left-ventricular-apical-aneurysms) *(p. 57)*
        - [7.1.5.2. Left ventricular systolic dysfunction](#7152-left-ventricular-systolic-dysfunction) *(p. 57)*
        - [7.1.5.3. Late gadolinium enhancement on cardiac magnetic resonance imaging](#7153-late-gadolinium-enhancement-on-cardiac-magnet) *(p. 57)*
        - [7.1.5.4. Abnormal exercise blood pressure response](#7154-abnormal-exercise-blood-pressure-response) *(p. 57)*
        - [7.1.5.5. Sarcomeric variants](#7155-sarcomeric-variants) *(p. 58)*
        - [7.1.5.6. Prevention of sudden cardiac death](#7156-prevention-of-sudden-cardiac-death) *(p. 58)*
    - [7.2. Dilated cardiomyopathy](#72-dilated-cardiomyopathy) *(p. 60)*
      - [7.2.1. Diagnosis](#721-diagnosis) *(p. 60)*
        - [7.2.1.1. Index case](#7211-index-case) *(p. 60)*
        - [7.2.1.2. Relatives](#7212-relatives) *(p. 60)*
        - [7.2.1.3. Diagnostic work-up](#7213-diagnostic-work-up) *(p. 60)*
        - [7.2.1.4. Echocardiography](#7214-echocardiography) *(p. 60)*
        - [7.2.1.5. Cardiac magnetic resonance](#7215-cardiac-magnetic-resonance) *(p. 61)*
        - [7.2.1.6. Nuclear medicine](#7216-nuclear-medicine) *(p. 61)*
      - [7.2.2. Genetic testing and family screening](#722-genetic-testing-and-family-screening) *(p. 61)*
        - [7.2.2.1. Genetic testing](#7221-genetic-testing) *(p. 61)*
      - [7.2.3. Assessment of symptoms](#723-assessment-of-symptoms) *(p. 62)*
      - [7.2.4. Management](#724-management) *(p. 62)*
      - [7.2.5. Sudden cardiac death prevention in dilated cardiomyopathy](#725-sudden-cardiac-death-prevention-in-dilated-car) *(p. 62)*
        - [7.2.5.1. Secondary prevention of sudden cardiac death](#7251-secondary-prevention-of-sudden-cardiac-death) *(p. 62)*
        - [7.2.5.2. Primary prevention of sudden cardiac death](#7252-primary-prevention-of-sudden-cardiac-death) *(p. 62)*
    - [7.3. Non-dilated left ventricular cardiomyopathy](#73-non-dilated-left-ventricular-cardiomyopathy) *(p. 64)*
      - [7.3.1. Diagnosis](#731-diagnosis) *(p. 64)*
        - [7.3.1.1. Index case](#7311-index-case) *(p. 64)*
        - [7.3.1.2. Relatives](#7312-relatives) *(p. 64)*
        - [7.3.1.3. Diagnostic work-up](#7313-diagnostic-work-up) *(p. 64)*
        - [7.3.1.4. Electrocardiographic features](#7314-electrocardiographic-features) *(p. 65)*
        - [7.3.1.5. Echocardiography](#7315-echocardiography) *(p. 65)*
        - [7.3.1.6. Cardiac magnetic resonance](#7316-cardiac-magnetic-resonance) *(p. 65)*
        - [7.3.1.7. Nuclear medicine](#7317-nuclear-medicine) *(p. 65)*
        - [7.3.1.8. Endomyocardial biopsy](#7318-endomyocardial-biopsy) *(p. 65)*
      - [7.3.2. Genetic testing](#732-genetic-testing) *(p. 65)*
      - [7.3.3. Assessment of symptoms](#733-assessment-of-symptoms) *(p. 65)*
      - [7.3.4. Management](#734-management) *(p. 65)*
      - [7.3.5. Sudden cardiac death prevention in non-dilated left ventricular cardiomyopathy](#735-sudden-cardiac-death-prevention-in-non-dilated) *(p. 66)*
        - [7.3.5.1. Secondary prevention of sudden cardiac death](#7351-secondary-prevention-of-sudden-cardiac-death) *(p. 66)*
        - [7.3.5.2. Primary prevention of sudden cardiac death](#7352-primary-prevention-of-sudden-cardiac-death) *(p. 66)*
    - [7.4. Arrhythmogenic right ventricular cardiomyopathy](#74-arrhythmogenic-right-ventricular-cardiomyopathy) *(p. 67)*
      - [7.4.1. Diagnosis](#741-diagnosis) *(p. 67)*
        - [7.4.1.1. Index case](#7411-index-case) *(p. 67)*
        - [7.4.1.2. Relatives](#7412-relatives) *(p. 67)*
        - [7.4.1.3. Diagnostic work-up](#7413-diagnostic-work-up) *(p. 67)*
        - [7.4.1.4. Electrocardiography and Holter monitoring](#7414-electrocardiography-and-holter-monitoring) *(p. 67)*
        - [7.4.1.5. Echocardiography and cardiac magnetic resonance](#7415-echocardiography-and-cardiac-magnetic-resonan) *(p. 67)*
        - [7.4.1.6. Endomyocardial biopsy](#7416-endomyocardial-biopsy) *(p. 67)*
        - [7.4.1.7. Nuclear medicine](#7417-nuclear-medicine) *(p. 67)*
        - [7.4.1.8. Arrhythmogenic right ventricular cardiomyopathy phenocopies](#7418-arrhythmogenic-right-ventricular-cardiomyopat) *(p. 68)*
      - [7.4.2. Genetic testing and family screening](#742-genetic-testing-and-family-screening) *(p. 68)*
      - [7.4.3. Assessment of symptoms](#743-assessment-of-symptoms) *(p. 68)*
      - [7.4.4. Management](#744-management) *(p. 68)*
        - [7.4.4.1. Antiarrhythmic therapy](#7441-antiarrhythmic-therapy) *(p. 68)*
      - [7.4.5. Sudden cardiac death prevention in arrhythmogenic right ventricular cardiomyopathy](#745-sudden-cardiac-death-prevention-in-arrhythmoge) *(p. 68)*
        - [7.4.5.1. Secondary prevention of sudden cardiac death](#7451-secondary-prevention-of-sudden-cardiac-death) *(p. 69)*
        - [7.4.5.2. Primary prevention of sudden cardiac death](#7452-primary-prevention-of-sudden-cardiac-death) *(p. 69)*
    - [7.5. Restrictive cardiomyopathy](#75-restrictive-cardiomyopathy) *(p. 70)*
      - [7.5.1. Diagnosis](#751-diagnosis) *(p. 70)*
      - [7.5.2. Genetic testing](#752-genetic-testing) *(p. 70)*
      - [7.5.3. Assessment of symptoms](#753-assessment-of-symptoms) *(p. 71)*
      - [7.5.4. Management](#754-management) *(p. 71)*
    - [7.6. Syndromic and metabolic cardiomyopathies](#76-syndromic-and-metabolic-cardiomyopathies) *(p. 72)*
      - [7.6.1. Anderson–Fabry disease](#761-anderson–fabry-disease) *(p. 72)*
        - [7.6.1.1. Definition](#7611-definition) *(p. 72)*
        - [7.6.1.2. Diagnosis, clinical work-up, and differential diagnosis](#7612-diagnosis,-clinical-work-up,-and-differential) *(p. 72)*
        - [7.6.1.3. Clinical course, outcome, and risk stratification](#7613-clinical-course,-outcome,-and-risk-stratifica) *(p. 72)*
        - [7.6.1.4. Management](#7614-management) *(p. 75)*
      - [7.6.2. RASopathies](#762-rasopathies) *(p. 75)*
        - [7.6.2.1. Definition](#7621-definition) *(p. 75)*
        - [7.6.2.2. Diagnosis, clinical work-up, and differential diagnosis](#7622-diagnosis,-clinical-work-up,-and-differential) *(p. 75)*
        - [7.6.2.3. Clinical course, management, and sudden death risk stratification](#7623-clinical-course,-management,-and-sudden-death) *(p. 75)*
        - [7.6.2.4. Management](#7624-management) *(p. 75)*
      - [7.6.3. Friedreich ataxia](#763-friedreich-ataxia) *(p. 76)*
        - [7.6.3.1. Definition](#7631-definition) *(p. 76)*
        - [7.6.3.2. Diagnosis, clinical work-up, and differential diagnosis](#7632-diagnosis,-clinical-work-up,-and-differential) *(p. 76)*
        - [7.6.3.3. Clinical course, management, and risk stratification](#7633-clinical-course,-management,-and-risk-stratif) *(p. 77)*
        - [7.6.3.4. Management](#7634-management) *(p. 77)*
      - [7.6.4. Glycogen storage disorders](#764-glycogen-storage-disorders) *(p. 77)*
        - [7.6.4.1. Definition](#7641-definition) *(p. 77)*
        - [7.6.4.2. Diagnosis, clinical work-up, and differential diagnosis](#7642-diagnosis,-clinical-work-up,-and-differential) *(p. 77)*
        - [7.6.4.3. Clinical course, management, and risk stratification](#7643-clinical-course,-management,-and-risk-stratif) *(p. 77)*
        - [7.6.4.4. Management](#7644-management) *(p. 77)*
    - [7.7. Amyloidosis](#77-amyloidosis) *(p. 77)*
      - [7.7.1. Definition](#771-definition) *(p. 77)*
      - [7.7.2. Diagnosis, clinical work-up, and differential diagnosis](#772-diagnosis,-clinical-work-up,-and-differential-) *(p. 77)*
      - [7.7.3. Clinical course and risk stratification](#773-clinical-course-and-risk-stratification) *(p. 78)*
      - [7.7.4. Management](#774-management) *(p. 78)*
        - [7.7.4.1. Specific therapies](#7741-specific-therapies) *(p. 79)*
  - [8. Other recommendations](#8-other-recommendations) *(p. 79)*
    - [8.1. Sports](#81-sports) *(p. 79)*
      - [8.1.1. Cardiovascular benefits of exercise](#811-cardiovascular-benefits-of-exercise) *(p. 79)*
      - [8.1.2. Exercise-related sudden cardiac death and historical exercise recommendations for patients with cardiomyopathy](#812-exercise-related-sudden-cardiac-death-and-hist) *(p. 80)*
      - [8.1.3. Exercise recommendations in hypertrophic cardiomyopathy](#813-exercise-recommendations-in-hypertrophic-cardi) *(p. 80)*
      - [8.1.4. Exercise recommendations in arrhythmogenic right ventricular cardiomyopathy](#814-exercise-recommendations-in-arrhythmogenic-rig) *(p. 80)*
      - [8.1.5. Exercise recommendations in dilated cardiomyopathy and non-dilated left ventricular cardiomyopathy](#815-exercise-recommendations-in-dilated-cardiomyop) *(p. 80)*
    - [8.2. Reproductive issues](#82-reproductive-issues) *(p. 81)*
      - [8.2.1. Contraception, in vitro fertilization, and hormonal treatment](#821-contraception,-in-vitro-fertilization,-and-hor) *(p. 81)*
      - [8.2.2. Pregnancy management](#822-pregnancy-management) *(p. 81)*
        - [8.2.2.1. Pre-pregnancy](#8221-pre-pregnancy) *(p. 81)*
        - [8.2.2.2. Pregnancy](#8222-pregnancy) *(p. 81)*
        - [8.2.2.3. Timing and mode of delivery](#8223-timing-and-mode-of-delivery) *(p. 82)*
        - [8.2.2.4. Post-partum](#8224-post-partum) *(p. 82)*
        - [8.2.2.5. Pharmacological treatment: general aspects](#8225-pharmacological-treatment:-general-aspects) *(p. 82)*
        - [8.2.2.6. Specific cardiomyopathies](#8226-specific-cardiomyopathies) *(p. 82)*
        - [8.2.2.7. Peripartum cardiomyopathy](#8227-peripartum-cardiomyopathy) *(p. 83)*
    - [8.3. Recommendations for non-cardiac surgery](#83-recommendations-for-non-cardiac-surgery) *(p. 83)*
  - [9. Requirements for specialized cardiomyopathy units](#9-requirements-for-specialized-cardiomyopathy-unit) *(p. 84)*
  - [10. Living with cardiomyopathy: advice for patients](#10-living-with-cardiomyopathy:-advice-for-patients) *(p. 84)*
  - [11. Sex differences in cardiomyopathies](#11-sex-differences-in-cardiomyopathies) *(p. 85)*
  - [12. Comorbidities and cardiovascular risk factors in cardiomyopathies](#12-comorbidities-and-cardiovascular-risk-factors-i) *(p. 85)*
    - [12.1. Cardiovascular risk factors](#121-cardiovascular-risk-factors) *(p. 85)*
    - [12.2. Dilated cardiomyopathy](#122-dilated-cardiomyopathy) *(p. 86)*
    - [12.3. Hypertrophic cardiomyopathy](#123-hypertrophic-cardiomyopathy) *(p. 86)*
    - [12.4. Arrhythmogenic right ventricular cardiomyopathy](#124-arrhythmogenic-right-ventricular-cardiomyopath) *(p. 86)*
  - [13. Coronavirus disease (COVID-19) and cardiomyopathies](#13-coronavirus-disease-(covid-19)-and-cardiomyopat) *(p. 86)*
  - [14. Key messages](#14-key-messages) *(p. 86)*
  - [15. Gaps in evidence](#15-gaps-in-evidence) *(p. 87)*
  - [16. ‘What to do’ and ‘What not to do’ messages from the Guidelines](#16-‘what-to-do’-and-‘what-not-to-do’-messages-from) *(p. 89)*
  - [17. Supplementary data](#17-supplementary-data) *(p. 93)*
  - [18. Data availability statement](#18-data-availability-statement) *(p. 93)*
  - [19. Author information](#19-author-information) *(p. 93)*
  - [Appendix](#appendix) *(p. 94)*
  - [21. Acknowledgements](#21-acknowledgements) *(p. 95)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2023 ESC Guidelines for the management 
of cardiomyopathies
Developed by the task force on the management of 
cardiomyopathies of the European Society of Cardiology (ESC)
Authors/Task Force Members: Elena Arbelo  *†, (Chairperson) (Spain), 
Alexandros Protonotarios  
‡, (Task Force Co-ordinator) (United Kingdom), 
Juan R. Gimeno  
‡, (Task Force Co-ordinator) (Spain), Eloisa Arbustini  
(Italy), 
Roberto Barriales-Villa  
(Spain), Cristina Basso  
(Italy), Connie R. Bezzina  
(Netherlands), Elena Biagini  
(Italy), Nico A. Blom1 (Netherlands), 
Rudolf A. de Boer  
(Netherlands), Tim De Winter (Belgium), Perry M. Elliott  
(United Kingdom), Marcus Flather  
(United Kingdom), Pablo Garcia-Pavia  
(Spain), Kristina H. Haugaa  
(Sweden), Jodie Ingles  
(Australia), 
Ruxandra Oana Jurcut  
(Romania), Sabine Klaassen  
(Germany), 
Giuseppe Limongelli  
(Italy), Bart Loeys  
2 (Belgium), Jens Mogensen  
(Denmark), Iacopo Olivotto  
(Italy), Antonis Pantazis  
(United Kingdom), 
Sanjay Sharma  
(United Kingdom), J. Peter Van Tintelen  
(Netherlands), 
James S. Ware  
(United Kingdom), Juan Pablo Kaski  *†, (Chairperson) 
(United Kingdom), and ESC Scientific Document Group
* Corresponding authors: Elena Arbelo, Arrhythmia Section, Cardiology Department, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain, IDIBAPS, Institut d’Investigació August Pi i 
Sunyer (IDIBAPS), Barcelona, Spain, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain, and European Reference Network for Rare, Low 
Prevalence and Complex Diseases of the Heart, ERN GUARD-Heart, Barcelona, Spain. Tel: +34 93 22 75 55 11, E-mail: elenaarbelo@secardiologia.es; and Juan Pablo Kaski, Centre for 
Paediatric Inherited and Rare Cardiovascular Disease, University College London, Institute of Cardiovascular Science, London, United Kingdom and Centre for Inherited Cardiovascular 
Diseases, Great Ormond Street Hospital, London, United Kingdom. Tel: +44 78 29 88 39, E-mail: j.kaski@ucl.ac.uk
† The two Chairpersons contributed equally to the document and are joint corresponding authors.
‡ The two Task Force Co-ordinators contributed equally to the document.
Author/Task Force Member affiliations are listed in author information.
1 Representing the Association for European Paediatric and Congenital Cardiology (AEPC)
2 Representing the European Society of Human Genetics (ESHG)
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Cardiovascular Imaging (EACVI), European Association of Preventive 
Cardiology (EAPC), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).
Councils: Council on Cardiovascular Genomics.
Working Groups: Development Anatomy and Pathology, Myocardial and Pericardial Diseases.
Patient Forum  
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC 
Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford 
University Press, the publisher of the European Heart Journal, and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time 
of their publication. The ESC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC Guidelines and any other official recommendations or 
guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the 
ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; 
however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each 
patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from 
taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case 
in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and 
regulations relating to drugs and medical devices at the time of prescription.
© The European Society of Cardiology 2023. All rights reserved. For permissions please email: journals.permissions@oup.com.
https://doi.org/10.1093/eurheartj/ehad194
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Philippe Charron, (CPG Review Co-ordinator) (France), Massimo Imazio, (CPG Review 
Co-ordinator) (Italy), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Michael Arad (Israel), Folkert 
W. Asselbergs (Netherlands), Riccardo Asteggiano (Italy), Zofia Bilinska (Poland), Damien Bonnet (France), 
Henning Bundgaard (Denmark), Nuno Miguel Cardim (Portugal), Jelena Čelutkienė (Lithuania), Maja Cikes 
(Croatia), Gaetano Maria De Ferrari (Italy), Veronica Dusi (Italy), Volkmar Falk (Germany), Laurent Fauchier 
(France), Estelle Gandjbakhch (France), Tiina Heliö (Finland), Konstantinos Koskinas (Switzerland), Dipak Kotecha 
(United Kingdom), Ulf Landmesser (Germany), George Lazaros (Greece), Basil S. Lewis (Israel), Ales Linhart 
(Czechia), Maja-Lisa Løchen (Norway), Benjamin Meder (Germany), Richard Mindham (United Kingdom), 
James Moon (United Kingdom), Jens Cosedis Nielsen (Denmark), Steffen Petersen (United Kingdom), Eva Prescott 
(Denmark), Mary N. Sheppard (United Kingdom), Gianfranco Sinagra (Italy), Marta Sitges (Spain), 
Jacob Tfelt-Hansen (Denmark), Rhian Touyz (Canada), Rogier Veltrop (Netherlands), Josef Veselka (Czechia), 
Karim Wahbi (France), Arthur Wilde (Netherlands), and Katja Zeppenfeld (Netherlands)
All experts involved in the development of these guidelines have submitted declarations of interest. These have 
been compiled in a report and simultaneously published in a supplementary document to the guidelines. The 
report is also available on the ESC website www.escardio.org/Guidelines
See the European Heart Journal online for supplementary documents that include background information and 
evidence tables.
Keywords 
Guidelines • Arrhythmia • Arrhythmogenic right ventricular cardiomyopathy • Cardiomyopathies • Diagnosis • 
Dilated cardiomyopathy • Genetics • Genetic counselling • Genetic testing • Hypertrophic cardiomyopathy • 
Implantable cardioverter defibrillator • Management • Multimodality imaging • Non-dilated left ventricular 
cardiomyopathy • Pregnancy • Restrictive cardiomyopathy • Risk stratification • Screening • Sports • 
Sudden cardiac death
Table of contents 
1. Preamble .............................................................................................................. 3509 
2. Introduction ....................................................................................................... 3511 
3. Phenotypic approach to cardiomyopathies .......................................... 3511 
3.1. Definitions .................................................................................................
3514 
3.2. Cardiomyopathy phenotypes ............................................................
3514 
3.2.1. Hypertrophic cardiomyopathy ................................................. 3514 
3.2.2. Dilated cardiomyopathy .............................................................. 3514 
3.2.3. Non-dilated left ventricular cardiomyopathy ..................... 3514 
3.2.4. Arrhythmogenic right ventricular cardiomyopathy ......... 3516 
3.2.5. Restrictive cardiomyopathy ........................................................ 3517 
3.3. Other traits and syndromes associated with cardiomyopathy 
phenotypes ........................................................................................................
3517 
3.3.1. Left ventricular hypertrabeculation (left ventricular non- 
compaction) .................................................................................................. 3517 
3.3.2. Takotsubo syndrome .................................................................... 3517 
4. Epidemiology ...................................................................................................... 3517 
4.1. Special populations ................................................................................
3518 
5. Integrated patient management ................................................................. 3518 
5.1. Multidisciplinary cardiomyopathy teams ......................................
3518 
5.2. Co-ordination between different levels of care ........................
3518 
6. The patient pathway ....................................................................................... 3519 
6.1. Clinical presentation .............................................................................
3520 
6.2. Initial work-up ..........................................................................................
3520 
6.3. Systematic approach to diagnosis of cardiomyopathy ...........
3520 
6.4. History and physical examination ...................................................
3520 
6.5. Resting and ambulatory electrocardiography ............................
3521 
6.6. Laboratory tests ......................................................................................
3524 
6.7. Multimodality imaging ...........................................................................
3524 
6.7.1. General considerations ................................................................ 3524 
6.7.2. Echocardiography ........................................................................... 3524 
6.7.3. Cardiac magnetic resonance ...................................................... 3525 
6.7.3.1. Special considerations ..........................................................
3525 
6.7.4. Computed tomography and nuclear medicine 
techniques ...................................................................................................... 3528 
6.7.5. Endomyocardial biopsy ................................................................ 3528 
6.8. Genetic testing and counselling ........................................................
3529 
6.8.1. Genetic architecture ..................................................................... 3529 
6.8.2. Genetic testing ................................................................................. 3529 
6.8.2.1. Non-Mendelian cardiomyopathies and implications 
for genetic testing ..................................................................................
3534 
6.8.2.2. Genetic test reports and variant interpretation .......
3534 
6.8.3. Genetic counselling ........................................................................ 3534


<!-- PAGE 3 -->

### Page 3

6.8.3.1. Genetic counselling in children ........................................
3534 
6.8.3.2. Pre- and post-test genetic counselling (proband) ....
3535 
6.8.3.3. Genetic counselling for cascade testing ........................
3535 
6.8.3.4. Pre-natal or pre-implantation genetic diagnosis .......
3536 
6.9. Diagnostic approach to paediatric patients ................................
3537 
6.9.1. Infantile and early childhood-onset cardiomyopathy ...... 3538 
6.10. General principles in the management of patients with 
cardiomyopathy ...............................................................................................
3539 
6.10.1. Assessment of symptoms ......................................................... 3539 
6.10.2. Heart failure management ........................................................ 3539 
6.10.2.1. Preventive heart failure medical therapy of 
asymptomatic carriers/early disease expression .......................
3540 
6.10.2.2. Cardiac transplantation .....................................................
3540 
6.10.2.3. Left ventricular assist devices .........................................
3540 
6.10.3. Management of atrial arrhythmias ........................................ 3541 
6.10.3.1. Anticoagulation .....................................................................
3541 
6.10.3.2. Rate control ...........................................................................
3541 
6.10.3.3. Rhythm control ....................................................................
3543 
6.10.3.4. Comorbidities and risk factor management ............
3543 
6.10.4. Management of ventricular arrhythmias ............................ 3544 
6.10.5. Device therapy: implantable cardioverter defibrillator
3544 
6.10.6. Routine follow-up of patients with cardiomyopathy ... 3546 
6.11. Family screening and follow-up evaluation of relatives .......
3546 
6.11.1. Special considerations in family screening ......................... 3547 
6.12. Psychological support in cardiomyopathy patients and family 
members .............................................................................................................
3548 
6.13. The patient pathway ..........................................................................
3549 
7. Specific cardiomyopathy phenotypes ...................................................... 3549 
7.1. Hypertrophic cardiomyopathy .........................................................
3549 
7.1.1. Diagnosis ............................................................................................ 3549 
7.1.1.1. Diagnostic criteria ..................................................................
3549 
7.1.1.2. Diagnostic work-up ...............................................................
3549 
7.1.1.3. Echocardiography ...................................................................
3549 
7.1.1.4. Cardiac magnetic resonance .............................................
3550 
7.1.1.5. Nuclear imaging ......................................................................
3551 
7.1.2. Genetic testing and family screening ...................................... 3551 
7.1.3. Assessment of symptoms ........................................................... 3552 
7.1.4. Management of symptoms and complications ................... 3552 
7.1.4.1. Management of left ventricular outflow tract 
obstruction ...............................................................................................
3553 
7.1.4.1.1. General measures ..........................................................
3553 
7.1.4.1.2. Drug therapy ...................................................................
3553 
7.1.4.1.3. Invasive treatment of left ventricular outflow 
tract (septal reduction therapy) .................................................
3555 
7.1.4.2. Management of symptoms in patients without left 
ventricular outflow tract obstruction ...........................................
3557 
7.1.4.2.1. Heart failure and chest pain ......................................
3557 
7.1.4.2.2. Cardiac resynchronization therapy ........................
3557 
7.1.5. Sudden cardiac death prevention in hypertrophic 
cardiomyopathy ........................................................................................... 3558 
7.1.5.1. Left ventricular apical aneurysms ....................................
3559 
7.1.5.2. Left ventricular systolic dysfunction ...............................
3559 
7.1.5.3. Late gadolinium enhancement on cardiac magnetic 
resonance imaging .................................................................................
3559 
7.1.5.4. Abnormal exercise blood pressure response ............
3559 
7.1.5.5. Sarcomeric variants ...............................................................
3560 
7.1.5.6. Prevention of sudden cardiac death ..............................
3560 
7.2. Dilated cardiomyopathy ......................................................................
3562 
7.2.1. Diagnosis ............................................................................................ 3562 
7.2.1.1. Index case ..................................................................................
3562 
7.2.1.2. Relatives .....................................................................................
3562 
7.2.1.3. Diagnostic work-up ...............................................................
3562 
7.2.1.4. Echocardiography ...................................................................
3562 
7.2.1.5. Cardiac magnetic resonance .............................................
3563 
7.2.1.6. Nuclear medicine ...................................................................
3563 
7.2.2. Genetic testing and family screening ...................................... 3563 
7.2.2.1. Genetic testing ........................................................................
3563 
7.2.3. Assessment of symptoms ........................................................... 3564 
7.2.4. Management ...................................................................................... 3564 
7.2.5. Sudden cardiac death prevention in dilated 
cardiomyopathy ........................................................................................... 3564 
7.2.5.1. Secondary prevention of sudden cardiac death .......
3564 
7.2.5.2. Primary prevention of sudden cardiac death .............
3564 
7.3. Non-dilated left ventricular cardiomyopathy .............................
3566 
7.3.1. Diagnosis ............................................................................................ 3566 
7.3.1.1. Index case ..................................................................................
3566 
7.3.1.2. Relatives .....................................................................................
3566 
7.3.1.3. Diagnostic work-up ...............................................................
3566 
7.3.1.4. Electrocardiographic features ...........................................
3567 
7.3.1.5. Echocardiography ...................................................................
3567 
7.3.1.6. Cardiac magnetic resonance .............................................
3567 
7.3.1.7. Nuclear medicine ...................................................................
3567 
7.3.1.8. Endomyocardial biopsy ........................................................
3567 
7.3.2. Genetic testing ................................................................................. 3567 
7.3.3. Assessment of symptoms ........................................................... 3567 
7.3.4. Management ...................................................................................... 3567 
7.3.5. Sudden cardiac death prevention in non-dilated left 
ventricular cardiomyopathy .................................................................... 3568 
7.3.5.1. Secondary prevention of sudden cardiac death .......
3568 
7.3.5.2. Primary prevention of sudden cardiac death .............
3568 
7.4. Arrhythmogenic right ventricular cardiomyopathy .................
3569 
7.4.1. Diagnosis ............................................................................................ 3569 
7.4.1.1. Index case ..................................................................................
3569 
7.4.1.2. Relatives .....................................................................................
3569 
7.4.1.3. Diagnostic work-up ...............................................................
3569 
7.4.1.4. Electrocardiography and Holter monitoring ..............
3569 
7.4.1.5. Echocardiography and cardiac magnetic resonance
3569 
7.4.1.6. Endomyocardial biopsy ........................................................
3569 
7.4.1.7. Nuclear medicine ...................................................................
3569 
7.4.1.8. Arrhythmogenic right ventricular cardiomyopathy 
phenocopies .............................................................................................
3570 
7.4.2. Genetic testing and family screening ...................................... 3570 
7.4.3. Assessment of symptoms ........................................................... 3570 
7.4.4. Management ...................................................................................... 3570 
7.4.4.1. Antiarrhythmic therapy .......................................................
3570 
7.4.5. Sudden cardiac death prevention in arrhythmogenic right 
ventricular cardiomyopathy .................................................................... 3570 
7.4.5.1. Secondary prevention of sudden cardiac death .......
3571 
7.4.5.2. Primary prevention of sudden cardiac death .............
3571 
7.5. Restrictive cardiomyopathy ...............................................................
3572 
7.5.1. Diagnosis ............................................................................................ 3572 
7.5.2. Genetic testing ................................................................................. 3572 
ESC Guidelines                                                                                                                                                                                          3505


<!-- PAGE 4 -->

### Page 4

7.5.3. Assessment of symptoms ........................................................... 3573 
7.5.4. Management ...................................................................................... 3573 
7.6. Syndromic and metabolic cardiomyopathies .............................
3574 
7.6.1. Anderson–Fabry disease .............................................................. 3574 
7.6.1.1. Definition ...................................................................................
3574 
7.6.1.2. Diagnosis, clinical work-up, and differential diagnosis
3574 
7.6.1.3. Clinical course, outcome, and risk stratification .......
3574 
7.6.1.4. Management .............................................................................
3577 
7.6.2. RASopathies ...................................................................................... 3577 
7.6.2.1. Definition ...................................................................................
3577 
7.6.2.2. Diagnosis, clinical work-up, and differential diagnosis
3577 
7.6.2.3. Clinical course, management, and sudden death risk 
stratification ..............................................................................................
3577 
7.6.2.4. Management .............................................................................
3577 
7.6.3. Friedreich ataxia .............................................................................. 3578 
7.6.3.1. Definition ...................................................................................
3578 
7.6.3.2. Diagnosis, clinical work-up, and differential diagnosis
3578 
7.6.3.3. Clinical course, management, and risk stratification
3579 
7.6.3.4. Management .............................................................................
3579 
7.6.4. Glycogen storage disorders ....................................................... 3579 
7.6.4.1. Definition ...................................................................................
3579 
7.6.4.2. Diagnosis, clinical work-up, and differential diagnosis
3579 
7.6.4.3. Clinical course, management, and risk stratification
3579 
7.6.4.4. Management .............................................................................
3579 
7.7. Amyloidosis ...............................................................................................
3579 
7.7.1. Definition ........................................................................................... 3579 
7.7.2. Diagnosis, clinical work-up, and differential diagnosis ..... 3579 
7.7.3. Clinical course and risk stratification ..................................... 3580 
7.7.4. Management ...................................................................................... 3580 
7.7.4.1. Specific therapies ....................................................................
3581 
8. Other recommendations .............................................................................. 3581 
8.1. Sports ..........................................................................................................
3581 
8.1.1. Cardiovascular benefits of exercise ........................................ 3581 
8.1.2. Exercise-related sudden cardiac death and historical 
exercise recommendations for patients with cardiomyopathy
3582 
8.1.3. Exercise recommendations in hypertrophic 
cardiomyopathy ........................................................................................... 3582 
8.1.4. Exercise recommendations in arrhythmogenic right 
ventricular cardiomyopathy .................................................................... 3582 
8.1.5. Exercise recommendations in dilated cardiomyopathy 
and non-dilated left ventricular cardiomyopathy .......................... 3582 
8.2. Reproductive issues ...............................................................................
3583 
8.2.1. Contraception, in vitro fertilization, and hormonal 
treatment ........................................................................................................ 3583 
8.2.2. Pregnancy management ............................................................... 3583 
8.2.2.1. Pre-pregnancy ..........................................................................
3583 
8.2.2.2. Pregnancy ..................................................................................
3583 
8.2.2.3. Timing and mode of delivery ............................................
3584 
8.2.2.4. Post-partum ..............................................................................
3584 
8.2.2.5. Pharmacological treatment: general aspects ..............
3584 
8.2.2.6. Specific cardiomyopathies ..................................................
3584 
8.2.2.7. Peripartum cardiomyopathy .............................................
3585 
8.3. Recommendations for non-cardiac surgery ...............................
3585 
9. Requirements for specialized cardiomyopathy units ........................ 3586 
10. Living with cardiomyopathy: advice for patients ............................. 3586 
11. Sex differences in cardiomyopathies ..................................................... 3587 
12. Comorbidities and cardiovascular risk factors in 
cardiomyopathies .................................................................................................. 3587 
12.1. Cardiovascular risk factors ..............................................................
3587 
12.2. Dilated cardiomyopathy ...................................................................
3588 
12.3. Hypertrophic cardiomyopathy ......................................................
3588 
12.4. Arrhythmogenic right ventricular cardiomyopathy ..............
3588 
13. Coronavirus disease (COVID-19) and cardiomyopathies ........... 3588 
14. Key messages .................................................................................................. 3588 
15. Gaps in evidence ............................................................................................ 3589 
16. ‘What to do’ and ‘What not to do’ messages from the 
Guidelines ................................................................................................................. 3591 
17. Supplementary data ...................................................................................... 3595 
18. Data availability statement ......................................................................... 3595 
19. Author information ...................................................................................... 3595 
20. Appendix ........................................................................................................... 3596 
21. Acknowledgements ...................................................................................... 3597 
Tables of Recommendations 
Recommendation Table 1 — Recommendations for the provision of 
service of multidisciplinary cardiomyopathy teams ................................ 3519 
Recommendation Table 2 — Recommendations for diagnostic 
work-up in cardiomyopathies .......................................................................... 3520 
Recommendation Table 3 — Recommendations for laboratory 
tests in the diagnosis of cardiomyopathies ................................................ 3524 
Recommendation Table 4 — Recommendation for 
echocardiographic evaluation in patients with cardiomyopathy ...... 3524 
Recommendation Table 5 — Recommendations for cardiac 
magnetic resonance indication in patients with cardiomyopathy .... 3526 
Recommendation Table 6 — Recommendations for computed 
tomography and nuclear imaging ................................................................... 3528 
Recommendation Table 7 — Recommendation for endomyocardial 
biopsy in patients with cardiomyopathy ..................................................... 3528 
Recommendation Table 8 — Recommendations for genetic 
counselling and testing in cardiomyopathies ............................................. 3537 
Recommendation Table 9 — Recommendations for cardiac 
transplantation in patients with cardiomyopathy ................................... 3540 
Recommendation Table 10 — Recommendation for left ventricular 
assist device therapy in patients with cardiomyopathy ........................ 3540 
Recommendation Table 11 — Recommendations for management of 
atrial fibrillation and atrial flutter in patients with cardiomyopathy ....
3543 
Recommendation Table 12 — Recommendations for implantable 
cardioverter defibrillator in patients with cardiomyopathy ................ 3545 
Recommendation Table 13 — Recommendations for routine 
follow-up of patients with cardiomyopathy .............................................. 3546 
Recommendation Table 14 — Recommendations for family 
screening and follow-up evaluation of relatives ....................................... 3546 
Recommendation Table 15 — Recommendations for psychological 
support in patients and family members with cardiomyopathies .... 3549 
Recommendation Table 16 — Recommendation for evaluation of 
left ventricular outflow tract obstruction .................................................. 3549 
Recommendation Table 17 — Additional recommendation for 
cardiovascular magnetic resonance evaluation in hypertrophic 
cardiomyopathy ..................................................................................................... 3550 
Recommendation Table 18 — Recommendations for treatment of 
left ventricular outflow tract obstruction (general measures) .......... 3553 
Recommendation Table 19 — Recommendations for medical 
treatment of left ventricular outflow tract obstruction ....................... 3554 
Recommendation Table 20 — Recommendations for septal 
reduction therapy ................................................................................................. 3556


<!-- PAGE 5 -->

### Page 5

Recommendation Table 21 — Recommendations for indications for 
cardiac pacing in patients with obstruction ............................................... 3557 
Recommendation Table 22 — Recommendations for chest pain on 
exertion in patients without left ventricular outflow tract 
obstruction .............................................................................................................. 3557 
Recommendation Table 23 — Additional recommendations for 
prevention of sudden cardiac death in patients with hypertrophic 
cardiomyopathy ..................................................................................................... 3561 
Recommendation Table 24 — Recommendations for an implantable 
cardioverter defibrillator in patients with dilated cardiomyopathy
3566 
Recommendation Table 25 — Recommendation for resting and 
ambulatory electrocardiogram monitoring in patients with 
non-dilated left ventricular cardiomyopathy ............................................. 3567 
Recommendation Table 26 — Recommendations for an implantable 
cardioverter defibrillator in patients with non-dilated left ventricular 
cardiomyopathy ..................................................................................................... 3568 
Recommendation Table 27 — Recommendation for resting and 
ambulatory electrocardiogram monitoring in patients with 
arrhythmogenic right ventricular cardiomyopathy ................................. 3569 
Recommendation Table 28 — Recommendations for the 
antiarrhythmic management of patients with arrhythmogenic right 
ventricular cardiomyopathy .............................................................................. 3570 
Recommendation Table 29 — Recommendations for sudden 
cardiac death prevention in patients with arrhythmogenic right 
ventricular cardiomyopathy .............................................................................. 3571 
Recommendation Table 30 — Recommendations for the 
management of patients with restrictive cardiomyopathy ................. 3574 
Recommendation Table 31 — Exercise recommendations for 
patients with cardiomyopathy ......................................................................... 3582 
Recommendation Table 32 — Recommendations for reproductive 
issues in patients with cardiomyopathy ...................................................... 3585 
Recommendation Table 33 — Recommendations for non-cardiac 
surgery in patients with cardiomyopathy ................................................... 3585 
Recommendation Table 34 — Recommendation for management 
of cardiovascular risk factors in patients with cardiomyopathy ....... 3588
List of tables 
Table 1 Classes for recommendations ........................................................ 3510 
Table 2 Levels of evidence ................................................................................ 3510 
Table 3 Morphological and functional traits used to describe 
cardiomyopathy phenotypes ............................................................................ 3514 
Table 4 Key epidemiological metrics in adults and children for the 
different cardiomyopathy phenotypes ......................................................... 3517 
Table 5 Examples of inheritance patterns that should raise the 
suspicion of specific genetic aetiologies, grouped according to 
cardiomyopathy phenotype ............................................................................. 3521 
Table 6 Examples of signs and symptoms that should raise the 
suspicion of specific aetiologies, grouped according to 
cardiomyopathy phenotype ............................................................................. 3522 
Table 7 Examples of electrocardiographic features that should raise 
the suspicion of specific aetiologies, grouped according to 
cardiomyopathy phenotype ............................................................................. 3523 
Table 8 First-level (to be performed in each patient) and 
second-level (to be performed in selected patients following 
specialist evaluation to identify specific aetiologies) laboratory tests, 
grouped by cardiomyopathy phenotype .................................................... 3525 
Table 9 Frequently encountered actionable results on multimodality 
imaging ....................................................................................................................... 3528 
Table 10 Overview of genes associated with monogenic, 
non-syndromic cardiomyopathies, and their relative contributions 
to different cardiomyopathic phenotypes .................................................. 3530 
Table 11 Utility of genetic testing in cardiomyopathies ....................... 3533 
Table 12 Specific issues to consider when counselling children ....... 3534 
Table 13 Key discussion points of pre- and post-test genetic 
counselling ................................................................................................................ 3536 
Table 14 Pre-natal and pre-implantation options and implications
3536 
Table 15 Atrial fibrillation burden and management in 
cardiomyopathies .................................................................................................. 3542 
Table 16 Psychological considerations ......................................................... 3548 
Table 17 Imaging evaluation in hypertrophic cardiomyopathy ......... 3550 
Table 18 Echocardiographic features that suggest specific aetiologies 
in hypertrophic cardiomyopathy .................................................................... 3551 
Table 19 Major clinical features associated with an increased risk of 
sudden cardiac death ........................................................................................... 3558 
Table 20 Non-genetic causes of dilated cardiomyopathy .......................
3563 
Table 21 High-risk genotypes and associated predictors of sudden 
cardiac death ........................................................................................................... 3566 
Table 22 Clinical features and management of syndromic and 
metabolic cardiomyopathies ............................................................................ 3575 
Table 23 Anderson–Fabry disease red flags .............................................. 3577 
Table 24 General guidance for daily activity for patients with 
cardiomyopathies .................................................................................................. 3586 
Table 25 Modulators of the phenotypic expression of 
cardiomyopathies .................................................................................................. 3588
List of figures 
Figure 1 Central illustration .............................................................................. 3512 
Figure 2 Clinical diagnostic workflow of cardiomyopathy .................. 3513 
Figure 3 Examples of non-dilated left ventricular cardiomyopathy 
phenotypes and their aetiological correlates ............................................ 3515 
Figure 4 Worked example of the non-dilated left ventricular 
cardiomyopathy phenotype ............................................................................. 3516 
Figure 5 Multidisciplinary care of cardiomyopathies .............................. 3519 
Figure 6 Multimodality imaging process in cardiomyopathies ........... 3526 
Figure 7 Examples of cardiac magnetic resonance imaging tissue 
characterization features that should raise the suspicion of specific 
aetiologies, grouped according to cardiomyopathy phenotype ....... 3527 
Figure 8 The genetic architecture of the cardiomyopathies .............. 3533 
Figure 9 A patient-centred approach to cascade genetic testing of 
children ...................................................................................................................... 3535 
Figure 10 Clinical approach to infantile and childhood 
cardiomyopathy ..................................................................................................... 3538 
Figure 11 Algorithm for the approach to family screening and 
follow-up of family members ........................................................................... 3547 
Figure 12 Protocol for the assessment and treatment of left 
ventricular outflow tract obstruction .......................................................... 3551 
Figure 13 Algorithm for the treatment of heart failure in 
hypertrophic cardiomyopathy ......................................................................... 3552 
Figure 14 Flow chart on the management of left ventricular outflow 
tract obstruction ................................................................................................... 3554 
Figure 15 Pre-assessment checklist for patients being considered for 
invasive septal reduction therapies ................................................................ 3555 
Figure 16 Flow chart for implantation of an implantable cardioverter 
defibrillator in patients with hypertrophic cardiomyopathy .............. 3561 
Figure 17 Implantation of implantable cardioverter defibrillators in 
patients with dilated cardiomyopathy or non-dilated left ventricular 
cardiomyopathy flowchart ................................................................................ 3565 
ESC Guidelines                                                                                                                                                                                          3507


<!-- PAGE 6 -->

### Page 6

Figure 18 Algorithm to approach implantable cardioverter 
defibrillator decision-making in patients with arrhythmogenic right 
ventricular cardiomyopathy .............................................................................. 3572 
Figure 19 Spectrum of restrictive heart diseases .................................... 3573 
Figure 20 Anderson–Fabry disease diagnostic algorithm ..................... 3578 
Figure 21 Screening for cardiac amyloidosis ............................................. 3580 
Figure 22 Diagnosis of cardiac amyloidosis ............................................... 3581
Abbreviations and acronyms
18F-FDG
18F-fluorodeoxyglucose
2D
Two-dimensional
3D
Three-dimensional
99mTc
99mTechnetium
AAD
Antiarrhythmic drug
ABC
Atrial Fibrillation Better Care approach
ACE
Angiotensin-converting enzyme
ACE-I
Angiotensin-converting enzyme inhibitor
ACM
Arrhythmogenic cardiomyopathy
AD
Autosomal dominant
AED
Automated external defibrillator
AF
Atrial fibrillation
AFD
Anderson–Fabry disease
AHA/ACC
American Heart Association/American College of 
Cardiology
AL
Monoclonal immunoglobulin light chain amyloidosis
ALCAPA
Anomalous left coronary artery from the pulmonary 
artery
ALT
Alanine aminotransferase
ALVC
Arrhythmogenic left ventricular cardiomyopathy
APHRS
Asia Pacific Heart Rhythm Society
AR
Autosomal recessive
ARB
Angiotensin receptor blocker
ARNI
Angiotensin receptor neprilysin inhibitor
ARVC
Arrhythmogenic right ventricular cardiomyopathy
ASA
Alcohol septal ablation
AST
Aspartate transaminase
ATPase
Adenosine triphosphatase
ATTR
Transthyretin amyloidosis
ATTR-CA
Transthyretin cardiac amyloidosis
ATTR-CM
Transthyretin amyloid cardiomyopathy
ATTRv
Hereditary transthyretin amyloidosis
ATTRwt
Wild-type OR Acquired transthyretin amyloidosis
AV
Atrioventricular b.p.m.
Beats per minute
BAG3
BAG cochaperone-3
BNP
Brain natriuretic peptide
CAD
Coronary artery disease
CCB
Calcium channel blocker
CHA2DS2-VASc
Congestive heart failure or left ventricular 
dysfunction, hypertension, age ≥75 (doubled), 
diabetes, stroke (doubled)-vascular disease, age 65– 
74, sex category (female) (score)
CHD
Congenital heart disease
CK
Creatinine kinase
CMR
Cardiac magnetic resonance
COVID-19
Severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) infection
CPET
Cardio-pulmonary exercise testing
CPR
Cardio-pulmonary resuscitation
CRT
Cardiac resynchronization therapy
CrCl
Creatinine clearance
CT
Computed tomography
CTCA
Computed tomography coronary angiography
DBS
Deep brain stimulation
DCM
Dilated cardiomyopathy
DES
Desmin
DMD
Duchenne muscular dystrophy
DOAC
Direct-acting oral anticoagulant
DPD
3,3-diphosphono-1,2-propanodicarboxylic acid
DSP
Desmoplakin
EAST-AFNET
Early Treatment of Atrial Fibrillation for Stroke 
Prevention Trial
ECG
Electrocardiogram
ECHO
Echocardiogram
ECV
Extracellular volume
EF
Ejection fraction
EHRA
European Heart Rhythm Association
EMB
Endomyocardial biopsy
EMF
Endomyocardial fibrosis
EORP
EURObservational Research Programme
ERN
European Reference Network
ERT
Enzyme replacement therapy
FLNC
Filamin C
FRA
Friedreich ataxia
FTX
Frataxin
Gb3
Globotriaosylceramide
GDMT
Guideline-directed medical therapy
GSD
Glycogen storage disorder
GWAS
Genome-wide association study
HbA1c
Haemoglobin A1C
HBP
His-Bundle pacing
HCM
Hypertrophic cardiomyopathy
HCMR
Hypertrophic Cardiomyopathy Registry
HF
Heart failure
HFmrEF
Heart failure with mildly reduced ejection fraction
HFpEF
Heart failure with preserved ejection fraction
HFrEF
Heart failure with reduced ejection fraction
HMDP
Hydroxymethylene diphosphonate
HR
Hazard ratio
HRS
Heart Rhythm Society hs-cTnT
High-sensitivity cardiac troponin T
ICD
Implantable cardioverter defibrillator
INR
International normalized ratio
ITFC
International Task Force Consensus statement
IVF
In vitro fertilization
LA
Left atrium
LAHRS
Latin American Heart Rhythm Society
LBBB
Left bundle branch block
LGE
Late gadolinium enhancement
LMNA
Lamin A/C
LMWH
Low-molecular-weight heparin
LSD
Lysosomal storage disease
LV
Left ventricular
LVAD
LV assist device
LVEDV
Left ventricular end-diastolic volume
LVEF
Left ventricular ejection fraction
LVH
Left ventricular hypertrophy


<!-- PAGE 7 -->

### Page 7

LVNC
Left ventricular non-compaction
LVOT
Left ventricular outflow tract
LVSD
Left ventricular systolic dysfunction
LVOTO
Left ventricular outflow tract obstruction
MCS
Mechanical circulatory support
MELAS
Mitochondrial encephalomyopathy, lactic acidosis, 
and stroke-like episodes (syndrome)
MERRF
Mitochondrial epilepsy with ragged-red fibres
MGUS
Monoclonal gammopathy of undetermined 
significance
MICONOS
Mitochondrial Protection with Idebenone in Cardiac 
or Neurological Outcome (study group)
MLVWT
Maximum left ventricular wall thickness
MRA
Mineralocorticoid receptor antagonist
MRI
Magnetic resonance imaging
MV
Mitral valve mWHO
Modified World Health Organization  
(classification)
NCS
Non-cardiac surgery
NDLVC
Non-dilated left ventricular cardiomyopathy
NGS
Next-generation sequencing
NSML
Noonan syndrome with multiple lentigines
NSVT
Non-sustained ventricular tachycardia
NT-proBNP
N-terminal pro-brain natriuretic peptide
NYHA
New York Heart Association
OMT
Optimal medical therapy
P/LP
Pathogenic/likely pathogenic
PES
Programmed electrical stimulation
PET
Positron emission tomography
PKP2
Plakophilin 2
PLN
Phospholamban
PPCM
Peripartum cardiomyopathy
PRKAG2
Protein kinase AMP-activated non-catalytic subunit 
gamma 2
PRS
Polygenic risk scores
PTH
Parathyroid hormone
PVR
Pulmonary vascular resistance
PYP
Pyrophosphate
QoL
Quality of life
QRS
Q, R, and S waves of an ECG
RAS-HCM
RASopathy-associated HCM
RBBB
Right bundle branch block
RBM20
RNA binding motif protein
RCM
Restrictive cardiomyopathy
RCT
Randomized controlled trial
RV
Right ventricular
RVEF
Right ventricular ejection fraction
RVOTO
Right ventricular outflow tract obstruction
RWMA
Regional wall motion abnormality
SAECG
Signal-averaged electrocardiogram
SAM
Systolic anterior motion
SCD
Sudden cardiac death
SGLT2i
Sodium–glucose co-transporter 2 inhibitor
SMVT
Sustained monomorphic ventricular tachycardia
SPECT
Single-photon emission computed tomography
SRT
Septal reduction therapy
TIA
Transient ischaemic attack
TMEM43
transmembrane protein 43
TRED-HF
Therapy withdrawal in REcovered Dilated 
cardiomyopathy—Heart Failure
TTE
Transthoracic echocardiography
TTN
Titin
TTNtv
Titin gene truncating variants
TTR
Transthyretin
TWI
T wave inversion
UFH
Unfractionated heparin
VALOR-HCM
A Study to Evaluate Mavacamten in Adults With 
Symptomatic Obstructive HCM Who Are Eligible 
for Septal Reduction Therapy
VE
Ventricular extrasystole
VF
Ventricular fibrillation
VKA
Vitamin K antagonist
VT
Ventricular tachycardia
VUS
Variant of unknown significance
WHO
World Health Organization
1. Preamble
Guidelines evaluate and summarize available evidence with the aim of 
assisting health professionals in proposing the best diagnostic or thera­
peutic approach for an individual patient with a given condition. 
Guidelines are intended for use by health professionals and the 
European Society of Cardiology (ESC) makes its Guidelines freely 
available.
ESC Guidelines do not override the individual responsibility of health 
professionals to make appropriate and accurate decisions in consider­
ation of each patient’s health condition and in consultation with that pa­
tient or the patient’s caregiver where appropriate and/or necessary. It is 
also the health professional’s responsibility to verify the rules and reg­
ulations applicable in each country to drugs and devices at the time of 
prescription, and, where appropriate, to respect the ethical rules of 
their profession.
ESC Guidelines represent the official position of the ESC on a given 
topic and are regularly updated. ESC Policies and Procedures for for­
mulating and issuing ESC Guidelines can be found on the ESC website 
(https://www.escardio.org/Guidelines).
The Members of this Task Force were selected by the ESC to re­
present professionals involved with the medical care of patients with 
this pathology. The selection procedure aimed to include members 
from across the whole of the ESC region and from relevant ESC 
Subspecialty Communities. Consideration was given to diversity and in­
clusion, notably with respect to gender and country of origin. The Task 
Force performed a critical evaluation of diagnostic and therapeutic ap­
proaches, including assessment of the risk-benefit ratio. The strength of 
every recommendation and the level of evidence supporting them were 
weighed and scored according to predefined scales as outlined below. 
The Task Force followed ESC voting procedures, and all approved re­
commendations were subject to a vote and achieved at least 75% 
agreement among voting members.
The experts of the writing and reviewing panels provided declaration 
of interest forms for all relationships that might be perceived as real or 
potential sources of conflicts of interest. Their declarations of interest 
were reviewed according to the ESC declaration of interest rules and 
can be found on the ESC website (http://www.escardio.org/ 
Guidelines) and have been compiled in a report published in a supple­
mentary document with the guidelines. The Task Force received its
ESC Guidelines                                                                                                                                                                                          3509


<!-- PAGE 8 -->

### Page 8

Table 1 Classes for recommendations
©ESC 2023
Classes of recommendations
Class I 
Evidence and/or general agreement that a given treatment or procedure is beneﬁcial, useful, eﬀective. 
Conﬂicting evidence and/or a divergence of opinion about the usefulness/ 
eﬃcacy of the given treatment or procedure. 
Is recommended or is indicated
Wording to use
Deﬁnition
Class III 
Evidence or general agreement that the given treatment or procedure is not useful/eﬀective, and in some cases may be harmful. 
Is not recommended
     Class IIb
Usefulness/eﬃcacy is less well established by evidence/opinion.
May be considered
 
   Class IIa
Weight of evidence/opinion is in favour of usefulness/eﬃcacy. 
Should be considered
Class II 
© ESC 2023
Table 2 Levels of evidence
Level of evidence A
Level of evidence B
Level of evidence C
Data derived from multiple randomized clinical trials or meta-analyses.
Data derived from a single randomized clinical trial or large non-randomized studies.
Consensus of opinion of the experts and/or small studies,
retrospective studies, registries.
©ESC 2023
© ESC 2023


<!-- PAGE 9 -->

### Page 9

entire financial support from the ESC without any involvement from 
the healthcare industry.
The ESC Clinical Practice Guidelines (CPG) Committee supervises 
and co-ordinates the preparation of new guidelines and is responsible 
for the approval process. ESC Guidelines undergo extensive review 
by the CPG Committee and external experts, including members 
from across the whole of the ESC region and from relevant ESC 
Subspecialty Communities and National Cardiac Societies. After appro­
priate revisions, the guidelines are signed off by all the experts involved 
in the Task Force. The finalized document is signed off by the CPG 
Committee for publication in the European Heart Journal. The guidelines 
were developed after careful consideration of the scientific and medical 
knowledge and the evidence available at the time of their writing. Tables 
of evidence summarizing the findings of studies informing development 
of the guidelines are included. The ESC warns readers that the technical 
language may be misinterpreted and declines any responsibility in this 
respect.
Off-label use of medication may be presented in this guideline if a suf­
ficient level of evidence shows that it can be considered medically ap­
propriate for a given condition.
However, the final decisions concerning an individual patient must be 
made by the responsible health professional giving special consideration 
to: 
• The specific situation of the patient. Unless otherwise provided for 
by national regulations, off-label use of medication should be limited 
to situations where it is in the patient’s interest, with regard to the 
quality, safety, and efficacy of care, and only after the patient has 
been informed and has provided consent.
• Country-specific health regulations, indications by governmental 
drug regulatory agencies, and the ethical rules to which health profes­
sionals are subject, where applicable.
2. Introduction
The objective of this European Society of Cardiology (ESC) Guideline is 
to help healthcare professionals diagnose and manage patients with car­
diomyopathies according to the best available evidence. Uniquely for 
relatively common cardiovascular diseases, there are very few rando­
mized controlled clinical trials in patients with cardiomyopathies. For 
this reason, the majority of the recommendations in this guideline are 
based on observational cohort studies and expert consensus opinion. 
The aim is to provide healthcare professionals with a practical diagnos­
tic and treatment framework for patients of all ages and, as an increasing 
number of patients have a known genetic basis for their disease, the 
guideline also considers the implications of a diagnosis for families 
and provides advice on reproduction and contraception. As cardio­
myopathies can present at any age and can affect individuals and families 
across the entire life course, this guideline follows the principle of con­
sidering cardiomyopathies in all age groups as single disease entities, 
with recommendations applicable to children and adults with cardio­
myopathy throughout, while accepting that the evidence base for 
many of the recommendations is significantly more limited for children. 
Age-related differences are specifically highlighted.
This is a new guideline, not an update of existing guidelines, with the 
exception of the section on hypertrophic cardiomyopathy (HCM), in 
which we have provided a focused update to the 2014 ESC Guidelines 
on diagnosis and management of hypertrophic cardiomyopathy.1 As such, 
most of the recommendations in this guideline are new. It is beyond 
the scope of this guideline to provide detailed descriptions and 
recommendations for each individual cardiomyopathy phenotype; in­
stead, the aim is to provide a guide to the diagnostic approach to car­
diomyopathies, highlight general evaluation and management issues, 
and signpost the reader to the relevant evidence base for the 
recommendations.
Adoption of morphological and functional disease definitions means 
that the number of possible aetiologies is considerable, particularly in 
young children. As it is impractical to provide an exhaustive compen­
dium of all possible causes of cardiomyopathy, the guideline focuses 
on the most common disease phenotypes, but additional references 
for less common disorders are also provided. Similarly, treatment re­
commendations focus largely on generic management issues but refer 
to specific rare diseases when appropriate. The central illustration 
(Figure 1) highlights key aspects in the evaluation and management of 
cardiomyopathies addressed in this guideline.
This is the first major international guideline to address cardiomyop­
athies other than HCM. Other major innovations include: 
• A new phenotypic description of cardiomyopathies, including up­
dated descriptions of dilated and non-dilated left ventricular (LV) car­
diomyopathy phenotypes, and highlighting the key role of ventricular 
myocardial scar assessment using cardiac magnetic resonance (CMR) 
imaging.
• A focus on the patient pathway, from presentation, through initial as­
sessment and diagnosis, to management, highlighting the importance 
of considering cardiomyopathy as a cause of common clinical presen­
tations (e.g. heart failure, arrhythmia) and the importance of utilizing a 
multiparametric approach following the identification of the present­
ing phenotype to arrive at an aetiological diagnosis.
• Updated recommendations for clinical and genetic cascade screening 
for relatives of individuals with cardiomyopathies.
• A focus on cardiomyopathies across the life course, from paediatric 
to adult age (including transition), and considering the different clin­
ical phases (e.g. concealed, overt, end stage).
• New recommendations on sudden cardiac death (SCD) risk stratifi­
cation for different cardiomyopathy phenotypes, including in child­
hood, and highlighting the important role of genotype in the 
assessment of sudden death risk.
• Updated recommendations for the management of left ventricular 
outflow tract obstruction (LVOTO) in HCM.
• A multidisciplinary approach to cardiomyopathies that has the pa­
tient and their family at its heart.
3. Phenotypic approach to 
cardiomyopathies
In medicine, classification systems are used to standardize disease no­
menclature by grouping disorders according to shared characteristics. 
In 2008, the ESC promoted a pragmatic system for the clinical descrip­
tion of cardiomyopathies in which a historical focus on ventricular 
morphology and function was maintained, while signposting aetiological 
diversity through subdivision into genetic and non-genetic subtypes.2
Since then, knowledge of cardiomyopathies has increased substantially 
through the application of new imaging and molecular technologies.
In this guideline, the Task Force took a number of considerations into 
account when deciding its approach to disease description. These in­
cluded: (i) a historical legacy which, while still useful, has led to contra­
dictory and confusing terminology in many situations; (ii) the evolving 
nature of cardiomyopathies over a lifetime; (iii) aetiological complexity 
with multiple disease processes contributing to disease phenotypes;
ESC Guidelines                                                                                                                                                                                          3511


<!-- PAGE 10 -->

### Page 10

Symptoms
Ventricular morphology/
function
Ventricular scar and tissue characterization
Pedigree analysis
Genetic testing
HCM
DCM
NDLVC
ARVC
RCM
Extracardiac involvement
Laboratory markers
Pathology
Incidental findings
Family screening
Phenotypespecific management
General management principles
LVOTO management
SCD risk prediction
GDMT for HF symptoms
Aetiology-specific SCD
risk prediction
Antiarrhythmic therapy
SCD risk prediction
GDMT for HF symptoms
PVR study to guide timing of transplantation
Drug therapy
Mechanical circulatory 
support/transplantation
Symptom management
Genetic testing and counselling
Family screening and monitoring
Family screening and genetic risk to relatives
Exercise recommendations
Pregnancy
School, employment,
psychological support
Lifestyle
Prevention of diseaserelated complications
SCD
Stroke thromboembolic prophylaxis
ICD
Clinical scenario
Morphological/functional characterization
Phenotype
Additional traits
4
5
6
1
2
3
GDMT for HF symptoms
Aetiology-specific SCD
risk prediction
Arrhythmias/conduction disease
Arrhythmias/conduction disease
Figure 1 Central illustration. Key aspects in the evaluation and management of cardiomyopathies. ARVC, arrhythmogenic right ventricular cardiomyop­
athy; CMR, cardiac magnetic resonance; DCM, dilated cardiomyopathy; GDMT, guideline-directed medical therapy; HCM, hypertrophic cardiomyopathy; HF, 
heart failure ICD, implantable cardioverter defibrillator; LVOTO, left ventricular outflow tract obstruction; MCS, mechanical circulatory support; NDLVC, 
non-dilated left ventricular cardiomyopathy; PVR, pulmonary vascular resistance; RCM, restrictive cardiomyopathy; SCD, sudden cardiac death.Image %:


<!-- PAGE 11 -->

### Page 11

(iv) differential disease expression in families; and (v) emerging 
aetiology-focused therapies.
The Task Force concluded that a single classification system that em­
braces all possible causes of disease and every clinical scenario remains 
an aspiration that is outside the scope of this clinical guideline. Instead, 
the Task Force updated the existing clinical classification to include new 
phenotypic descriptions and to simplify terminology, while simultan­
eously providing a conceptual framework for diagnosis and treatment. 
This nomenclature prompts clinicians to consider cardiomyopathy as 
the cause of several clinical presentations (e.g. arrhythmia, heart failure), 
and focuses on morphological and functional characteristics of the 
myocardium (Figure 2). It is important to recognize that different 
Suspected cardiomyopathy
Ventricular morphology/function
Hypertrophy
Dilatation
Systolic/diastolic function
Ventricular scar/fatty replacement
Non-ischaemic ventricular scar on
CMR/pathological examination
Other tissue characterization parameters on CMR
Symptoms
Incidental findings
Family screening
Dyspnoea
Chest pain
Palpitation
Syncope/presyncope
Cardiac arrest
1st degree relative with CMP
Family history of sudden death
Abnormal ECG
Murmur
Arrhythmia
Clinical scenario
Arrhythmias/conduction disease
(atrial, ventricular, atrioventricular block)
Pedigree analysis
Laboratory markers
Pathology
Genetic testing
Extracardiac involvement
Phenotype-based integrated aetiological diagnosis
Phenotype
HCM
DCM
ARVC
RCM
NDLVC
Morphological/
functional characterization
Additional traits
Figure 2 Clinical diagnostic workflow of cardiomyopathy. ARVC, arrhythmogenic right ventricular cardiomyopathy; CMP, cardiomyopathy; CMR, cardiac 
magnetic resonance; DCM, dilated cardiomyopathy; ECG, electrocardiogram; HCM, hypertrophic cardiomyopathy; NDLVC, non-dilated left ventricular car­
diomyopathy; RCM, restrictive cardiomyopathy.
ESC Guidelines                                                                                                                                                                                          3513


<!-- PAGE 12 -->

### Page 12

cardiomyopathy phenotypes may coexist in the same family, and that 
disease progression in an individual patient can include evolution 
from one cardiomyopathy phenotype to another. Nevertheless, the 
Task Force recommends an approach to disease nomenclature and 
diagnosis that is based on the predominant cardiac phenotype at 
presentation.
While recognizing the fact that genes encoding cardiac ion channels 
may be implicated in some patients with dilated cardiomyopathy 
(DCM), conduction disorders, and arrhythmias, the Task Force was 
not persuaded that there is sufficient evidence to consider cardiac chan­
nelopathies as cardiomyopathies, in keeping with the approach taken by 
other recent ESC Guidelines.3
The most important changes in this guideline relate to the group of 
conditions variously included under the umbrella term ‘arrhythmogenic 
cardiomyopathies’. This term refers to a group of conditions that fea­
ture structural and functional abnormalities of the myocardium (identi­
fied by cardiac imaging and/or macroscopic and microscopic 
pathological investigation) and ventricular arrhythmia. This nosology 
has evolved in response to the recognition of the clinical and genetic 
overlap between right ventricular (RV) and LV cardiomyopathies, but 
a lack of a generally accepted definition has meant that the term encom­
passes a broad range of diverse pathologies and has introduced a num­
ber of inconsistencies and contradictions when applied in a clinical 
setting.4 The term ‘arrhythmogenic right ventricular (dysplasia/) cardio­
myopathy’ (ARVC) was originally used by physicians who first discov­
ered the disease, in the pre-genetic and pre-CMR era, to describe a 
new heart muscle disease predominantly affecting the right ventricle, 
whose cardinal clinical manifestation was the occurrence of malignant 
ventricular arrhythmias. Subsequently, autopsy investigations, geno­
type–phenotype correlation studies and the increasing use of 
contrast-enhancement CMR led to the identification of fibro-fatty re­
placement of the myocardium as a key phenotypic feature of the dis­
ease that affects the myocardium of both ventricles, with LV 
involvement which may even exceed the severity of RV involvement. 
This has led to the catch-all term of arrhythmogenic cardiomyopathy 
(ACM), which represents the evolution of the original term of 
ARVC.5 Consistent with its general approach, the Task Force agreed 
to highlight the vital importance of arrhythmia as a diagnostic red flag 
and prognostic marker across a range of clinical phenotypes, but did 
not recommend the use of the term ACM as a distinct cardiomyopathy 
subtype as it lacks a morphological or functional definition consistent 
with the existing classification scheme. While acknowledging that 
‘ACM’ as an umbrella term that encompasses diverse clinical pheno­
types has been previously used, this decision will, it is hoped, help to re­
solve many of the circular arguments that currently bedevil the field. 
The fundamental tenet throughout this guideline is that aetiology is vital 
to the management of patients with heart muscle disease and that a 
careful and consistent description of the morphological and functional 
phenotype is a crucial first step in the diagnostic pathway, while the final 
diagnosis will ideally describe aetiology alongside the phenotype.6,7
3.1. Definitions
A cardiomyopathy is defined as ‘a myocardial disorder in which the 
heart muscle is structurally and functionally abnormal, in the absence 
of coronary artery disease (CAD), hypertension, valvular disease, and 
congenital heart disease (CHD) sufficient to cause the observed myo­
cardial abnormality’.2 This definition applies to both children and 
adults and makes no a priori assumptions about aetiology (which 
can be familial/genetic or acquired) or myocardial pathology. While 
the focus of this guideline is on genetic cardiomyopathies, the system­
atic approach to diagnosis starting from the phenotype at presenta­
tion described in this guideline enables clinicians to reach precise 
diagnoses that may also include non-genetic (e.g. inflammatory, toxic, 
and multisystem diseases) causes. It is important to note that cardio­
myopathies can coexist with ischaemic, valvular, and hypertensive dis­
ease and that the presence of one does not exclude the possibility of 
the other.
The morphological and functional traits used to describe the cardio­
myopathy phenotypes are shown in Table 3. The major innovation is 
the specific inclusion of myocardial tissue characterization traits, includ­
ing non-ischaemic ventricular scarring or fatty replacement, which can 
occur with and without ventricular dilatation, wall motion abnormal­
ities, or global systolic or diastolic dysfunction. This phenotype is im­
portant to recognize, as it may be the sole clue to the diagnosis of a 
cardiomyopathy and has prognostic significance that varies with the 
underlying aetiology.
Atrial dilatation (left and/or right) is an important additional clinical 
finding in the phenotypic description of cardiomyopathies. Ultra-rare, 
usually autosomal recessive, cases of pure dilated atrial cardiomyopathy 
are reported,8 but these are outside the scope of this guideline.
3.2. Cardiomyopathy phenotypes
3.2.1. Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is defined as the presence of in­
creased LV wall thickness (with or without RV hypertrophy) or mass 
that is not solely explained by abnormal loading conditions.2
3.2.2. Dilated cardiomyopathy
Dilated cardiomyopathy (DCM) is defined as the presence of LV dilata­
tion and global or regional systolic dysfunction unexplained solely by ab­
normal loading conditions (e.g. hypertension, valve disease, CHD) or 
CAD.2 Very rarely, LV dilatation can occur with normal ejection frac­
tion (EF) in the absence of athletic remodelling or other environmental 
factors; this is not in itself a cardiomyopathy, but may represent an early 
manifestation of DCM. The preferred term for this is isolated left ven­
tricular dilatation.
Right ventricular dilatation and dysfunction may be present but are 
not necessary for the diagnosis. When dilatation or wall motion abnor­
malities are confined or predominant to the right ventricle, the possibil­
ity of ARVC should be considered (see Section 3.2.4).
3.2.3. Non-dilated left ventricular cardiomyopathy
Hitherto, the definition of DCM had a number of important limita­
tions, most notably the exclusion of genetic and acquired disorders
Table 3 Morphological and functional traits used to de­
scribe cardiomyopathy phenotypes
Morphological traits
Ventricular hypertrophy: left and/or right
Ventricular dilatation: left and/or right
Non-ischaemic ventricular scar and other myocardial tissue 
characterization features on cardiac magnetic resonance
Functional traits
Ventricular systolic dysfunction (global, regional)
Ventricular diastolic dysfunction (restrictive physiology)
© ESC 2023


<!-- PAGE 13 -->

### Page 13

that manifest as intermediate phenotypes that do not meet standard 
disease definitions in spite of the presence of myocardial disease on 
cardiac imaging or tissue analysis. In a previous ESC statement, this 
phenomenon inspired the creation of a new disease category, hypo­
kinetic non-dilated cardiomyopathy.9 In this guideline, we propose 
replacement of this term with non-dilated left ventricular cardiomy­
opathy (NDLVC), which can be further characterized by the pres­
ence or absence of systolic dysfunction (regional or global). 
Isolated LV dysfunction (regional or global) without scarring should 
also be considered under this diagnostic category. The NDLVC 
phenotype is defined as the presence of non-ischaemic LV scarring 
or fatty replacement regardless of the presence of global or regional 
wall motion abnormalities (RWMAs), or isolated global LV hypokine­
sia without scarring.
The NDLVC phenotype will include individuals that up until now may 
have variably been described as having DCM (but without LV dilata­
tion), arrhythmogenic left ventricular cardiomyopathy (ALVC), left- 
dominant ARVC, or arrhythmogenic DCM (but often without fulfilling 
diagnostic criteria for ARVC) (Figure 3). The simple worked example 
(Figure 4) shows how the identification of an NDLVC phenotype should 
trigger a multiparametric approach that leads to a specific aetiological 
diagnosis, with implications for clinical treatment.
DSP
LMNA
PLN
BAG3
FLNC
LMNA
TTN
BAG3 (no LGE)
RBM20
LMNA (no LGE)
Myocarditis
DMD
Figure 3 Examples of non-dilated left ventricular cardiomyopathy phenotypes and their aetiological correlates. BAG3, BAG cochaperone-3; DMD, 
Duchenne muscular dystrophy; DSP, desmoplakin; FLNC, filamin C; LGE, late gadolinium enhancement; LMNA, lamin A/C; NDLVC, non-dilated left ven­
tricular cardiomyopathy; PLN, phospholamban; RBM20, RNA binding motif protein 20; TTN, titin. Distribution of LGE (arrowheads) in NDLVC and aetio­
logical correlates. Desmoplakin (DSP), filamin C (FLNC) and phospholamban (PLN) genotypes show a characteristic subepicardial, ring-like LGE pattern, 
whereas titin (TTN), BAG3 (BAG3), lamin A/C (LMNA), DMD, RBM20 genotypes and myocarditis are more heterogeneous, but with overall less scar (some­
times without) and lower left ventricular ejection fraction.
ESC Guidelines                                                                                                                                                                                          3515


<!-- PAGE 14 -->

### Page 14

3.2.4. Arrhythmogenic right ventricular 
cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is 
defined as the presence of predominantly RV dilatation and/or dys­
function in the presence of histological involvement and/or 
electrocardiographic abnormalities in accordance with published 
criteria.10
For decades, ARVC has been one of the principal cardiomyopathy 
subtypes. It has been defined in accordance with published consensus 
criteria that comprise RV dysfunction (global or regional), histological 
abnormalities in the form of fibro-fatty replacement of cardiomyocytes, 
electrocardiographic characteristics, ventricular arrhythmia of RV ori­
gin, and the presence of familial disease and/or pathogenic variants in 
desmosomal protein genes.
Over time, the clinical paradigm of ARVC has moved from a focus on 
severe RV disease and malignant ventricular arrhythmia to a broader 
concept that includes concealed or subclinical phenotypes and biventri­
cular or even left-dominant disease. This has led to a plethora of new 
terms, including ‘arrhythmogenic left ventricular cardiomyopathy 
(ALVC)’, ‘left and right dominant cardiomyopathy’, ‘arrhythmogenic di­
lated cardiomyopathy’, and most recently, the catch-all term ‘arrhyth­
mogenic cardiomyopathy’. The term ARVC can be used to describe 
the original variant in which ventricular dilatation or wall motion abnor­
malities are predominantly confined to the right ventricle, with or with­
out LV involvement, and the 2010 modified Task Force criteria for the 
diagnosis of ARVC can be applied.10 Predominant LV disease can also 
occur in the same family;5 see Section 7.3 for recommendations on as­
sessment and management of this phenotype.
Previous classification
17 y/o male; palpitation
Family history SCD
Normal physical examination
DCM
ALVC
ACM
DSP Trp180*
Non-dilated LV
EF 55%
Subepicardial scar
Sinus rhythm, minor intraventricular conduction delay 
200 VEs, few couplets
Clinical presentation
Cardiac morphology/
function
ECG/
arrhythmia
Genetics
Diagnostic pathway
Proposed phenotypebased integrated approach
Autosomal dominant 
DSP-related non-dilated LV 
cardiomyopathy phenotype 
with subepicardial scar and low-normal EF
Figure 4 Worked example of the non-dilated left ventricular cardiomyopathy phenotype. ACM, arrhythmogenic cardiomyopathy; ALVC, arrhythmogenic 
left ventricular cardiomyopathy; DCM, dilated cardiomyopathy; DSP, desmoplakin; ECG, electrocardiogram; EF, ejection fraction; LV, left ventricular; 
NDLVC, non-dilated left ventricular cardiomyopathy; SCD, sudden cardiac death; VE, ventricular extrasystole. Worked example of the NDLVC phenotype 
showing how a systematic multiparametric approach to clinical phenotyping, starting from the recognition of a clinical phenotype and integrating extended 
phenotypic information and targeted diagnostics, including genetic testing, can be used to arrive at highly specific phenotypic descriptions that can result in 
personalized treatment plans. In this worked example, the diagnosis transforms from a simplistic categorization to a complex genetic disorder characterized 
by myocardial scar and a propensity to ventricular arrhythmia.


<!-- PAGE 15 -->

### Page 15

3.2.5. Restrictive cardiomyopathy
Restrictive cardiomyopathy (RCM) is defined as restrictive left and/or 
RV pathophysiology in the presence of normal or reduced diastolic vo­
lumes (of one or both ventricles), normal or reduced systolic volumes, 
and normal ventricular wall thickness.2
Restrictive cardiomyopathy commonly presents as biatrial enlarge­
ment. Left ventricular systolic function can be preserved, but it is rare 
for contractility to be completely normal. Restrictive pathophysiology 
may not be present throughout the natural history, but only at an initial 
stage (with an evolution towards a hypokinetic-dilated phase).11
Restrictive physiology can also occur in patients with end-stage hyper­
trophic and dilated cardiomyopathy; the preferred terms are ‘hyper­
trophic’ or ‘dilated cardiomyopathy with restrictive physiology’. 
Restrictive ventricular physiology can also be caused by endocardial 
pathology (fibrosis, fibroelastosis, and thrombosis) that impairs diastolic 
function.
3.3. Other traits and syndromes associated 
with cardiomyopathy phenotypes
3.3.1. Left ventricular hypertrabeculation (left 
ventricular non-compaction)
The term ‘left ventricular non-compaction’ (LVNC) has been used to 
describe a ventricular phenotype characterized by prominent LV tra­
beculae and deep intertrabecular recesses. The myocardial wall is often 
thickened with a thin, compacted epicardial layer and a thicker endocar­
dial layer. In some patients, this abnormal trabecular architecture is as­
sociated with LV dilatation and systolic dysfunction. Left ventricular 
non-compaction is frequently a familial trait and is associated with var­
iants in a range of genes, including those encoding proteins of the sarco­
mere, Z-disc, cytoskeleton, and nuclear envelope.12–16
Left ventricular non-compaction has also been used to describe an 
acquired and sometimes transient phenomenon of excessive LV trabe­
culation (e.g. in athletes, during pregnancy, or following vigorous activ­
ity)17–19 that must reflect increased prominence of an otherwise 
normal myocardial architecture, given that cardiomyocytes are termin­
ally differentiated and the formation of new cardiac structures is 
impossible.20
The Task Force does not consider LVNC to be a cardiomyopathy in 
the general sense. Instead, it is seen as a phenotypic trait that can occur 
either in isolation or in association with other developmental abnormal­
ities, ventricular hypertrophy, dilatation, and/or systolic dysfunction. 
Given the lack of morphometric evidence for ventricular compaction 
in humans,21,22 the term ‘hypertrabeculation’, rather than LVNC, is re­
commended, particularly when the phenomenon is transient or clearly 
of adult onset.
3.3.2. Takotsubo syndrome
Transient LV apical ballooning syndrome, or takotsubo syndrome, is 
characterized, in its most typical variant, by transient regional systolic 
dysfunction, dilatation, and oedema involving the LV apex and/or mid- 
ventricle in the absence of obstructive coronary disease on coronary 
angiography.23 Patients present with an abrupt onset of angina-like 
chest pain and have diffuse T wave inversion (TWI), sometimes pre­
ceded by ST-segment elevation and mild cardiac enzyme elevation. 
Most reported cases occur in post-menopausal women. Symptoms 
are often preceded by emotional or physical stress. Norepinephrine 
concentration is elevated in most patients and a transient, dynamic out­
flow tract pressure gradient is reported in some cases. Left ventricular 
function usually normalizes over a period of days to weeks, and recur­
rence is rare. The same kind of reversible myocardial dysfunction is oc­
casionally encountered in patients with intracranial haemorrhage or 
other acute cerebral accidents (neurogenic myocardial stunning).
Takotsubo syndrome is sometimes referred to as takotsubo or 
stress cardiomyopathy. Given the transient nature of the phenomenon, 
the Task Force does not recommend its classification as a 
cardiomyopathy.
4. Epidemiology
Cardiomyopathies have a variable expression throughout life.24
Geographical distribution of genetic variants influences estimated 
prevalence in different populations, ethnicities, regions, and countries. 
The complexity of diagnostic criteria for some conditions, such as 
ARVC, limits the evaluation of the true prevalence of the disease in 
the general population. Moreover, epidemiological data are often not 
collected systematically at population level. For example, the preva­
lence of idiopathic DCM has been recently estimated to be almost 
10 times higher based on several population-based estimates and indir­
ect assumptions of the prevalence of genetic variants associated with 
the disease in general populations,25 and with less stringent diagnostic 
criteria.9
There are no specific data on the epidemiology of the NDLVC 
phenotype, but patients affected by it have previously been included 
in DCM or ARVC cohorts, from which extrapolations may be pos­
sible. Contemporary epidemiological metrics for the main cardiomy­
opathies are shown in Table 4. Further details on the epidemiology of 
cardiomyopathies can be found in the Supplementary data online, 
Section 1.
Table 4 Key epidemiological metrics in adults and 
children for the different cardiomyopathy phenotypes
Cardiomyopathy 
phenotype
Adults
Children
HCM
Prevalence: 
0.2%26–33
Childhood incidence: 
0.002–0.005%34–36
Childhood prevalence: 
0.029%36
DCM
Prevalence:  
0.036–0.400%25,37
Childhood incidence: 
0.003–0.006% 
Childhood prevalence: 
0.026%36
Infantile incidence: 
0.038–0.046%34–36,38
NDLVC
To be determined
To be determined
ARVC
Prevalence: 
0.078%39–41
Very rare in infancy and 
early childhood; to be 
determined in older 
children and adolescents
RCM
Rare
Childhood incidence: 
0.0003%34
© ESC 2023
ARVC, arrhythmogenic right ventricular cardiomyopathy; DCM, dilated cardiomyopathy; 
HCM, 
hypertrophic 
cardiomyopathy; 
NDLVC, 
non-dilated 
left 
ventricular 
cardiomyopathy; RCM, restrictive cardiomyopathy.
ESC Guidelines                                                                                                                                                                                          3517


<!-- PAGE 16 -->

### Page 16

4.1. Special populations
Several forms of cardiomyopathy previously considered secondary to 
external factors were recently proved to have genetic contributors, 
leading to the ‘second hit theory’, and a genetic aetiology should be 
kept in mind for family history taking and genetic testing. 
• Titin gene truncating variants (TTNtv) represent a prevalent genetic 
predisposition for alcoholic cardiomyopathy (present in 13.5% of pa­
tients vs. 2.9% in controls), as they are associated with a worse left 
ventricular ejection fraction (LVEF) in DCM patients who consume 
alcohol above recommended levels.42
• Unrecognized rare variants in cardiomyopathy-associated genes, par­
ticularly TTNtv (in 7.5% of cases), appear to be associated with an in­
creased risk of cancer therapy-induced cardiomyopathy in children 
and adults.43
• Rare truncating variants in eight genes are found in 15% of women 
with peripartum cardiomyopathy (PPCM), and two-thirds are 
TTNtv (10% of patients vs. 1.4% of the reference population).44,45
Additionally, other truncating variants are identified in the DSP 
(1%), FLNC (1%), and BAG3 (0.2%) genes.45
• Anderson–Fabry disease is found in 0.94% of males and 0.90% of fe­
males in cardiac screening programmes for left ventricular hyper­
trophy (LVH) in selected populations and HCM.46
• Screening with bone scintigraphy found a high prevalence of trans­
thyretin cardiac amyloidosis (ATTR-CA) in specific populations: 8% 
in severe aortic stenosis, 12% in heart failure with preserved ejection 
fraction (HFpEF) with LVH, 7% in LVH/HCM depending on the age, 
and 7% in carpal tunnel syndrome undergoing surgery (a higher 
prevalence if it is bilateral), mainly for the wild-type form.47,48
• Disease-causing variants in genes implicated in DCM, NDLVC, and 
ARVC have been identified in 8–22% of adults and children present­
ing with acute myocarditis.49–51 Individuals with an acute myocarditis 
presentation and desmosomal protein gene variants were shown to 
have a higher rate of myocarditis recurrence and ventricular arrhyth­
mia compared with myocarditis patients without a desmosomal vari­
ant identified.52
5. Integrated patient management
The diagnosis, assessment, and management of patients with cardiomy­
opathy requires a co-ordinated, systematic, and individualized pathway 
that delivers optimized care by a multidisciplinary and expert team. 
Central to this approach is not only the individual patient, but also 
the family as a whole; clinical findings in relatives are essential for under­
standing what happens to the patient, and vice versa.53,54
5.1. Multidisciplinary cardiomyopathy 
teams
Healthcare professionals encounter diseases affecting the myocardium 
in many and varied clinical settings. Some may manifest for the first time 
with an acute event, including sudden unexplained death, whereas 
others present with progressive symptoms or are detected incidentally. 
Patients with cardiomyopathy can also have extracardiac manifesta­
tions (e.g. neurological, neuromuscular, ophthalmological, nephrologic­
al). Patient care requires the collaboration of different specialties.55 The 
composition of the multidisciplinary team will depend on the patient’s 
and family’s needs and the local availability of services (Figure 5). Patients 
with complex needs benefit from a multidisciplinary team, including 
relevant specialties as well as the general cardiologist, general practi­
tioner, and the family/carer. In addition, the integration of genetics 
into mainstream cardiology services requires expertise from different 
specialties: 
• Adult and paediatric cardiologists subspecialized in cardiogenetic 
conditions.
• Cardiac imaging specialists (technicians, cardiologists, radiologists), in­
cluding CMR experts.
• Specialist nurses and/or genetic counsellors with skills in family his­
tory taking, drawing pedigrees, and patient/family management, par­
ticularly when the number of disciplines or the complexity implicated 
in a patient’s/family’s care increases.
• Clinical psychologists to support patients and their relatives.
• Geneticists and bioinformaticians to interpret results of genetic 
investigations.
• Expert pathologists to interpret findings by endomyocardial biopsy 
(EMB) and autopsy of individuals dying from a suspected inherited 
cardiac condition. Specialist cardiovascular pathology centres play a 
crucial role in the autopsy diagnosis of cardiomyopathy when local 
expertise is not available.56,57
Finally, patients’ associations should be promoted and integrated into 
the healthcare process for rare and very rare cardiac conditions.
One particularly important aspect of the multidisciplinary approach 
to patient care in cardiomyopathies is the need for appropriate transi­
tion of care from paediatric to adult services. Children with a genetic 
cardiomyopathy generally need lifelong cardiac follow-up. The transi­
tion to adulthood, including the transfer of care to adult cardiomyop­
athy services, can be challenging for both the child and the parents. 
The process of transition should include adequate and timely prepar­
ation and joint consultations, taking into consideration the child’s 
wishes, and level of understanding and independence at different life 
stages. Evidence from the field of CHD highlights the importance of 
specific interventions that can help the process of transition of clinical 
care, including adequate and timely preparation for transition and joint 
consultations.58,59
5.2. Co-ordination between different 
levels of care
A shared care approach between cardiomyopathy specialists and gen­
eral adult and paediatric cardiology centres is strongly recommended. 
While referral cardiomyopathy units are essential for complex cases 
with diagnostic and/or treatment difficulties that require expertise 
that may only be available in high-volume centres, general adult and 
paediatric cardiologists have a key role to play in the diagnosis, manage­
ment, and follow-up of patients with cardiomyopathy (see Section 9). A 
shared approach between cardiomyopathy units and between general 
cardiologist/paediatric cardiologist is strongly recommended. This ap­
proach can be facilitated by the implementation of telemedical contact 
between units and the use of remote monitoring with patients.60 The 
creation of local/regional/national/international networks, such as the 
European Reference Network for Rare and Low Prevalence 
Complex Diseases of the Heart (ERN GUARD-Heart) (https:// 
guardheart.ern-net.eu) allows clinicians and health professionals to 
share information about these pathologies, for the benefit of cardiomy­
opathy patients.61


<!-- PAGE 17 -->

### Page 17

### 6 The patient pathway

The diagnosis of cardiomyopathy rests on the identification of struc­
tural and/or functional myocardial abnormalities, including myocardial 
fibrosis, that are not explained solely by abnormal loading conditions 
or CAD. However, disease phenotypes can also include arrhythmic 
and electrocardiographic manifestations, morphological abnormalities 
of the cardiac valves, and abnormal coronary microcirculatory function. 
As a key theme throughout this guideline, the Task Force highlights the 
importance of using a systematic approach to the identification and as­
sessment of patients with a suspected cardiomyopathy. Central to this 
is the need for clinicians to consider a diagnosis of cardiomyopathy as 
the cause of several common adult and paediatric clinical presentations. 
The identification of a cardiomyopathy phenotype is only the beginning 
of the diagnostic process and should prompt a systematic search for the 
underlying aetiology, which may be genetic or acquired.
Cardiologist with cardiomyopathy expertise
Paediatric cardiologist with cardiomyopathy expertise
Specialist nurse
Cardiac genetic counsellor
Heart failure team
Arrhythmia team
Cardiac imaging team
Interventional cardiologist team
Cardiologist with expertise in sports cardiology
Geneticist
Family/carer(s)
Psychologist
Patient associations
Patient support
Cardiomyopathy specialists
Other related specialtiesa
Other related cardiology experts
Pathologist
Other: cardiac surgeon, primary care physician, paediatrician, internist,
nephrologist, neurologist,
dermatologist, endocrinologist,
ophthalmologist, pharmacist,
rheumatologist etc.
Figure 5 Multidisciplinary care of cardiomyopathies. aThe list presented is not exhaustive and represents examples of specialties that often interact in the 
care of cardiomyopathy patients.Image %:   
Recommendation Table 1 — Recommendations for the 
provision of service of multidisciplinary cardiomyopathy 
teams
Recommendations
Classa
Levelb
It is recommended that all patients with 
cardiomyopathy and their relatives have access to 
multidisciplinary teams with expertise in the 
diagnosis and management of cardiomyopathies.
I
C
Timely and adequate preparation for transition of 
care from paediatric to adult services, including joint 
consultations, is recommended in all adolescents 
with cardiomyopathy.58,59
I
C
© ESC 2023
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3519


<!-- PAGE 18 -->

### Page 18

6.1. Clinical presentation
Patients with cardiomyopathy may access health services through sev­
eral pathways. Referral from primary care (e.g. general practitioners 
and general paediatricians) may be triggered by symptoms (most 
commonly dyspnoea, chest pain, palpitation, syncope) or incidental 
findings (e.g. an abnormal electrocardiogram [ECG] in the context of 
community, school, work-related medical check-ups, or sports pre- 
participation screening; the incidental detection of a murmur; or, in­
creasingly, genotype-first identification as a result of secondary findings 
during research or clinical sequencing for other indications). In second­
ary and tertiary care (general cardiology and paediatric cardiology), pa­
tients with cardiomyopathy may present to the heart failure clinic with 
symptoms of heart failure with reduced ejection fraction (HFrEF), mild­
ly reduced ejection fraction (HFmrEF), or preserved ejection fraction 
(HFpEF); to the arrhythmia clinic with early-onset conduction disease, 
atrial arrhythmia, or ventricular arrhythmia; or to the emergency de­
partment with suspected myocarditis. Frequently, patients enter the 
cardiomyopathy pathway in primary, secondary, or tertiary care as a re­
sult of family screening following the diagnosis of cardiomyopathy or a 
sudden death in a relative, and may also be identified as part of the 
work-up for multiorgan disease known to be associated with cardiovas­
cular involvement. Clinicians in all these settings therefore need to con­
sider the possibility of cardiomyopathy as a cause and use a systematic, 
cardiomyopathy-oriented approach to clinical evaluation.
6.2. Initial work-up
The cardiomyopathy-oriented approach is based on interpreting clinic­
al and instrumental findings to suspect and ultimately generate a 
phenotype-based aetiological diagnosis to guide disease-specific man­
agement.62 This approach requires deliberate analysis of multipara­
metric investigations in the individual and their relatives and an 
integrated probabilistic analysis of clinical investigations. Re-analysis of 
clinical data is required as new information emerges, and family infor­
mation can provide important clues to the diagnosis, given the variable 
expression and incomplete penetrance of most cardiomyopathies, and 
can result in differences in diagnostic criteria between probands and re­
latives. In this context, relatives of individuals with cardiomyopathy can 
have non-diagnostic morphological and electrocardiographic abnor­
malities that can indicate mild and early phenotypic expression of dis­
ease and can increase diagnostic accuracy for predicting disease in 
genotyped populations. The identification of diagnostic clues, or red 
flags, is a crucial aspect of the initial work-up.
6.3. Systematic approach to diagnosis of 
cardiomyopathy
A multiparametric approach to the evaluation of patients with sus­
pected cardiomyopathy is recommended, with the aims of: (i) establish­
ing and characterizing the presence of a cardiomyopathy phenotype; 
and (ii) identifying the underlying aetiological diagnosis.62 Clinicians 
should approach a patient with suspected cardiomyopathy using a ‘car­
diomyopathy mindset’ (Figure 2): 
• Use multimodality imaging to characterize the phenotype and iden­
tify abnormal ventricular morphology (e.g. hypertrophy, dilatation) 
and function (systolic/diastolic, global/regional), and detect abnormal­
ities of tissue characterization (e.g. non-ischaemic myocardial scar 
and fatty replacement).
• Use a combination of personal and family history, clinical examin­
ation, electrocardiography, and laboratory investigations to achieve 
an aetiological diagnosis, looking for specific signs and symptoms 
and laboratory markers suggestive of a specific diagnosis; the pres­
ence of ventricular and atrial arrhythmia and conduction disease to 
aid diagnosis, suggest specific causes, and monitor disease progres­
sion and risk stratification; and clues from the pedigree to suggest 
specific inheritance patterns and identify at-risk relatives. This ap­
proach should result in a timely and accurate diagnosis to enable early 
treatment of symptoms and prevention of disease-related 
complications.
6.4. History and physical examination
Age is one of the most important factors to take into account when 
considering the possible causes of cardiomyopathy. For example, inher­
ited metabolic disorders and congenital dysmorphic syndromes are 
more common in neonates and infants (see Section 6.9.1) than in older 
children or adults, whereas wild-type transthyretin amyloidosis 
(ATTRwt) is a disease mostly of adults over the age of 65 years (see 
Section 7.6).
Construction of a three- to four-generation family pedigree helps to 
identify Mendelian forms of inheritance and identifies other family 
members who may be at risk of disease development.62 Specific fea­
tures to note in the family history include premature deaths (taking 
into account that SCDs may sometimes be reported as accidental 
deaths, e.g. drowning, unexplained traffic accident, and, rarely, as still­
birth or sudden infant death syndromes), unexplained heart failure, car­
diac transplantation, pacemaker and defibrillator implants, and evidence 
for systemic disease (e.g. stroke at a young age, skeletal muscle weak­
ness, renal dysfunction, diabetes, deafness). Most Mendelian forms of 
cardiomyopathy are autosomal dominant and are therefore character­
ized by the presence of affected individuals across generations, with 
transmission from parents of either sex (including male-to-male) and 
a 50% risk of allele transmission to offspring (although, due to incom­
plete penetrance, the proportion of affected individuals in an individual 
pedigree will be lower). X-linked inheritance should be suspected if 
males are the most severely affected individuals and there is no 
male-to-male transmission. Autosomal recessive inheritance, the least 
common pattern, is likely when both parents of the proband are
Recommendation Table 2 — Recommendations for 
diagnostic work-up in cardiomyopathies
Recommendations
Classa
Levelb
It is recommended that all patients with suspected or 
established cardiomyopathy undergo systematic 
evaluation using a multiparametric approach that 
includes clinical evaluation, pedigree analysis, ECG, 
Holter monitoring, laboratory tests, and 
multimodality imaging.63
I
C
It is recommended that all patients with suspected 
cardiomyopathy undergo evaluation of family history 
and that a three- to four-generation family tree is 
created to aid in diagnosis, provide clues to 
underlying aetiology, determine inheritance pattern, 
and identify at-risk relatives.64–66
I
C
© ESC 2023
ECG, electrocardiogram. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 19 -->

### Page 19

unaffected and consanguineous, although severe autosomal recessive 
cardiomyopathies can also occur in the absence of familial consanguin­
ity.67,68 When women—but not men—transmit the disease to children 
of either sex, mitochondrial DNA variants should be considered 
(Table 5). It is important to note that the absence of familial disease 
does not exclude a genetic origin (see Section 6.8).
Patients with cardiomyopathy may experience dyspnoea, chest pain, 
palpitation, and syncope and/or pre-syncope, although many individuals 
complain of few, if any, symptoms (see Section 6.4 for assessment of 
symptoms in specific cardiomyopathy subtypes). A number of non- 
cardiac symptoms act as pointers for specific diagnoses (Table 6). 
Similarly, general physical examination can provide diagnostic clues in 
patients with syndromic or metabolic causes of cardiomyopathy.62
6.5. Resting and ambulatory 
electrocardiography
The resting 12-lead ECG is often the first test that suggests the possi­
bility of cardiomyopathy. Although the ECG can be normal in a small 
proportion of individuals with cardiomyopathy, standard ECG abnor­
malities are common in all cardiomyopathy subtypes and can precede 
the development of an overt morphological or functional phenotype 
by many years; for example, in genotype-positive individuals identified 
during family screening. When interpreted in conjunction with findings 
on echocardiography and CMR imaging, features that would normally 
indicate other conditions, such as myocardial ischaemia or infarction, 
can—with age at diagnosis, inheritance pattern, and associated clinical 
features—suggest an underlying diagnosis or provide clues to the
Table 5 Examples of inheritance patterns that should raise the suspicion of specific genetic aetiologies, grouped ac­
cording to cardiomyopathy phenotype
Cardiomyopathy phenotype
AD
AR
X-linked
Matrilineal
HCM
Sarcomeric
X
Anderson–Fabry
X
Danon
X
TTR amyloidosis
X
RASopathy
X
(X)
Friedreich ataxia
X
Mitochondrial
Mitochondrial DNA
X
Nuclear DNA
X
X
X
DCM
LMNA
X
RBM20
X
Sarcomeric
X
Dystrophin
X
Emerin
X
Barth syndrome
X
Mitochondrial
Mitochondrial DNA
X
Nuclear DNA
X
X
X
NDLVC
LMNA
X
DES
X
X
FLNC
X
PLN
X
TMEM43
X
RBM20
X
ARVC
PLN
X
Desmosomal
X
X
TMEM43
X
RCM
Sarcomeric
X
DES
X
X
FLNC
X
BAG3
X
RASopathy
X
(X)
© ESC 2023
AD, autosomal dominant; AR, autosomal recessive; ARVC, arrhythmogenic right ventricular cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; NDLVC, 
non-dilated left ventricular cardiomyopathy; RCM, restrictive cardiomyopathy; TTR, transthyretin; DNA, deoxyribonucleic acid; RASopathies, Ras/mitogen-activated protein kinase pathway 
dysregulation. 
(X) indicates the presence of a correlation between a cardiomyopathy and a pattern of inheritance.
ESC Guidelines                                                                                                                                                                                          3521


<!-- PAGE 20 -->

### Page 20

Table 6 Examples of signs and symptoms that should raise the suspicion of specific aetiologies, grouped according to 
cardiomyopathy phenotype
Finding
Cardiomyopathy phenotype
HCM
DCM
NDLVC
ARVC
RCM
Learning difficulties, developmental 
delay
Mitochondrial 
diseases
Dystrophinopathies
Noonan 
syndrome
Noonan syndrome
Mitochondrial diseases
Danon disease
Myotonic dystrophy
FKTN variants
Sensorineural deafness
Mitochondrial 
diseases
Epicardin variants
NSML
Mitochondrial diseases
Visual impairment
Mitochondrial 
diseases
CRYAB
ATTRv or hereditary 
ATTR
Type 2 myotonic 
dystrophy
Danon disease
Anderson–Fabry 
diseasea
Gait disturbance
Friedreich ataxia
Dystrophinopathies
Myofibrillar 
myopathies
Sarcoglycanopathies
Myofibrillar myopathies
Myotonia
Myotonic dystrophy
Paraesthesia/sensory 
abnormalities/neuropathic pain
Amyloidosis
Amyloidosis
Anderson–Fabry 
disease
Carpal tunnel syndrome
TTR-related 
amyloidosis
Muscle weakness
Mitochondrial 
diseases
Dystrophinopathies
Laminopathies
Desminopathies
Glycogenoses
Sarcoglycanopathies
Desminopathies
FHL1 variants
Laminopathies
Myotonic dystrophy
Desminopathies
Palpebral ptosis
Mitochondrial 
diseases
Mitochondrial diseases
Myotonic dystrophy
Lentigines
NSML
Angiokeratomata
Anderson–Fabry 
disease
Pigmentation of skin and scars
Haemochromatosis
Palmoplantar keratoderma and 
woolly hair
Carvajal syndrome
Naxos and Carvajal 
syndromes
DSP variants
DSP variants
DSP variants
© ESC 2023
ARVC, arrhythmogenic right ventricular cardiomyopathy; ATTR, transthyretin amyloidosis; ATTRv, hereditary transthyretin amyloidosis; DCM, dilated cardiomyopathy; DSP, desmoplakin; 
HCM, hypertrophic cardiomyopathy; NDLVC, non-dilated left ventricular cardiomyopathy; NSML, Noonan syndrome with multiple lentigines; RCM, restrictive cardiomyopathy; TTR, 
transthyretin. 
aCornea verticillata, characteristic of Anderson–Fabry disease, does not cause visual impairment per se.


<!-- PAGE 21 -->

### Page 21

underlying diagnosis. For this reason, the ECG is recommended at the 
first clinic visit in all individuals with known or suspected cardiomyop­
athy and should be repeated whenever there is a change in symptoms 
in patients with an established diagnosis. Although the ECG is often 
non-specific, there are particular features that can suggest a certain aeti­
ology or morphological diagnosis, including atrioventricular (AV) block, 
ventricular pre-excitation pattern, distribution of repolarization abnor­
malities, and high or low QRS voltages (Table 7).
Patients with cardiomyopathy may seek cardiology evaluation due 
to arrhythmia-related symptoms or documented arrhythmia, 
including bradyarrhythmias and tachyarrhythmias, ranging from symp­
tomatic atrial/ventricular premature beats to life-threating ventricular 
arrhythmias. The frequency of arrhythmias detected during ambula­
tory electrocardiographic monitoring is age related and variable 
across different cardiomyopathy subtypes. Some arrhythmias are 
relatively common in the context of cardiomyopathy (e.g. atrial fibril­
lation [AF] or ventricular premature beats), while others may suggest 
a specific diagnosis. ECG monitoring is therefore useful at the initial 
clinical assessment and at regular intervals to assess the risk of SCD 
and stroke.
Table 7 Examples of electrocardiographic features that should raise the suspicion of specific aetiologies, grouped 
according to cardiomyopathy phenotype
Cardiomyopathy phenotype
Finding
Specific diseases to be considered
HCM
Short PR interval/pre-excitation
Glycogenosis 
Danon disease 
PRKAG2 cardiomyopathy 
Anderson–Fabry disease 
Mitochondrial disease
AV block
Amyloidosis 
Anderson–Fabry disease (late stage) 
Danon disease 
Sarcoidosis 
PRKAG2 cardiomyopathy
Extreme LVH
Danon disease 
Glycogenosis (e.g. Pompe disease) 
PRKAG2 cardiomyopathy
Low QRS voltagea
Amyloidosis 
Friedreich ataxia
Superior QRS axis (‘northwest axis’)
Noonan syndrome
Q waves/pseudoinfarction pattern
Amyloidosis
DCM
AV block
Laminopathy 
Emery–Dreifuss 1 
Myocarditis (esp. Chagas disease, Lyme disease, diphtheria) 
Sarcoidosis 
Desminopathy 
Myotonic dystrophy
Low P wave amplitude
Emery–Dreifuss 1 and 2
Atrial standstill
Emery–Dreifuss 1 and 2
Posterolateral infarction pattern
Dystrophinopathy 
Limb-girdle muscular dystrophy 
Sarcoidosis
Extremely low QRS amplitude
PLN variant
NDLVC
AV block
Laminopathy 
Desminopathy
Extremely low QRS amplitude
PLN variant
Low QRS voltage + atypical RBBB
Desmosomal variants
ARVC
T wave inversion V1-V3 + terminal activation delay  
+/− low right ventricular voltages +/− atypical RBBB
RCM
AV block
Desminopathy 
Amyloidosis
© ESC 2023
ARVC, arrhythmogenic right ventricular cardiomyopathy; AV, atrioventricular; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LVH, left ventricular hypertrophy; 
NDLVC, non-dilated left ventricular cardiomyopathy; PKP2, plakophilin 2; PLN, phospholamban; PRKAG2, protein kinase AMP-activated non-catalytic subunit gamma 2; QRS, Q, R, and S 
waves of an ECG; RBBB, right bundle branch block; RCM, restrictive cardiomyopathy. 
aIn the absence of obesity, pericardial effusion, chronic obstructive pulmonary disease, abnormalities of the chest, or other reasons that may cause low voltage. 
Adapted from Rapezzi et al.62
ESC Guidelines                                                                                                                                                                                          3523


<!-- PAGE 22 -->

### Page 22

6.6. Laboratory tests
Routine laboratory testing aids the detection of extracardiac conditions 
that cause or exacerbate ventricular dysfunction (e.g. thyroid disease, 
renal dysfunction, and diabetes mellitus) and secondary organ dysfunc­
tion in patients with severe heart failure. High levels of brain natriuretic 
peptide (BNP), N-terminal pro-brain natriuretic peptide (NT-proBNP), 
and high-sensitivity cardiac troponin T (hs-cTnT) are associated with 
cardiovascular events, heart failure, and death, and may have diagnostic, 
prognostic, and therapeutic monitoring value.69 Routine blood tests for 
comorbidities, including full blood count, renal and liver function para­
meters and electrolytes, thyroid function, fasting glucose, and 
Haemoglobin A1C (HbA1c) are recommended in all patients with 
heart failure symptoms.69 Persistently elevated serum creatinine kinase 
(CK) levels can be suggestive of myopathies or neuromuscular disor­
ders including dystrophinopathies (e.g. Becker muscular dystrophy or 
X-linked DCM), laminopathies, desminopathies, or less often, a myofi­
brillar myopathy.62 Elevated C-reactive protein levels may be present in 
patients with ARVC and NDLVC, particularly in the context of recur­
rent myocarditis-like episodes.70 Elevated serum levels of iron and fer­
ritin and high transferrin saturation can suggest a diagnosis of 
haemochromatosis and should trigger further aetiological refinement 
(primary vs. secondary) based on genetic testing. Lactic acidosis, myo­
globinuria, and leucocytopaenia can be suggestive of mitochondrial dis­
eases. A list of recommended laboratory tests in adults and children is 
shown in Table 8. Following specialist evaluation, additional tests to de­
tect rare metabolic causes are often required in children, including 
measurement of lactate, pyruvate, pH, uric acid, ammonia, ketones, 
free fatty acids, carnitine profile, urine organic acids, and amino acids 
(see Section 6.9).
6.7. Multimodality imaging
6.7.1. General considerations
Non-invasive imaging modalities represent the backbone of diagnosis 
and follow-up in patients with cardiomyopathies, including ultrasound- 
based techniques, CMR imaging, computed tomography (CT), and nu­
clear techniques, such as positron emission tomography (PET) and scin­
tigraphy (Figure 6).1,71,72 Physicians should always consider the yield of 
actionable results vs. the costs, advantages, and limitations of each tech­
nique, as well as patient safety and patient exposure to ionizing radi­
ation and contrast media. Standardized algorithms should be in place 
to move hierarchically from simpler and cheaper to more complex 
and expensive tests. A bi-directional flow of information between the 
clinician and the imager is key to maximizing appropriateness: clinicians 
should formulate and share clear pre-test hypotheses, based on avail­
able information, to aid the interpretation of novel findings. The imager 
should respond in a similarly focused fashion, assessing the likelihood of 
alternative diagnoses and refraining from diagnoses that are not com­
patible/plausible based on the overall clinical context.
6.7.2. Echocardiography
The non-invasive nature and widespread availability of echocardiography 
make it the main imaging tool, from initial diagnosis to follow-up. 
Transthoracic echocardiography (TTE) provides relevant information 
on global and regional RV and LV anatomy and function as well as valve 
function and the presence of dynamic obstruction, pulmonary hyperten­
sion, or pericardial effusions.71–73 Myocardial deformation imaging 
(speckle tracking or tissue Doppler) with global longitudinal strain is a 
more sensitive marker than EF to detect subtle ventricular dysfunction 
(e.g. in genotype-positive HCM, DCM, and ARVC family mem­
bers72,74,75), and may help discriminate between different aetiologies of 
hypertrophy76 (e.g. amyloidosis, HCM, and athlete’s heart). Mechanical 
dispersion is a marker of contraction inhomogeneity and highlights fine 
structural changes that may be missed by other modalities.77–80
Three-dimensional echocardiography reliably assesses volumes of car­
diac chambers but needs an adequate acoustic window. Contrast agents 
can be considered for better endocardial delineation to depict the pres­
ence of hypertrabeculation, apical HCM, or apical aneurysms, and to ex­
clude thrombus. Stress echocardiography can be helpful in selected 
patients to evaluate myocardial ischaemia and exercise echocardiography 
is useful to identify provocable LVOTO in symptomatic patients with 
HCM (see Section 7.1.1.3). Transoesophageal echocardiography is limited 
to selected indications, such as the exclusion of atrial thrombi related to 
AF, elucidating the mechanism of mitral regurgitation, or in planning inva­
sive interventions (e.g. septal myectomy in HCM).
When measuring cardiac dimensions and wall thickness in children, it 
is important to correct for body size, using z-scores (defined as the 
number of standard deviations from the population mean). Of note, 
there are inherent limitations with the use of z-scores in the diagnosis 
of cardiomyopathies, including the fact that there are many different 
normative data published resulting in significant variation in z-scores 
for the same patient.81 In addition, there are no normative data for 
wall thickness other than at the basal interventricular septum or poster­
ior wall. The Task Force recommends using the normative data from 
the Paediatric Heart Network consortium.82
Recommendation Table 3 — Recommendations for 
laboratory tests in the diagnosis of cardiomyopathies
Recommendations
Classa
Levelb
Routine (first-level) laboratory testsc are 
recommended in all patients with suspected or 
confirmed cardiomyopathy to evaluate aetiology, 
assess disease severity, and aid in detection of 
extracardiac manifestations and assessment of 
secondary organ dysfunction.
I
C
Additional (second-level) testsc should be considered 
in patients with cardiomyopathy and extracardiac 
features to aid in detection of metabolic and 
syndromic causes, following specialist evaluation.
IIa
C
© ESC 2023
aClass of recommendation. 
bLevel of evidence. 
cSee Table 8.
Recommendation Table 4 — Recommendation for 
echocardiographic 
evaluation 
in 
patients 
with 
cardiomyopathy
Recommendation
Classa
Levelb
A comprehensive evaluation of cardiac dimensions 
and LV and RV systolic (global and regional) and LV 
diastolic function is recommended in all patients with 
cardiomyopathy at initial evaluation, and during 
follow-up, to monitor disease progression and aid 
risk stratification and management.78,83–102
I
B
© ESC 2023
LV, left ventricular; RV, right ventricular. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 23 -->

### Page 23

6.7.3. Cardiac magnetic resonance
Cardiac magnetic resonance imaging (MRI) combines the advantages of 
non-invasiveness and independence of acoustic window with the ability 
for tissue characterization. The latter advantage is particularly import­
ant in the diagnosis of NDLVC, ARVC, myocarditis, amyloidosis, sar­
coidosis and other forms of inflammatory disease, and iron overload/ 
haemochromatosis. Cardiac magnetic resonance is particularly useful 
if echocardiography provides poor image quality. Initial evaluation 
should routinely include cine imaging sequences, T2-weighted se­
quences, pre- and post-contrast T1 mapping, and late gadolinium en­
hancement (LGE). When suspecting haemochromatosis, T2* 
mapping should be employed. Cardiac magnetic resonance findings 
can provide important aetiological clues (Figure 7), with potential thera­
peutic implications (Table 9) and should be assessed collectively with 
genetic results and other clinical features by experienced operators 
in cardiac imaging and the evaluation of heart muscle disease. Serial 
follow-up CMR, every 2–5 years depending on initial severity and clin­
ical course, can assist in evaluating disease progression as well as the 
benefits of therapy (e.g. evaluation of extracellular volume [ECV] in 
amyloidosis, or of iron deposition in haemochromatosis), and should 
be considered in all patients with cardiomyopathy.
6.7.3.1. Special considerations
• Recently developed rapid CMR techniques allow scans to be performed 
without general anaesthesia even in very young children.103 In children 
(and adults) unable to undergo CMR without general anaesthesia, the 
relative risks and benefits of the procedure should be considered.
• Imaging artefacts caused by cardiac implantable electronic devices 
have posed limitations for CMR imaging in the past.104–110 A number 
of solutions are available to reduce artefacts, including reducing in­
homogeneity, technical adjustments, and the use of special sequences, 
which reduce the rate of uninterpretable studies to one in five.111,112
Cardiac magnetic resonance can therefore be considered in patients 
with conditional devices and nearly all non-conditional devices pro­
vided appropriate protocols are put in place.113
• Nephrogenic systemic fibrosis is a rare complication reported in pa­
tients with first-generation linear unstable gadolinium chelates and
Table 8 First-level (to be performed in each patient) and second-level (to be performed in selected patients following 
specialist evaluation to identify specific aetiologies) laboratory tests, grouped by cardiomyopathy phenotype
Level
HCM
DCM
NDLVC
ARVC
RCM
First
• CK
• Liver function
• NT-proBNPa
• Proteinuria
• Renal function
• Troponin
• Calcium
• CK
• Ferritin
• Full blood count
• Liver function
• NT-proBNPa
• Phosphate
• Proteinuria
• Renal function
• Serum iron
• Thyroid function
• Troponin
• Vitamin D (children)
• Calcium
• CK
• C-reactive protein
• Full blood count
• Liver function
• NT-proBNPa
• Phosphate
• Proteinuria
• Renal function
• Troponin
• C-reactive 
protein
• Liver function
• NT-proBNPa
• Renal function
• Troponin
• CK
• Ferritin
• Full blood count
• Liver function
• NT-proBNPa
• Proteinuria
• Renal function
• Serum 
angiotensin-converting 
enzyme
• Serum iron
• Troponin
• Urine and plasma protein 
immunofixation, free light 
chains
Second
• Alpha-galactosidase A 
levels (males) and 
lyso-Gb3
• Carnitine profile
• Free fatty acids
• Immunofixation and free 
light chains
• Lactic acid
• Myoglobinuria
• Pyruvate
• PTH
• Urine and plasma protein
• Urine organic acids and 
plasma amino acids
• Carnitine profile
• Free fatty acids
• Lactic acid
• Organ- and non– 
organ-specific serum 
autoantibodies
• Serum 
angiotensin-converting 
enzyme
• Thiamine
• Viral serology
• Urine organic acids and 
plasma amino acids
• Organ- and 
non-organ-specific 
serum autoantibodies
• Viral serology
• Organ- and non– 
organ-specific 
autoantibodies
• Serum 
angiotensin-converting 
enzyme
© ESC 2023
ARVC, arrhythmogenic right ventricular cardiomyopathy; BNP, brain natriuretic peptide; CK, creatinine kinase; DCM, dilated cardiomyopathy; Gb3, globotriaosylceramide; HCM, 
hypertrophic cardiomyopathy; NDLVC, non-dilated left ventricular cardiomyopathy; NT-proBNP, N-terminal pro-brain natriuretic peptide; PTH, parathyroid hormone; RCM, restrictive 
cardiomyopathy. 
aAlternatively, BNP can be considered depending on the local availability.
ESC Guidelines                                                                                                                                                                                          3525


<!-- PAGE 24 -->

### Page 24

severe renal disease.114 However, gadolinium-based contrast agents 
can be safely administered for patients with an estimated glomerular fil­
tration rate >30 mL/min/1.73 m2, and nephrogenic systemic fibrosis is 
virtually unreported with the use of newer linear or macrocyclic gado­
linium contrasts. For patients with severe renal impairment, new CMR 
modalities and mapping procedures, which are very informative and do 
not require the use of contrast, are particularly valuable when assessing 
Anderson–Fabry disease and cardiac amyloidosis.115–117
• The use of gadolinium contrast is generally not advised in pregnancy 
due to the potential for adverse outcomes in the foetus and 
neonate.118
Multimodality imaging
LV functional and structural abnormalities
Ventricular function
Hypertrophy
Dilatation
Echocardiography and CMR
Tissue characterization (T1/T2/T2* /LGE)
CMR
Amyloidosis
Bone scintigraphy
Myocardial inflammation
PET-CT
Targeted studies
Valvular and dynamic gradients
Stress echocardiography
Myocardial ischaemia
CTCA/stress tests
Functional abnormalities
Clinical suspicion of cardiomyopathy
Risk stratification and disease prognostication
Disease progression
(follow-up)
Cardiomyopathy diagnosis
Phenotype identification
Rule out phenocopies
Figure 6 Multimodality imaging process in cardiomyopathies. CMR, cardiac magnetic resonance; CTCA, computed tomography coronary angiography; 
LGE, late gadolinium enhancement; LV, left ventricular; PET, positron emission tomography.
Recommendation Table 5 — Recommendations for 
cardiac magnetic resonance indication in patients with 
cardiomyopathy
Recommendations
Classa
Levelb
Contrast-enhanced CMR is recommended in 
patients with cardiomyopathy at initial 
evaluation.10,90,116,119–143
I
B
Continued 
Contrast-enhanced CMR should be considered in 
patients with cardiomyopathy during follow-up to 
monitor disease progression and aid risk stratification 
and management.89,90,120–122,127,129,136–147
IIa
C
Contrast-enhanced CMR should be considered for 
the serial follow-up and assessment of therapeutic 
response in patients with cardiac amyloidosis, 
Anderson–Fabry disease, sarcoidosis, inflammatory 
cardiomyopathies, and haemochromatosis with 
cardiac involvement.148–152
IIa
C
In families with cardiomyopathy in which a 
disease-causing variant has been identified, 
contrast-enhanced CMR should be considered in 
genotype-positive/phenotype-negative family 
members to aid diagnosis and detect early 
disease.10,122,126,128,129,135–143,145,153–159
IIa
B
In cases of familial cardiomyopathy without a genetic 
diagnosis, contrast-enhanced CMR may be 
considered in phenotype-negative family members to 
aid diagnosis and detect early disease.10,128
IIb
C
© ESC 2023
CMR, cardiac magnetic resonance. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 25 -->

### Page 25

Finding
Cardiomyopathy phenotype
Cardiac CMR examples
Specific diseases to be considered
Posterolateral LGE and concentric LVH
Low native T1
Anderson–Fabry disease
Amyloidosis
Sarcomeric HCM
Haemochromatosis
Post-myocarditis
Dystrophinopathy
Sarcoidosis
Chagas disease
DSP variants
FLNC variants
DES variants
Laminopathy
Desmosomal variants
EMF/hypereosinophilia
Diffuse subendocardial LGE,
high native T1
Patchy mid-wall in hypertrophied areas
Short T2*
Subepicardial LGE
Lateral wall epicardial LGE
Subepicardial and midwall LGE at basal septum +/- extension into inferolateral wall and RV insertion points
Apical transmural LGE
Ring-like and/or subepicardial
LGE pattern
Septal mid-wall LGE
Fat and LGE (transmural RV plus sub-epicardial-midmural LV free wall)
Partial LV or RV apical obliteration +
LGE at endocardial level
HCM
DCM
NDLVC
ARVC
RCM
Figure 7 Examples of cardiac magnetic resonance imaging tissue characterization features that should raise the suspicion of specific aetiologies, grouped 
according to cardiomyopathy phenotype. ARVC, arrhythmogenic right ventricular cardiomyopathy; CMR, cardiac magnetic resonance; DCM, dilated cardio­
myopathy; DES, desmin; DSP, desmoplakin; EMF, endomyocardial fibrosis; FLNC, filamin C; HCM, hypertrophic cardiomyopathy; LGE, late gadolinium en­
hancement; LV, left ventricular; LVH, left ventricular hypertrophy; NDLVC, non-dilated left ventricular cardiomyopathy; RCM, restrictive 
cardiomyopathy; RV, right ventricular. Examples of CMR tissue characterization features that should raise the suspicion of specific aetiologies (column 
4), grouped according to cardiomyopathy phenotype (column 1). CMR images features (column 3) correspond to the listed findings (column 2).Image %:   
ESC Guidelines                                                                                                                                                                                          3527


<!-- PAGE 26 -->

### Page 26

6.7.4. Computed tomography and nuclear medicine 
techniques
Other imaging modalities, including nuclear medicine-based techniques 
and CT, are indicated in selected subsets of patients with cardiomyop­
athy.160,161 Indications and the risk-benefit ratio should be evaluated on 
an individual patient basis, always taking into account radioprotection 
issues, which are particularly relevant in the young. Nuclear medicine 
is particularly helpful in the aetiological diagnosis of cardiac amyloidosis 
(see Section 7.7). 18FDG-PET is useful in the identification of myocardial 
inflammation associated with active sarcoidosis and, potentially, in 
other atypical forms of myocarditis.162–164 However, a negative scan 
does not exclude sarcoidosis in its inactive form. In patients with 
HCM, DCM, and Anderson–Fabry disease, H2
15O or 13NH3 dipyrid­
amole or regadenoson PET has been used to evaluate microvascular 
dysfunction, an important predictor of adverse outcome.165
However, this test does not currently have a role in aetiological diagno­
sis (e.g. in distinguishing phenocopies) and is largely confined to re­
search purposes.
Computed tomography-based imaging is primarily used in patients 
with a suspicion of cardiomyopathy to rule out CAD, either as an alter­
native diagnosis (e.g. in individuals with DCM, NDLVC, or ARVC phe­
notypes) or as a comorbidity affecting clinical manifestations and 
course. In children and adolescents, CT angiography can be useful to ex­
clude congenital vascular malformations (e.g. anomalous left coronary 
artery from the pulmonary artery [ALCAPA] or anomalous pulmonary 
venous return). Standard CT imaging provides additional information 
regarding concomitant pulmonary disease (e.g. sarcoidosis), pericardial 
disease, and chest wall deformities affecting the heart.
6.7.5. Endomyocardial biopsy
Endomyocardial biopsy (EMB) with immunohistochemical quantifica­
tion of inflammatory cells and identification of viral genomes remains 
the gold standard for the identification of cardiac inflammation. It 
may confirm the diagnosis of autoimmune disease in patients with un­
explained heart failure and suspected giant cell myocarditis, eosinophilic 
myocarditis, vasculitis, and sarcoidosis. Electron microscopy should be 
employed when storage or mitochondrial cardiomyopathies are sus­
pected. Endomyocardial biopsy should be reserved for specific situa­
tions where its results may affect treatment after careful evaluation 
of the risk-benefit ratio. Importantly, EMB is not completely risk-free 
and should be performed by experienced teams. Likewise, the diagnos­
tic work-up of a biopsy should be performed by pathologists with ex­
pertise in cardiomyopathies.
Table 9 Frequently encountered actionable results on 
multimodality imaging
Parameter/finding
Action
RWMAs on echocardiography or 
CMR
Raise suspicion of concomitant CAD, 
myocarditis, ARVC, NDLVC, or 
sarcoidosis
Systolic impairment on 
echocardiography or CMR
Assessment of risk in DCM, NDLVC, 
and ARVC; evaluation of treatment 
efficacy
Measurement of the wall 
thickness on echocardiography or 
CMR
Diagnosis of HCM (when 
echocardiography is inconclusive); risk 
stratification in HCM
Diastolic dysfunction on 
echocardiography
Explain symptoms; evaluation of 
treatment efficacy
Left atrial size on 
echocardiography
SCD risk prediction in HCM; 
systematic screening for AF in case of 
left atrial enlargement
LVOTO in HCM on resting/ 
exercise echocardiography
Explain symptoms; guide management
Non-invasive evaluation of 
pulmonary pressures
Explain symptoms; guide management
Tissue characterization on CMR
Diagnosis; risk assessment
Inflammation on CMR or 
18F-FDG-PET
Diagnosis; evaluation of treatment 
efficacy in inflammatory 
cardiomyopathies
© ESC 2023
18F-FDG-PET, fluorodeoxyglucose positron emission tomography; AF, atrial fibrillation; 
ARVC, arrhythmogenic right ventricular cardiomyopathy; AF, atrial fibrillation; CAD, 
coronary artery disease; CMR, cardiac magnetic resonance; DCM, dilated 
cardiomyopathy; HCM, hypertrophic cardiomyopathy; LVOTO, left ventricular outflow 
tract obstruction; NDLVC, non-dilated left ventricular cardiomyopathy; RWMA, regional 
wall motion abnormality; SCD, sudden cardiac death.
Recommendation Table 6 — Recommendations for 
computed tomography and nuclear imaging
Recommendations
Classa
Levelb
DPD/PYP/HMDP bone-tracer scintigraphy is 
recommended in patients with suspected 
ATTR-related cardiac amyloidosis to aid 
diagnosis.166–168
I
B
Contrast-enhanced cardiac CT should be considered 
in patients with suspected cardiomyopathy who have 
inadequate echocardiographic imaging and 
contraindications to CMR.169,170
IIa
C
In patients with suspected cardiomyopathy, 
CT-based imaging should be considered to exclude 
congenital or acquired coronary artery disease as a 
cause of the observed myocardial abnormality.171
IIa
C
18F-FDG-PET scanning should be considered for the 
diagnostic work-up in patients with cardiomyopathy 
in whom cardiac sarcoidosis is suspected.164,172,173
IIa
C
© ESC 2023
18F-FDG-PET, 
18F-fluorodeoxyglucose 
positron 
emission 
tomography; 
ATTR, 
transthyretin amyloidosis; CMR, cardiac magnetic resonance; CT, computed 
tomography; 
DPD, 
3,3-diphosphono-1,2-propanodicarboxylic 
acid; 
HMDP, 
hydroxymethylene diphosphonate; PYP, pyrophosphate. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 7 — Recommendation for 
endomyocardial biopsy in patients with cardiomyopathy
Recommendation
Classa
Levelb
In patients with suspected cardiomyopathy, EMB 
should be considered to aid in diagnosis and 
management when the results of other clinical 
investigations suggest myocardial inflammation, 
infiltration, or storage that cannot be identified by 
other means.174–177
IIa
C
© ESC 2023
EMB, endomyocardial biopsy. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 27 -->

### Page 27

6.8. Genetic testing and counselling
6.8.1. Genetic architecture
Familial forms of cardiomyopathies show diverse modes of inheritance. 
Gene identification has, over the last three decades, primarily focused 
on the identification of Mendelian (monogenic) disease genes that most 
commonly display autosomal dominant inheritance, although other inher­
itance patterns including autosomal recessive, X-linked, and mitochondrial 
(matrilineal) are also observed (Table 5). Major genes currently associated 
with different types of cardiomyopathies are listed in Table 10. 
Cardiomyopathies are characterized by a marked genetic and allelic het­
erogeneity, that is, many different variants in many different genes can 
cause the same phenotype. Rare pathogenic variants associated with car­
diomyopathies often exhibit the phenomena of incomplete and 
age-related penetrance, and variable expressivity.178,179 That is, not all in­
dividuals carrying a causative variant manifest the disease and, among those 
who do, there is broad variability in age of onset and disease severity. Thus, 
while some individuals may have severe disease necessitating cardiac trans­
plantation at a young age, others may remain unaffected throughout their 
lives or are only mildly affected. This variability could be due to heterogen­
eity among causative variants, the additional contribution of non-genetic 
(clinical, environmental) factors (e.g. hypertension in HCM,180 exercise 
in ARVC181), and the co-inheritance of additional genetic factors, which 
act to exacerbate or attenuate the effect of the principal Mendelian genetic 
variant on the phenotype. This is an active area of research, and recent 
genome-wide association studies conducted in patients with HCM have 
provided strong evidence for the modulatory role of common genetic var­
iants of individually small effect that collectively modulate the effects of 
Mendelian variants (Figure 8).182,183
Across the different cardiomyopathies, the proportion of cases with a 
confident genetic diagnosis (that is with identification of a likely causal 
Mendelian genetic variant) is relatively low (e.g. as low as ∼40% in 
HCM124 and ∼30% in DCM184–186). Genome-wide association studies 
of common variants in HCM and DCM have provided empirical evi­
dence for substantial polygenic inheritance in these cardiomyop­
athies.182,183,187 Contrary to Mendelian inheritance, where a single, 
large-effect variant primarily determines susceptibility to the disorder, 
complex inheritance rests on the co-inheritance of multiple susceptibil­
ity variants. Although not yet studied systematically, besides common 
variants of small effect, intermediate-effect variants with effect sizes 
and frequencies between common and Mendelian variants are also ex­
pected to contribute to such complex inheritance.188 It is likely that car­
diomyopathies span a continuum of genetic complexity, with Mendelian 
forms at one end, determined primarily by the inheritance of an ultra- 
rare large-effect genetic variant, and highly polygenic forms at the other 
(see Figure 8). Variants that contribute to disease susceptibility in the set­
ting of complex inheritance likely overlap with those that modulate dis­
ease penetrance and expressivity in the Mendelian form of the 
disease.182,183
6.8.2. Genetic testing
Genetic testing of Mendelian cardiomyopathy genes has become a 
standard aspect of clinical management in affected families.3 First-line 
testing should be focused on genes robustly associated with the pre­
senting phenotype. If initial testing does not reveal a cause, but suspicion 
of a monogenic cause remains high, then more extended sequencing or 
analysis may be indicated, depending on the family structure and other 
factors. Once a genetic cause is established in one family member, then 
other family members may undergo testing for only the causative 
variant.
Genetic testing in an individual with cardiomyopathy (known as con­
firmatory testing or diagnostic testing) is recommended for their direct 
benefit: (i) to confirm the diagnosis; (ii) where it may inform prognosis; 
(iii) where it may inform treatment selection; or (iv) where it may in­
form their reproductive management. Genetic testing of an affected in­
dividual may be indicated, even if it is unlikely to alter their management, 
if there are relatives who may benefit from testing, particularly if there 
are relatives who will be enrolled in longitudinal surveillance if the gen­
etic aetiology is not established and who may be spared this burden if a 
genetic diagnosis is made in the family (Table 11). Testing may also be 
helpful in broader contexts, even when not obviously informative for 
immediate management; for example, a genetic diagnosis may provide 
psychological benefit in a patient struggling to understand their disease.
Genetic testing in a clinically unaffected relative of an individual with 
cardiomyopathy may be indicated irrespective of age, even in very 
young children, if a genetic diagnosis has been established with confi­
dence in the affected individual (known as cascade testing, predictive 
testing, or pre-symptomatic testing). Once a pathogenic/likely patho­
genic (P/LP) variant has been identified within an index patient following 
investigations of relevant disease genes associated with the specific 
phenotype, it is possible to offer cascade genetic testing of first-degree 
at-risk relatives, including pre-test genetic counselling (see Section 
6.8.3). In a scenario where a first-degree relative has died, evaluation 
of close relatives of the deceased individual (i.e. second-degree relatives 
of the index patient) should also be considered.
Individuals who are found not to harbour the familial variant can usu­
ally be discharged from clinical follow-up; those who do carry the famil­
ial variant are recommended to undergo clinical evaluation and usually 
ongoing surveillance. Cascade testing is not indicated when a variant of 
uncertain significance is identified in the proband.
Sequencing may also be indicated for segregation analysis (rather 
than as a diagnostic test) to inform interpretation of a variant of uncer­
tain significance found in an affected individual. This is usually limited to 
individuals who are clearly affected, or to testing of the parents to iden­
tify a de novo variant. Genetic counselling in this circumstance would in­
volve clear communication to family members that this is not a 
diagnostic test, but rather is contributing to clarifying the pathogenicity 
of the uncertain variant.
Finally, the evaluation of cardiac genes for secondary findings where data 
are generated in the setting of genetic testing for another clinical indication 
(also referred to as opportunistic screening) may be reasonable where the 
balance of benefits and harm is known, and if the cost is acceptable. 
Broader population screening might also prove reasonable if the balance 
of benefits and harm proves favourable. At present there is insufficient 
data to evaluate the balance of benefits and harm in either context, and 
this should currently only be performed in a research context in order 
to obtain such data. Careful genetic counselling to fully explain benefits 
and risks in this setting is critical. At present, there are very little data to 
evaluate this balance and this is an important evidence gap. In the United 
States of America, the American College of Medical Genetics and 
Genomics has recommended that cardiomyopathy-associated genes be 
evaluated for secondary findings whenever broad clinical sequencing is 
undertaken, regardless of the initial indication for testing.192,193 There is 
currently no international consensus around this recommendation.
ESC Guidelines                                                                                                                                                                                          3529


<!-- PAGE 28 -->

### Page 28

Table 10 Overview of genes associated with monogenic, non-syndromic cardiomyopathies, and their relative contribu­
tions to different cardiomyopathic phenotypes
Gene
Cardiomyopathy phenotype
Associated phenotype
HCM
DCM
NDLVC
ARVC
RCM
ABCC9
a a Cantu syndrome
ACTA1
ACTC1
ACTN2b
ALPK3
ANKRD1
BAG3
a a Myofibrillar myopathy
CACNA1C
c c Timothy syndrome
CACNB2
CALR3
CASQ2
CAV3
a a Caveolinopathy
CDH2
COX15
a a Leigh syndrome
CRYAB
a a Alpha-B crystallinopathy
CSRP3
CTF1
CTNNA3
DES
c c Desminopathy
DMD
c c X-linked progressive MD
DMPK
DSC2
DSG2
DSP
DTNA
EYA4
FHL1
c c Emery–Dreifuss MD
FLNC
c c Myofibrillar myopathy
FHOD3
FXN
a a Friedreich ataxia
GAA
a a Pompe disease
Continued


<!-- PAGE 29 -->

### Page 29

GATA4
GATAD1
GLA
c c Anderson–Fabry disease
HCN4
ILK
JPH2
JUP
a
Naxos disease (cardiocutaneous syndrome)
KCNQ1
KLF10
LAMA4
LAMP2
c c Danon disease
LDB3
a a Myofibrillar myopathy
LMNA
LRRC10
MIB1
MYBPC3
MYH6
MYH7
MYL2
MYL3
MYLK2
MYOM1
MYOZ2
MYPN
NEBL
NEXN
NKX2–5
NNT
NONO
NPPA
OBSCN
PDLIM3
PKP2
PLEKHM2
PLN b
Continued 
ESC Guidelines                                                                                                                                                                                          3531


<!-- PAGE 30 -->

### Page 30

PRDM16
PRKAG2
c c PRKAG2 cardiomyopathy
PSEN1
PSEN2
PTPN11
c c Noonan syndrome
RAF1
c c Noonan syndrome
RBM20
RIT1
c c Noonan syndrome
RYR2
SCN5A
SGCD
SLC25A4
a a Mitochondrial disease
TAZ
TBX5
TBX20
TCAP
TGFB3
TJP1
TMEM43
a
TMEM70
TMPO
TNNC1
TNNI3
TNNI3K
TNNT2
TPM1
TRIM63
TTN
TTR
c c Transthyretin amyloidosis
VCL
© ESC 2023
ARVC, arrhythmogenic right ventricular cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LVH, left ventricular hypertrophy; MD, muscular dystrophy; 
NDLVC, non-dilated left ventricular cardiomyopathy; RCM, restrictive cardiomyopathy. 
Based on ClinGen gene validation efforts;189–191a ooo: very common (>10% of tested cases); oo: common (1–10% of tested cases); o: less common (<1% of tested cases); blue circle: 
definitive/strong evidence; light blue circle: moderate evidence; white circle: limited, no association or refuted/dispute evidence; blank cells: not classified; grey circle: has been described 
(generally rare, sporadic cases), yet not classified/evaluated by ClinGen. The yield may be higher in subgroups with more specific phenotypes, e.g. the yield of testing LMNA is higher in 
groups with DCM and conduction disease. As NDLVC is a new phenotypic description, genes have not been formally curated for associations with this phenotype. Values shown are 
based on curations for related cardiomyopathies where the phenotypic spectrum is understood to include NDLVC. 
a indicates genes associated with syndromic presentations that can include cardiomyopathy as a feature, but where cardiomyopathy is not expected to occur as the only or presenting feature 
of the syndrome. 
bACTN2 and PLN can present a mixed phenotypic picture that may not fit into classical cardiomyopathy descriptions. 
cindicates genes associated with syndromic presentations that can include cardiomyopathy as a feature, and where cardiomyopathy may be the only or presenting feature of the syndrome.  These 
are sometimes referred to as genocopies. E.g. GLA is shown as definitive for HCM, because it causes Anderson–Fabry disease which can present with LVH fulfilling diagnostic criteria for HCM.


<!-- PAGE 31 -->

### Page 31

+
+
+
-
-
+
-
-
+
+
+
-
+
+
-
+
+
-
+
+
+
+
-
+
-
+
Severity
Disease susceptibility
Disease threshold
Severity
Disease susceptibility
Disease threshold
Rare pathogenic variant
Intermediate effect variant
Small effect common variant
Non-genetic factors
Panel A
Panel B
Panel C
Severity
Disease susceptibility
Disease threshold
Low familial aggregation
Autosomal dominant with incomplete penetrance and variable severity/expressivity
Sporadic presentation
(negative family history)
Autosomal dominant with complete penetrance
Rare Mendelian variant
Population MAF <0.01%
Intermediate effect variant
Population MAF <1–2%
Common variants (GWAS)
Population MAF >1–5%
Figure 8 The genetic architecture of the cardiomyopathies. GWAS, genome-wide association studies; MAF, minor allele frequency. Cardiomyopathy can be 
Mendelian, caused by genetic variants that are ultra-rare in the general population and have large effect sizes. Such variants can display complete penetrance; i.e. all 
individuals with the variant in the family manifest the disease (panel A). However, individual variants are often insufficient to yield a disease phenotype in isolation, and 
their effect is modulated by the co-inheritance of modulatory genetic factors and by non-genetic factors (panel B). Besides increasing disease penetrance, such mod­
ulatory variants also affect the severity of the disease (panel B). Modulatory genetic factors are thought to comprise common variants with individually small-effect 
sizes and intermediate-effect variants that have population frequencies and effect sizes between rare and common variants. Some patients have a more complex 
aetiology (non-Mendelian/polygenic inheritance) in which a substantial number of non-Mendelian genetic factors and non-genetic factors are required to reach the 
threshold for disease (panel C). Such patients typically have a sporadic presentation or present with a less pronounced familial clustering of the disease. Family trees 
demonstrate the male (square) and female (circle) family members that are affected (black filled), with incomplete phenotype (grey filled) or unaffected (white filled). 
The presence or absence of the variant of interest is noted with “+” or “-”, respectively.
Table 11 Utility of genetic testing in cardiomyopathies
For the patient
• Diagnosis: for the affected individual, the diagnosis of cardiomyopathy is primarily made on the basis of a phenotypic definition of disease, without reference to 
genetic aetiology. However, with appropriate genetic counselling and acknowledging the caveat that the finding will only be clinically actionable when a P/LP 
variant is found, genetic testing may be of value in clarifying borderline cases (e.g. where LVH is observed in the context of mild or controlled hypertension, but 
the clinician is not able to confidently distinguish between early sarcomeric HCM and a hypertensive phenocopy). Genetic testing can also identify genocopies: 
distinct genetic conditions that mimic a particular cardiomyopathy.
• Prognosis: for an increasing number of conditions, a genetic diagnosis can provide prognostic information. For example, DCM due to variants in LMNA has an 
adverse prognosis requiring more frequent surveillance and shifting therapeutic decision thresholds with a lower threshold for primary prevention ICD 
implantation.
• Therapy: a genetic diagnosis may directly stratify choice of therapy. In addition to decisions on primary prevention ICD implantation, an increasing number of 
treatments are either established or under trial for a specific molecular subtype of cardiomyopathy. In addition, with an increasingly sophisticated toolbox for                    
Continued 
ESC Guidelines                                                                                                                                                                                          3533


<!-- PAGE 32 -->

### Page 32

6.8.2.1. Non-Mendelian cardiomyopathies and implications for 
genetic testing
The preceding discussion has focused on genetic testing to identify 
monogenic forms of cardiomyopathy. The recognition that an import­
ant proportion of cardiomyopathies have a more complex genetic 
architecture has important implications for the use of genetic tests.
The absence of a monogenic disease-causing variant on conventional 
genetic testing (i.e. sequencing for rare variants of large effect) leaves 
three possibilities: (i) either there is a monogenic cause that has not 
been identified (i.e. not detected or recognized as causative by current 
testing); (ii) the cardiomyopathy does not have a genetic aetiology; or 
(iii) the cardiomyopathy is attributable to the effects of multiple variants 
of individually smaller effect (Figure 8). Recent data suggest that for many 
cardiomyopathies, the absence of a rare causative variant on comprehen­
sive testing indicates that the disease is unlikely to have a monogenic aeti­
ology.182,183,194 This, in turn, implies a different inheritance pattern, with a 
lower risk to first-degree relatives, such that ongoing surveillance may 
not be indicated if an initial clinical evaluation is reassuring. The use of gen­
etic testing to identify families in whom the disease is unlikely to be 
monogenic represents a likely new application of conventional testing, 
which is gathering evidence but not yet established.
Polygenic risk scores (PRS) (sometimes known as genomic risk 
scores) are another form of genetic test that may, in the future, have 
relevance in the management of cardiomyopathies. Instead of trying 
to identify a single genetic variant that is responsible for disease, 
many variants across the genome are evaluated, each associated with 
a small effect on disease risk, and a score representing the aggregate 
risk is calculated.182,183,195–197 To date, the value of a PRS in the clinical 
management of cardiomyopathies has not yet been demonstrated, and 
access to genetic counselling will be even more important in conveying 
risks and uncertainties to patients and families.
6.8.2.2. Genetic test reports and variant interpretation
Many genetic diagnostic laboratories use a standardized framework to 
interpret and report diagnostic genetic test results.3,198–200 A negative 
genetic test result in a proband indicates that no causative variant has 
been found in a known disease-associated gene. This does not necessar­
ily mean the patient does not have a genetic disease, but reflects our 
limited knowledge of the genetic architecture of inherited cardiomyop­
athies at this point in time. Aspects concerning the genetic testing ap­
proach, genetic testing methods, and variant interpretation are 
further elaborated in the Supplementary data online, Section 2, and in 
the European Heart Rhythm Association (EHRA)/Heart Rhythm 
Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin 
American Heart Rhythm Society (LAHRS) Expert Consensus 
Statement on the state of genetic testing for cardiac diseases.3
6.8.3. Genetic counselling
Genetic counselling is a process that aims to support patients and their 
families to understand and adapt to the medical, psychosocial, and familial 
impact of genetic diseases.201,202 It should be performed by healthcare 
professionals with specific training, such as genetic counsellors, genetic 
nurses, or clinical/medical geneticists, regardless of whether genetic testing 
is being considered. Genetic counselling can include a discussion of inher­
itance risks, provide education including the need for clinical evaluation, 
perform pre- and post-genetic test counselling, review variant classifica­
tions, obtain a three-generation family history, and provide psychosocial 
support.203–205For patients with a new diagnosis of cardiomyopathy, there 
can be difficulty adjusting to life with an inherited cardiomyopathy, chal­
lenges living with an implantable cardioverter defibrillator (ICD), and on­
going trauma and grief for those who have experienced a young SCD in 
their family. Attention to the psychological support needs of patients is 
therefore critical (see Section 6.12). Indeed, in the general setting, genetic 
counselling can improve knowledge, recall, and patient empowerment; in­
crease satisfaction with decision-making; and reduce anxiety.206–209
6.8.3.1. Genetic counselling in children
There are specific issues to be considered when counselling children 
and their families and considering clinical screening and cascade genetic 
testing,75,210,211 (Table 12) and a patient-centred approach that takes in manipulation of the genome, further waves of therapies aiming to replace, alter, or remove abnormal genes and transcripts responsible for cardiomyopathies are 
anticipated once a precise molecular aetiology is established in a patient.
• Reproductive advice: a genetic diagnosis informs reproductive advice and management for an affected adult and/or the parents of an affected child, enabling 
tailored advice on inheritance patterns and the risk of transmission to future children, and opening the door to management of risk; e.g. through pre-natal 
diagnostics or pre-implantation genetic diagnosis.
For relatives
• Cardiomyopathies display incomplete and age-related penetrance, with great variability, therefore it is very difficult to identify clinically those relatives who are 
not at risk of developing cardiomyopathy. A normal one-off assessment is of limited value, and relatives without cardiomyopathy on initial evaluation may require 
long-term longitudinal surveillance. Genetic testing can eliminate this uncertainty: an individual who does not carry the genetic variant proved to be responsible 
for disease in their family can be confidently reassured and discharged without surveillance, while an individual who carries a disease-causing variant can be 
followed closely, and potentially treated early.
© ESC 2023
DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter defibrillator; LMNA, lamin A/C; LVH, left ventricular hypertrophy; P/LP, pathogenic/likely pathogenic.
Table 12 Specific issues to consider when counselling 
children
Issue
Implications
Autonomy
Competence of child to decide on testing
Informed consent
Appropriate to understanding of child
Right to know/not to know 
the result
Consider wishes of child and family
Confidentiality
Context of family history
Incomplete and age-related 
penetrance
Symptoms/features of disease may not 
become apparent for many years
Lifestyle
School, sports, employment
Life stages and transition
Moving from primary to secondary 
education; transition to adult medical 
services
© ESC 2023


<!-- PAGE 33 -->

### Page 33

to account the experiences and values of the family is needed (Figure 9). 
The guiding principle remains that any testing, clinical or genetic, should 
be in the best interests of the child and have an impact on management, 
lifestyle, and/or ongoing clinical testing.75 With appropriate multidiscip­
linary support in a paediatric setting, psychosocial outcomes in children 
undergoing clinical screening and cascade genetic testing are no differ­
ent than those of the general population.212
6.8.3.2. Pre- and post-test genetic counselling (proband)
One critical role for genetic counselling is that it should be done along­
side genetic testing (see Section 6.8.2).3 This includes a discussion prior 
to a decision to undertake genetic testing (pre-test), and at the time of 
the return of the results (post-test). Key discussion points during pre- 
and post-test counselling are summarized in Table 13.
6.8.3.3. Genetic counselling for cascade testing
Once a P/LP variant has been identified within an index patient follow­
ing investigations of relevant disease genes associated with the specific 
phenotype, it is possible to offer cascade genetic testing of first-degree 
at-risk relatives, including pre-test genetic counselling (see Section 6.8). 
In a scenario where a first-degree relative has died, evaluation of close 
relatives of the deceased individual (i.e. second-degree relatives of the 
index patient) should also be considered.
Undergo cascade genetic testing
Genotype-positive
Genotype-negative
Continue clinical screening
Release from further clinical screening
Risk of developing disease
Continue clinical screening
Risk of developing disease
Remove unnecessary worry
Decline cascade genetic testing
Understand motivations for testing
Minimize healthcare burden of unnecessary clinical screening
Tolerance to uncertainty
Willingness to undergo periodic clinical screening
Age of the child
Family experience with disease
Life stage
Explore worry and fear
Genetic counselling
Access to information and resources
Preferences of the parents
Wish to include children in decisionmaking when older
Respectful discussion
Potential impact on lifestyle, sport,
wellbeing
Family values and beliefs
Cascade genetic testing in children: a patient-centred approach
Figure 9 A patient-centred approach to cascade genetic testing of children. Factors to consider when supporting families to decide whether to pursue 
cascade genetic testing in children.
ESC Guidelines                                                                                                                                                                                          3535


<!-- PAGE 34 -->

### Page 34

The right assignment of the level of pathogenicity of a variant is cru­
cial for cascade genetic testing. Inappropriate use of genetic testing in a 
family has the potential to introduce unnecessary worry and fear, as 
well as potential harm related to the misinterpretation of genetic var­
iants. Variants should therefore be classified by a specialized multidiscip­
linary cardiac genetic team with an appropriate level of expertise. 
Systematic reclassification of identified variants and communication 
to families is crucial. Conveying information on the importance of clin­
ical and genetic testing of at-risk relatives is typically reliant on the pro­
band in the family understanding the information and passing it on to 
the appropriate relatives. Common barriers to communication can in­
clude poor family relationships, guilt regarding passing a causative vari­
ant on to children, psychosocial factors including distress, and 
comprehension of the result.214,215 A patient will often selectively com­
municate genetic information to relatives, assessing their ability to 
understand and cope with the information, their life stage, and their 
risk status.216 Poor health literacy is an important barrier to effectively 
communicating genetic risk information to relatives, highlighting the 
need for targeted resources and mechanisms for support.217
6.8.3.4. Pre-natal or pre-implantation genetic diagnosis
Pre-natal or pre-implantation genetic testing can be offered to par­
ents who have had a previous affected child with an inherited cardio­
myopathy due to a single or multiple pathogenic variant(s), or to 
couples where one or both partners carries a known pathogenic (fa­
milial) variant. The decision to pursue pre-natal or pre-implantation 
genetic testing should consider a spectrum of disease- and 
parent-related aspects, including cultural, religious, legal, and avail­
ability issues.218 Options for pre-natal or pre-implantation genetic 
diagnosis should be discussed as part of the genetic counselling pro­
cess and in a timely manner. If pre-natal diagnostics are performed, it 
should be done early enough in pregnancy to give the patient options 
regarding pregnancy continuation, or co-ordination of pregnancy, de­
livery, and neonatal care.219
Options for pre-natal and pre-implantation genetic diagnosis are 
summarized in Table 14. Most reproductive diagnostic testing op­
tions are for established pregnancies, except pre-implantation genet­
ic diagnosis which allows for selective implantation of unaffected 
embryos.
Table 13 Key discussion points of pre- and post-test 
genetic counselling
Pre-test genetic 
counselling
Detailed family history
Genetic education
Process and logistics of genetic testing and 
return of the result
Explanation of all possible outcomes
Implications for clinical care
Lifestyle implications including sport, exercise, 
and employment
Implications for the family
Risk of reclassification
Secondary genetic findings
Potential insurance implications (country 
dependent)
Exploration of feelings and understanding
Psychosocial support
Post-test genetic 
counselling
Re-cap on key points of pre-test session
Result disclosure
Specific implications for clinical care
Specific implications for the family and how to 
approach relatives
Risk of reclassification, plan for resolving 
uncertain variant status if applicable
Exploration of feelings and understanding
Provision of details about how family members 
can access genetic counselling
Offer information about reproductive genetic 
testing options for those with a genetic 
diagnosis
Psychosocial support
© ESC 2023
Modified from Ingles et al.213
Table 14 Pre-natal and pre-implantation options and 
implications
Issue
Implications
Chorionic villus sampling
• Transcervical or transabdominal sampling of 
the placenta at 10–14 weeks of gestation. 
The procedure-related foetal loss rate is 
∼0.2%.220
• Performed at early gestational age; short 
testing turnaround time.
Amniocentesis
• Direct sampling of amniotic fluid is 
performed after 15 weeks of gestation The 
loss rate is ∼0.1%.220
Non-invasive pre-natal 
testing
• Performed for a single gene disorder.
• Cell-free foetal DNA isolated from maternal 
plasma sample.
• Offered in early pregnancy (approximately 
week 9); miscarriage risk not increased.
• Not widely available (method still largely 
under development and therefore not 
readily available).
Pre-implantation genetic 
diagnosis
• IVF procedure with a success rate of 25–30% 
per embryo transfer though dependent on 
the mother’s age and fertility, followed by 
biopsy and genetic testing of a single cell of 
the embryo.
• Risks to mother and offspring of IVF, such as 
multiple birth, premature labour and low 
birth weight, as well as emotional health 
effects for those undergoing the procedure.
• Availability and methods differ across 
countries.
© ESC 2023
IVF, in vitro fertilization.


<!-- PAGE 35 -->

### Page 35

6.9. Diagnostic approach to paediatric 
patients
Traditionally, cardiomyopathies in children have been considered to be 
distinct entities from adolescent and adult cardiomyopathies, with dif­
ferent aetiologies, natural history, and management. Although substan­
tially rarer than in adults, contemporary data have shown that, beyond 
the first year of life, in most cases, paediatric cardiomyopathies re­
present part of the spectrum of the same diseases that are seen in ado­
lescents and adults.245 Given their rarity, data on clinical management 
and outcomes are more limited than in adults, but large population- 
based or international consortium data have provided important 
information on clinical presentation, natural history, and outcomes of 
cardiomyopathies in children.245 Paediatric-onset cardiomyopathies of­
ten represent two opposite ends of the spectrum of heart muscle dis­
ease: (i) severe, early-onset disease, with rapid disease progression and 
poor prognosis, in keeping with the most severe presentations in adults; 
or (ii) early phenotypic expression of adult cardiomyopathy 
phenotypes, increasingly identified as a result of family screening. For 
this reason, the Task Force highlights the principle of considering car­
diomyopathies in all age groups as single disease entities, with recom­
mendations applicable to paediatric and adult populations throughout 
this guideline, accepting that the evidence base for many of the recom­
mendations is significantly more limited for children. Where there are 
age-related differences, these are specifically highlighted.
Recommendation Table 8 — Recommendations for 
genetic counselling and testing in cardiomyopathies
Recommendations
Classa
Levelb
Genetic counselling
Genetic counselling, provided by an appropriately 
trained healthcare professional and including genetic 
education to inform decision-making and 
psychosocial support, is recommended for families 
with an inherited or suspected inherited 
cardiomyopathy, regardless of whether genetic 
testing is being considered.204,206,208,209,221–224
I
B
It is recommended that genetic testing for 
cardiomyopathy is performed with access to a 
multidisciplinary team, including those with expertise 
in genetic testing methodology, sequence variant 
interpretation, and clinical application of genetic 
testing, typically in a specialized cardiomyopathy 
service or in a network model with access to 
equivalent expertise.222,224–226
I
B
Pre- and post-test genetic counselling is 
recommended in all individuals undergoing genetic 
testing for cardiomyopathy.204,208,227–236
I
B
If pre-natal diagnostic testing is to be pursued by the 
family, it is recommended that this is performed early 
in pregnancy, to allow decisions regarding 
continuation or co-ordination of pregnancy to be 
made.
I
C
A discussion about reproductive genetic testing 
options with an appropriately trained healthcare 
professional should be considered for all families with 
a genetic diagnosis.
IIa
C
Index patients
Genetic testing is recommended in patients fulfilling 
diagnostic criteria for cardiomyopathy in cases where 
it enables diagnosis, prognostication, therapeutic 
stratification, or reproductive management of the 
patient, or where it enables cascade genetic 
evaluation of their relatives who would otherwise be 
enrolled into long-term surveillance.227–231,237,238
I
B
Genetic testing is recommended for a deceased 
individual identified to have cardiomyopathy at 
post-mortem if a genetic diagnosis would facilitate 
management of surviving relatives.239–243
I
C
Genetic testing may be considered in patients 
fulfilling diagnostic criteria for cardiomyopathy when 
it will have a net benefit to the patient, considering 
the psychological impact and preference, even if it 
does not enable diagnosis, prognostication, or 
therapeutic stratification, or cascade genetic 
screening of their relatives.
IIb
C
Genetic testing in patients with a borderline 
phenotype not fulfilling diagnostic criteria for a 
cardiomyopathy may be considered only after 
detailed assessment by specialist teams.
IIb
C
Continued 
Family members
It is recommended that cascade genetic testing, with 
pre- and post-test counselling, is offered to adult 
at-risk relatives if a confident genetic diagnosis (i.e. a 
P/LP variant) has been established in an individual 
with cardiomyopathy in the family (starting with 
first-degree relatives if available, and cascading out 
sequentially).204,227–232
I
B
Cascade genetic testing with pre- and post-test 
counselling should be considered in paediatric at-risk 
relatives if a confident genetic diagnosis (i.e. a P/LP 
variant) has been established in an individual with 
cardiomyopathy in the family (starting with 
first-degree relatives, if available, and cascading out 
sequentially), considering the underlying 
cardiomyopathy, expected age of onset, 
presentation in the family, and clinical/legal 
consequences.233–236,244
IIa
B
Testing for the presence of a familial variant of 
unknown significance, typically in parents and/or 
affected relatives, to determine if the variant 
segregates with the cardiomyopathy phenotype 
should be considered if this might allow the variant to 
be interpreted with confidence.
IIa
C
Diagnostic genetic testing is not recommended in a 
phenotype-negative relative of a patient with 
cardiomyopathy in the absence of a confident genetic 
diagnosis (i.e. a P/LP variant) in the family.
III
C
© ESC 2023
P/LP, pathogenic/likely pathogenic. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3537


<!-- PAGE 36 -->

### Page 36

The general approach to paediatric and adult cardiomyopathies is 
based on age of onset, clinical presentation, and cardiac and systemic 
phenotype.246 When a syndromic or metabolic disease is suspected, 
a step-by-step approach taking into consideration age of onset, consan­
guinity and family history, cardiac and systemic involvement, ECG and 
imaging, and laboratory work-up is recommended to define phenotype, 
aetiology, and tailored management.247 As in adults, clinical presenta­
tion varies, from an absence of symptoms to SCD as the first and un­
ique manifestation.35,81,248,249
6.9.1. Infantile and early childhood-onset 
cardiomyopathy
In contrast, the aetiology, natural history, and outcomes of 
infant-onset (<1 year of age) cardiomyopathies can be substantially 
different than those seen in older children, adolescents, and adults. 
In infantile and early childhood-onset cardiomyopathies, clinical 
presentation, cardiac phenotype, and aetiology are the main determi­
nants of management.2 Severe clinical onset of infantile cardiomyop­
athies is generally managed in intensive or subintensive care units by 
neonatologists and paediatric cardiologists, for respiratory distress 
and/or metabolic acidosis, and/or hypoglycaemia, and/or hypo­
tonia.247,250–252 A comprehensive clinical approach, taking into con­
sideration both the cardiac and systemic phenotype (consanguinity; 
dysmorphisms or skeletal anomalies; mental retardation; muscle 
hypotonia and weakness; hypoglycaemia with or without metabolic 
acidosis; increased CK and transaminases; presence of urine ketones, 
organic aciduria, acylcarnitine, and free fatty acid profiles; and calcium 
and vitamin D metabolism), and involving a multidisciplinary team 
(geneticist and experts in metabolic and neurological diseases), is 
mandatory to guide management when reversible or specific diseases 
are present (Figure 10).
Clinical approach to infantile and childhood cardiomyopathy
Friedreich
GSD
Danon
Concentric LVH
Danon
Danon
GSD
Extreme LVH
Global hypokinesia
Posterolateralakinesia
Pulmonary stenosis/CHD
Barth
Dysmorphia,
skeletal abnormalities
Skin abnormalities
Metabolic acidosis
Encephalopathy
GSD
LSD
MYH7
Ataxia
Muscle weakness
Deafness
Learning difficulties,
intellectual disability
Hypoglycaemia, 
   AST/ALT
Friedreich
Friedreich
GSD
Mitochondrial
Desmosomal
Dystrophin
RASopathy
RASopathy
RASopathy
Mitochondrial
Mitochondrial
Mitochondrial
RASopathy
Friedreich
Dystrophin/
NMD
Dystrophin/
NMD
Mitochondrial
Mitochondrial
NSML
Epicardin
Mitochondrial
Inheritance patterna
Echocardiogram
Systemic phenotype
ECGb
HCM
DCM
RCM
ARVC
NDLVC
Desmosomal
Figure 10 Clinical approach to infantile and childhood cardiomyopathy. ALT, alanine aminotransferase; ARVC, arrhythmogenic right ventricular cardio­
myopathy; AST, aspartate transaminase; CHD, congenital heart disease; DCM, dilated cardiomyopathy; ECG, electrocardiogram; GSD, glycogen storage dis­
order; HCM, hypertrophic cardiomyopathy; LSD, lysosomal storage disease; LVH, left ventricular hypertrophy; MYH7, myosin heavy chain 7; NDLVC, 
non-dilated left ventricular cardiomyopathy; NSML, Noonan syndrome with multiple lentigines; RCM, restrictive cardiomyopathy. aSee Table 5. bSee 
Table 7.Image %:


<!-- PAGE 37 -->

### Page 37

In infants with HCM, after exclusion of reversible causes (maternal dia­
betes,253 twin–twin syndrome, corticosteroid use254,255), it is important to 
define, along with the pattern of hypertrophy (asymmetric, concentric, bi­
ventricular), the presence of LVOTO, diastolic and/or systolic dysfunc­
tion,1,256 and RV involvement. Early-onset sarcomeric disease (including 
double/compound variants) should be excluded even in the absence of a 
family history for HCM and SCD; these infants present with severe heart 
failure symptoms, and survival beyond the first year of life is uncommon.257
In contrast, clinical presentation with heart failure is rare in infants with het­
erozygous sarcomeric disease compared with malformation syndromes or 
metabolic disorders, in whom survival rates are <90% and <70% at 1 year, 
respectively.248,258,259 In infants with HCM, in the presence of biventricular 
outflow tract obstruction and ≥1 red flag for a neurocardiofaciocutaneous 
syndrome (dysmorphisms, cutaneous abnormalities, skeletal anomalies, 
etc.), a diagnosis of RASopathies should be strongly suspected.260–263
Severe LVOTO in RASopathy-related HCM often requires high-dose 
beta blockade and, in some cases, consideration of septal myectomy.264– 
267 In infants with HCM, biventricular hypertrophy, often presenting 
with signs of heart failure and systolic dysfunction, and ≥1 red flag for meta­
bolic disease (muscle hypotonia, increased CK, and transaminases, consan­
guinity or matrilineal pattern of inheritance), it is mandatory to exclude 
inborn errors of metabolism, including glycogenosis type II (Pompe dis­
ease), fatty acid oxidation defects, and mitochondrial disorders.268–272 In 
infants with Pompe disease, enzyme replacement therapy (ERT) has 
been shown to result in reversal of LVH.269,273–275
In infants with DCM, reversible causes (i.e. hypocalcaemic vitamin 
D-dependent rickets) and CHD (aortic coarctation and ALCAPA, re­
quiring immediate surgical management) should be ruled out.249,276,277
Viral myocarditis should also be excluded by non-invasive (i.e. laboratory) 
and invasive (EMB) investigations, in selected cases.278,279 Neuromuscular 
(dystrophin- and sarcoglycan-related cardiomyopathies) should be ex­
cluded in patients presenting with muscle hypotonia and increased CK, 
and a multidisciplinary approach involving a neurologist and experts in 
metabolic disease is required.280–282 When a DCM phenotype is asso­
ciated with LV hypertrabeculation, other mitochondrial/metabolic dis­
eases, including Barth syndrome, should be considered.283–285
Isolated RCM is rare in infants, but a mixed RCM/HCM phenotype is 
more frequently encountered. Familial cases are frequent, particularly 
in patients with an RCM/HCM phenotype.286–289 Independently of 
the phenotype, it is generally associated with poor prognosis, though 
the RCM/HCM phenotype has significantly better transplant-free sur­
vival than isolated RCM.286
Arrhythmogenic RV cardiomyopathy and non-dilated LV cardiomy­
opathy phenotypes are very rare in infants, and are most commonly 
autosomal recessive forms associated with cutaneous manifestations 
(e.g. Naxos disease and Carvajal syndrome),290–292 although this may 
reflect a lack of systematic clinical screening for these conditions in early 
childhood. Recent data suggest that ∼15% of ARVC patients present 
with paediatric-onset disease and paediatric ARVC patients more often 
present with severe phenotype and higher risk of SCD.293 Increasingly, 
children with ARVC and NDLVC phenotypes presenting with acute 
myocarditic presentations are recognized.294–297
6.10. General principles in the 
management of patients with 
cardiomyopathy
6.10.1. Assessment of symptoms
Some people with subtle structural abnormalities with cardiomyopathy 
remain asymptomatic and have a normal lifespan; however, others may 
develop symptoms, often many years after the appearance of ECG or 
imaging evidence of disease. In infants, symptoms and signs of heart fail­
ure include tachypnoea, poor feeding, excessive sweating, and failure to 
thrive. Older children, adolescents, and adults complain of fatigue and 
dyspnoea as well as chest pain, palpitations, and syncope. Because the 
New York Heart Association (NYHA) classification to grade heart fail­
ure is not applicable to children under the age of 5 years, the Ross 
Heart Failure classification has been adopted in children <5 years of 
age but has not been validated against outcomes.298 Systematic 
two-dimensional (2D) and Doppler echocardiography, resting and am­
bulatory ECG monitoring, and exercise testing are usually sufficient to 
determine the most likely cause of symptoms. Additional investigations 
(e.g. coronary CT scanning or coronary angiography, cardio-pulmonary 
exercise testing [CPET], electrophysiological study, loop recorder im­
plantation) should be considered to investigate specific symptoms of 
chest pain, syncope, and palpitation, according to established clinical 
practice and guidelines.1,4,69,299–301 Cardiac catheterization to evaluate 
right and left heart function and pulmonary arterial resistance, and 
CPET with simultaneous measurement of respiratory gases, is not a 
standard part of the work-up, but remains recommended in severely 
symptomatic patients with systolic and/or diastolic LV dysfunction 
when uncertainty about filling status exists, or for those being consid­
ered for heart transplantation or mechanical circulatory support.69
6.10.2. Heart failure management
The clinical management of heart failure has been described in the 2021 ESC 
Guidelines for the diagnosis and treatment of acute and chronic heart failure.69In 
that document, recommendations are generally independent from the aeti­
ology of heart failure and include current medical therapy, devices, and LV 
assist device (LVAD)/transplantation. As such, the treatment recommenda­
tions must be regarded as generic and not specific to the different forms of 
cardiomyopathy. Medical therapies for HFrEF based on randomized con­
trolled trials (RCTs) from large cohorts, including angiotensin-converting 
enzyme inhibitors (ACE-I)/angiotensin receptor neprilysin inhibitors 
(ARNIs), beta-blockers, mineralocorticoid receptor antagonists (MRA), 
and sodium–glucose co-transporter 2 inhibitors (SGLT2i), would be mostly 
applicable to genetic DCM, NDLVC, and other phenotypes associated with 
LV dysfunction (e.g. end-stage HCM, RCM, and ARVC). Indications for a 
cardiac resynchronization therapy (CRT) device and heart transplant 
would also be generally applicable accordingly. Recommendations for man­
agement of HFpEF would be mainly applicable to non-obstructive HCM, 
RCM, and cardiac amyloidosis. A Focused Update is due to be published 
in 2023.69a
Individual response to heart failure therapies may not be the same 
for different specific genetic causes, as has been demonstrated in sev­
eral observational studies.302,303 Further management considerations 
applicable to specific cardiomyopathy subtypes in adults and children, 
and in particular contexts, such as pregnancy and rare metabolic geno­
copies, are rapidly developing304 and are discussed in the specific car­
diomyopathy sections (see Sections 7.6 and 8.2.2).
Cardiac amyloidosis and some forms of RCM deserve special consid­
eration regarding heart failure management. Fluid control and mainten­
ance of euvolaemia are central. If heart failure symptoms are present, 
loop diuretics should be given, although orthostatic hypotension may 
cause intolerance, and excessive fluid loss may worsen symptoms 
due to restriction (e.g. in HCM or amyloidosis). The role of beta- 
blockers, ACE-Is, angiotensin receptor blockers (ARBs), or ARNIs in 
the treatment of these patients has not been determined and they 
may not be well tolerated because of hypotension.305 Moreover, 
ESC Guidelines                                                                                                                                                                                          3539


<!-- PAGE 38 -->

### Page 38

withdrawal of these drugs frequently leads to improvement in symp­
toms and should be considered.
Heart failure with an LVEF >40–50% recovered from HFrEF or 
HFmrEF (improved LVEF306) is not separately considered in the 2021 
ESC Guidelines for the diagnosis and treatment of acute and chronic heart 
failure, but is particularly important for genetic DCM, as a substantial 
proportion of patients with HFrEF or HFmrEF will improve their 
LVEF with guideline-directed medical therapy (GDMT).69 Patients 
and physicians are faced with the dilemma of whether to continue life­
long pharmacotherapy or wean at some point. The TRED-HF (Therapy 
withdrawal in REcovered Dilated cardiomyopathy—Heart Failure) trial 
is the only RCT that evaluated if weaning GDMT is safe. The results 
showed that a large proportion of the patients had recurrent LV dys­
function or heart failure, so current recommendations caution against 
weaning.307
6.10.2.1. Preventive heart failure medical therapy of asymptomatic 
carriers/early disease expression
Heart failure therapy should be guided according to the 2021 ESC 
Guidelines for the diagnosis and treatment of acute and chronic heart failure 
for HFrEF, HFmrEF, and HFpEF in patients with cardiomyopathy and 
heart failure symptoms.69,69a Evidence for treatment recommendations 
in asymptomatic LV dysfunction is scarce, which presents a challenge 
for genetic cardiomyopathies, where a sizeable proportion of the pa­
tients are young with no or only mild symptoms, and where asymptom­
atic patients are frequently discovered through cascade screening. 
Because heart failure medication has proved to affect LV remodelling 
in symptomatic patients with LV dysfunction, first-line heart failure 
therapy may be considered in patients with early forms of DCM/ 
NDLVC to prevent progression of LV dilatation and dysfunction (e.g. 
ACE-I, ARBs, beta-blockers and MRAs, Class IIb Level C). Biomarkers 
may help to identify pre-symptomatic patients who might benefit 
from early neuro-hormonal blockade.308 The effect of heart failure 
drugs to prevent progression into overt disease in genetic carriers of 
DCM-/NDLVC-causing variants is currently unsettled. A placebo- 
controlled trial (EARLY-Gene trial) is under way to test the utility of 
candesartan to prevent LV dysfunction/dilatation in this scenario 
(EudraCT: 2021-004577-30).
Management in other asymptomatic affected patients with diagnoses 
of HCM, ARVC, and RCM should be decided individually, as medication 
has not been proved to affect disease expression.
There is no evidence to support the use of current pharmacological 
agents for the prevention of disease development in non-affected car­
riers. Randomized controlled trials are warranted in order to address 
the value of new pharmacologic agents in this scenario.309
Heart failure therapies are given to children with cardiomyopathies, 
applying the evidence from adults to children or based on a limited 
number of clinical studies.310 Heart failure therapies routinely used in 
children with LV dysfunction are ACE-Is, beta-blockers, diuretics, and 
aldosterone antagonists. Angiotensin receptor blockers are an alterna­
tive for ACE-Is. Early results of the multicentric randomized control 
PANORAMA-HF Trial and the subsequent Food and Drug 
Administration (FDA) approval for ARNI in children have paved the 
way for this newer class of drugs for paediatric patients with symptom­
atic heart failure with systemic left ventricle systolic dysfunction, 1 year 
of age and older. Dosing recommendations in younger children are cur­
rently pending,311 but for children <40 kg a starting dose of 1.6 mg/kg 
titrated to a maximum of 3.1 mg/kg has been suggested.312 There are 
currently no clinical trial or efficacy data available for SGLT-2 inhibitors 
in children.
6.10.2.2. Cardiac transplantation
Orthotopic cardiac transplantation should be considered in patients 
with moderate-to-severe drug-refractory symptoms (NYHA function­
al class III–IV) who meet standard eligibility criteria (see the 2021 ESC 
Guidelines for the diagnosis and treatment of acute and chronic heart fail­
ure).69 This may include patients with RCM and HCM with normal LVEF 
but severe drug-refractory symptoms (NYHA functional class III–IV) 
caused by diastolic dysfunction.313–316 In patients with refractory ven­
tricular arrhythmias that cannot be solely attributed to an acute decom­
pensation in the setting of end-stage heart failure, a comprehensive 
evaluation of all potential therapeutic options (e.g. pharmacotherapy; 
ventricular tachycardia [VT] ablation including epicardial access if indi­
cated and feasible; cardiac sympathetic denervation in patients with 
electrical storm and/or refractory polymorphic VT or rapid mono­
morphic VT) should be undertaken before recommending cardiac 
transplantation (see Section 6.10.4).
6.10.2.3. Left ventricular assist devices
As there are increasing numbers of patients with end-stage heart fail­
ure, and the organ donor pool remains limited, mechanical circulatory 
support (MCS) with an LVAD or biventricular assist device is
Recommendation Table 9 — Recommendations for 
cardiac transplantation in patients with cardiomyopathy
Recommendations
Classa
Levelb
Orthotopic cardiac transplantation is recommended 
for eligible cardiomyopathy patients with advanced 
heart failure (NYHA class III–IV) or intractable 
ventricular arrhythmia refractory to medical/invasive/ 
device therapy, and who do not have absolute 
contraindications.317–319
I
C
© ESC 2023
NYHA, New York Heart Association. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 10 — Recommendation for 
left ventricular assist device therapy in patients with 
cardiomyopathy
Recommendation
Classa
Levelb
Mechanical circulatory support therapy should be 
considered in selected cardiomyopathy patients with 
advanced heart failure (NYHA class III–IV) despite 
optimal pharmacological and device treatment, who 
are otherwise suitable for heart transplantation, to 
improve symptoms and reduce the risk of heart failure 
hospitalization from worsening heart failure and 
premature death while awaiting a transplant.320–324
IIa
B
Mechanical circulatory support therapy should be 
considered in selected cardiomyopathy patients with 
advanced heart failure (NYHA class III–IV) despite 
optimal pharmacological and device therapy, who are 
not eligible for cardiac transplantation or other 
surgical options, and without severe right ventricular 
dysfunction, to reduce the risk of death and improve 
symptoms.321,325–330
IIa
B
© ESC 2023
NYHA, New York Heart Association. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 39 -->

### Page 39

increasingly used as a bridge to transplant. Long-term MCS should also 
be considered as destination therapy for cardiomyopathy patients with 
advanced heart failure despite optimal medical therapy who are not eli­
gible for transplantation.69
6.10.3. Management of atrial arrhythmias
Atrial fibrillation is the most common arrhythmia in all subtypes of 
cardiomyopathies and is associated with an increased risk of 
cardio-embolic events, heart failure, and death.331–333 Data from 
3208 consecutive adult patients in the EURObservational 
Research Programme (EORP) Cardiomyopathy Registry showed 
an AF prevalence of 28.2% at baseline and 31.1% during follow- 
up,331–333 although it differed among cardiomyopathy types (see 
Table 15). Overall, annual incidence in this registry was 
3.0%.332,333 In patients with cardiomyopathies, the presence of AF 
is associated with more severe symptoms, an increased prevalence 
of cardiovascular risk factors and comorbidities, and an increased 
incidence of stroke and death (from any cause and from heart 
failure).332,334–336
Both the 2020 ESC Guidelines for the diagnosis and management of at­
rial fibrillation and the 2021 ESC Guidelines for the diagnosis and treatment 
of acute and chronic heart failure recommend an integrated and struc­
tured approach to facilitate guideline-adherent management. The 
Atrial Fibrillation Better Care (ABC) approach has been shown to re­
duce the risk of stroke and systemic embolism, myocardial infarction, 
and mortality in the general population.337–361 Although this approach 
has not been specifically assessed in patients with cardiomyopathies, 
heart failure was present in ∼20% of the individuals of these studies 
and, where specified, cardiomyopathy in ∼5.5–6.5%. In particular, 
two RCTs support integrated care.347,361 The RACE 3, combining 
the components of the ABC pathway into structured care, resulted 
in reduced AF burden and better rhythm control among 245 patients 
with early persistent AF and stable heart failure (119 randomized to tar­
geted and 126 to conventional therapy).347 The mobile Atrial 
Fibrillation App Trial (mAFA-II), which included 714 patients with heart 
failure (21.5%), 54 with HCM (1.6%), and 105 with DCM (3.2%), 
showed the superiority of integrated care supported by mobile tech­
nology in the composite outcome of ‘ischaemic stroke/systemic 
thrombo-embolism, death, and re-hospitalization’ (1.9% vs. 6.0%; haz­
ard ratio [HR] 0.39; 95% confidence interval [CI], 0.22 to 0.67; P <  
0.001) and re-hospitalization rates (1.2% vs. 4.5%; HR 0.32; 95% CI, 
0.17 to 0.60; P < 0.001).361 Adherence to the mobile health technology 
beyond 1 year was good, and was associated with a reduction in ad­
verse clinical outcomes.362
6.10.3.1. Anticoagulation
Thrombo-embolic risk varies in different cardiomyopathy phenotypes 
(see Section 7).332,363–367 Cardiac amyloidosis, HCM, and RCM368 are 
associated with a particularly increased risk of stroke.332,365,369,370
The EORP registry indicated a worse prognosis for the population 
with cardiomyopathy and concurrent AF with an annual incidence of 
stroke/transient ischaemic attack (TIA) about three times higher in 
the cardiomyopathy group with AF.332,334 Hence, considering anticoa­
gulation is key in patients with any type of AF or atrial flutter.
Importantly, patients with cardiomyopathy and AF have more 
cardio-embolic risk factors, including greater age, more advanced 
NYHA class and more frequent history of stroke/TIA, hypertension, 
and diabetes mellitus, among others.332,333 The CHA2DS2-VASc (con­
gestive heart failure or left ventricular dysfunction, hypertension, age 
≥75 [doubled], diabetes, stroke [doubled]-vascular disease, age 65– 
74, sex category [female]) score has not been specifically tested in pa­
tients with cardiomyopathies,369 and retrospective evidence suggests 
that it may perform suboptimally with respect to stroke prediction in 
HCM and ATTR amyloidosis.334,365,371–374 For this reason, although 
there are no RCTs evaluating the role of anticoagulation among pa­
tients with HCM, given the high incidence of stroke, prophylactic antic­
oagulation is recommended in all patients with HCM and 
AF.334,371,372,374 A similar recommendation is given in patients with 
AF and RCM or cardiac amyloidosis.375 In patients with DCM, 
NDLVC, or ARVC and AF, chronic oral anticoagulation should be con­
sidered on an individual basis, taking into consideration the 
CHA2DS2-VASc score, as proposed by the 2020 ESC Guidelines for 
the diagnosis and management of atrial fibrillation.336 Atrial fibrillation is 
a rare finding in children with genetic cardiomyopathies and no data 
are available regarding the performance of CHA2DS2-VASc or any 
other risk stratification score, nor the risk and benefit of prescribing 
oral anticoagulation. There are no data on long-term prophylactic antic­
oagulation in children with DCM in sinus rhythm.
In the general population, direct-acting oral anticoagulants (DOACs) 
are preferred for the prevention of thrombo-embolic events in patients 
with AF and without severe mitral stenosis and/or mechanical valve 
prosthesis, as they have similar efficacy to vitamin K antagonists 
(VKAs) but a lower risk of intracranial haemorrhage.376 There are no 
randomized data comparing direct oral anticoagulants with VKAs in pa­
tients with cardiomyopathy, although data suggest that they may be 
used in a similar manner as the general population.373,374,377–380
6.10.3.2. Rate control
Rate control should be considered in any patient with cardiomyopathy 
presenting with AF.336 A strict rate control (resting heart rate 
<80 beats per minute [b.p.m.] and heart rate during moderate exercise 
<110 b.p.m.) did not show any benefit over lenient rate control (resting 
heart rate <110 b.p.m.) in RACE II381 and a pooled analysis of RACE II 
and AFFIRM.382 However, only 8–12% of patients had a history of car­
diomyopathy (type unspecified) in the RACE II trial, and only 10% of the 
patients in RACE II and 17% of those in the pooled analysis had a history 
of heart failure hospitalization or NYHA class II or III, respectively.381,382
No data are available for the different cardiomyopathy subtypes, but 
observational studies suggest that higher heart rates are associated 
with worse outcomes in patients with heart failure.383,384
Accordingly, the 2021 ESC Guidelines for the diagnosis and treatment 
of acute and chronic heart failure consider lenient rate control to be ac­
ceptable as an initial approach but to target a lower heart rate in case of 
persistent symptoms or suspicion of associated tachycardia-induced 
cardiac dysfunction.69
Very little data are available regarding the choice of pharmacological 
treatment for rate control in patients with cardiomyopathies. 
Beta-blockers are the preferred choice in patients with cardiomyop­
athies given their long-established safety in the presence of LV dysfunc­
tion.385,386 Digoxin is an alternative, particularly in patients with 
contraindication or intolerance to beta-blockers and among patients 
with AF and heart failure symptoms (RATE-AF trial), having shown 
no difference in quality of life (QoL) at 6 months compared with biso­
prolol.387 When administering digoxin, close monitoring of plasma drug 
ESC Guidelines                                                                                                                                                                                          3541


<!-- PAGE 40 -->

### Page 40

Table 15 Atrial fibrillation burden and management in cardiomyopathies
Condition
AF epidemiology
AF management
Prevalence
Annual 
incidence
Anticoagulation
Long-term rate control
Long-term rhythm control
HCM
17–39%331–334,365,413,421–428
2.8– 
4.8%332,333,365
Always (if no 
contraindication)371,429
Beta-blockers (preferred) 
Verapamil or diltiazem (only if 
preserved LVEF) 
Digoxin 
AV node ablation + CRT or 
physiological pacing388–390
Rhythm control is preferred
Amiodarone, dofetilide 
disopyramide, sotalol,a 
dronedaroneb
Ablation397,412,415,416,418,430– 
435
DCM
25–49%331–333,426,436,437
LMNA related438–441
3.8–5.5%332,333
According to cardio-embolic 
risk 
(always if HF or reduced 
LVEF)c
Beta-blockers (preferred) 
Digoxin 
AV node ablation + CRT or 
physiological pacing388–390
Rhythm control preferred in case of symptoms or/and heart failure or 
LV dysfunction
Amiodarone, sotalola
Ablation
NDLVC
39.2–43.1%d 442–444
4.4–12%d 
442,444,445
According to cardio-embolic 
risk 
(always if HF or reduced 
LVEF)
Beta-blockers (preferred) 
Digoxin 
Verapamil or diltiazem (only if 
LVEF ≥40%) 
AV node ablation + CRT or 
physiological pacing388–390
Rhythm control preferred in case of symptoms or/and heart failure or 
LV dysfunction
Flecainidee, amiodarone, sotalola
Ablation446
ARVC
9–30%331–333,437,447–451
2.1–2.8%332,333
According to cardio-embolic 
risk 
(always if HF or reduced 
LVEF)
Beta-blockers (preferred) 
Verapamil or diltiazem (only if 
LVEF ≥40%) 
AV node ablation + CRT or 
physiological pacing388–390
Rhythm control preferred in case of symptoms or/and heart failure or 
LV dysfunction
Flecainidee (associated with 
beta-blockers) 
Amiodarone, sotalola
Ablation
RCM
45–51%331–333
4.5–10.3%332,333
Always (if no 
contraindication)
Beta-blockersd (preferred) 
Digoxinf 
Verapamil or diltiazem (only if 
≥40%) 
AV node ablation + CRT or 
physiological pacing388–390
Rhythm control is preferred
Amiodarone
No data
© ESC 2023
AF, atrial fibrillation; ARVC, arrhythmogenic right ventricular cardiomyopathy; AV, atrioventricular; CrCl, creatinine clearance; CRT, cardiac magnetic resonance; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; HF, heart failure; 
HFpEF, heart failure with preserved ejection fraction; LMNA, lamin A/C; LV, left ventricular; LVEF, left ventricular ejection fraction; NDLVC, non-dilated left ventricular cardiomyopathy; QRS, Q, R, and S waves of an ECG; RCM, restrictive 
cardiomyopathy. 
aUse with caution as evidence suggests that it may be associated with increased all-cause mortality.452
bDronedarone is not contraindicated in LV hypertrophy but has no significant studies in HCM. 
cLMNA-related DCM: increased risk of stroke (8–22%).368,440
dExtrapolated from studies reporting prevalent and incident AF in HFpEF. 
eContraindicated in patients with ischaemic heart disease or reduced LVEF. Should not be used in patients with CrCl <35 mL/min/1.73 m2 and significant liver disease. Should be discontinued in case of QRS widening >25% above baseline and patients 
with left bundle branch block or any other conduction block >120 ms. Caution when sinoatrial/atrioventricular conduction disturbances. 
fIn cardiac amyloidosis, beta-blockers in low dosage and digoxin with caution.453,454 Non-dihydropyridine calcium channel blockers may worsen LV systolic function and heart failure.455


<!-- PAGE 41 -->

### Page 41

levels is needed, as observational data suggest higher mortality in pa­
tients with AF, regardless of heart failure; the risk of death was related 
to serum digoxin concentration and was highest in patients with con­
centrations ≥1.2 ng/mL. On the contrary, a lower mortality with beta- 
blocker therapy in AF patients with concomitant heart failure has been 
observed. Non-dihydropyridine calcium channel blockers (CCBs) (ver­
apamil or diltiazem) may only be used in patients with LVEF ≥40%.336
Atrioventricular node ablation is also an alternative in patients with 
poor ventricular rate control despite medical treatment not eligible 
for rhythm control by catheter ablation or in patients with biventricular 
pacing.336 In patients with symptomatic persistent AF (>6 months) un­
suitable for AF ablation or in which AF ablation had failed, narrow QRS 
and at least one admission for heart failure, AV node ablation in asso­
ciation with CRT has been shown to be superior to rate control with 
pharmacological therapy, reducing the composite outcome of death 
due to heart failure, or hospitalization due to heart failure, or worsening 
heart failure,388 and all-cause mortality,389 irrespective of baseline EF 
(APAF-CRT Trial). Whether conduction system-pacing is a (better) al­
ternative to CRT needs to be further explored with only one small 
crossover trial (ALTERNATIVE-AF) comparing His-Bundle pacing 
(HBP) and biventricular pacing in 50 patients with LVEF ≤40% with per­
sistent AF undergoing AV node ablation.390 In this study, both arms sig­
nificantly improved LVEF at 9 months, with a small, but statistically 
significant superiority with HBP.69,336
6.10.3.3. Rhythm control
Atrial fibrillation can result in haemodynamic and clinical decompensa­
tion due to shortening of the diastolic filling time with rapid heart rates 
and dependence on atrial contraction for LV filling. Therefore, mainten­
ance of sinus rhythm is highly desirable and a rhythm control strategy is 
preferred, particularly in the presence of symptoms.
Regarding long-term pharmacological treatment,336 antiarrhythmic 
drugs (AADs) have shown limited success in maintaining sinus rhythm 
over time both in the general population and in patients with cardiomy­
opathies,391–393 show high rates of withdrawal due to intolerance,394
and, most importantly, are associated with significant side effects, includ­
ing proarrhythmia and extracardiac side effects, and, in some cases (so­
talol and class IA drugs, such as quinidine and disopyramide), increased 
mortality.394 As a consequence, a degree of caution is recommended 
when using antiarrhythmic drugs in this population. Data on antiarrhyth­
mic therapy for the specific management of AF in the context of genetic 
cardiomyopathies other than HCM are scarce. It is important to note the 
potential for proarrhythmia of class I antiarrhythmics, particularly in the 
presence of significant structural heart disease; these should therefore be 
used with caution. Antiarrhythmic drug–drug treatment has mostly been 
limited to amiodarone or sotalol, as there are no available data regarding 
other antiarrhythmics such as dofetilide or dronedarone. Importantly, 
sotalol should not be used in patients with HFrEF, significant LVH, pro­
longed QT, asthma, hypokalaemia, or creatinine clearance (CrCl) 
<30 ml/min. Likewise, dronedarone should be avoided in patients with 
recent decompensated heart failure or permanent AF as it has been 
shown to increase mortality.395,396
Catheter ablation of AF is a safe and superior alternative to AAD ther­
apy for maintenance of sinus rhythm, reducing AF-related symptoms, and 
improving QoL, and can be considered an alternative to AAD therapy in 
practically any type and context of AF.336,397 In patients with AF and nor­
mal LVEF, catheter ablation has not been shown to reduce total mortality 
or stroke.398 In selected patients with HFrEF,399–401 ablation has shown a 
reduction in all-cause mortality and hospitalizations, and should be con­
sidered as a first-line option. In the general AF population, the Early 
Treatment of Atrial Fibrillation for Stroke Prevention Trial 
(EAST-AFNET 4) randomized 2789 patients with early AF and associated 
cardiovascular comorbidities to an early rhythm control strategy or usual 
care (28.6% with heart failure).402 The trial was stopped early after a me­
dian follow-up of 5.1 years for a lower occurrence of the primary out­
come of death, stroke, or hospitalization for worsening heart failure or 
acute coronary syndrome in the patients in the early rhythm control 
group vs. those assigned to usual care. A pre-specified analysis evaluated 
the effects in patients with heart failure, showing the benefit of early 
rhythm control in this subgroup of patients,403 findings which corrobo­
rated those of the CABANA trial.400 In patients with AF and heart failure, 
several RCTs have demonstrated an improvement in outcomes with 
catheter ablation when compared with medical therapy.399–401,404–409
Some observational studies in patients with HFpEF have also suggested 
better results in terms of freedom from AF and all-cause mortality,410
but proper RCTs are warranted.
The role of catheter ablation in patients with cardiomyopathies has 
been reported in several registries, mainly in HCM patients.397,411–420
Overall, maintenance is achieved in up to two-thirds of patients, although 
repeat procedures or continuation of antiarrhythmic medications are of­
ten necessary.397,411,415–419 Patients with cardiomyopathies may have a 
higher risk of AF recurrence, particularly in the presence of atrial remod­
elling/dilatation.397
6.10.3.4. Comorbidities and risk factor management
Cardiovascular risk factors and comorbidities are also more frequent 
in patients with cardiomyopathies and AF. These include smoking, 
alcohol consumption, hypertension, diabetes mellitus type 2, hyperlip­
idaemia, renal impairment, chronic obstructive pulmonary disease, 
valvular 
and 
ischaemic 
heart 
disease, 
and 
anaemia.332,334
Furthermore, these patients have a larger body mass index and report 
less physical activity than those without AF.332,334 These risk factors 
and comorbidities are associated with the risk of AF and its 
complications and should therefore be appropriately identified and 
managed to prevent AF progression and the occurrence of adverse 
outcomes.336
Recommendation Table 11 — Recommendations for 
management of atrial fibrillation and atrial flutter in 
patients with cardiomyopathy
Recommendations
Classa
Levelb
Anticoagulation
Oral anticoagulation in order to reduce the risk of 
stroke and thrombo-embolic events is recommended 
in all patients with HCM or cardiac amyloidosis and AF 
or atrial flutter (unless 
contraindicated).332,365,369,371,373,378,413,427,428,456–464
I
B
Oral anticoagulation to reduce the risk of stroke and 
thrombo-embolic events is recommended in patients 
with DCM, NDLVC, or ARVC, and AF or atrial 
flutter with a CHA2DS2-VASc score ≥2 in men or 
≥3 in women.465–469
I
B
Continued 
ESC Guidelines                                                                                                                                                                                          3543


<!-- PAGE 42 -->

### Page 42

6.10.4. Management of ventricular arrhythmias
Ventricular arrhythmias, particularly in the form of electrical storm and/ 
or repetitive appropriate ICD interventions, contribute to a significant­
ly increased risk of morbidity and mortality in patients with 
cardiomyopathies.299
The 2022 ESC Guidelines for the management of patients with ventricu­
lar arrhythmias and the prevention of sudden cardiac death provide de­
tailed recommendations on acute and long-term management of 
ventricular arrhythmias in patients with cardiomyopathies.299 Limited 
data exist addressing ventricular arrhythmia management in patients 
with specific genetic cardiomyopathies. Nonetheless, some general 
concepts can be highlighted: 
• Any reversible cause and/or precipitating factor, such as electrolyte 
imbalances, ischaemia, hypoxaemia, or drugs, should be identified 
and corrected when possible.
• Extensive efforts should be made in the attempt to understand the 
aetiology (i.e. underlying mechanism and substrate, and their relation­
ship with the underlying cardiomyopathy) as this will influence the 
choice of treatment.
• Acute termination of sustained ventricular arrhythmias can be 
achieved with electrical cardioversion, AADs, or pacing. The initial 
choice of treatment will depend on the haemodynamic tolerance, 
the underlying aetiology, and the patient profile.
• In patients presenting with electrical storm, mild-to-moderate sed­
ation is recommended to alleviate psychological distress and reduce 
sympathetic tone. If the electrical storm remains intractable despite 
antiarrhythmic therapies, deep sedation/intubation should be 
considered.
• In case of incessant ventricular arrhythmias and electrical storm not 
responding to antiarrhythmic medication, catheter ablation is recom­
mended. In refractory cases or whenever VT ablation is either not in­
dicated or not immediately available, autonomic modulation (i.e. 
stellate ganglion block or cardiac sympathetic denervation, depending 
on the setting) and/or MCS may be considered.
• In patients with cardiomyopathies and scar-related ventricular ar­
rhythmias, the therapeutic arsenal for long-term prevention of recur­
rent ventricular arrhythmias includes antiarrhythmic medications 
(mostly limited to beta-blockers, sotalol, and amiodarone) and cath­
eter ablation (particularly in the case of sustained monomorphic VT 
or in the case of polymorphic VT triggered by a premature ventricu­
lar complex of similar morphology). Additional strategies, performed 
by experienced centres, may be considered, depending on the char­
acteristics of the patient and the ventricular arrhythmia, including 
acute neuromodulation strategies (stellate ganglion block and thor­
acic epidural anaesthesia), chronic neuromodulation strategies (car­
diac sympathetic denervation), and stereotactic non-invasive VT 
ablation.514–520 Limited data are available at present concerning the 
long-term cardiac and extracardiac safety of stereotactic non-invasive 
VT ablation, as well as the dose–response relationship, therefore its 
usage should be limited to compassionate cases or within prospective 
clinical studies.
• The acute as well as the chronic management of patients with cardio­
myopathies and refractory ventricular arrhythmias, particularly in 
case of concomitant moderate-to-severe ventricular dysfunction, 
should involve an integrated evaluation by a heart team including car­
diomyopathy specialists, electrophysiologists with specific experi­
ence in catheter ablation of ventricular arrhythmias and 
neuromodulation, anaesthesiologists, and cardiac surgeons.
6.10.5. Device therapy: implantable cardioverter 
defibrillator
Implantable cardioverter defibrillators are effective at correcting poten­
tially lethal ventricular arrhythmias and preventing SCD, but are also as­
sociated with complications, particularly in young patients who will 
Oral anticoagulation to reduce the risk of stroke and 
thrombo-embolic events should be considered in 
patients with RCM and AF or atrial flutter (unless 
contraindicated).
IIa
C
Oral anticoagulation to reduce the risk of stroke and 
thrombo-embolic events should be considered in 
patients with DCM, NDLVC, or ARVC, and AF or 
atrial flutter with a CHA2DS2-VASc score of 1 in men 
or of 2 in women.470–472
IIa
B
Control of symptoms and heart failure
Atrial fibrillation catheter ablation is recommended 
for rhythm control after one failed or intolerant class 
I or III AAD to improve symptoms of AF recurrences 
in patients with paroxysmal or persistent AF and 
cardiomyopathy.335,397–399,412,415–420,430– 
435,447,451,473–498
I
B
Atrial fibrillation catheter ablation is recommended 
to reverse LV dysfunction in AF patients with 
cardiomyopathy when tachycardia-induced 
component is highly probable, independent of their 
symptom status.405,407,408,499–501
I
B
Maintenance of sinus rhythm rather than rate control 
should be considered at an early stage for patients 
with a cardiomyopathy and AF without major risk 
factors for recurrence, regardless of symptoms.402
IIa
C
Atrial fibrillation catheter ablation should be 
considered as first-line rhythm control therapy to 
improve symptoms in selected patients with 
cardiomyopathy and paroxysmal or persistent AF 
without major risk factors for recurrences as an 
alternative to class I or III AADs, considering patient 
choice, benefit, and risk.392,393,480,502–506
IIa
C
Atrial fibrillation catheter ablation should be 
considered in selected patients with cardiomyopathy, 
AF, and heart failure and/or reduced LVEF to prevent 
AF recurrences and improve QoL, LVEF, and survival 
and reduce heart failure hospitalization.399–401,403– 
408,499–501,507
IIa
B
Comorbidities and associated risk factors management
Modification of unhealthy lifestyle and targeted 
therapy of intercurrent conditions is recommended 
to reduce AF burden and symptom severity in 
patients with cardiomyopathy.347,508–513
I
B
© ESC 2023
AAD, antiarrhythmic drug; AF, atrial fibrillation; ARVC, arrhythmogenic right ventricular 
cardiomyopathy; CHA2DS2-VASc, congestive heart failure or left ventricular dysfunction, 
hypertension, age ≥75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65–74, 
sex category (female) (score); DCM, dilated cardiomyopathy; HCM, hypertrophic 
cardiomyopathy; LV, left ventricular; LVEF, left ventricular ejection fraction; NDLVC, 
non-dilated left ventricular cardiomyopathy; QoL, quality of life; RCM, restrictive 
cardiomyopathy. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 43 -->

### Page 43

require several replacements during their lifetimes. Implantable cardio­
verter defibrillators reduce mortality in survivors of cardiac arrest and 
in patients who have experienced haemodynamically compromising 
sustained ventricular arrhythmias.521–523 An ICD is recommended in 
such patients when the intent is to increase survival; the decision to im­
plant should consider the patient’s view and their QoL, as well as the 
absence of other diseases likely to cause death within the following 
year.
Arrhythmic risk calculators may be useful tools to predict the risk of 
SCD and, where available, they may provide a clinical benefit compared 
with a risk factor approach.524–526 The issue of the threshold for ICD 
implantation may be a reasonable concern as every cut-off point comes 
with a trade-off between unnecessary ICDs with their potential compli­
cations vs. the potential for unprotected SCD. The relative weight of 
these opposing undesirable events varies significantly from one person 
to another and should be part of the individualized decision-making 
process. Risk stratification strategies in each cardiomyopathy and the 
role of ICDs for primary prevention are discussed in Section 7.
The 2022 ESC Guidelines for the management of patients with ventricu­
lar arrhythmias and the prevention of sudden cardiac death provide de­
tailed recommendations regarding optimal device programming and 
prevention/treatment of inappropriate therapy. The implantation of 
conditional devices is reasonable taking into account the expected 
need for CMR during follow-up. In children, simpler ICD devices (e.g. 
single chamber/single coil or subcutaneous) should be considered, bear­
ing in mind specific issues of body size/shape and growth. The wearable 
cardioverter defibrillator has been shown to detect and treat ventricu­
lar arrhythmias successfully.527 However, data on its benefit for primary 
prevention other than the early phase of myocardial infarction (e.g. 
myocarditis, PPCM etc.) are scarce and no recommendation can be 
made at present.
Recommendation Table 12 — Recommendations for 
implantable cardioverter defibrillator in patients with 
cardiomyopathy
Recommendations
Classa
Levelb
General recommendations
Implantation of a cardioverter defibrillator is only 
recommended in patients who have an expectation 
of good quality survival >1 year.
I
C
It is recommended that ICD implantation be guided 
by shared decision-making that: 
• is evidence-based;
• considers a person’s individual preferences, beliefs, 
circumstances, and values; and
• ensures that the person understands the benefits, 
harms, and possible consequences of different 
treatment options.c
I
C
It is recommended that prior to ICD implantation, 
patients are counselled on the risk of inappropriate 
shocks, implant complications, and the social, 
occupational, and driving implications of the device.
I
C
It is not recommended to implant an ICD in patients 
with incessant ventricular arrhythmias until the 
ventricular arrhythmia is controlled.
III
C
Continued 
Secondary prevention
Implantation of an ICD is recommended:d
• in patients with HCM, DCM, and ARVC who have 
survived a cardiac arrest due to VT or VF, or who 
have spontaneous sustained ventricular arrhythmia 
causing syncope or haemodynamic compromise in 
the absence of reversible causes.528–534
I
B
• in patients with NDLVC and RCM who have 
survived a cardiac arrest due to VT or VF, or who 
have spontaneous sustained ventricular arrhythmia 
causing syncope or haemodynamic compromise in 
the absence of reversible causes.
I
C
ICD implantation should be considered in patients with 
cardiomyopathy presenting with haemodynamically 
tolerated VT, in the absence of reversible causes.
IIa
C
Primary prevention
Comprehensive SCD risk stratification is 
recommended in all cardiomyopathy patients who 
have not suffered a previous cardiac arrest/sustained 
ventricular arrhythmia at initial evaluation and at 1–2 
year intervals, or whenever there is a change in 
clinical status.
I
C
The use of validated SCD algorithms/scores as aids to the shared 
decision-making when offering ICD implantation, where available:e
• is recommended in patients with HCM.81,525,535
I
B
• should be considered in patients with DCM, 
NDLVC, and ARVC.185,186,524,526,536–542
IIa
B
If a patient with cardiomyopathy requires pacemaker 
implantation, comprehensive SCD risk stratification 
to evaluate the need for ICD implantation should be 
considered.
IIa
C
Choice of ICD
When an ICD is indicated, it is recommended to 
evaluate whether the patient could benefit from 
CRT.533
I
A
Subcutaneous defibrillators should be considered as 
an alternative to transvenous defibrillators in patients 
with an indication for an ICD when pacing therapy 
for bradycardia, cardiac resynchronization, or 
antitachycardia pacing is not anticipated.543
IIa
B
The wearable cardioverter defibrillator should be 
considered for adult patients with a secondary 
prevention ICD indication who are temporarily not 
candidates for ICD implantation.
IIa
C
© ESC 2023
ARVC, arrhythmogenic right ventricular cardiomyopathy; CRT, cardiac resynchronization 
therapy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; ICD, 
implantable 
cardioverter 
defibrillator; 
NDLVC, 
non-dilated 
left 
ventricular 
cardiomyopathy; RCM, restrictive cardiomyopathy; SCD, sudden cardiac death; VF, 
ventricular fibrillation; VT, ventricular tachycardia. 
aClass of recommendation. 
bLevel of evidence. 
cShared decision-making is greatly enhanced by patient decision aids tailored specifically to 
receivers of care as well as more traditional decision-support tools for healthcare 
practitioners. 
dThe difference in level of evidence reflects the different levels of evidence available for the 
various cardiomyopathy phenotypes. 
eThe difference in class of recommendation reflects different performance of available 
models for different cardiomyopathy phenotypes.
ESC Guidelines                                                                                                                                                                                          3545


<!-- PAGE 44 -->

### Page 44

6.10.6. Routine follow-up of patients with 
cardiomyopathy
In general, patients with cardiomyopathy require lifelong follow-up to 
detect changes in symptoms, risk of adverse events, ventricular func­
tion, and cardiac rhythm.
The frequency of monitoring is determined by the severity of disease, 
age, and symptoms. A clinical examination, including 12-lead ECG and 
TTE, should be performed every 1–2 years, or sooner should patients 
complain of new symptoms. Ambulatory electrocardiography is re­
commended every 1–2 years in most patients to detect asymptomatic 
atrial and ventricular arrhythmia, and is indicated whenever patients 
experience syncope or palpitations. Cardiac magnetic resonance evalu­
ation should be considered every 2–5 years or more frequently in pa­
tients with progressive disease (see Section 6.7.3). Cardio-pulmonary 
exercise testing can provide objective evidence for worsening disease 
but need only be performed every 2–3 years unless there is a change 
in symptoms. Ergometry and treadmill exercise testing may also pro­
vide valuable functional information in patients unable to perform 
CPET.
6.11. Family screening and follow-up 
evaluation of relatives
All first-degree relatives of patients with cardiomyopathy should be of­
fered clinical screening with ECG and cardiac imaging (echocardiogram 
[ECHO] and/or CMR). In families in whom a disease-causing genetic 
variant has been identified, cascade genetic testing should be offered 
(see Section 6.8.3). Individuals found not to carry the familial variant 
and who do not have a clinical phenotype can usually be discharged, 
with advice to seek re-assessment if they develop symptoms or when 
new clinically relevant data emerge in the family. Those relatives har­
bouring the familial genetic variant(s) should undergo regular clinical 
evaluation with ECG, multimodality cardiac imaging, and additional in­
vestigations (e.g. Holter monitoring) guided by age, family phenotype, 
and genotype (Figure 11). Similarly, if a genetic cause of the disease 
has not been identified, either because P/LP variants are absent in the 
proband or because genetic testing has not been performed, clinical 
follow-up of all first-degree relatives is recommended; in families with­
out a known disease-causing variant, children should be offered ongoing 
clinical surveillance, due to age-related penetrance, and ongoing surveil­
lance should also be offered to adult relatives dependent on family 
history and other factors. In families where there is only one affected 
individual and where no genetic variant has been identified, the fre­
quency and duration of clinical follow-up may be reduced (see 
Figure 11).
Generally, the frequency of the clinical cardiac evaluation in relatives 
will be based on the inheritance pattern, the risk of events in the af­
fected individual(s), and the quality-adjusted life-year. It would also de­
pend on age, type of cardiomyopathy, and family history (penetrance, 
phenotype expression, and risk of complications in affected relatives).
Disease-penetrance studies have demonstrated a similar sigmoid 
shape pattern of phenotypic expression throughout life in families 
with confirmed genetic cardiomyopathies. The penetrance during child­
hood is ∼5% during the first decade of life, increasing to 10–20% per 
decade from the second to the seventh decades, after which the slope 
flattens to 5–10% in the last decades, although up to 25% of diagnoses 
can be made in individuals older than 65 years in some populations.544
The slope in childhood and early adulthood can be steeper (20% per 
decade) and similar to that in middle age for HCM, where male sex, sub­
tle ECG abnormalities, and particular genes are predictors of disease 
expression during follow-up.178
Penetrance in most cardiomyopathies is incomplete, reaching 
70–90% by the age of 70 years in families with cardiomyopathy.178
Recommendation Table 13 — Recommendations for 
routine follow-up of patients with cardiomyopathy
Recommendations
Classa
Levelb
It is recommended that all clinically stable patients 
with cardiomyopathy undergo routine follow-up 
using a multiparametric approach that includes ECG 
and echocardiography every 1 to 2 years.
I
C
Clinical evaluation with ECG and multimodality 
imaging is recommended in patients with 
cardiomyopathy whenever there is a substantial or 
unexpected change in symptoms.
I
C
© ESC 2023
ECG, electrocardiogram. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 14 — Recommendations for 
family screening and follow-up evaluation of relatives
Recommendations
Classa
Levelb
Following cascade genetic testing, clinical evaluation 
using a multiparametric approach that includes ECG 
and cardiac imaging and long-term follow-up is 
recommended in first-degree relatives who have the 
same disease-causing variant as the 
proband.178,544,547
I
B
Following cascade genetic testing, it is recommended 
that first-degree relatives without a phenotype who 
do not have the same disease-causing variant as the 
proband are discharged from further follow-up but 
advised to seek re-assessment if they develop 
symptoms or when new clinically relevant data 
emerge in the family.
I
C
It is recommended that when no P/LP variant is 
identified in the proband or genetic testing is not 
performed, an initial clinical evaluation using a 
multiparametric approach that includes ECG and 
cardiac imaging is performed in first-degree relatives.
I
C
When no P/LP variant is identified in the proband or 
genetic testing is not performed, regular, long-term 
clinical evaluation using a multiparametric approach 
that includes ECG and cardiac imaging should be 
considered in first-degree relatives.
IIa
C
During cascade screening, where a first-degree 
relative has died, clinical evaluation of close relatives 
of the deceased individual (i.e. second-degree 
relatives of the index patient) should be considered.
IIa
C
© ESC 2023
ECG, electrocardiogram, P/LP, pathogenic/likely pathogenic. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 45 -->

### Page 45

With some exceptions using the current diagnostic criteria, the pene­
trance of the disease in women has been shown to be delayed (shifted) 
by 10 years compared with men.178,545–548
Cardiac screening in: (i) carriers of genetic P/LP variants associated 
with cardiomyopathies; or (ii) in those with demonstration of a familial 
disease should be offered from childhood to old age. The proposed fre­
quency of screening is every 1–3 years with ECG and ECHO (plus add­
itional tests where this is considered appropriate) before the age of 60 
years, and then every 3–5 years thereafter.
These recommendations apply to families affected by cardiomyop­
athy. The penetrance of similar variants identified outside this context 
is likely to be much lower, and the benefits and harm of screening and 
surveillance remain under evaluation.549–551
6.11.1. Special considerations in family screening
If the comprehensive study of the index cardiomyopathy patient (includ­
ing negative genetic testing) and first-degree relatives from informative 
families (i.e. with a large enough pedigree) leads to the conclusion that 
the cardiomyopathy presents in isolation (i.e. the index patient is the 
only individual affected), termination of periodic surveillance could be 
considered in first-degree relatives ≥50 years of age with normal cardiac 
investigations.
When the pattern of inheritance is likely to be, or is definitively, other 
than autosomal dominant, consideration for periodic evaluation of re­
latives should be individualized, e.g. (i) heterozygous carriers from clear 
recessive forms of cardiomyopathy could be discharged; (ii) heterozy­
gous carriers of X-linked disease may delay cardiac evaluation, as
Genetic testing results
Variant status
Phenotype
Genetic testing in proband
P/LP variant
Variant positive
+/- clinical phenotype
Variant negative
Long-term follow-up
(Class I)
Discharge
(Class I)
Cardiomyopathy phenotype
Normal
Long-term follow-up
(Class I)
Repeat screening at regular intervalsa
(Class IIa)
VUS
No variant/genetic testing not performed
Reconsider other causes
Segregation analysis/functional studies where possible
Cascade clinical and genetic testing
(Class I)
Cascade clinical screening
(Class I)
Figure 11 Algorithm for the approach to family screening and follow-up of family members. P/LP, pathogenic/likely pathogenic, VUS, variant of unknown 
significance. aIf no additional affected relatives and no variant identified on genetic testing, consider earlier termination of clinical screening.
ESC Guidelines                                                                                                                                                                                          3547


<!-- PAGE 46 -->

### Page 46

phenotype may express later in life; and (iii) follow-up in families with 
more than one likely or definitively pathogenic variant (oligo- 
polygenicity) should be discussed in the cardiomyopathy team.
6.12. Psychological support in 
cardiomyopathy patients and family 
members
Adjusting to a diagnosis of an inherited cardiomyopathy can pose a psy­
chosocial challenge. This includes coming to terms with a new diagnosis, 
exclusion from competitive sports, or living with the small risk of 
SCD.205 While studies show patients with inherited cardiomyopathies 
adjust well following an ICD, there is an important subgroup who do 
require additional support.552–556 The decision to have an ICD, and liv­
ing with the device, can also pose psychological challenges, especially in 
those who are young or who have experienced multiple shocks and/or 
have poor baseline psychosocial functioning.553,554,557 The SCD of a 
young relative not only leads to profound grief, but one in two relatives 
report post-traumatic stress or prolonged grief on average 6 years after 
the death.558 Clinical psychological support for patients and their fam­
ilies affected by inherited cardiomyopathies is an important aspect of 
the multidisciplinary team’s care approach and should be available as re­
quired.559 Clinicians should be aware of the potential for poor psycho­
logical outcomes and should have a low threshold for referral.
Psychological challenges for patients and their family members are 
summarized in Table 16. While many patients and family members 
will benefit from psychosocial counselling provided by any number of 
healthcare professionals, it is important to highlight that for some, 
treatment by a trained professional such as a clinical psychologist is 
required.
Table 16 Psychological considerations
Patient group
Psychological considerations 
New diagnosis
• Stigma associated with cardiovascular disease and misconception that it only affects older people.
• Fear of sudden cardiac death can shake confidence and create anxiety around exercise.
• Fear of inheritance risk to other relatives, especially children.
• Confidence and self-efficacy to manage their disease.
• Direct experience with the disease will affect perceptions about prognosis.211
ICD
• Most patients will adjust well following ICD insertion, although there might be an initial decline in health-related quality of life and 
psychological well-being, this often returns to normal.552,560,561
• Up to 30% will develop anxiety and/or symptoms of post-traumatic stress and need additional support.562
• Those who are young, who experience multiple ICD shocks, and/or have poor baseline psychological functioning are at greater risk 
of poor psychological outcomes.553–555,561,563
• In young people, especially women, body image concerns can be a major consideration.554
• Decision-making for those recommended to have an ICD should be patient-centred and include balanced discussion of benefits 
and risks and careful attention to questions and concerns.564
Exercise restrictions
• Physical inactivity is a major determinant of poor health outcomes.
• Can reduce health-related quality of life for those who become fearful of performing even low-intensity exercise.
• Athletes who are recommended to reduce their activity levels can experience a profound grief and difficulty adjusting to this 
advice.565
• Patient-centred discussions and careful attention to concerns is critical in helping to support people make drastic lifestyle 
changes.566–568
Family history of young 
SCD
• Relatives who experience the SCD of a young relative have significant risk of poor psychological functioning, including 
post-traumatic stress and prolonged grief.558
• Grief is a normal response to a loss. Prolonged grief occurs when the grieving process becomes ‘stuck’.569
• Those who witness the death or discover the decedents body have a greater risk of psychological difficulties.558
• Mothers of the decedent have greater anxiety.558
• Psychological support for family members is an important and often unmet need following a young SCD.570,571
Children and adolescents
• Diagnosis during childhood can raise anxiety especially among parents. Access to resources to support practical issues like 
information for schools is important.
• Navigating transition from paediatric to adult care can be challenging for children and their families.
• Decision-making regarding genetic testing of asymptomatic children can often benefit from the inclusion of a clinical psychologist to 
support adjustment to the result.
Symptomatic disease
• Those managing symptoms will likely perceive a greater impact on their health-related quality of life. Factors influencing self-efficacy 
will impact on a patient’s ability to manage their disease, including medication adherence.572
• Need for major intervention such as cardiac transplantation can raise significant psychological challenges and clinical psychological 
support is very important.573
Genetic testing
• Despite potential adjustment issues, most patients who undertake genetic testing do not report distress.574
• Genetic counselling should cover any psychosocial concerns or needs.204
• Additional support to patients to convey the genetic risk information to at-risk family members should be provided as necessary.575
© ESC 2023
ICD, implantable cardioverter defibrillator; SCD, sudden cardiac death.


<!-- PAGE 47 -->

### Page 47

6.13. The patient pathway
The systematic, multiparametric approach to diagnosis and evaluation 
of patients with suspected cardiomyopathy described in this section al­
lows clinicians to establish the presence of a cardiomyopathy and iden­
tify its aetiology and guides the management of symptoms and 
prevention of disease-related complications. While many of the aspects 
of clinical care and the accompanying recommendations are common 
to all cardiomyopathy phenotypes, achieving an aetiological diagnosis 
is key to delivering disease-specific management; this is discussed in de­
tail in the subsequent sections of this guideline (see Section 7).
7. Specific cardiomyopathy 
phenotypes
7.1. Hypertrophic cardiomyopathy
The 2014 ESC Guidelines on diagnosis and management of hypertrophic 
cardiomyopathy provide detailed recommendations on the assessment 
and management of patients with HCM.1 The aim in this guideline is 
to provide a focused update to the 2014 document, highlighting novel 
aspects and signposting the reader to the assessment and management 
of HCM in adults and children. Further details to support the recom­
mendations are available in Supplementary data online, Table S1.
7.1.1. Diagnosis
7.1.1.1. Diagnostic criteria
Adults: in an adult, HCM is defined by an LV wall thickness ≥15 mm in 
any myocardial segment that is not explained solely by loading condi­
tions. Lesser degrees of wall thickening (13–14 mm) require evaluation 
of other features including family history, genetic findings, and ECG 
abnormalities.
Children: the diagnosis of HCM requires an LV wall thickness more than 
2 standard deviations greater than the predicted mean (z-score >2).578
Relatives: the clinical diagnosis of HCM in adult first-degree relatives 
of patients with unequivocal disease is based on the presence of LV wall 
thickness ≥13 mm. In child first-degree relatives with LV wall thickness 
z-scores of <2, the presence of associated morphological or ECG ab­
normalities should raise the suspicion but are not on their own diagnos­
tic for HCM.
7.1.1.2. Diagnostic work-up
The initial work-up for HCM includes personal and family history, phys­
ical examination, electrocardiography, cardiac imaging, and first-line la­
boratory tests, as described in Section 6.
7.1.1.3. Echocardiography
As increased ventricular wall thickness can be found at any location (in­
cluding the right ventricle), the presence, distribution, and severity of 
hypertrophy should be documented using a standardized protocol 
for cross-sectional imaging from several projections.579 Table 17 sum­
marizes the key imaging features to assess in patients with suspected 
or confirmed HCM. Several imaging features can point to a specific diag­
nosis (Table 18 and Section 6).62
Identification of LVOTO is important in the management of 
symptoms and assessment of SCD risk (see Section 7.1.5). 
Two-dimensional and Doppler echocardiography during a Valsalva 
manoeuvre in the sitting and semi-supine position—and then on 
standing if no gradient is provoked—is recommended in all patients 
(Figure 12).587,588 Exercise stress echocardiography is recom­
mended in symptomatic patients if bedside manoeuvres fail to in­
duce LVOTO ≥50 mmHg. Pharmacological provocation with 
dobutamine is not advised, as it is not physiological and can be 
poorly tolerated.
Recommendation Table 15 — Recommendations for 
psychological support in patients and family members 
with cardiomyopathies
Recommendations
Classa
Levelb
It is recommended that psychological support by an 
appropriately trained health professional be offered 
to all individuals who have experienced the 
premature sudden cardiac death of a family member 
with cardiomyopathy.558,570,571,576,577
I
B
It is recommended that psychological support by an 
appropriately trained health professional be offered 
to all individuals with an inherited cardiomyopathy 
who receive an implantable cardioverter 
defibrillator.552–556,561,563
I
B
Psychological support by an appropriately trained 
health professional should be considered in all 
patients and families with an inherited 
cardiomyopathy and in particular for those issues 
described in the text.c
IIa
C
© ESC 2023
aClass of recommendation. 
bLevel of evidence. 
cSee Table 16.
Recommendation Table 16 — Recommendation for 
evaluation of left ventricular outflow tract obstruction
Recommendations
Classa
Levelb
In all patients with HCM, at initial evaluation, 
transthoracic 2D and Doppler echocardiography are 
recommended, at rest and during Valsalva 
manoeuvre in the sitting and semi-supine positions— 
and then on standing if no gradient is provoked—to 
detect LVOTO.84,86,365,525,584,587,589–594
I
B
In symptomatic patients with HCM and a resting or 
provokedc peak instantaneous LV outflow tract 
gradient <50 mmHg, 2D and Doppler 
echocardiography during exercise in the standing, 
sitting (when possible), or semi-supine position are 
recommended to detect provocable LVOTO and 
exercise-induced mitral regurgitation.588,595–598
I
B
Transoesophageal echocardiography should be 
considered in patients with HCM and LVOTO if the 
mechanism of obstruction is unclear or when 
assessing the mitral valve apparatus before a septal 
reduction procedure, or when severe mitral 
regurgitation caused by intrinsic valve abnormalities 
is suspected.599–602
IIa
C
Continued 
ESC Guidelines                                                                                                                                                                                          3549


<!-- PAGE 48 -->

### Page 48

7.1.1.4. Cardiac magnetic resonance
Cardiac magnetic resonance is recommended in patients with HCM at 
their baseline assessment (general recommendations are described in 
Section 6.7.3 and Recommendation Table 5). CMR imaging can be par­
ticularly helpful in patients with suspected apical or lateral wall hyper­
trophy or LV apical aneurysm. Table 17 summarizes the main 
features to be assessed.
Late gadolinium enhancement is present in 65% of patients (range 
33–84%), typically in a patchy mid-wall pattern in areas of hypertrophy 
and at the anterior and posterior RV insertion points.604 Late gadolin­
ium enhancement is unusual in non-hypertrophied segments except in 
advanced stages of disease, when full-thickness LGE in association with 
wall thinning is common.604 Late gadolinium enhancement may be as­
sociated with increased myocardial stiffness and adverse LV
remodelling and the extent of LGE is associated with a higher incidence 
of RWMAs. Late gadolinium enhancement varies substantially with the 
quantification method used but the 2-standard deviation technique is 
the only one validated against necropsy.605
Although CMR rarely distinguishes the causes of HCM by their 
magnetic properties alone, the distribution and severity of intersti­
tial expansion can, in context, suggest specific diagnoses (see Section 
6). The absence of fibrosis may be helpful in differentiating HCM 
from physiological adaptation in athletes, but LGE may be absent 
in people with HCM, particularly young people and those with 
mild disease.
Table 17 Imaging evaluation in hypertrophic cardiomyopathy
Item to assess
Primary imaging 
modality
Comments
LV wall thickness
ECHO/CMR
• All LV segments from base to apex examined in end-diastole, preferably in the 2D short-axis view, 
ensuring that the wall thickness is recorded at mitral, mid-LV, and apical levels.
• CMR is superior in the detection of LV apical and anterolateral hypertrophy, aneurysms,580 and 
thrombi,581 and is more sensitive in the detection of subtle markers of disease in patients with 
sarcomeric protein gene variants (e.g. myocardial crypts, papillary muscle abnormalities).159,582,583
Systolic function (global 
and regional)
ECHO/CMR
• Ejection fraction is a suboptimal measure of LV systolic performance when hypertrophy is present.
• Doppler myocardial velocities and deformation parameters (strain and strain rate) are typically reduced 
at the site of hypertrophy despite a normal EF and may be abnormal before the development of 
increased wall thickness in genetically affected patients.
Diastolic function
ECHO
• Routine examination should include mitral inflow assessment, tissue Doppler imaging, pulmonary vein 
flow velocities, pulmonary artery systolic pressure, and LA size/volume.
Mitral valve
ECHO
• Assess presence and degree of SAM and mitral regurgitation. The presence of a central- or anteriorly 
directed jet of mitral regurgitation should raise suspicion of an intrinsic/primary mitral valve abnormality 
and prompt further assessment.
LVOT
ECHO
• See Figure 12.
LA dimensions
ECHO/CMR
• Provides important prognostic information.365,525,584
• Most common mechanisms of LA enlargement are SAM-related mitral regurgitation and elevated LV 
filling pressures.
Myocardial fibrosis/LGE
CMR
• The distribution and severity of interstitial expansion can suggest specific diagnoses. Anderson–Fabry 
disease is characterized by a reduction in non-contrast T1 signal and the presence of posterolateral 
LGE.134,155 In cardiac amyloidosis, there is often global, subendocardial or segmental LGE and a highly 
specific pattern of myocardial and blood-pool gadolinium kinetics caused by similar myocardial and 
blood T1 signals.585,586
© ESC 2023
2D, two-dimensional; CMR, cardiac magnetic resonance; ECHO, echocardiogram; EF, ejection fraction; LA, left atrium; LGE, late gadolinium enhancement; LV, left ventricular; LVOT, left 
ventricular outflow tract; SAM, systolic anterior motion; SCD, sudden cardiac death.
In symptomatic patients with HCM and inconclusive 
non-invasive cardiac imaging, left and right heart 
catheterization may be considered to assess the 
severity of LVOTO and to measure LV filling 
pressures.603
IIb
C
© ESC 2023
2D, two-dimensional; HCM, hypertrophic cardiomyopathy; LV, left ventricular; LVOTO, 
left ventricular outflow tract obstruction. 
aClass of recommendation. 
bLevel of evidence. 
cProvocation with Valsalva, standing, or oral nitrate.
Recommendation Table 17 — Additional recommen­
dation for cardiovascular magnetic resonance evaluation 
in hypertrophic cardiomyopathy
Recommendation
Classa
Levelb
Contrast-enhanced CMR may be considered before 
ASA or myectomy to assess the extent and 
distribution of hypertrophy and myocardial 
fibrosis.606,607
IIb
C
© ESC 2023
ASA, alcohol septal ablation; CMR, cardiac magnetic resonance. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 49 -->

### Page 49

7.1.1.5. Nuclear imaging
The major clinical contribution of nuclear imaging in HCM is the detec­
tion of TTR-related cardiac amyloidosis (see Section 7.7). 
Recommendations on the utility of bone scintigraphy and cardiac CT 
are described in Section 6.7.4.
7.1.2. Genetic testing and family screening
In about half of cases, HCM is inherited as a Mendelian genetic trait. In 
such cases, the inheritance is primarily autosomal dominant, i.e. with a 
50% risk of transmission to offspring.608 Apparently sporadic cases can 
have a monogenic cause, either because of incomplete penetrance of a 
Table 18 Echocardiographic features that suggest specific aetiologies in hypertrophic cardiomyopathy
Finding
Specific diseases to be considered
Increased interatrial septum thickness
Amyloidosis
Increased AV valve thickness
Amyloidosis; Anderson–Fabry disease
Increased RV free wall thickness
Amyloidosis, myocarditis, Anderson–Fabry disease, Noonan syndrome, and related disorders
Mild-to-moderate pericardial effusion
Amyloidosis, myocarditis/myopericarditis
Ground-glass appearance of ventricular myocardium 
on 2D echocardiography
Amyloidosis
Concentric LVH
Glycogen storage disease, Anderson–Fabry disease, PRKAG2 variants, Friedreich ataxia
Extreme concentric LVH (wall thickness ≥30 mm)
Danon disease, Pompe disease
Global LV hypokinesia (with or without LV dilatation)
Mitochondrial disease, TTR-related amyloidosis, PRKAG2 variants, Danon disease, myocarditis, advanced 
sarcomeric HCM, Anderson–Fabry disease, Friedreich ataxia
RVOTO
Noonan syndrome and associated disorders
Apical sparing pattern on longitudinal strain imaging
Amyloidosis
© ESC 2023
2D, two-dimensional; AV, atrioventricular; HCM, hypertrophic cardiomyopathy; LV, left ventricular; LVH, left ventricular hypertrophy; PRKAG2, protein kinase AMP-activated non-catalytic 
subunit gamma 2; RV, right ventricular; RVOTO, right ventricular outflow tract obstruction; TTR, transthyretin. 
Modified from Rapezzi et al.62
N
N
2D and Doppler echocardiography at rest,  Valsalva manoeuvre, and standing
Maximum provoked peak
LVOTO ≥50 mmHg
Maximum provoked peak
LVOTO ≥50 mmHg
Symptoms
Exercise stress echocardiogram
(Class I)
Repeat echocardiogram at 1 year see LVOTO management
Medical therapy
Y
Y
Asymptomatica
Symptomatic
Figure 12 Protocol for the assessment and treatment of left ventricular outflow tract obstruction. 2D, two-dimensional; LVOTO, left ventricular outflow 
tract obstruction. aExercise echocardiography may be considered in individual patients when the presence of an left ventricular outflow tract gradient is 
relevant to lifestyle advice and decisions on medical treatment.
ESC Guidelines                                                                                                                                                                                          3551


<!-- PAGE 50 -->

### Page 50

variant inherited from a parent or due to de novo variants that were not 
carried by the parents or, less commonly, due to autosomal recessive 
inheritance. In those who undergo genetic testing, ∼40–60% will have 
a single variant identified as the cause of their disease, although this is 
influenced by the cohort studied.124 The likelihood of finding a causal 
variant is highest in young patients with familial disease and lowest 
in older patients and individuals with non-classical features. 
Phenotype-based scores to predict genetic yield in HCM have been de­
veloped and may be used to prioritize genetic testing where resources 
are limited.609,610 Genes with definitive evidence for gene–disease asso­
ciation with HCM are summarized in Table 10. An important subgroup 
characterized by no identifiable monogenic variant, no family history of 
disease and often being older, more likely to be male and with a history 
of hypertension, and less risk of major cardiovascular events is likely to 
be underlied by complex aetiology.238,611,612
Less than 5% of adult patients, but up to 25% of children, with HCM, 
will have a causative variant in a gene that is known to mimic the HCM 
phenotype. Such genocopies can have clinically important differences 
such as altered inheritance risks, and management and therapy options. 
The aetiology of HCM in childhood is more heterogeneous than that 
seen in adult populations, and includes inborn errors of metabolism, 
malformation syndromes, and neuromuscular disorders.613–615 Most 
cases of HCM in childhood, however, are caused by variants in the car­
diac sarcomere protein genes, inherited as autosomal dominant 
traits.616,617 The relative prevalence of different HCM aetiologies varies 
according to age: HCM related to inborn errors of metabolism and mal­
formation syndromes is most commonly diagnosed in the first 2 years 
of life, whereas HCM due to neuromuscular disorders (e.g. Friedreich 
ataxia) most commonly presents in adolescence.613–615 Outside of 
infancy, sarcomere protein gene variants account for 55–75% of cases 
of childhood-onset HCM,616–619 and even in infancy, sarcomeric dis­
ease is present in up to 40% of cases.616,620 Although rarer, inborn er­
rors of metabolism and malformation syndromes can also present for 
the first time in older children and adolescents (see Section 7.6).614
A thorough and comprehensive diagnostic work-up is essential in the 
diagnosis of childhood-onset HCM in order to confirm the diagnosis, 
identify the underlying aetiology, and guide treatment (see Section 6).
Recommendations for clinical screening, genetic counselling, and 
testing are described in Sections 6.8.3 and 6.11, respectively.
7.1.3. Assessment of symptoms
Most people with HCM are asymptomatic and have a normal lifespan, 
but some develop symptoms, often many years after the appearance of 
ECG or echocardiographic evidence of LVH. Assessment of symptoms 
in patients with cardiomyopathies is described in Section 6.4. 
Assessment of LVOTO, as outlined in Figure 12, should be part of 
the routine evaluation of all symptomatic patients.
7.1.4. Management of symptoms and complications
In the absence of many randomized trials,621–623 pharmacological ther­
apy is mostly administered on an empirical basis to improve functional 
capacity and reduce symptoms. In symptomatic patients with LVOTO, 
the aim is to improve symptoms by using drugs, surgery, or alcohol sep­
tal ablation. Therapy in symptomatic patients without LVOTO focuses 
on management of arrhythmia, reduction of LV filling pressures, and 
treatment of angina. Patients with progressive LV systolic or diastolic 
dysfunction refractory to medical therapy may be candidates for car­
diac transplantation (Figure 13).
N
N
Patient with heart failure  NYHA II–IV
Atrial fibrillation
LVEF value
LVOTO management
Rate/rhythm control
Anticoagulation
Still symptomatic
Consider MCS/cardiac transplantation
Beta-blockers, ACEi, ARB
MRA, ARNI, SGLT2i
Low-dose diuretics
Beta-blockers,
verapamil, diltiazem
Low-dose diuretics
Resting/provocable
LVOTO ≥50 mmHg?
Y
Y
≥50%
<50%
Figure 13 Algorithm for the treatment of heart failure in hypertrophic cardiomyopathy. ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin 
receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; LVEF, left ventricular ejection fraction; LVOTO, left ventricular outflow tract obstruction; 
MCS, mechanical circulatory support; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; SGLT2i, sodium–glucose co- 
transporter 2 inhibitor.Image %:


<!-- PAGE 51 -->

### Page 51

7.1.4.1. Management of left ventricular outflow tract obstruction
By convention, LVOTO is defined as a peak instantaneous Doppler LV 
outflow tract gradient of ≥30 mmHg, but the threshold for invasive 
treatment is usually considered to be ≥50 mmHg (the threshold at 
which theoretical models examining the relationship between the gra­
dient and stroke volume predict that this becomes haemodynamically 
significant).587,624,625 Most patients with a maximum resting or pro­
voked LV outflow tract gradient <50 mmHg should be managed in ac­
cordance with the recommendations for non-obstructive HCM but, in 
a very small number of selected cases with LV outflow tract gradients 
between 30 and 50 mmHg and no other obvious cause of symptoms, 
invasive gradient reduction may be considered, acknowledging that 
data covering this group are lacking. Most asymptomatic patients 
with LVOTO do not require treatment but, in a very small number 
of selected cases, pharmacological treatment to reduced LV pressures 
may be considered.626,627
7.1.4.1.1. General measures. All patients with LVOTO should avoid 
dehydration and excess alcohol consumption, and weight loss should 
be encouraged. Arterial and venous dilators, including nitrates and 
phosphodiesterase type 5 inhibitors, can exacerbate LVOTO and 
should be avoided if possible (see Section 12.2).626 New-onset or 
poorly controlled AF can exacerbate symptoms caused by LVOTO 
and should be managed by prompt restoration of sinus rhythm or ven­
tricular rate control.628
7.1.4.1.2. Drug therapy. Figure 14 describes the management of 
LVOTO in patients with HCM. By consensus, patients with symptom­
atic LVOTO have been treated initially with non-vasodilating beta- 
blockers titrated to the maximum tolerated dose, but there are very 
few studies comparing individual beta-blockers. A recent small, rando­
mized placebo-controlled trial showed reduction of resting and exer­
tional LVOTO, and improvement in symptoms and QoL with 
metoprolol therapy.631
If beta-blockers alone are ineffective, disopyramide, titrated up to a 
maximum tolerated dose (usually 400–600 mg/day), may be 
added.632–634 This class IA AAD can abolish basal LV outflow pressure 
gradients and improve exercise tolerance and functional capacity with a 
low risk of proarrhythmic effects and without an increased risk of 
SCD.632,633 Dose-limiting anticholinergic side effects include dry eyes 
and mouth, urinary hesitancy or retention, and constipation.632,633,635
The QTc interval should be monitored during dose up-titration and 
the dose reduced if it exceeds 500 ms. Disopyramide should be avoided 
in patients with glaucoma, in men with prostatism, and in patients taking 
other drugs that prolong the QT interval, such as amiodarone and so­
talol. Disopyramide may be used in combination with verapamil.633
Verapamil (starting dose 40 mg three times daily to maximum 
480 mg daily) can be used when beta-blockers are contraindicated or 
ineffective but, based on limited data, should be used cautiously in pa­
tients with severe obstruction (≥100 mmHg) or elevated pulmonary 
artery systolic pressures, as it may provoke pulmonary oedema.636
Short-term oral administration may increase exercise capacity, improve 
symptoms, and normalize or improve LV diastolic filling without altering 
systolic function.637–640 Similar findings have been demonstrated for dil­
tiazem (starting dose 60 mg three times daily to maximum 360 mg dai­
ly),641 and it should be considered in patients who are intolerant or 
have contraindications to beta-blockers and verapamil.
Low-dose loop or thiazide diuretics may be used cautiously to im­
prove dyspnoea associated with LVOTO, but it is important to avoid 
hypovolaemia.
Cardiac myosin ATPase inhibitors. Mavacamten is a first-in-class cardiac 
myosin adenosine triphosphatase (ATPase) inhibitor that acts by redu­
cing actin–myosin cross-bridge formation, thereby reducing contractil­
ity and improving myocardial energetics. In the recently published 
Clinical Study to Evaluate Mavacamten in Adults with Symptomatic 
Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM) trial, 
mavacamten reduced the left ventricular outflow tract (LVOT) gradient 
and improved exercise capacity compared with placebo in patients with 
HCM and symptomatic LVOTO (NYHA II–III and EF >55%); 27% of 
patients on mavacamten had an LVOT gradient reduction to 
<30 mmHg and improved to NYHA class I.622 The drug was well tol­
erated and has a good safety profile; only a small subset of patients de­
veloped transient LV systolic dysfunction, which resolved after 
temporary discontinuation of the drug. A second study (A Study to 
Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM 
Who Are Eligible for Septal Reduction Therapy [VALOR-HCM]) in 
adult patients with obstructive HCM referred for septal reduction ther­
apy (SRT) due to intractable symptoms showed that mavacamten sig­
nificantly reduced the proportion of patients meeting criteria for SRT 
at 16 and 32 weeks.642,643 Small CMR and ECHO substudies suggest 
that mavacamten may also lead to positive myocardial remodelling, 
with reduction in myocardial mass, LV wall thickness, and left atrial vol­
ume.644–646 Aficamten, a next-in-class cardiac myosin inhibitor, was 
also recently shown in a Phase II randomized placebo-controlled study 
(Randomized Evaluation of Dosing With CK-3773274 in Obstructive 
Outflow Disease in HCM [REDWOOD-HCM]) to significantly reduce 
LVOT gradients and NT-proBNP levels in adult patients with symp­
tomatic obstructive HCM.647
In the absence of a direct head-to-head comparison, the Task Force 
was unable to recommend the use of cardiac myosin ATPase inhibitors 
as first-line medical therapy, but did consider the evidence sufficiently 
robust to support the recommendation that their use as second-line 
therapy should be considered when optimal medical therapy with beta- 
blockers, calcium antagonists, and/or disopyramide is ineffective or 
poorly tolerated. In the absence of evidence to the contrary, cardiac 
myosin ATPase inhibitors should not be used with disopyramide, but 
may be coadministered with beta-blockers or calcium antagonists. 
Up-titration of medication to a maximum dose of 15 mg should be 
monitored in accordance with licensed recommendations using echo­
cardiography. In patients with contraindications or known sensitivity 
to beta-blockers, calcium antagonists, and disopyramide, cardiac my­
osin ATPase inhibitors may be considered as monotherapy.
Recommendation Table 18 — Recommendations for 
treatment of left ventricular outflow tract obstruction 
(general measures)
Recommendations
Classa
Levelb
Avoidance of digoxin and arterial and venous dilators, 
including nitrates and phosphodiesterase inhibitors, 
should be considered, if possible, in patients with 
resting or provocable LVOTO.626,627
IIa
C
Restoration of sinus rhythm or appropriate rate 
control should be considered before invasive 
management of LVOTO in patients with new-onset 
or poorly controlled AF.629,630
IIa
C
© ESC 2023
AF, atrial fibrillation; LVOTO, left ventricular outflow tract obstruction. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3553


<!-- PAGE 52 -->

### Page 52

Recommendation Table 19 — Recommendations for 
medical treatment of left ventricular outflow tract 
obstruction
Recommendations
Classa
Levelb
Non-vasodilating beta-blockers, titrated to 
maximum tolerated dose, are recommended as 
first-line therapy to improve symptoms in patients 
with resting or provokedc LVOTO.631–633,648–650
I
B
Verapamil or diltiazem, titrated to maximum 
tolerated dose, are recommended to improve 
symptoms in symptomatic patients with resting or 
provokedc LVOTO who are intolerant or have 
contraindications to beta-blockers.633,637–641
I
B
Disopyramide,d titrated to maximum tolerated dose, 
is recommended in addition to a beta-blocker (or, if 
this is not possible, with verapamil or diltiazem) to 
improve symptoms in patients with resting or 
provokedc LVOTO.632–634
I
B
Cardiac myosin ATPase inhibitor (mavacamten), 
titrated to maximum tolerated dose with 
echocardiographic surveillance of LVEF, should be 
considered in addition to a beta-blocker (or, if this is 
not possible, with verapamil or diltiazem) to improve 
symptoms in adult patients with resting or provokedc 
LVOTO.622,642–646
IIa
A
Continued 
N
Resting/provocable LVOTO ≥50 mmHg
Symptoms
Beta-blockers or verapamil may be considered
(Class IIb)
Beta-blockers
(Class I)
Verapamil
(Class I)
 Diltiazem
(Class I)
Septal reduction therapies
(Class I)
OR
Y
Still symptomatic or intolerant/contraindication to beta-blockers
Disopyramide
(Class I)
 Mavacamten
(Class IIa)
OR
Still symptomatic
Still symptomatic
Figure 14 Flow chart on the management of left ventricular outflow tract obstruction. LVOTO, left ventricular outflow tract obstruction.Image %:   
Cardiac myosin ATPase inhibitor (mavacamten), 
titrated to maximum tolerated dose with 
echocardiographic surveillance of LVEF, should be 
considered as monotherapy in symptomatic adult 
patients with resting or provokedc LVOTO (exercise 
or Valsalva manoeuvre) who are intolerant or have 
contraindications to beta-blockers, verapamil/ 
diltiazem, or disopyramide.622,644–646
IIa
B
Oral or i.v. beta-blockers and vasoconstrictors 
should be considered in patients with severe 
provocablec LVOTO presenting with hypotension 
and acute pulmonary oedema who do not respond 
to fluid administration.627
IIa
C
Disopyramide, titrated to maximum tolerated dose, 
may be considered as monotherapy in patients who 
are intolerant to or have contraindications to 
beta-blockers and verapamil/diltiazem to improve 
symptoms in patients with resting or provokedc 
LVOTO.632
IIb
C
Beta-blockers or verapamil may be considered in 
selected cases in asymptomatic patients with resting 
or provokedc LVOTO to reduce LV pressures.623,639
IIb
C
The cautious use of low-dose diuretics may be 
considered in symptomatic LVOTO to improve 
exertional dyspnoea.
IIb
C
© ESC 2023
ATPase, adenosine triphosphatase; i.v., intravenous; LV, left ventricular; LVEF, left 
ventricular ejection fraction; LVOTO, left ventricular outflow tract obstruction. 
aClass of recommendation. 
bLevel of evidence. 
cProvocation with Valsalva manoeuvre, upright exercise, or oral nitrates if unable to 
exercise. 
dQTc interval should be monitored during up-titration of disopyramide and the dose 
reduced if it exceeds 500 ms.


<!-- PAGE 53 -->

### Page 53

7.1.4.1.3. Invasive treatment of left ventricular outflow tract (septal 
reduction therapy). There are no data to support the use of invasive 
procedures to reduce LVOTO in asymptomatic patients, regardless 
of its severity. However, some retrospective data suggest that indivi­
duals with high LVOT gradients, even if minimally symptomatic, have 
a higher mortality than those without markedly elevated gradients.651
Delay in SRT may have an impact on long-term outcomes, particularly 
when >5 years from first detection of gradient, even when successful 
relief of symptoms and gradient is achieved. Earlier interventions may 
be associated with lower complication rates and better prognosis.652
Invasive treatment (SRT) to reduce LVOTO should be considered in 
patients with a LVOTO gradient ≥50 mmHg, severe symptoms 
(NYHA functional class III–IV), and/or exertional or unexplained recur­
rent syncope in spite of maximally tolerated drug therapy. Invasive ther­
apy may also be considered in patients with mild symptoms (NYHA 
class II) refractory to medical therapy who have a resting or maximum 
provoked gradient of ≥50 mmHg (exercise or Valsalva) and 
moderate-to-severe systolic anterior motion-related mitral regurgita­
tion, AF, or moderate-to-severe left atrial dilatation in expert centres 
with demonstrable low procedural complication rates.653
Surgery. The most commonly performed surgical procedure to treat 
LVOTO is ventricular septal myectomy, in which a rectangular trough 
that extends distally to beyond the point of the mitral leaflet–septal 
contact is created in the basal septum below the aortic valve.654 This
Assess alternative/additional explanations
Assess the mechanism of obstruction
Assess MV anatomy/function
Assess distribution and severity of hypertrophy
Obesity
Respiratory disease
Coronary artery disease
Anaemia
Thyroid disease
Arrhythmia (e.g.  AF)
Drug side effects
Systemic disease (e.g. amyloid)
RVOTO
Mid-cavity
Sub-aortic membrane
Aortic stenosis
Anomalous papillary muscle insertion
Accessory MV tissue
SAM related
MV prolapse
Other intrinsic MV abnormalities
Minimum anterior septal thickness 15 mm
1
2
3
4
Figure 15 Pre-assessment checklist for patients being considered for invasive septal reduction therapies. AF, atrial fibrillation; MV, mitral valve; RVOTO, 
right ventricular outflow tract obstruction; SAM, systolic anterior motion.
ESC Guidelines                                                                                                                                                                                          3555


<!-- PAGE 54 -->

### Page 54

abolishes or substantially reduces LV outflow tract gradients in over 
90% of cases, reduces systolic anterior motion-related mitral regurgita­
tion, and improves exercise capacity and symptoms. Long-term symp­
tomatic benefit is achieved in >80% of patients with a long-term survival 
comparable to that of the general population.655–665 Pre-operative de­
terminants of a good long-term outcome are age <50 years, left atrial 
size <46 mm, absence of AF, and male sex.663
The main surgical complications are AV nodal block, left bundle 
branch block (LBBB), ventricular septal defect, and aortic regurgitation, 
but these are uncommon (except LBBB) in experienced centres using 
intra-operative transoesophageal echocardiography guidance.662,666,667
When there is coexisting mid-cavity obstruction, the standard myect­
omy can be extended distally into the mid-ventricle around the base 
of the papillary muscles; however, data on the efficacy and long-term 
outcomes of this approach are limited.668
In patients with intrinsic/primary mitral valve disease or marked mi­
tral leaflet elongation and/or moderate-to-severe mitral regurgitation, 
septal myectomy can be combined with mitral valve repair or replace­
ment.669–675 In patients with AF, concomitant ablation using the Cox– 
Maze procedure can also be performed.676 In infants and very young 
children, the modified Konno procedure may be an alternative to 
myectomy when the aortic annulus is too small.677
Alcohol septal ablation (ASA). In experienced centres, selective injection 
of alcohol into a septal perforator artery to create a localized septal scar 
has outcomes similar to surgery in terms of gradient reduction, symptom 
improvement, and exercise capacity, including in younger adults.678–685 In 
many centres, ASA has become the primary SRT modality. The main non- 
fatal complication is AV block in 7–20% of patients, and the procedural 
mortality is lower than isolated myectomy.679–683,686,687
Due to the variability of the septal blood supply, myocardial contrast 
echocardiography is essential prior to alcohol injection. Injection of 
large volumes of alcohol in multiple septal branches—with the aim of 
gradient reduction—in the catheter laboratory is generally not recom­
mended, as it can be associated with a high risk of complications and 
arrhythmic events.688
Alternative methods have been reported in small numbers of pa­
tients, including non-ASA techniques (coils,689,690 polyvinyl alcohol 
foam particles,691 cyanoacrylate692) and direct endocavitary and intra­
muscular ablation (radiofrequency, cryotherapy).693,694 These alterna­
tive methods have not been directly compared with other septal 
reduction therapies and long-term outcome/safety data are not avail­
able. Alcohol septal ablation and alternative methods should not be 
used in children with HCM outside experimental settings, due to a 
lack of medium- to long-term safety and efficacy data.
Surgery vs. alcohol septal ablation. Because of specific anatomic fea­
tures of the LVOT and the mitral valve, some patients with HCM will 
be more suitable candidates for septal myectomy than ASA. 
Experienced multidisciplinary teams should assess all patients before 
intervention, as morbidity and mortality are highly dependent on the 
available level of expertise (see Section 9).687,695,696 A summary of the 
key points in pre-operative assessment is shown in Figure 15.
There are no randomized trials comparing surgery and ASA, but sev­
eral meta-analyses have shown that both procedures improve functional 
status with a similar procedural mortality.697–703 Alcohol septal ablation 
is associated with a higher risk of AV block, requiring permanent pace­
maker implantation, and larger residual LV outflow tract gradients.697– 
702 The risk of AV block following surgery and ASA is highest in patients 
with pre-existing conduction disease, and prophylactic permanent pacing 
before intervention has been advocated,704 although recent data suggest 
that the long-term outcome of patients after ASA with implanted per­
manent pacemaker is similar to those without pacemaker.705 Repeat 
ASA or myectomy procedure is reported in 7–20% of patients after 
ASA, which is higher than reported following surgical myectomy.702
Septal ablation may be less effective in patients with very severe hyper­
trophy (≥30 mm), but systematic data are limited.706 In general, the 
risk of ventricular septal defect following septal myectomy is very small 
and could be higher in patients with mild hypertrophy (≤16 mm) at 
the point of the mitral leaflet–septal contact. This risk is exceedingly 
rare with ASA, but alternatives such as dual-chamber pacing or mitral 
valve repair/replacement may also be considered in such cases.707
Recommendation Table 20 — Recommendations for 
septal reduction therapy
Recommendations
Classa
Levelb
It is recommended that SRT be performed by 
experienced operators working as part of a 
multidisciplinary team expert in the management of 
HCM.664,665,687,695,696,708–710
I
C
SRT to improve symptoms is recommended in 
patients with a resting or maximum provoked LVOT 
gradient of ≥50 mmHg who are in NYHA/Ross 
functional class III–IV, despite maximum tolerated 
medical therapy.697–702
I
B
Septal myectomy, rather than ASA, is recommended 
in children with an indication for SRT, as well as in 
adult patients with an indication for SRT and other 
lesions requiring surgical intervention (e.g. mitral 
valve abnormalities).673
I
C
SRT should be considered in patients with recurrent 
exertional syncope caused by a resting or maximum 
provoked LVOTO gradient ≥50 mmHg despite 
optimal medical therapy.686,711–713
IIa
C
Mitral valve repair or replacement should be 
considered in symptomatic patients with a resting or 
maximum provoked LVOTO gradient ≥50 mmHg 
and moderate-to-severe mitral regurgitation that 
cannot be corrected by SRT alone.661,669–672,714
IIa
C
Mitral valve repair should be considered in patients 
with a resting or maximum provoked LVOTO 
gradient ≥50 mmHg when there is 
moderate-to-severe mitral regurgitation following 
isolated myectomy.
IIa
C
SRT may be considered in expert centres with 
demonstrable low procedural complication rates in 
patients with mild symptoms (NYHA class II) 
refractory to medical therapy who have a resting or 
maximum provoked (exercise or Valsalva) gradient 
of ≥50 mmHg and: 
• moderate-to-severe SAM-related mitral 
regurgitation; or
• AF; or
• moderate-to-severe left atrial dilatation.653,715
IIb
C
Continued


<!-- PAGE 55 -->

### Page 55

Dual-chamber pacing. Three small, randomized, placebo-controlled 
studies of dual-chamber pacing and several long-term observational 
studies have reported reductions in LV outflow tract gradients and vari­
able improvement in symptoms and QoL, including one paediatric 
study.719–724 A Cochrane review concluded that the data on the ben­
efits of pacing are based on physiological measures and lack information 
on clinically relevant endpoints.725
Left ventricular mid-cavity obstruction and apical aneurysms. Left ventricu­
lar mid-cavity obstruction occurs in ∼10% of patients with HCM.727,728
Patients with mid-cavity obstruction tend to be very symptomatic and, 
in a number of studies, have shown an increased risk of progressive heart 
failure and SCD.727–729 Approximately 25% of patients also have an LV 
apical aneurysm (see Section 7.1.5).580,727,728,730 Patients with LV mid- 
cavity obstruction should be treated with high-dose beta-blockers, ver­
apamil, or diltiazem, but the response is often suboptimal. Limited experi­
ence, mostly from single centres, suggests that mid-ventricular 
obstruction can be relieved by transaortic myectomy, a transapical ap­
proach, or combined transaortic and transapical incisions, with good 
short-term outcomes but uncertain long-term survival.731,732
Left ventricular apical aneurysms by themselves rarely need treatment. 
A few patients develop monomorphic ventricular tachycardia related to 
adjacent apical scarring, which may be amenable to mapping and ablation 
(see Section 7.1.5).730,733 Rarely, thrombi are present within the aneur­
ysm and should be treated with long-term oral anticoagulation.734,735
Anticoagulation may also be considered in patients with HCM and apical 
aneurysms in the absence of documented thrombi.736,737
7.1.4.2. Management of symptoms in patients without left 
ventricular outflow tract obstruction
7.1.4.2.1. Heart failure and chest pain. Management of heart failure 
in patients without LVOTO should follow the recommendations of 
the 2021 ESC Guidelines for the diagnosis and treatment of acute and 
chronic heart failure, summarized in Section 6.10.2. The aim of drug 
therapy is to reduce LV diastolic pressures and improve LV filling by 
slowing the heart rate with beta-blockers, verapamil, or diltiazem 
(ideally monitored by ambulatory ECG recording), and cautious use 
of loop diuretics. Beta-blockers or calcium antagonists should be con­
sidered in patients with exertional or prolonged episodes of angina- 
like pain even in the absence of resting or provocable LVOTO or ob­
structive CAD. In the absence of LVOTO, cautious use of oral nitrates 
may be considered. Ranolazine may also be considered to improve 
symptoms in patients with angina-like chest pain and no evidence 
for LVOTO.738,739
7.1.4.2.2. Cardiac resynchronization therapy. Regional heterogen­
eity of LV contraction and relaxation can be seen in patients with 
HCM, and LV dyssynchrony may be a marker of poor prognosis.745
Data on the impact of CRT on symptoms, LV function, and prognosis 
in patients with non-obstructive HCM remain limited, but new evi­
dence has emerged since the 2014 ESC Guidelines on diagnosis and man­
agement of hypertrophic cardiomyopathy.746,747 There is one small study 
using a blinded crossover design of biventricular and sham pacing and a 
pre-specified analysis stratified by changes in LV end-diastolic volume 
(LVEDV) with exercise at baseline.748 Biventricular pacing was asso­
ciated with significant increases in LVEDV and stroke volume in patients 
Recommendation Table 21 — Recommendations for 
indications 
for 
cardiac 
pacing 
in 
patients 
with 
obstruction
Recommendations
Classa
Levelb
Sequential AV pacing, with optimal AV interval to 
reduce the LV outflow tract gradient or to facilitate 
medical treatment with beta-blockers and/or 
verapamil, may be considered in selected patients 
with resting or provocable LVOTO ≥50 mmHg, 
sinus rhythm, and drug-refractory symptoms, who 
have contraindications for ASA or septal myectomy 
or are at high risk of developing heart block following 
ASA or septal myectomy.633,719–724
IIb
C
In patients with resting or provocable LVOTO 
≥50 mmHg, sinus rhythm, and drug-refractory 
symptoms, in whom there is an indication for an ICD, 
a dual-chamber ICD (instead of a single-lead device) 
may be considered, to reduce the LV outflow tract 
gradient or to facilitate medical treatment with 
beta-blockers and/or verapamil.633,719–724,726
IIb
C
© ESC 2023
ASA, alcohol septal ablation; AV, atrioventricular; ICD, implantable cardioverter 
defibrillator; LV, left ventricular; LVOTO, left ventricular outflow tract obstruction. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 22 — Recommendations for 
chest pain on exertion in patients without left ventricu­
lar outflow tract obstruction
Recommendations
Classa
Levelb
Beta-blockers and calcium antagonists (verapamil or 
diltiazem) should be considered to improve symptoms 
in patients with angina-like chest pain even in the 
absence of LVOTO or obstructive CAD.740–744
IIa
C
Oral nitrates may be considered to improve 
symptoms in patients with angina-like chest pain, 
even in the absence of obstructive CAD, if there is no 
LVOTO.
IIb
C
Ranolazine may be considered to improve symptoms 
in patients with angina-like chest pain even in the 
absence of LVOTO or obstructive CAD. 738,739
IIb
C
© ESC 2023
CAD, coronary artery disease; LVOTO, left ventricular outflow tract obstruction. 
aClass of recommendation. 
bLevel of evidence.
Mitral valve replacement may be considered in 
patients with a resting or maximum provoked 
LVOTO gradient ≥50 mmHg when there is 
moderate-to-severe mitral regurgitation following 
isolated myectomy.661,674,714,716
IIb
C
Surgical AF ablation and/or left atrial appendage 
occlusion procedures during septal myectomy may 
be considered in patients with HCM and 
symptomatic AF.717,718
IIb
C
© ESC 2023
AF, atrial fibrillation; ASA, alcohol septal ablation; HCM, hypertrophic cardiomyopathy; 
LVOT, left ventricular outflow tract; LVOTO, left ventricular outflow tract obstruction; 
NYHA, New York Heart Association; SAM, systolic anterior motion; SRT, septal 
reduction therapy. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3557


<!-- PAGE 56 -->

### Page 56

who had a reduction in exercise LVEDV pre-pacing (consistent with the 
relief of diastolic ventricular interaction). This translated into improve­
ments in peak maximum oxygen consumption (VO2) (1.4 mL/kg/min) 
and QoL scores.748 Together, they suggest that symptomatic responses 
to CRT may occur in individual patients, but that these are not asso­
ciated with consistent changes in LVEF or evidence for a reduction in 
progression to end-stage heart failure.
The 2021 ESC Guidelines on cardiac pacing and cardiac resynchroniza­
tion therapy recommend that standard criteria for CRT are used in pa­
tients with HCM.724 The Task Force considered these of limited utility 
in HCM, as the unique pathology of this disease means that patients 
with contractile impairment rarely have an LVEF ≤35%. While ac­
knowledging this as an area of unmet research need, the Task Force 
suggests a more pragmatic approach in which CRT might be consid­
ered in individual symptomatic patients with LV impairment (LVEF 
<50%) that meet current ESC ECG criteria (LBBB, QRS 130– 
149 ms). Cardiac resynchronization therapy might also be considered 
in patients with HCM and impaired systolic function who require per­
manent ventricular pacing.746 In keeping with the 2021 ESC Guidelines 
on cardiac pacing and cardiac resynchronization therapy, the Task Force 
did not include these as specific recommendations, given the limited 
evidence base.
7.1.5. Sudden cardiac death prevention in 
hypertrophic cardiomyopathy
Most contemporary series of adult patients with HCM report an annual 
incidence for cardiovascular death of 1–2%, with SCD, heart failure, and 
thrombo-embolism being the main causes of death.749 The most com­
monly recorded fatal arrhythmic event is spontaneous ventricular fibril­
lation (VF), but asystole, AV block, and pulseless electrical activity are 
described.532,750–754 In children with HCM, although initial studies, usu­
ally from small, highly selected cohorts, reported SCD rates of up to 
10% per year,755–757 more recent, larger, population-based studies 
have shown SCD rates in the region of 1.2–1.5% per year.81,535,758
While much lower than previously thought, this is still >50% higher 
than reported in adult HCM populations. Sudden cardiac death appears 
to be very rare below the age of 6 years.81,759
Estimation of SCD risk is an integral part of clinical management. Clinical 
features that are associated with an increased SCD risk and that have been 
used in previous guidelines to estimate risk are shown in Table 19.
Table 19 Major clinical features associated with an increased risk of sudden cardiac death
Risk factor
Comment
Age
• The effect of age on SCD has been examined in a number of studies86,525,584,760–764 and two have shown a significant 
association, with an increased risk of SCD in younger patients.525,584
• Some risk factors appear to be more important in younger patients, most notably NSVT,765 severe LVH,766 and 
unexplained syncope.584
• Sudden cardiac death is very rare below the age of 6 years,535,767 and there are some data to suggest a peak of SCD in 
childhood HCM between 9 and 15 years;757 however, the association between age at diagnosis and SCD risk in 
childhood HCM remains unclear.
NSVT
• NSVT (defined as ≥3 consecutive ventricular beats at ≥120 b.p.m. lasting <30 s) occurs in 20–30% of patients during 
ambulatory ECG monitoring and is an independent predictor of SCD.81,525,535,590,764,765,768–773
• There is no evidence that the frequency, duration, or rate of NSVT influences the risk of SCD.765,774
• NSVT occurring during or immediately following exercise is very rare, but may be associated with a high risk of SCD.768
Maximum LV wall thickness
• The severity and extent of LVH measured by TTE are associated with the risk of SCD.81,535,592,593,763,765,770–772,775–780
• Several studies have shown the greatest risk of SCD in patients with a maximum wall thickness of ≥30 mm; however, 
there are few data in patients with extreme hypertrophy (≥35 mm).525,592,763,765,769,781–784
Family history of sudden cardiac death 
at a young age
• While definitions vary,525,592,762,782 a family history of SCD is usually considered clinically significant when one or 
more first-degree relatives have died suddenly aged <40 years with or without a diagnosis of HCM, or when SCD has 
occurred in a first-degree relative at any age with an established diagnosis of HCM.
• Family history of SCD does not appear to be an independent risk factor for SCD in childhood HCM.81,535 This may be 
due to a higher prevalence of de novo variants in childhood HCM, the inclusion of non-sarcomeric disease, and/or 
under-reporting of family history in paediatric cohorts.
Syncope
• Syncope is common in patients with HCM but is challenging to assess, as it has multiple causes.785
• Non-neurocardiogenic syncope for which there is no explanation after investigation is associated with an increased 
risk of SCD.81,525,535,584,590,755,761,768,769,781,786–788
• Episodes within 6 months of evaluation may be more predictive of SCD.584
Left atrial diameter
• Several studies have reported a positive association between LA size and SCD.81,525,535,584,772,789 There are no data 
on the association between SCD and LA area or volume. Measurement of LA size is also important in assessing the 
risk of AF (see Section 6.10.3).
LV outflow tract obstruction
• A number of studies have reported a significant association between LVOTO and SCD risk.86,525,590,762,768,790 Several 
unanswered questions remain, including the prognostic importance of provocable LVOTO and the impact of 
treatment (medical or invasive) on SCD.
• In childhood HCM, there are conflicting data on the association between LVOTO and SCD risk.81,535,772,777
© ESC 2023
AF, atrial fibrillation; b.p.m., beats per minute; ECG, electrocardiogram; HCM, hypertrophic cardiomyopathy; LA, left atrium; LV, left ventricular; LVH, left ventricular hypertrophy; LVOTO, 
left ventricular outflow tract obstruction; NSVT, non-sustained ventricular tachycardia; SCD, sudden cardiac death; TTE, transthoracic echocardiogram.


<!-- PAGE 57 -->

### Page 57

7.1.5.1. Left ventricular apical aneurysms
Left ventricular apical aneurysms are defined as a discrete thin-walled 
dyskinetic or akinetic segment of the most distal portion of the left 
ventricle and are often associated with a mid-cavity gradient. Their 
prevalence in unselected patients is uncertain but they were re­
ported in 3% of individuals in the prospective Hypertrophic 
Cardiomyopathy Registry (HCMR).124 The first descriptions of LV 
apical aneurysms in HCM suggested an association with sustained 
monomorphic ventricular tachycardia (SMVT)730—a relatively rare 
occurrence in HCM—and a number of studies have suggested that 
they are a useful marker of SCD risk.580,728,736,737,791,792 Based on 
these data, LV aneurysms were included in the recent 2020 
American Heart Association/American College of Cardiology 
(AHA/ACC) HCM guideline as a major independent SCD risk factor 
and were considered a reasonable sole indication for an ICD.793 In a 
review for this guideline, the data from two published studies and a 
meta-analysis were evaluated (see Supplementary data online, 
Table S2). All these studies were retrospective and the absolute num­
ber of events is too small to assess the independent predictive value 
of apical aneurysms. In two small series that described a selected sub­
group of HCM patients with mid-ventricular obstruction, there was 
no increase in incidence of SCD events. In the only series that pro­
vides a detailed analysis of SCD events, the majority were appropri­
ate ICD interventions for monomorphic VT, suggesting significant 
inclusion bias.737 Finally, a large proportion of individuals with events 
had other important risk markers including prior sustained ventricu­
lar arrhythmia. Based on the current data, the Task Force recom­
mends that individualized ICD decisions should be based using 
well-established risk factors and not solely on the presence of an 
LV apical aneurysm.
7.1.5.2. Left ventricular systolic dysfunction
A small number of retrospective studies and two larger registries 
have examined the relation between prognosis in patients with 
HCM and LV systolic dysfunction (most frequently defined by a 
LVEF <50%) (see Supplementary data online, Table S3). All studies 
consistently show an increased rate of SCD events in patients with 
left ventricular systolic dysfunction (LVSD) ranging from 7 to 20% 
compared with that of patients with normal LV systolic function. 
However, the independent and additional value of LVSD compared 
with current risk stratification tools has not been investigated. 
There is only one multivariable model that investigates the independ­
ent relation of LVSD to the risk of SCD events but the covariables 
examined were limited (age, sex, and follow-up time).315 As with 
other recently proposed risk markers in HCM, the Task Force main­
tains its recommendation to first estimate SCD risk using the 
HCM-SCD Risk and HCM Risk-Kids tools, and then to use the pres­
ence of an LVEF <50% in shared decision-making about prophylactic 
ICD implantation, with full disclosure of the lack of robust data on its 
impact on prognosis.
7.1.5.3. Late gadolinium enhancement on cardiac magnetic 
resonance imaging
In the 2014 ESC Guidelines on diagnosis and management of hypertrophic 
cardiomyopathy, the extent of LGE on CMR was considered helpful in 
predicting cardiovascular mortality, but data at that time were felt insuf­
ficient to support the use of LGE in prediction of SCD risk. Since then, 
more studies have been published (see Supplementary data online, 
Table S1). In aggregate, the data show that LGE is common and, that 
when extensive (expressed as a percentage of LV mass), is associated 
with an increase in SCD risk and other events, particularly in the pres­
ence of other markers of disease severity including LV systolic impair­
ment. A meta-analysis of nearly 3000 patients from several studies 
suggests that the presence of LGE is associated with a 2.32-fold in­
creased risk of SCD/aborted SCD/appropriate ICD discharge, and a 
2.1-fold increase in all-cause mortality.794 It has been suggested that 
the addition of LGE to the current AHA/ACC sudden death algorithm 
or the HCM-SCD risk model improves stratification of patients who 
are otherwise considered low or intermediate risk.793
As in 2014, a number of uncertainties persist. These include the in­
evitable confounders in the retrospective studies that bias towards 
high-risk patients or patients referred specifically for septal myectomy. 
There also remains some debate about the methods used to quantify 
LGE with the 2-standard deviation technique; the only one that is vali­
dated against necropsy.605 Retrospective CMR series also report rela­
tively high event rates suggesting that they are not representative of the 
broad spectrum of disease. In HCMR, a prospective CMR study of 2755 
patients, LGE was present in 50% of patients based on visual criteria and 
in 60% based on >6 SCD signal criteria, but only 2% of patients had LGE 
>15% of LV mass.124 In the most recent report from the registry, there 
have been 24 deaths from any cause after a mean follow-up of 33.5 ±  
12.4 months (median: 36 months and range 1–64 months); the relation 
with LGE is not reported.795 There are very limited data on the role of 
CMR over and above validated risk algorithms in SCD risk prediction in 
children with HCM.796,797
On balance, the Task Force maintains the recommendation to first 
estimate SCD risk using the HCM-SCD Risk calculators. For patients 
who are in the low to intermediate risk category, the presence of ex­
tensive LGE (≥15%) may be used in shared decision-making with pa­
tients about prophylactic ICD implantation, acknowledging the lack of 
robust data on the impact of scar quantification on the personalized 
risk estimates generated by the HCM-SCD Risk calculators.
7.1.5.4. Abnormal exercise blood pressure response
Approximately one-third of adult patients with HCM have an abnormal 
systolic blood pressure response to exercise characterized by progres­
sive hypotension or a failure to augment the systolic blood pressure 
that is caused by an inappropriate drop in systemic vascular resistance 
and a low cardiac output reserve.798,799 Various definitions for abnor­
mal blood pressure response in patients with HCM have been re­
ported;590,765,768,782 for the purposes of this guideline, an abnormal 
blood pressure response is defined as a failure to increase systolic pres­
sure by at least 20 mmHg from rest to peak exercise or a fall of 
>20 mmHg from peak pressure.590,765,768,782,800
Abnormal exercise blood pressure response may be associated 
with a higher risk of SCD in adult patients aged ≤40 years, but it 
has a low positive predictive accuracy and its prognostic significance 
in patients >40 years of age is unknown, and recent data have sug­
gested that, although it may be associated with increased overall mor­
tality largely related to heart failure, it is not consistently associated 
with an increased risk of ventricular arrhythmia or SCD.800,801
There is no evidence to suggest that abnormal blood pressure re­
sponse to exercise is associated with a higher risk of SCD in children 
with HCM.802 The Task Force, therefore, does not recommend the 
use of abnormal blood pressure response to exercise as an indication 
ESC Guidelines                                                                                                                                                                                          3559


<!-- PAGE 58 -->

### Page 58

for primary prevention ICD implantation in patients with a low or 
intermediate risk category.
7.1.5.5. Sarcomeric variants
A small number of studies have explored the prognostic value of sarco­
meric variants in HCM. Despite initial attempts to classify variants as 
‘malignant’ or ‘benign’,803–807 no studies have shown an independent 
role for specific sarcomeric variants in SCD risk prediction. Variants ini­
tially classified as ‘malignant’ or ‘benign’ can have very different pheno­
typic expression, even in members of the same family,808–810 and, as 
variants are often found in individual families, evaluation of their prog­
nostic implications is problematic. Similarly, while the presence of mul­
tiple sarcomeric variants in an individual has been suggested to be 
associated with a worse prognosis,608,811–813 other cohorts have not 
consistently reported this association.807,814–816 Recent studies have 
evaluated the potential prognostic role of the presence of any sarco­
meric variant. The largest of these, comprising 2763 patients, showed 
a statistically significant impact on overall prognosis in those with vs. 
without a sarcomeric variant, but did not assess its association specific­
ally with SCD.238 A smaller study of 512 probands and 114 relatives, of 
whom 327 had a disease-causing sarcomeric variant, suggested that the 
presence of a pathogenic variant was independently associated with all- 
cause, cardiovascular, and heart failure mortality as well as SCD/ 
aborted SCD (HR 2.88; 95% CI, 1.23–6.71).817 Patients with a sarco­
meric variant were younger and were more likely to have NSVT, syn­
cope, and LVOTO and the association with SCD lost statistical 
significance (HR 2.44; 95% CI, 0.99–6.01; P = 0.052) after adjusting 
for ≥2 major clinical risk factors. The role of sarcomeric variants as a 
predictor of SCD independent of SCD risk-prediction models (e.g. 
HCM Risk-SCD and HCM Risk-Kids) remains to be demonstrated. 
Based on the available data, the Task Force does not recommend the 
use of the presence of sarcomeric variant(s) to guide decisions around 
ICD implantation for primary prevention in individuals with a low or 
intermediate SCD risk score.
7.1.5.6. Prevention of sudden cardiac death
There are no randomized, controlled data to support the use of AADs 
for the prevention of SCD in HCM. Amiodarone was associated with a 
lower incidence of SCD in one small observational study of patients 
with non-sustained ventricular tachycardia (NSVT) on Holter monitor­
ing, but observational data suggest that amiodarone often fails to pre­
vent SCD.818,819 Disopyramide does not appear to have a significant 
impact on the risk of SCD.632 However, beta-blockers and/or amiodar­
one are recommended in patients with an ICD who continue to have 
symptomatic ventricular arrhythmias, paroxysmal AF, or recurrent 
shocks despite optimal treatment and device re-programming.820
There are no randomized trials or statistically validated prospective 
prediction models that can be used to guide ICD implantation in pa­
tients with HCM. Recommendations are instead based on observation­
al, retrospective cohort studies that have determined the relationship 
between clinical characteristics and prognosis. The 2014 ESC 
Guidelines on diagnosis and management of hypertrophic cardiomyopathy 
recommended a risk-prediction model—HCM Risk-SCD (https:// 
qxmd.com/calculate/calculator_303/hcm-risk-scd)—that provides indi­
vidualized, quantitative risk estimates using an enhanced phenotypic ap­
proach.525 This approach has since been validated in independent 
cohorts and a meta-analysis of available published data, relevant to 
the 2014 ESC Guidelines on diagnosis and management of hypertrophic 
cardiomyopathy performance, for SCD prevention has shown that 
pooled estimates are concordant with the observed SCD risk in pa­
tients designated as high or low risk.821–824 In children, risk stratification 
for SCD has traditionally been based on risk factors extrapolated from 
adults with HCM, but this approach does not identify the children most 
at risk of SCD. In 2019, the first validated paediatric-specific risk model 
for SCD was developed (HCM Risk-Kids; https://hcmriskkids.org), using 
a similar approach to HCM Risk-SCD,81,825 and has since been inde­
pendently externally validated.535,797,826 A similar paediatric risk- 
prediction model (PRIMaCY Childhood HCM Sudden Cardiac Death 
Risk Prediction tool) has also been developed, using similar clinical para­
meters and with similar reported accuracy to HCM Risk-Kids (https:// 
primacy.shinyapps.io/calculator/).535
In this update, the Task Force maintains the principle of risk esti­
mation using the validated HCM Risk-SCD tool as the first step in 
sudden death prevention in patients aged 16 years or more, and re­
commends the use of a validated risk score (e.g. HCM Risk-Kids tool) 
for children and adolescents <16 years. This is in contrast to the 
2020 AHA/ACC Guideline for the diagnosis and treatment of patients 
with hypertrophic cardiomyopathy,793 in which the tool is considered 
an aid to a shared decision-making process for ICD placement in pa­
tients with clinical risk markers. This approach by the AHA/ACC, in 
part, reflected concerns that reliance on a risk tool does not account 
for individual patient perception and acceptance of pre-determined 
thresholds for medical intervention, as well as the omission of clinical 
risk markers such as LV systolic impairment from the HCM Risk-SCD 
model.
The Task Force acknowledges the challenges associated with defining 
universal thresholds for acceptable risk, but feels that reliance on an un­
quantified estimate of risk does nothing to resolve this dilemma. 
Instead, the Task Force recommends more overt shared decision- 
making based on real-world data as well as individual preferences, be­
liefs, circumstances, and values. Gaps in evidence are acknowledged 
and should be shared with patients. Similarly, competing risks related 
to the disease (heart failure, stroke) and to age and comorbidity, as 
well as device-related complications, should be discussed.726,827,828
Critically, the Task Force calls for development of enhanced patient de­
cision aids tailored specifically to receivers of care as well as more trad­
itional decision-support tools for healthcare practitioners.
Figure 16 summarizes the recommendations for primary preven­
tion ICD implantation in HCM in each risk category. These take 
into account not only the absolute statistical risk, but also the age 
and general health of the patient, socioeconomic factors, and the psy­
chological impact of therapy. The recommendations are meant to be 
sufficiently flexible to account for scenarios that are not encompassed 
by the HCM Risk-SCD or HCM Risk-Kids models. These models 
should not be used in elite athletes or in individuals with metabolic/in­
filtrative diseases (e.g. Anderson–Fabry disease) and syndromes (e.g. 
Noonan syndrome). The models do not use exercise-induced LV out­
flow tract gradients and have not been validated before and after 
myectomy. The HCM Risk-SCD model has been validated in one 
study of adult patients following ASA,829 and a recent study has 
suggested that severe LVH and residual LVOTO are associated with 
an increased risk of SCD following ASA, with a modest C-statistic 
of 0.68.830


<!-- PAGE 59 -->

### Page 59

shared decision making
Secondary prevention
Primary prevention
HCM-risk scores
≥1 clinical risk factorsa
ICD
(Class IIb)
ICD
(Class IIb)
ICD
(Class IIa)
ICD
(Class I)
Low risk
5-year risk <4%
Intermediate risk
5-year risk ≥4 to <6%
High risk
5-year risk ≥6%
History
2D and Doppler echocardiogram
Ambulatory ECG
Symptom limited exercise test
Age 
Unexplained syncope
 LV outflow gradient 
Maximum LV wall thickness 
Left atrial diameter
 NSVT
Family history of SCD
LV systolic function
 Extent of myocardial scar
Cardiac arrest due to VT or VF 
Spontaneous sustained VT 
causing syncope or 
haemodynamic compromise
AND
Life expectancy ≥1 year
Figure 16 Flow chart for implantation of an implantable cardioverter defibrillator in patients with hypertrophic cardiomyopathy. 2D, two-dimensional; 
CMR, cardiac magnetic resonance; ECG, electrocardiogram; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter defibrillator; LGE, late gado­
linium enhancement; LV, left ventricular; LVEF, left ventricular ejection fraction; NSVT, non-sustained ventricular tachycardia; SCD, sudden cardiac death; VF, 
ventricular fibrillation; VT, ventricular tachycardia. aClinical risk factors: extensive LGE (>15%) on CMR; LVEF <50%.
Recommendation Table 23 — Additional recommen­
dations for prevention of sudden cardiac death in 
patients with hypertrophic cardiomyopathy
Recommendations
Classa
Levelb
Secondary prevention
Implantation of an ICD is recommended in patients 
who have survived a cardiac arrest due to VT or VF, 
or who have spontaneous sustained VT with 
haemodynamic compromise.532,534,726,831,832
I
B
Continued 
Primary prevention
The HCM Risk-SCD calculator is recommended as a 
method of estimating risk of sudden death at 5 years 
in patients aged ≥16 years for primary 
prevention.525,821–824
I
B
Validated paediatric-specific risk prediction models 
(e.g. HCM Risk-Kids) are recommended as a method 
of estimating risk of sudden death at 5 years in 
patients aged <16 years for primary prevention.81,833
I
B
Continued 
ESC Guidelines                                                                                                                                                                                          3561


<!-- PAGE 60 -->

### Page 60

7.2. Dilated cardiomyopathy
7.2.1. Diagnosis
7.2.1.1. Index case
Dilated cardiomyopathy is defined by the presence of LV dilatation and 
systolic dysfunction unexplained solely by abnormal loading conditions 
or CAD. Left ventricular dilatation is defined by LV end-diastolic dimen­
sions or volumes >2 z-scores above population mean values corrected 
for body size, sex, and/or age. For adults this represents an LV end- 
diastolic diameter >58 mm in males and >52 in females and an 
LVEDV index of ≥75 mL/m2 in males and ≥62 mL/m2 in females by 
ECHO.9,845,846 Left ventricular global systolic dysfunction is defined 
by LVEF <50%.9
7.2.1.2. Relatives
Clinical testing in relatives often reveals mild non-diagnostic abnormal­
ities that overlap with normal variation or mimic changes seen in other 
more common diseases such as hypertension and obesity. In this con­
text, the presence of isolated LV dilatation with preserved systolic func­
tion or in the presence of a familial causative variant is sufficient for a 
diagnosis of DCM in a relative. Additional electrocardiographic or im­
aging abnormalities in the context of a family history of DCM are sug­
gestive of disease and warrant close follow-up.9,75,817 In the absence of 
conclusive genetic information in a family, DCM is considered familial if: 
(i) one or more first- or second-degree relatives have DCM; or (ii) 
when an otherwise unexplained SCD has occurred in a first-degree 
relative at any age with an established diagnosis of DCM.
7.2.1.3. Diagnostic work-up
The key elements of the diagnostic work-up for all patients with DCM 
are described in Section 6 and include clinical and family history, labora­
tory tests, ECG, Holter monitoring, cardiac imaging, and genetic testing. 
Echocardiography is central for the diagnosis and CMR provides more 
detailed morphological and prognostic information. Additional labora­
tory tests, exercise testing, EMB, cardiac CT, and cardiac catheteriza­
tion should also be considered, as detailed in Section 6.
7.2.1.4. Echocardiography
Comprehensive TTE is recommended for all DCM patients as it pro­
vides all the relevant information on the global and regional LV anat­
omy, function and haemodynamics, valvular heart disease, right heart 
function, pulmonary pressure, atrial geometry, and associated fea­
tures.71 Advanced echocardiographic techniques (tissue Doppler and 
speckle tracking deformation imaging) can allow the early detection 
of subclinical myocardial dysfunction in specific situations (e.g. genetic 
DCM carriers, recipients of known cardiotoxic chemotherapy).71,74
Contrast agents may be considered for better endocardial delinea­
tion, to better depict the presence of hypertrabeculation, or to exclude 
intraventricular thrombus. Transoesophageal echocardiography is rare­
ly necessary except for when atrial thrombi are present in patients with 
AF, or for assessing valvular function and guiding transcatheter therapy 
in patients with concomitant secondary mitral or tricuspid 
regurgitation.
It is recommended that the 5-year risk of SCD be 
assessed at first evaluation and re-evaluated at 1–2 
year intervals or whenever there is a change in clinical 
status.525
I
B
Implantation of an ICD should be considered in 
patients with an estimated 5-year risk of sudden 
death of ≥6%, following detailed clinical assessment 
that considers: 
(i) the lifelong risk of complications;
(ii) competing mortality risk from the disease and 
comorbidities;
AND 
(iii) the impact of an ICD on lifestyle, 
socio-economic status, and psychological 
health.81,521,525,726,832,833
IIa
B
In patients with LV apical aneurysms, decisions about 
primary prevention ICD based on an assessment of 
risk using the HCM Risk-SCD or a validated 
paediatric risk-prediction (e.g. HCM Risk-Kids) tool 
and not solely on the presence of the aneurysm 
should be considered.580,728,737,791,792
IIa
B
Implantation of an ICD may be considered in 
individual patients with an estimated 5-year risk of 
SCD of between ≥4% and <6%, following detailed 
clinical assessment that takes into account the 
lifelong risk of complications and the impact of an 
ICD on lifestyle, socio-economic status, and 
psychological health.81,521,525,726,832,833
IIb
B
For patients who are in the low-risk category (<4% 
estimated 5-year risk of SCD), the presence of 
extensive LGE (≥15%) on CMR may be considered in 
shared decision-making with patients about 
prophylactic ICD implantation, acknowledging the 
lack of robust data on the impact of scar 
quantification on the personalized risk estimates 
generated by HCM Risk-SCD or a validated 
paediatric model (e.g. HCM Risk-Kids).141,796,797,834– 
841
IIb
B
For patients who are in the low-risk category (<4% 
estimated 5-year risk of SCD), the presence of LVEF 
<50% may be considered in shared decision-making 
with patients about prophylactic ICD implantation, 
acknowledging the lack of robust data on the impact 
of systolic dysfunction on the personalized risk 
estimates generated by HCM Risk-SCD or a 
validated paediatric model (e.g. HCM 
Risk-Kids).89,315,841–844
IIb
B
© ESC 2023
CMR, cardiac magnetic resonance; HCM, hypertrophic cardiomyopathy; ICD, implantable 
cardioverter defibrillator; LGE, late gadolinium enhancement; LV, left ventricular; LVEF, left 
ventricular ejection fraction; SCD, sudden cardiac death; VF, ventricular fibrillation; VT, 
ventricular tachycardia. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 61 -->

### Page 61

7.2.1.5. Cardiac magnetic resonance
Cardiac magnetic resonance provides additional information on tissue 
characterization in patients with DCM, including the presence of myo­
cardial oedema, which may suggest a myocarditic or inflammatory 
cause, and LGE, to determine the presence and extent of fibrosis, as 
well as its distribution, which may allow exclusion of myocardial infarc­
tion and also point towards specific aetiologies (e.g. subepicardial distri­
bution in post-myocarditis forms, patchy in sarcoidosis, extensive 
inferolateral in dystrophinopathies, septal mid-wall in LMNA carriers, 
and ring-like in DSP and FLNC-truncating variant carriers) (see Section 
7.3).71,847 Late gadolinium enhancement distribution and extent hold 
prognostic value both for arrhythmia and heart failure severity.137,848
Dedicated T2* sequences describe myocardial iron deposition, which 
is useful for the diagnosis of haemochromatosis.71
7.2.1.6. Nuclear medicine
There is a limited role for radionuclide imaging in DCM. Measurement 
of 18F-fluorodeoxyglucose (18F-FDG) uptake using PET, with focal or 
focal-on-diffuse FDG uptake patterns especially if there is concomitant 
abnormal 18F-FDG-PET uptake in extracardiac tissues, can be useful in 
suspected cardiac sarcoidosis.849
7.2.2. Genetic testing and family screening
The aetiology of DCM is highly heterogeneous and includes inherited 
(genetic/familial) and acquired causes.9,545,850,851 Direct causes of 
DCM include pathogenic gene variants, toxins, auto-immunity, infec­
tions, storage diseases, and tachyarrhythmias. Monogenic gene variants 
causing DCM are highly heterogeneous, implicating many genes and di­
verse pathways. Moreover, only 30–40% of DCM cases are attributable 
to pathogenic rare variants, with a substantial polygenic/common vari­
ant contribution in this population. Furthermore, disease modifiers can 
play a role in the acceleration of the DCM phenotype.7,9,850 This in­
cludes conditions that may aggravate or trigger DCM, including epigen­
etic factors and acquired modifiers, such as pregnancy, hypertension, 
excessive alcohol use, and other toxins.42–44 It is important to consider 
the interplay between genetic and acquired causes during the diagnostic 
work-up. Identification of an acquired cause does not exclude an under­
lying causative gene variant, whereas the latter may require an addition­
al acquired cause and/or disease modifier to manifest. Within the genes 
that can cause DCM, there are genes robustly associated with classical 
DCM that have been recently curated,189 and also others classically as­
sociated with ARVC but that very commonly can present with LV dila­
tation and predominantly LV dysfunction. Moreover, genes described in 
the context of hypertrabeculation/LVNC (e.g. NKX2.5 and PRDM16), 
or that can cause DCM with or without skeletal involvement (such as 
DMD or EMD), should also be considered DCM-associated genes and 
examined, particularly if phenotype is concordant. The most common 
genetic and acquired causes of DCM are shown in Table 10 and 
Table 20. Detailed lists of causes of DCM have been previously 
published.9,852
7.2.2.1. Genetic testing
Causative gene variants occur in up to 40% of DCM patients in contem­
porary cohorts,185,186,853,854
and between 10 and 15% in 
chemotherapy-induced, alcoholic, or peripartum DCM.42–44 Although 
the prevalence of genetic variants is higher in familial DCM, causative 
genetic variants are also identified in over 20% of non-familial DCM 
cases.185,854,855 Finding a causative gene variant in a patient with 
DCM allows better prediction of the disease outcome and progression,
Table 20 Non-genetic causes of dilated cardiomyopathy
Infection (post-myocarditis)
Viral (enteroviruses, adenoviruses, echoviruses, herpes viruses, parvovirus B19, 
HIV, SARS-CoV-2, etc.)
Bacterial (Lyme disease)
Mycobacterial
Fungal
Parasitic (Chagas disease)
Toxic and overload
Alcohol (ethanol)
Cocaine, amphetamines, ecstasy
Cobalt
Anabolic/androgenic steroids
Haemochromatosis and other causes of iron overload
Endocrinology
Hypo- and hyperthyroidism
Cushing/Addison disease
Phaeochromocytoma
Acromegaly
Diabetes mellitus
Nutritional deficiency
Selenium deficiency
Thiamine deficiency (Beri-Beri)
Zinc and copper deficiency
Carnitine deficiency
Electrolyte disturbance
Hypocalcaemia
Hypophosphataemia
Peripartum
Autoimmune diseases
Giant cell myocarditis
Inflammatory (biopsy-proven, non-infectious myocarditis)
Eosinophilic granulomatosis with polyangiitis
Systemic lupus erythematosus
Sarcoidosis
Rheumatoid arthritis
Coeliac disease
Primary biliary cirrhosis
Myasthenia gravis
Pemphigus pemphigoid
Crohn disease
Ulcerative colitis
Polymyositis/dermatomyositis
Reactive arthritis
Drugs
Antineoplastic 
drugs
Anthracyclines; antimetabolites; alkylating agents; Taxol; 
hypomethylating agent; monoclonal antibodies; tyrosine 
kinase inhibitors; immunomodulating agents
Psychiatric drugs
Clozapine, olanzapine; chlorpromazine, risperidone, 
lithium; methylphenidate; tricyclic antidepressants
Other drugs
All-trans retinoic acid; antiretroviral agents; phenothiazines
© ESC 2023
HIV, human immunodeficiency virus; SARS-CoV-2, severe acute respiratory syndrome 
coronavirus 2.
ESC Guidelines                                                                                                                                                                                          3563


<!-- PAGE 62 -->

### Page 62

may contribute to the indications for device implantation, informs gen­
etic counselling, and allows familial screening for relatives. Moreover, 
genetic testing in DCM has long-term implications in terms of cost- 
effectiveness by identifying at-risk family members with positive geno­
types, and thus reducing the number of family members requiring serial 
clinical follow-up.229 Genetic testing can therefore be beneficial in all 
patients with DCM, including children856,857 and those with alcohol-/ 
chemotherapy-induced and peripartum DCM. Where resources are 
limited, scores designed to identify DCM patients with a high probabil­
ity of a positive genotype (e.g. the Madrid DCM Genotype Score 
[https://madridDCMscore.com]) may be considered to prioritize gen­
etic testing.858 Of note, age should not be a limiting factor when decid­
ing which DCM patients should undergo genetic testing.185,858,859
Recommendations for clinical screening, genetic counselling, and 
testing are described in Sections 6.8.3 and 6.11. More detailed evalu­
ation of conduction defects or arrhythmia, which may be an early pres­
entation of certain genetic DCM subtypes, should be considered in the 
context of certain gene variants (e.g. LMNA, EMD, DES). Cardiac MRI 
should also be considered in relatives with normal cardiac function 
who carry causative genetic variants associated with increased risk of 
SCD (e.g. FLNC, DES, DSP, PLN, LMNA, TMEM43, RMB20). If there 
are no additional family members with DCM, other than the proband, 
periodic evaluation of first-degree relatives should follow the same in­
tervals according to age (see Section 6.11), but termination of periodic 
surveillance in families in whom a genetic variant has not been identified 
could be considered in first-degree relatives ≥50 years of age with nor­
mal ECG and normal cardiac imaging tests.
7.2.3. Assessment of symptoms
Patients with DCM often develop symptoms of heart failure, although 
this can occur many years after the appearance of ECG or echocardio­
graphic abnormalities. Assessment of symptoms in patients with cardio­
myopathies is described in Section 6.10.1.
7.2.4. Management
The clinical management of heart failure and other manifestations of 
DCM has been described in the 2021 ESC Guidelines for the diagnosis 
and treatment of acute and chronic heart failure, the 2020 ESC 
Guidelines for the diagnosis and management of atrial fibrillation, and the 
apy.69,336,724 In these guidelines, recommendations are generally inde­
pendent of the aetiology of heart failure, AF, and other clinical 
presentations. As such, although they summarize large and robust da­
tasets and trials, the treatment recommendations must be regarded 
as generic and not specific to the different forms of genetic DCM. 
However, as large cohorts of genetic DCMs with uniform genetic fea­
tures are relatively rare, adequately powered RCTs in cardiomyop­
athies are scarce. The Task Force therefore recommends applying 
the 2021 ESC Guidelines for the diagnosis and treatment of acute and 
chronic heart failure, which contain treatment guidelines for patients 
with signs and symptoms of heart failure, for symptom management 
of patients with DCM.69 Treatment recommendations for asymptom­
atic LV dysfunction or dilatation are scarce, which presents a challenge 
for genetic DCM, where a sizeable proportion of the patients are young 
with no or mild symptoms, and where asymptomatic patients are fre­
quently discovered through cascade screening. Recommendations for 
the pharmacological management of heart failure symptoms in patients 
with cardiomyopathies are described in Section 6.10.2.
7.2.5. Sudden cardiac death prevention in dilated 
cardiomyopathy
Predicting SCD is a challenging aspect of the clinical care of patients 
with DCM. Implantable cardioverter defibrillators are effective at treat­
ing potentially lethal ventricular arrhythmias and preventing SCD, but 
are also associated with complications, particularly in young patients, 
who will require several replacements during their lifetimes (see 
Section 6.10.5).
7.2.5.1. Secondary prevention of sudden cardiac death
Implantable cardioverter defibrillators reduce mortality in survivors of 
cardiac arrest and in patients who have experienced sustained symp­
tomatic ventricular arrhythmias with haemodynamic compromise.531
An ICD is recommended in such patients when the intent is to increase 
survival; the decision to implant should consider the patient’s view and 
their QoL, as well as the absence of other diseases likely to cause death 
within the following year.
7.2.5.2. Primary prevention of sudden cardiac death
Available RCTs examining the usefulness of ICDs to prevent SCD and 
improve survival have included only patients with LVEF ≤35%, with 
conflicting results. While a trial including both ischaemic and non- 
ischaemic symptomatic heart failure patients showed reduction in 
mortality,860 trials including only patients without CAD did not signifi­
cantly improve the overall risk of mortality despite the fact that there 
was an absolute reduction in SCD with ICDs, and subgroup analysis 
suggested that there was a survival benefit in patients ≤70 years.861,862
Nevertheless, in a recent meta-analysis of studies that examined the 
effect of ICDs in DCM, a survival benefit was observed, although 
the effect was modest compared with LVEF ≤35% patients with 
CAD.863
Although LVEF ≤35% has been reported as an independent risk 
marker of all-cause and cardiac death in DCM, it has also shown only 
modest ability in identifying DCM patients with higher risk of SCD, sug­
gesting that additional factors should be taken into consideration when 
deciding on ICD implantation in a disease with significant aetiological 
heterogeneity. Recent natural history studies suggest that phenotype 
plays a role a role in SCD risk, with patients harbouring disease-causing 
variants in PLN, DSP, LMNA, FLNC, TMEM43, and RBM20 having a sub­
stantially higher rate of major arrhythmic events than other causes of 
DCM regardless of LVEF.440,542,864–870 A recent retrospective study 
of 1161 individuals with DCM has shown that DCM patients with P/ 
LP DCM-causing genetic variants have a worse clinical evolution and 
higher rate of major arrhythmic events than genotype-negative DCM 
patients and particularly in DCM patients with LVEF ≤35%.185 The 
study also observed a higher risk of major arrhythmic events in DCM 
patients affected by DCM-causing variants in certain genotypes regard­
less of LVEF. Genes associated with higher arrhythmic risk included 
genes coding for nuclear envelope (LMNA, EMD, TMEM43), desmo­
somal (DSP, DSG2, DSC2, PKP2), and certain cytoskeletal proteins.185
Together, these data suggest that DCM patients harbouring 
DCM-causing variants in high-risk genes (LMNA, EMD, TMEM43, DSP, 
RBM20, PLN, FLNC-truncating variants) should be considered as pa­
tients with a high-risk genetic background for SCD and primary preven­
tion ICD implantation should be considered with LVEF thresholds 
higher than 35%, particularly in the presence of additional risk factors 
(e.g. NSVT, increased ventricular ectopic beats, male sex, significant 
LGE, specific gene variant). For some high-risk genotypes (e.g. LMNA 
[https://lmna-risk-vta.fr]541), gene-specific (or, in the case of the PLN


<!-- PAGE 63 -->

### Page 63

p.Arg14del variant, variant-specific [https://plnriskcalculator.shinyapps. 
io/final_shiny])542 risk-prediction scores have been developed that con­
sider genotype characteristics and additional phenotypic features. 
Where such scores are available, they should be used to guide primary 
prevention ICD implantation (Figure 17). As discussed in Section 7.1.5, 
the Task Force acknowledges the challenges associated with defining 
universal thresholds for acceptable risk across different cardiomyop­
athy phenotypes, but is of the opinion that a similar approach to that 
taken in risk stratification for HCM is reasonable. Although the 2022 
ESC Guidelines for the management of patients with ventricular arrhythmias 
and the prevention of sudden cardiac death have suggested a higher 
threshold of 10% risk at 5 years to guide primary prevention ICD im­
plantation in patients with DCM and LMNA variants,3 this Task Force 
recommends shared decision-making based on real-world data as 
well as individual preferences, beliefs, circumstances, and values. Gaps 
in evidence should be shared with patients, and competing risks related 
to the disease (heart failure, stroke), and to age and comorbidity, as well 
as device-related complications, should be discussed. In support of this, 
a recent study validating the LMNA-risk VTA calculator overestimated 
arrhythmic risk when using ≥7% predicted 5-year risk as threshold 
(specificity 26%, C-statistic 0.85), despite a high sensitivity.871
Importantly, there are also data to suggest that other genotypes (e.g. 
TTN truncating variants) are associated with recovery of LVEF with 
standard heart failure criteria from the 2021 ESC Guidelines for the diag­
nosis and treatment of acute and chronic heart failure.185,867,872
In patients without a high-risk genotype and LVEF >35%, the pres­
ence and extent of myocardial scarring determined by LGE on CMR im­
aging can be helpful in risk stratification in patients with DCM.873,874
Late gadolinium enhancement is observed in 25–35% of patients with 
DCM and its presence is a strong risk marker for all-cause mortality 
and ventricular arrhythmias, both in retrospective and prospective 
studies. A recent prospective study of 1020 DCM patients with a me­
dian follow-up of 5.2 years showed that myocardial scar had a strong 
and incremental prognostic value for predicting SCD, while LVEF 
≤35% was not associated with SCD.138 In another study, a risk calcula­
tor was developed that among others, incorporated the presence of 
LGE on CMR imaging540, although this has not yet been externally va­
lidated. There are at least two ongoing trials of ICD therapy according 
to the presence of scar on CMR imaging, including DCM patients 
(NCT04558723 and NCT03993730), but the Task Force’s opinion is 
that the existing level of evidence can support using LGE to guide 
ICD implantation in subgroups of patients with DCM (Figure 17). 
Additional risk factors, such as syncope or the presence of NSVT and 
burden of ventricular ectopy (VE), may also help guide ICD implant­
ation. There are no data currently to support a specific threshold for 
VE burden, and this will depend on the underlying genotype and other 
Cardiac arrest or VT with haemodynamic compromise
LVEF <35%
Gene specific risk assessmenta
High risk
ICD
(Class I)
ICD
(Class IIa)
ICD
(Class IIa/IIb)b
N
Additional risk factorsc
N
N
High-risk gene
N
Patients with DCM/NDLVC
Y
Y
Y
Y
ICD
(Class IIb)
Figure 17 Implantation of implantable cardioverter defibrillators in patients with dilated cardiomyopathy or non-dilated left ventricular cardiomyopathy 
flowchart. CMR, cardiac magnetic resonance; DCM, dilated cardiomyopathy; ICD, implantable cardioverter defibrillator; LGE, late gadolinium enhancement; 
LVEF, left ventricular ejection fraction; NDLVC, non-dilated left ventricular cardiomyopathy; VE, ventricular ectopic beats; VT, ventricular fibrillation. aSee 
Table 21. bStrength of recommendation depends on gene and context. cAdditional risk factors include syncope, LGE presence on CMR.
ESC Guidelines                                                                                                                                                                                          3565


<!-- PAGE 64 -->

### Page 64

clinical factors.542,867,872 In patients with unexplained syncope, pro­
grammed electrical stimulation (PES) may provide additional informa­
tion on the underlying cause.875 There are no definitive data 
supporting the routine use of PES for primary prevention risk stratifica­
tion in patients with DCM, but this may be beneficial in patients with 
DCM and myotonic dystrophy with an independent indication to elec­
trophysiological study to assess conduction disturbances,876 although 
the clinical value of this approach has not been consistently 
demonstrated.877
7.3. Non-dilated left ventricular 
cardiomyopathy
7.3.1. Diagnosis
7.3.1.1. Index case
The non-dilated LV cardiomyopathy phenotype is defined by the pres­
ence of non-ischaemic LV scarring or fatty replacement in the absence 
of LV dilatation, with or without global or regional wall motion abnor­
malities, or isolated global LV hypokinesia without scarring (as assessed by the presence of LGE on CMR) that is unexplained solely by abnormal 
loading conditions (hypertension, valve disease) or CAD. Global LV sys­
tolic dysfunction is defined by abnormal LVEF (i.e. <50%).9
7.3.1.2. Relatives
Clinical testing in relatives may reveal non-diagnostic abnormalities. In 
this context, the presence of LV systolic global or regional dysfunction, 
or additional electrocardiographic abnormalities (e.g. repolarization ab­
normalities, low QRS voltages, frequent ventricular extrasystoles 
[>500 per 24 h] or NSVT) in a first-degree relative of an individual 
with NDLVC (or a first-degree relative with autopsy-proven 
NDLVC) is highly suggestive of NDLVC and warrants close follow-up.
In the absence of conclusive genetic information in the family, 
NDLVC should be considered familial if one or more first- or second- 
degree relatives have NDLVC, or when SCD has occurred in a first- 
degree relative at any age with an established diagnosis of NDLVC. 
Familial disease should also be suspected if a first-degree relative has 
sudden death at <50 years of age and autopsy findings suggestive of 
the NDLVC phenotype.
7.3.1.3. Diagnostic work-up
The key elements of the diagnostic work-up for all patients with 
NDLVC are described in Section 6 and include clinical history, labora­
tory tests, Holter monitoring and cardiac imaging, and genetic testing.
Recommendation Table 24 — Recommendations for 
an implantable cardioverter defibrillator in patients 
with dilated cardiomyopathy
Recommendations
Classa
Levelb
Secondary prevention
An ICD is recommended to reduce the risk of 
sudden death and all-cause mortality in patients with 
DCM who have survived a cardiac arrest or have 
recovered from a ventricular arrhythmia causing 
haemodynamic instability.530,531,884
I
B
Primary prevention
An ICD should be considered to reduce the risk of 
sudden death and all-cause mortality in patients with 
DCM, symptomatic heart failure, and LVEF ≤35% 
despite >3 months of OMT.861,885
IIa
A
The patient’s genotype should be considered in the 
estimation of SCD risk in DCM.185,186,869,886
IIa
B
An ICD should be considered in patients with DCM 
with a genotype associated with high SCD risk and 
LVEF >35% in the presence of additional risk factors 
(see Table 21).541,542,867,869,873,878,881,886
IIa
C
An ICD may be considered in selected patients with 
DCM with a genotype associated with high SCD risk 
and LVEF >35% without additional risk factors (see 
Table 21).869,873,881,886
IIb
C
An ICD may be considered in patients with DCM 
without a genotype associated with high SCD risk 
and LVEF >35% in the presence of additional risk 
factors.c,138,873,874
IIb
C
© ESC 2023
CMR, cardiac magnetic resonance; DCM, dilated cardiomyopathy; ICD, implantable 
cardioverter defibrillator; LGE, late gadolinium enhancement; LVEF, left ventricular 
ejection fraction; OMT, optimal medical therapy; SCD, sudden cardiac death. 
aClass of recommendation. 
bLevel of evidence. 
cAdditional risk factors include syncope, LGE presence on CMR.
Table 21 High-risk genotypes and associated predic­
tors of sudden cardiac death
Gene
Annual 
SCD rate
Predictors of SCD
LMNA185,186,438,541,865,878,879
5–10%
Estimated 5-year risk of 
life-threatening arrhythmia 
using LMNA risk score 
(https://lmna-risk-vta.fr)
FLNC-truncating 
variants866,867,880
5–10%
LGE on CMR 
LVEF < 45%
TMEM43868,881
5–10%
Male 
Female and any of the 
following: LVEF <45%, 
NSVT, LGE on CMR, >200 
VE on 24h Holter ECG
PLN542,882,883
3–5%
Estimated 5-year risk of 
life-threatening arrhythmia 
using PLN risk score 
(https://plnriskcalculator. 
shinyapps.io/final_shiny) 
LVEF < 45% 
LGE on CMR 
NSVT
DSP185,186
3–5%
LGE on CMR 
LVEF < 45%
RBM20869
3–5%
LGE on CMR 
LVEF < 45%
© ESC 2023
CMR, cardiac magnetic resonance; DSP, desmoplakin; ECG, electrocardiogram; FLNC, 
filamin C; LGE, late gadolinium enhancement; LMNA, lamin A/C; LVEF, left ventricular 
ejection fraction; NSVT, non-sustained ventricular tachycardia; PLN, phospholamban; 
RMB, RNA binding motif protein; SCD, sudden cardiac death; VE, ventricular ectopic beats.


<!-- PAGE 65 -->

### Page 65

Echocardiography and CMR are both central to the diagnosis. 
Additional laboratory tests, exercise testing, EMB, and cardiac catheter­
ization may also be considered (see Section 6).
7.3.1.4. Electrocardiographic features
Recommendations on resting and ambulatory ECG testing are de­
scribed in Section 6.5 and are of particular importance in patients 
with NDLVC, as specific features can indicate the underlying genetic 
cause. Prolonged PR interval or AV block is frequent in neuromuscular 
causes of NDLVC and in sarcoidosis. Laminopathies are characterized 
by prolonged PR interval, AF, and ventricular ectopics (VEs), and fre­
quently show low voltage in pre-cordial leads.887 Depolarization abnor­
malities such as low QRS voltage are also a common finding in NDLVC 
caused by DSP and PLN variants.542 Ambulatory ECG monitoring is use­
ful in NDLVC patients to reveal supraventricular and ventricular ar­
rhythmias or bradycardias due to AV conduction block and is 
recommended at least yearly, or when there is a change in clinical sta­
tus. In some patients with NDLVC at high risk of developing conduction 
disease and/or arrhythmias (including laminopathies, neuromuscular 
disease, PLN, and FLNC-truncating variants), Holter monitoring may 
be considered more frequently.
7.3.1.5. Echocardiography
Comprehensive TTE is recommended for all patients with NDLVC as it 
provides all relevant information on the global and regional LV anatomy, 
function, and haemodynamics; valvular heart disease; right heart func­
tion; pulmonary pressure; atrial geometry; and other features.71,73
Advanced echocardiographic techniques (including deformation im­
aging using tissue Doppler and speckle tracking) can allow the early de­
tection of subclinical myocardial dysfunction in specific situations (e.g. 
genetic NDLVC carriers).71,74
7.3.1.6. Cardiac magnetic resonance
Cardiac magnetic resonance with LGE is the foremost imaging modality 
in NDLVC as it provides confirmation of the presence of non-ischaemic 
myocardial fibrosis that is essential for the diagnosis in most cases. 
Cardiac magnetic resonance can also be useful to detect the presence 
of myocardial oedema, which may suggest an inflammatory or myocar­
ditic aetiology, and to describe the extent and pattern of fibrosis 
distribution. This can provide clues to the underlying aetiology (e.g. sub­
epicardial distribution in post-myocarditis forms, patchy in sarcoidosis, 
extensive inferolateral in dystrophinopathies, septal mid-wall in LMNA 
carriers, and ring-like in DSP and FLNC variant carriers),71 and may pro­
vide additional prognostic value both for arrhythmia and heart failure 
severity.137,848
7.3.1.7. Nuclear medicine
The role of radionuclide imaging in NDLVC is limited. Measurement of 
18F-FDG uptake using PET, with focal or focal-on-diffuse FDG uptake 
patterns, especially if concomitant abnormal 18F-FDG-PET uptake in 
extracardiac tissues, can be useful in suspected cardiac sarcoidosis.849
Isolated cardiac uptake has also been described in patients with 
NDLVC caused by DSP variants.888
7.3.1.8. Endomyocardial biopsy
Endomyocardial biopsy (EMB) with immunohistochemical quantifi­
cation of inflammatory cells remains the gold standard investigation 
for the identification of cardiac inflammation. It may confirm the 
diagnosis of autoimmune disease in patients with unexplained heart 
failure and suspected giant cell myocarditis, eosinophilic myocardi­
tis, vasculitis, and sarcoidosis. In experienced centres, electroanato­
mical voltage mapping-guided EMB may improve the yield of 
diagnosis of NDLVC.889 The risks and benefits of EMB should be 
evaluated and this procedure should be reserved for specific situa­
tions where its results may affect diagnosis or treatment (see 
Section 6.7.5).
7.3.2. Genetic testing
The genes most commonly implicated in NDLVC are DSP, FLNC (trun­
cating variants), DES, LMNA, or PLN, but there is substantial overlap 
with the genetic background of both DCM and ARVC (Table 10). 
Desmoplakin (DSP) variants, in particular, cause a unique form of car­
diomyopathy with a high prevalence of LV fibrosis and myocardial in­
flammatory episodes.864
The identification of a P/LP gene variant in a patient with NDLVC al­
lows better prediction of the disease outcome and progression, may 
contribute to the indications for device implantation, informs genetic 
counselling, and allows familial screening for relatives (see Section 
6.8.3). Therefore, genetic testing is recommended in all patients with 
NDLVC.
Recommendations for clinical screening, genetic counselling, and 
testing are described in Sections 6.8.3 and 6.11. Evaluation of conduc­
tion disease, and atrial and ventricular arrhythmia, is of particular im­
portance in patients with NDLVC, as these may often be early 
phenotypic features. There are very few data on the natural history 
of phenotype-negative variant carriers or on the clinical yield of familial 
cascade screening in NDLVC, but cross-sectional studies suggest 
age-related increases in penetrance.9 Precautionary long-term evalu­
ation of first-degree relatives is therefore recommended.
7.3.3. Assessment of symptoms
Most patients with NDLVC are asymptomatic, but some develop 
symptoms related to arrhythmia or conduction disease (e.g. syncope, 
palpitation) or diastolic heart failure (e.g. dyspnoea). Sustained ventricu­
lar arrhythmia, cardiac arrest, or SCD can be the initial presentation in a 
proportion of patients. Assessment of symptoms in patients with car­
diomyopathies is described in Section 6.10.1.
7.3.4. Management
The clinical management of heart failure and other manifestations of 
NDLVC (atrial tachyarrhythmia, conduction disease) has been de­
scribed in the 2021 ESC Guidelines for the diagnosis and treatment of 
acute and chronic heart failure, the 2020 ESC Guidelines for the diagnosis 
and management of atrial fibrillation, the 2021 ESC Guidelines on cardiac 
Recommendation Table 25 — Recommendation for 
resting and ambulatory electrocardiogram monitoring 
in 
patients 
with 
non-dilated 
left 
ventricular 
cardiomyopathy
Recommendation
Classa
Levelb
Ambulatory ECG monitoring is recommended in 
patients with NDLVC annually or when there is a 
change in clinical status, to aid in management and 
risk stratification.
I
C
© ESC 2023
ECG, electrocardiogram; NDLVC, non-dilated left ventricular cardiomyopathy. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3567


<!-- PAGE 66 -->

### Page 66

pacing and cardiac resynchronization therapy, and the 2022 ESC Guidelines 
for the management of patients with ventricular arrhythmias and the pre­
vention of sudden cardiac death,69,299,336,724 and are discussed in 
Section 6.10.2.
7.3.5. Sudden cardiac death prevention in non-dilated 
left ventricular cardiomyopathy
The prediction and prevention of SCD is the cornerstone of the clinical 
care of patients with NDLVC.
7.3.5.1. Secondary prevention of sudden cardiac death
As in other cardiomyopathy subtypes, ICD implantation is recom­
mended in survivors of cardiac arrest and in patients who have experi­
enced sustained ventricular arrhythmias with haemodynamic 
compromise;531 the decision to implant should consider the patient’s 
view and their QoL, as well as the absence of other diseases likely to 
cause death within 1 year.
7.3.5.2. Primary prevention of sudden cardiac death
There are no available RCTs examining the usefulness of ICDs to 
prevent SCD in patients with mild or moderate LV dysfunction. 
Recommendations for ICD implantation in DCM individuals with 
LVEF <35% are discussed in Section 6.10.2 and also apply to pa­
tients with NDLVC and LVEF <35%. Most patients with NDLVC, 
however, have either normal or mildly impaired LV systolic func­
tion. Much of the data on the natural history and risk prediction 
in NDLVC are derived from cohorts that include either patients 
with DCM or with ARVC (see Sections 7.2 and 7.4), and data on 
patients with NDLVC are therefore necessarily very limited. 
However, the available data suggest that genotype is a major deter­
minant of SCD risk, with patients harbouring variants in PLN, 
TMEM43, DES, DSP, LMNA, FLNC (truncating variants), and 
RBM20 having a substantially higher rate of major arrhythmic events 
than other causes regardless of LVEF.440,542,864–869 For some 
high-risk 
genotypes 
(e.g. 
LMNA 
[https://lmna-risk-vta.fr]541), 
gene-specific (or, in the case of the PLN p.Arg14del variant, variant- 
specific [https://plnriskcalculator.shinyapps.io/final_shiny])542
risk- 
prediction scores have been developed that consider genotype 
characteristics and additional phenotypic features. Where such 
scores are available, they should be used to guide primary preven­
tion ICD implantation (Figure 12). As discussed in Sections 7.1.5 and 
7.2.5, the Task Force acknowledges the challenges associated with 
defining universal thresholds for acceptable risk across different car­
diomyopathy phenotypes, but is of the opinion that a similar ap­
proach to that taken in risk stratification for HCM is reasonable, 
although the 2022 ESC Guidelines for the management of patients 
with ventricular arrhythmias and the prevention of sudden cardiac death 
have suggested a higher threshold of 10% risk at 5 years to guide 
primary prevention ICD implantation in patients with NDLVC 
and LMNA variants.3 This Task Force recommends more overt 
shared decision-making based on real-world data as well as individ­
ual preferences, beliefs, circumstances, and values. Gaps in evidence 
are acknowledged and should be shared with patients, and compet­
ing risks related to the disease (heart failure, stroke) and to age and 
comorbidity, as well as device-related complications, should be 
discussed.
There are very few data to guide risk stratification in patients with 
NDLVC without a known causative gene variant, but on the basis of 
the existing literature, the Task Force suggests that it may be reasonable 
to consider primary prevention ICD implantation in patients with 
NSVT, a family history of SCD, or significant LGE. Additional risk fac­
tors, such as the burden of VE, may also help guide ICD implantation, 
but there are no data currently to support a specific threshold for 
VE burden, and this will depend on the underlying genotype and other 
clinical factors.542,867,872 In patients with unexplained syncope, PES may 
provide additional information on the underlying cause.875 There are no 
definitive data supporting the regular use of PES for primary prevention 
risk stratification in patients with NDLVC, but may be beneficial in pa­
tients with NDLVC and myotonic dystrophy with an independent indi­
cation to EP study to assess conduction disturbances,876 although the 
clinical value of this approach has not been consistently demon­
strated.877 Given the overlap with DCM and available data, and in keep­
ing with the 2022 ESC Guidelines for the management of patients with 
ventricular arrhythmias and the prevention of sudden cardiac death, the 
Task Force agreed that the recommendations for primary prevention 
ICD implantation in NDLVC should be the same as those for DCM 
(Figure 17), but the level of evidence is necessarily lower.
Recommendation Table 26 — Recommendations for 
an implantable cardioverter defibrillator in patients 
with non-dilated left ventricular cardiomyopathy
Recommendations
Classa
Levelb
Secondary prevention
An ICD is recommended to reduce the risk of 
sudden death and all-cause mortality in patients with 
NDLVC who have survived a cardiac arrest or have 
recovered from a ventricular arrhythmia causing 
haemodynamic instability.
I
C
Primary prevention
An ICD should be considered to reduce the risk of 
sudden death and all-cause mortality in patients with 
NDLVC, heart failure symptoms, and LVEF ≤35% 
despite >3 months of OMT.861,885
IIa
A
The patient’s genotype should be considered in the 
estimation of SCD risk in NDLVC.
IIa
C
An ICD should be considered in patients with 
NDLVC with a genotype associated with high SCD 
risk and LVEF >35% in the presence of additional risk 
factors (see Table 21).185,186,438,541,542,865–869,878–883
IIa
C
An ICD may be considered in selected patients with 
NDLVC with a genotype associated with high SCD 
risk and LVEF >35% without additional risk factors 
(see Table 21).
IIb
C
An ICD may be considered in patients with NDLVC 
without a genotype associated with high SCD risk 
and LVEF >35% in the presence of additional risk 
factors.c
IIb
C
© ESC 2023
ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; NDLVC, 
non-dilated left ventricular cardiomyopathy; OMT, optimal medical therapy; SCD, sudden 
cardiac death. 
aClass of recommendation. 
bLevel of evidence. 
cAdditional risk factors include syncope, LGE presence on CMR.


<!-- PAGE 67 -->

### Page 67

7.4. Arrhythmogenic right ventricular 
cardiomyopathy
7.4.1. Diagnosis
7.4.1.1. Index case
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is charac­
terized structurally by a progressive myocardial atrophy with fibro-fatty 
replacement of the RV myocardium.890 Lesions can also be present in 
the LV myocardium; predominant LV disease can coexist in the same 
family. Arrhythmogenic right ventricular cardiomyopathy usually mani­
fests in the second to fourth decade of life.891 Men are affected more 
frequently than women and an age-related penetrance has been de­
monstrated, with high clinical and genetic variability.
An ARVC diagnosis should be suspected in adolescents or young 
adults with palpitations, syncope, or aborted sudden death. Frequent 
VEs or VT of LBBB morphology are among the most common clinical 
presentation. The presence of right pre-cordial TWI (V1–V3) in routine 
ECG testing should also be suspected for ARVC.10,892 Less common 
ECG changes include low QRS voltages in the peripheral leads and ter­
minal activation delay in the right pre-cordial leads.893 Right ventricular 
dilatation on 2D echocardiography is also a frequent reason for patient 
referral. Less common presentations are RV or biventricular heart fail­
ure that can mimic DCM or NDLVC.894 Patients with multiple variants 
are thought to develop a more severe phenotype, and patients with a 
DSP or DSG2 variant are more prone to develop heart failure.895,896
In children and young adults, syncope, palpitations, and ventricular 
arrhythmias are also the usual presenting symptoms.897 However, 
chest pain, dynamic ST-T wave changes on basal 12-lead ECG, and myo­
cardial enzymes release in the setting of normal coronary arteries are 
often reported, requiring differential diagnosis with myocarditis or 
acute myocardial infarction.898
7.4.1.2. Relatives
Clinical testing in relatives often reveals non-diagnostic abnormalities. In 
this context, the presence of RV systolic global or regional dysfunction, 
or additional electrocardiographic abnormalities (e.g. repolarization ab­
normalities, prolonged terminal activation duration, low QRS voltages, 
frequent ventricular extrasystoles [>500 per 24 h], or NSVT) in a first- 
degree relative of an individual with ARVC (or a first-degree relative 
with autopsy-proven ARVC) is highly suggestive of ARVC and warrants 
close follow-up.
7.4.1.3. Diagnostic work-up
The key elements of the diagnostic work-up for all patients with ARVC 
are defined by the diagnostic criteria used for the identification of af­
fected individuals. The revised Task Force criteria for the diagnosis of 
ARVC published by Marcus et al. in 2010 have been used for the diag­
nosis of ARVC for more than a decade.10 More recently, the Padua cri­
teria have offered an updated iteration to include LV involvement but 
are yet to be externally validated.5 Key elements of the diagnostic work- 
up include ECG, Holter monitoring, cardiac imaging, genetic testing, 
and, in specific circumstances, EMB.4,10,892 Additional laboratory tests, 
exercise testing, and cardiac catheterization should also be considered, 
as detailed in Section 6.
7.4.1.4. Electrocardiography and Holter monitoring
Abnormalities of the repolarization and depolarization as well as ar­
rhythmias are key to the diagnosis of ARVC.5 The diagnostic utility 
of late potentials on signal-averaged electrocardiogram (SAECG) 
has been challenged in patients with ARVC for showing poor sensitiv­
ity and specificity.5,899 It has been noted that epsilon waves are fre­
quently overdiagnosed and that there is poor agreement even 
between experts regarding their presence.900 Furthermore, it has 
been demonstrated that they occur in the presence of severe struc­
tural disease and thus add little to the diagnosis.900,901 Therefore, ep­
silon waves and SAECG should be utilized for diagnostic purposes 
with caution.
7.4.1.5. Echocardiography and cardiac magnetic resonance
A comprehensive cardiac imaging assessment is recommended for all 
ARVC patients.71,73 Structural and functional alterations assessed by 
echocardiography and CMR are key to ARVC diagnosis.10 The key fea­
ture is the presence of wall motional abnormalities such as RV akinesia, 
dyskinesia, or bulging, and the determinant of the diagnostic perform­
ance is the level of RV dilatation or dysfunction (major and minor cri­
teria). Cardiac magnetic resonance should be considered the first-line 
test for assessment of the RV functional structural abnormalities criter­
ion as it has demonstrated superior sensitivity.10 Contrast-enhanced 
CMR is the only tool allowing the detection of LV involvement which 
remains otherwise underestimated by applying the 2010 Task Force 
Criteria. Tissue characterization by CMR or indirectly by electroanato­
mical voltage mapping may show signs of fibro-fatty replacement that 
can be present in either ventricle.889,903,904
7.4.1.6. Endomyocardial biopsy
Differential diagnosis in patients with suspected ARVC includes inflam­
matory processes affecting the right ventricle such as myocarditis and 
sarcoidosis. In some instances, especially when dealing with probands 
with a sporadic form, EMB may be helpful to rule out myocarditis 
and sarcoidosis.72,892,905 Endomyocardial biopsy can also be useful in 
selected patients in whom non-invasive assessment is inconclusive.4,72
Electroanatomic voltage mapping-guided EMB may be considered in se­
lected cases, particularly in case of negative CMR.906
7.4.1.7. Nuclear medicine
Measurement of 18F-FDG uptake using PET, with focal or 
focal-on-diffuse FDG uptake patterns, can be useful in suspected car­
diac sarcoidosis.849 However, it has been demonstrated that patients 
with ARVC can also show myocardial 18F-FDG-PET uptake.888,907
Therefore, there is a limited role for radionuclide imaging in ARVC un­
less there is concomitant abnormal 18F-FDG-PET uptake in extracar­
diac tissues, or other clinical features suggestive of cardiac 
sarcoidosis.904,908
Recommendation Table 27 — Recommendation for 
resting and ambulatory electrocardiogram monitoring 
in patients with arrhythmogenic right ventricular 
cardiomyopathy
Recommendation
Classa
Levelb
Annual ambulatory ECG monitoring is 
recommended in patients with ARVC to aid in 
diagnosis, management, and risk stratification.902
I
C
© ESC 2023
ARVC, arrhythmogenic right ventricular cardiomyopathy; ECG, electrocardiogram. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3569


<!-- PAGE 68 -->

### Page 68

7.4.1.8. Arrhythmogenic right ventricular cardiomyopathy 
phenocopies
In suspicion of ARVC, a systematic approach to investigation of pheno­
copies should be undertaken. Differential diagnosis in patients with sus­
pected ARVC includes myocarditis, sarcoidosis, RV infarction, DCM, 
Chagas disease, pulmonary hypertension, and CHD with volume over­
load (such as Ebstein anomaly, atrial septal defect, and partial anomal­
ous venous return, left-to-right shunt, and pericardial agenesis).909,910
Disease phenocopies also include non-structural diseases. In fact, one 
of the main diagnostic dilemmas is to distinguish ARVC from idiopathic 
RV outflow tract VT, since the latter is usually benign.4 The idiopathic 
nature of VT is supported by the absence of family history, a normal 
basal 12-lead ECG, a normal ventricular structure by cardiac imaging 
and electroanatomic mapping, a single VT morphology, and the non- 
inducibility at programmed ventricular stimulation.
In highly trained competitive athletes, differential diagnosis with 
physiological adaptation to training needs to be considered.911 Right 
ventricular enlargement, ECG abnormalities, and arrhythmias reflect 
the increased haemodynamic load during exercise. While global RV sys­
tolic dysfunction and/or RWMAs, such as bulgings or aneurysms, are 
more in keeping with ARVC, the absence of overt structural changes 
of the right ventricle, frequent VEs, or inverted T waves in pre-cordial 
leads all support a benign nature (so-called athlete’s heart).72,912,913
7.4.2. Genetic testing and family screening
The genes underlying ARVC mainly encode proteins of the cardiac 
desmosome: plakophilin-2 (PKP2), desmoplakin (DSP), desmoglein-2 
(DSG2), desmocollin-2 (DSC2), and plakoglobin (JUP). In addition to 
desmosomal genes, P/LP variants have also been described in other 
genes, including DES,914 TMEM43,915 and PLN.190,882 Pathogenic or like­
ly pathogenic variants can be identified in up to 60% of patients with a 
diagnosis of ARVC.230 Given the diagnostic importance of genetic test­
ing in ARVC, it is important that genetic variants are frequently re- 
appraised in terms of their pathogenicity.916 The pattern of inheritance 
in the majority of ARVC families is autosomal dominant. The pene­
trance of the disease in genetic carriers is age, gender, and physical ac­
tivity dependent.892,917
Recommendations for clinical screening, genetic counselling, and 
testing are described in Sections 6.8.3 and 6.11. Cardiac evaluation 
should be adapted to the particular risk of complications in the family. 
Evaluation every 1–2 years including ECG, ECHO, and Holter/ECG 
monitoring is generally recommended for relatives at risk of developing 
the disease. Cardiac magnetic resonance should be considered at the 
baseline evaluation.
7.4.3. Assessment of symptoms
Patients with ARVC commonly experience palpitations and can de­
velop symptoms of heart failure, although this may occur many years 
after the appearance of the initial abnormalities. Assessment of symp­
toms in patients with cardiomyopathies is described in Section 6.10.1.
7.4.4. Management
The aim of the clinical management of ARVC relies on the improve­
ment of symptoms, the reduction of the pace of disease progression, 
and the prevention of complications. Recommendations for the 
pharmacological management of atrial arrhythmias and heart failure 
symptoms in patients with cardiomyopathies are described in Sections 
6.10.2 and 6.10.3.
7.4.4.1. Antiarrhythmic therapy
Beta-blockers constitute the first option to reduce arrhythmic burden 
via a reduction in adrenergic tone, particularly on exercise. Titration to 
the maximal tolerated dose has been associated with an improvement 
in survival from major ventricular arrhythmias in retrospective observa­
tional studies.918
Amiodarone is often used when other beta-blockers fail to control 
arrhythmias.917,919,920 It should, however, be used with caution for 
the long-term management of ventricular arrhythmias, especially in 
young patients. Sotalol has been used for many years, but evidence re­
garding its efficacy remain limited and conflicting.921,922 Flecainide 
should be considered when single agent treatment has failed to control 
arrhythmia-related symptoms in patients with ARVC or when auto­
nomic side effects limit the use of beta-blockers.923,924 Experience 
with other antiarrhythmics (dofetilide, ranolazine) is limited to very 
small case series.919,923
A proportion of patients require invasive arrhythmic procedures 
and/or ICD implantation. Complex endocardial and/or epicardial ap­
proach guided by three-dimensional (3D) electroanatomical mapping 
can be recommended but with a high recurrence rate (30–50% in ex­
perienced centres).919,925–927 Sympathetic denervation has also been 
used.928 Such procedures do not confer adequate protection against 
SCD, but may be very useful in reducing the VT burden and the risk 
of electrical storm.917 Discontinuation of intense physical exercise 
has shown a potential to slow the pace of disease progression and re­
duce the ventricular arrhythmia burden.917,919
7.4.5. Sudden cardiac death prevention in 
arrhythmogenic right ventricular cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy is characterized by its 
high propensity for ventricular arrhythmias and SCD.919 Although esti­
mated to be a rare disease, it has been consistently reported as one of 
Recommendation Table 28 — Recommendations for 
the antiarrhythmic management of patients with 
arrhythmogenic right ventricular cardiomyopathy
Recommendations
Classa
Levelb
Beta-blocker therapy is recommended in ARVC 
patients with VE, NSVT, and VT.920–922
I
C
Amiodarone should be considered when regular 
beta-blocker therapy fails to control 
arrhythmia-related symptoms in patients with 
ARVC.921,922
IIa
C
Flecainide in addition to beta-blockers should be 
considered when single agent treatment has failed to 
control arrhythmia-related symptoms in patients 
with ARVC.923,924
IIa
C
Catheter ablation with availability for epicardial 
approach guided by 3D electroanatomical mapping 
of VT should be considered in ARVC patients with 
incessant VT or frequent appropriate ICD 
interventions for VT despite pharmacological 
therapy with beta-blockers.925,929–934
IIa
C
© ESC 2023
3D, three-dimensional; ARVC, arrhythmogenic right ventricular cardiomyopathy; ICD, 
implantable cardioverter defibrillator; NSVT, non-sustained ventricular tachycardia; VE, 
ventricular ectopic beats; VT, ventricular tachycardia. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 69 -->

### Page 69

the most common causes of SCD in registries around the world.935–937
Sudden cardiac death seems to be more prevalent in young athletic in­
dividuals affected by the disease.935,938
7.4.5.1. Secondary prevention of sudden cardiac death
Implantable cardioverter defibrillators reduce mortality in survivors of 
cardiac arrest and in patients who have experienced sustained symp­
tomatic ventricular arrhythmias.531 An ICD is recommended in such 
patients when the intent is to increase survival; the decision to implant 
should consider the patient’s view and their QoL, as well as the absence 
of other diseases likely to cause death within the following year.
7.4.5.2. Primary prevention of sudden cardiac death
Most of the current evidence on the outcomes of patients with ARVC 
and their predictors is limited to observational retrospective cohort 
studies that are typically of small size.939 Thus, the number of clinical pre­
dictors that can be studied using multivariate models is very limited, and 
most studies cannot be compared with one another. A systematic review 
and meta-analysis (n = 18 studies) has shown that the average risk of ven­
tricular arrhythmia ranges from 3.7 to 10.6% per year and that male sex, 
RV dysfunction, and prior non-sustained or sustained VT/VF consistently 
predict ventricular arrhythmias in populations with ARVC.939
The first comprehensive effort to offer an approach to risk stratifica­
tion in the context of decision-making for ICD implantation was made 
in the 2015 International Task Force consensus statement (ITFC) on 
the treatment of ARVC/dysplasia, where recommendations were 
made according to the presence of risk factors that would characterize 
the risk level of each patient.919 A follow-up study (n = 365) offered a 
modification on the International Task Force approach that resulted in 
better discrimination.940 The 2017 AHA/ACC/HRS guideline for manage­
ment of patients with ventricular arrhythmias and the prevention of sudden 
cardiac death941 and the 2019 HRS expert consensus statement on evalu­
ation, risk stratification, and management of arrhythmogenic cardiomyop­
athy4 have also offered alternative approaches to this issue. A 
risk-prediction model was developed from a multicentre collaboration 
(n = 528); it utilizes sex, age, recent syncope, NSVT, VE count, number 
of leads with TWI, and right ventricular ejection fraction (RVEF) as pre­
dictors to provide an individualized estimate of sustained ventricular ar­
rhythmias in patients with ARVC (arvcrisk.com).539
A study (n = 617) comparing the previous approaches to risk stratify 
patients has revealed that the modified ITFC approach provides the 
highest net benefit, up to an estimated 5-year risk of 25%, whereas 
AHA and HRS perform best in patients with an estimated 5-year risk 
>25%.538 In the same study, an estimated 5-year risk of 12.5% seems 
to be the optimal threshold, beyond which the risk-prediction model 
has the best performance. An external comparison (n = 140) of the dif­
ferent ARVC risk levels showed that the highest net benefit was seen 
with a 10% cut-off, using the 2019 ARVC risk calculator.536 In the 
same study, the 10% cut-off was superior to the HRS and ITFC ap­
proaches.536 Another external validation study (n = 128) of the 2019 
ARVC risk model showed that although discriminative ability is excel­
lent (c-index 0.84), the model seems to significantly overestimate the 
risk of patients below the 50% 5-year risk threshold.537 Recently, a cor­
rection to the 2019 ARVC risk calculator was issued.539 Two large ex­
ternal validation studies of the updated 2019 ARVC risk calculator have 
been published, suggesting a good discriminative performance, but the 
latter study revealed overestimation of risk.524,526 This raises concerns 
regarding the accuracy of the model in offering an individualized predic­
tion that can help inform patients during decision-making; however, it 
can remain informative due to its excellent discriminative performance. 
Furthermore, one study suggested that the updated 2019 ARVC risk 
calculator performs best in PKP2 patients, but its performance is 
more limited in gene-negative individuals.524
Therefore, a combination of these approaches is recommended to 
individualize risk quantification that can aid clinicians in balancing the 
risks and benefits of ICD implantation. The final decision should be 
made together with the patient, considering other competing risks 
and the patient’s risk tolerance. As discussed in Section 7.1.5, the 
Task Force acknowledges the challenges associated with defining uni­
versal thresholds for acceptable risk across different cardiomyopathy 
phenotypes, but is of the opinion that a similar approach to that taken 
in risk stratification for HCM, DCM, and NDLVC is reasonable. In this 
context, the Task Force recommends shared decision-making based on 
real-world data as well as individual preferences, beliefs, circumstances, 
and values. Gaps in evidence should be shared with patients, and com­
peting risks related to the disease (heart failure, stroke) and to age and 
comorbidity, as well as device-related complications, should be dis­
cussed. The suggested approach is summarized in Figure 18.
Patients with ARVC are known to suffer from sustained VTs that can 
be well tolerated without leading to SCD. Using appropriate ICD inter­
ventions as surrogate for SCD outcome has been shown to overesti­
mate SCD.942 Considering that, in most centres, a high ratio of ARVC 
patients will be implanted with an ICD, it is conceivable why this may 
hamper risk stratification for SCD in patients with ARVC. Efforts to ad­
dress this have been made within several studies,522,523,943–947 where
Recommendation Table 29 — Recommendations for 
sudden cardiac death prevention in patients with 
arrhythmogenic right ventricular cardiomyopathy
Recommendations
Classa
Levelb
Secondary prevention
An ICD is recommended to reduce the risk of 
sudden death and all-cause mortality in patients with 
ARVC who have survived a cardiac arrest or have 
recovered from a ventricular arrhythmia causing 
haemodynamic instability.939,943,944,948,949
I
A
An ICD should be considered in ARVC patients who 
have suffered a haemodynamically tolerated 
VT.522,939,943–945,948–950
IIa
B
Primary prevention
High-risk featuresc should be considered to aid 
individualized decision-making for ICD implantation 
in patients with ARVC.538,939
IIa
B
The updated 2019 ARVC risk calculator should be 
considered to aid individualized decision-making for 
ICD implantation in patients with ARVC.d,524,526,536– 
539
IIa
B
© ESC 2023
ARVC, arrhythmogenic right ventricular cardiomyopathy; ICD, implantable cardioverter 
defibrillator; LVEF, left ventricular ejection fraction; NSVT, non-sustained ventricular 
tachycardia; PES, programmed electrical stimulation; RVEF, right ventricular ejection 
fraction; SMVT, sustained monomorphic ventricular tachycardia; VT, ventricular 
tachycardia. 
aClass of recommendation. 
bLevel of evidence. 
cHigh-risk features: arrhythmic syncope, NSVT, RVEF <40%, LVEF <45%, SMVT at PES. 
dSee text for discussion of gene-specific differences in the performance of the updated 
2019 ARVC risk calculator.
ESC Guidelines                                                                                                                                                                                          3571


<!-- PAGE 70 -->

### Page 70

the outcome of interest is fast VT (>250 b.p.m.) rather than any sus­
tained VT. The largest of these studies (n = 864) has led to the develop­
ment of a separate score for the prediction of unstable VT/VF.945 Due to 
the lack of any external validation studies, there is insufficient informa­
tion to support the applicability of this risk score outside of its develop­
ment cohorts. Furthermore, a specific rate cut-off is also not well 
evidence-based and its performance to predict SCD remains unclear. 
Although it is likely that slower sustained VTs per se are not life- 
threatening, it remains unknown how frequently they would degenerate 
to faster VTs or VF. It is therefore reasonable to suggest that all patients 
at risk of any sustained ventricular arrhythmia should be offered primary 
prevention ICDs.
The role of PES in risk stratification of ARVC patients is not well de­
fined, particularly in those who are asymptomatic.523,939 However, cur­
rent practice suggests that inducibility of SMVT at PES might add value 
in patients with symptoms consistent with sustained ventricular ar­
rhythmia and this is further supported in this guideline3
7.5. Restrictive cardiomyopathy
7.5.1. Diagnosis
Patients with overt RCM manifest signs and symptoms typical of 
HFpEF.306 The systematic approach to diagnosis should include clinical 
examination, ECG, echocardiography, and CMR.951 Physical examin­
ation may show a prominent jugular venous pulse. In the advanced 
phases, the pulse volume is low, the stroke volume declines, and the 
heart rate may increase. Hepatomegaly, ascites, and peripheral oedema 
are common in decompensated patients. Echocardiography is the gold 
standard diagnostic tool; criteria for diagnosing and grading diastolic 
dysfunction have been previously described.951,952 Importantly, the de­
gree of diastolic dysfunction in patients with RCM is often only truly re­
strictive in advanced stages and most patients show milder grades of 
diastolic impairment at diagnosis.951 Cardiac catheterization should 
be performed in cases where the diagnosis is in doubt and to aid in 
the assessment for and timing of cardiac transplantation.953 Cardiac 
MRI distinguishes RCM from constrictive pericarditis, provides informa­
tion on the presence and extent of myocardial fibrosis, and contributes 
to distinguishing metabolic from inflammatory diseases.951,954
Endomyocardial biopsy is a precision diagnostic tool in restrictive 
cardio-desminopathies;955 iron myocardial overload, both intramyo­
cyte in haemochromatosis956 and mitochondrial in Friedreich ataxia 
cardiomyopathy;957 cystinosis;958 generalized arterial calcification of in­
fancy;955,959 and lysosomal storage diseases (LSDs).960,961 Deep pheno­
typing in probands should go beyond cardiac traits and explore 
extracardiac manifestations in syndromic diseases and in RCM asso­
ciated with neuromuscular disorders (see Section 6).962
7.5.2. Genetic testing
When inherited, RCM most commonly presents as an autosomal 
dominant disorder and, less commonly, autosomal recessive or spor­
adic. Genes associated with RCM encode sarcomeric structural and 
regulatory 
proteins 
and 
cytoskeletal 
intermediate 
filaments 
(Table 10). Although all major sarcomeric genes may cause RCM,963
the most common disease gene is TNNI3, which encodes the thin fila­
ment troponin I.964 Other less commonly involved genes include 
TNNT2, ACTC1, MYH7, MYBPC3, TTN, TPM1, MYPN, MYL3, and 
MYL2. Restrictive cardiomyopathy can be associated with intramyocyte 
accumulation of unfolded defective proteins, a feature that is increas­
ingly demonstrated in carriers of defects in DES, FLNC, and BAG3. 
These diseases have significant implications for prognosis and timely 
decision-making, both in children and adults. Restrictive cardiomyop­
athy may also occur in individuals with a family history of HCM289 or 
DCM.965 The observation of different cardiomyopathy phenotypes 
within families suggests a variable response to the variant, and
Cardiac arrest or syncopal VT
Non-syncopal sustained VT
ICDa
(Class I)
ICDa
(Class IIa)
N
N
Patients with ARVC
Y
Y
High risk featuresb
ICD
(Class IIa)
Figure 18 Algorithm to approach implantable cardioverter defibrillator decision-making in patients with arrhythmogenic right ventricular cardiomyopathy. 
ARVC, arrhythmogenic right ventricular cardiomyopathy; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; NSVT, non- 
sustained ventricular tachycardia; PES, programmed electrical stimulation; RVEF, right ventricular ejection fraction; SMVT, sustained monomorphic ventricu­
lar tachycardia; VT, ventricular tachycardia. aClinicians should aim to control ventricular arrhythmia with pharmacological or invasive antiarrhythmic therapies 
in addition to offering an ICD. bHigh-risk features are defined as either cardiac syncope, NSVT, RVEF <40%, LVEF <45%, SMVT at PES or as per the updated 
2019 ARVC risk calculator.539


<!-- PAGE 71 -->

### Page 71

implicates factors beyond the specific variant in the determination of 
ultimate clinical manifestation of disease.966 Hereditary infiltrative dis­
eases can also cause RCM, the most common of which is amyloidosis 
caused by pathogenic variants in the TTR gene, although this is usually in 
the presence of LVH (see Section 7.7).
7.5.3. Assessment of symptoms
Patients with RCM often develop symptoms of heart failure, although 
this can occur some years after the appearance of the initial abnormal­
ities. Assessment of symptoms in patients with cardiomyopathies is de­
scribed in Section 6.10.1.
7.5.4. Management
The administration of heart failure medications and device implantation, 
including ventricular assist device as a bridge-to-candidacy is guided by 
symptoms and heart failure phenotype and severity,967 and is described 
in Section 6.10.2. Precision diagnosis (phenotype and cause) is key to time­
ly planning of heart transplantation as it guarantees the exclusion of all 
genetic and acquired phenocopies that may be amenable to alternative 
treatment. Prevention of heart transplantation in all RCM patients with 
alternative treatments is a major goal for all adult and paediatric RCM.
Precise diagnosis is also essential for genetic phenocopies with avail­
able target treatments: ERT for Anderson–Fabry disease or glycogeno­
sis 
such 
as 
Pompe 
disease; 
therapeutic 
phlebotomy 
for 
haemochromatosis; immunosuppressive therapeutics for sarcoidosis; 
new biological drugs for systemic diseases (e.g. autoimmune diseases 
with cardiac involvement that can reverse or stabilize by treating the 
disease itself); and removal of the toxic causes (see Figure 19 and 
Supplementary data online, Table S4). Precision diagnosis today is es­
sential due to the increasing availability of disease-specific treatments 
and diagnostic tools to exclude geno/phenocopies.
Restrictive heart diseases
Intrinsic myocyte dysfunction
Genetic
Primary RCM
Variants in sarcomeric,
cytoskeletal, nuclear envelope, filamin, titin genes
Storage
AFD
Desmin
Danon
Glycogenoses
PRKAG2 variants
Iron overload/storage disorders
Non-genetic
Myocardial extracellular matrix disorders
Infiltrative
Fibrosis
Amyloidosis
Sarcoidosis
Diabetic heart disease
Drugs (e.g. chloroquine)
Hyperoxaluria
Radiation
Chemotherapy
Systemic sclerosis
Inflammatory/granulomatous
Endomyocardial disorders
Endomyocardial fibrosis
Hypereosinophilia
Carcinoid
Endocardial fibroelastosis
Endocardial neoplasms
Iatrogenic/drug toxicity
RCM
Myocardial diseases with occasional restrictive physiology, often in the context of LVH
Figure 19 Spectrum of restrictive heart diseases. AFD, Anderson–Fabry disease; LVH, left ventricular hypertrophy; PRKAG2, Protein kinase 
AMP-activated non-catalytic subunit gamma 2; RCM, restrictive cardiomyopathy. For a more detailed spectrum of restrictive heart disease, please refer 
to Supplementary data online, Table S4.Image %:   
ESC Guidelines                                                                                                                                                                                          3573


<!-- PAGE 72 -->

### Page 72

Restrictive cardiomyopathy is associated with the worst prognosis of 
all the cardiomyopathy phenotypes. Survival data are limited to small 
windows of observation. The prognosis of RCM largely depends on 
the restrictive physiology, regardless of the underlying cause.968–971
More than 50% of children with RCM are at risk of death (including 
SCD) or transplantation shortly after diagnosis; clinical features puta­
tively associated with increased risk of death or transplantation include: 
heart failure symptoms; reduced LV systolic function; increased left at­
rial size; syncope; ischaemia; and impaired LV diastolic function on 
echocardiography.286,969,972,973 Up to 75% of surviving patients demon­
strate heart failure, and the outcome is either death or heart transplant­
ation within a few years of diagnosis.968,969 Elevated pulmonary vascular 
resistance (PVR) is present in up to 40% of children with RCM, and can 
rise quickly even in the absence of other clinical changes, which has an 
impact on suitability for and timing of cardiac transplantation.953
Cardiac catheterization with an assessment of PVR is therefore recom­
mended in all children at diagnosis and every 6 to 12 months.953 In adult 
patients with genetic RCM, the main cause of death is heart failure 
(more than 40%), with a 5-year survival rate of ∼50% in cohorts that 
include patients with HCM and restrictive physiology.616
7.6. Syndromic and metabolic 
cardiomyopathies
It is beyond the scope of these guidelines to provide a detailed review 
and recommendations on specific cardiomyopathy genocopies and 
phenocopies. Instead, the Task Force refers the reader to detailed pos­
ition statements and consensus documents published on behalf of the 
ESC Working Group on Myocardial and Pericardial Diseases (e.g. on 
Anderson–Fabry Disease and amyloidosis ).370,375,974 This section high­
lights only the key diagnostic and management issues. Table 22 sum­
marizes the clinical features and management of syndromic and 
metabolic cardiomyopathies.
7.6.1. Anderson–Fabry disease
7.6.1.1. Definition
Anderson–Fabry disease is an inborn error of metabolism where a de­
ficient or absent enzyme, alpha-galactosidase A (α-Gal A), due to a 
pathogenic genetic variant in the GLA gene, causes the storage of 
some degradation cell products, mainly globotriaosylceramide (Gb3) 
in a patient’s lysosomes.975 This storage causes cell dysfunction in its 
own right and activates cellular hypertrophy pathways, common to 
other causes of HCM, as well as inflammation and immune activa­
tion.976 It is a multisystem disorder affecting particularly the heart, kid­
ney, and brain. 975 It is inherited in an X-linked manner; males are 
therefore always affected, while females’ organ involvement usually de­
velops later in life but can become similar to males due to the lyoniza­
tion phenomena.977,978
Two Anderson–Fabry phenotypes can be distinguished, depending 
on the gender, lyonization phenomena, and pathogenic genetic 
variant:976,979
• A severe clinical phenotype, known as ‘classic’ Anderson–Fabry char­
acterized by absent or severely reduced (<1% of mean normal) α-Gal 
A activity, marked Gb3 accumulation, and childhood or adolescent 
onset of symptoms followed by progressive multiorgan failure, is 
most often seen in males (but not exclusively) without residual en­
zyme activity.
• A ‘non-classical’ Anderson–Fabry phenotype or later-onset pheno­
type with incomplete systemic involvement, which is seen in both 
males and females, with some level of residual enzyme activity, and 
in most cases manifesting as isolated cardiac involvement.
7.6.1.2. Diagnosis, clinical work-up, and differential diagnosis
Anderson–Fabry disease should be suspected in patients with LVH and 
additional cardiac and extracardiac red flags (see Table 23) sought 
(Figure 20). The diagnosis is established by assessment of α-GalA activity 
and lyso-Gb3 measurement in male patients; in females, genetic testing 
is usually required to confirm the diagnosis. Severe LVH (>15 mm) is 
unlikely to be seen in patients <20 years of age.980 In children and ado­
lescents, diagnosis is made by family history or based on other extracar­
diac symptoms, but overt LVH is usually not present.981
7.6.1.3. Clinical course, outcome, and risk stratification
Cardiovascular involvement usually manifests as LVH, myocardial fibro­
sis, inflammation, heart failure, and arrhythmias, which limit QoL and 
are the most common cause of death. Clinical monitoring is essential 
to assess disease progression and requires a multidisciplinary 
approach.980
Recommendation Table 30 — Recommendations for 
the 
management 
of 
patients 
with 
restrictive 
cardiomyopathy
Recommendations
Classa
Levelb
It is recommended that multimodality imaging be 
used to differentiate RCM from HCM or DCM with 
restrictive physiology.
I
C
It is recommended that baseline cardiac and 
non-cardiac investigations are performed to assess 
involvement of the neuromuscular system or other 
syndromic disorders.
I
C
Cardiac catheterization is recommended in all 
children with RCM to measure pulmonary artery 
pressures and PVR at diagnosis and at 6–12 monthly 
intervals to assess change in PVR.953
I
B
ICD implantation is recommended to reduce the risk 
of sudden death and all-cause mortality in patients 
with RCM who have survived a cardiac arrest or have 
recovered from a ventricular arrhythmia causing 
haemodynamic instability.
I
C
Endomyocardial biopsy should be considered in 
patients with RCM to exclude specific diagnoses 
(including iron overload, storage disorders, 
mitochondrial cytopathies, amyloidosis, and 
granulomatous myocardial diseases) and to diagnose 
restrictive myofibrillar disease caused by desmin 
variants.
IIa
C
ICD implantation may be considered in children with 
RCM who have evidence of myocardial ischaemia and 
syncope.969
IIb
C
© ESC 2023
DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; ICD, implantable 
cardioverter defibrillator; PVR, pulmonary vascular resistance; RCM, restrictive 
cardiomyopathy. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 73 -->

### Page 73

Table 22 Clinical features and management of syndromic and metabolic cardiomyopathies
Clinical red flags
Diagnosis
Specific cause
Multidisciplinary 
team
Management
Abnormal facial features 
Cryptorchidism 
Pulmonary valve stenosis 
Congenital heart disease 
Extreme right-axis 
deviation at ECG 
Lymphangectasis 
Bleeding diathesis 
Café au lait spots 
Lentigines 
Growth retardation 
Sensorineural deafness
NGS panel testing for RASopathy
Noonan syndrome 
Costello syndrome 
Cardiofaciocutaneous 
syndrome 
Noonan syndrome with 
multiple lentigines
Cardiologist 
Geneticist 
Endocrinologist 
Paediatrician 
Dermatologist 
Radiologist
Beta-blockers/CCBs 
Selective management of RVOTO/ 
pulmonary valvuloplasty 
SCD risk stratification
Short PR interval 
End-stage, hypokynetic 
HCM 
AV block (Kearns–Sayre 
syndrome) 
Lactic acidosis 
Sensorineural deafness 
Neutropenia (Barth 
syndrome) 
Diabetes 
Stroke-like lesions at 
brain MRI
NGS panel for mtDNA and 
nuclear DNA 
Skeletal muscle biopsy/ 
endomyocardial biopsy
MELAS syndrome 
MERRF syndrome 
Leigh syndrome 
Other mitochondrial 
disease 
Beta-oxidation disorders
Cardiologist 
Neurologist 
Endocrinologist 
Paediatrician 
Metabolism expert 
Radiologist
Avoiding drugs or situational 
stressors 
Beta-oxidation disorders: 
nutritional management, avoidance 
of fasting, aggressive treatment 
during increased metabolic stress 
Carnitine supplementation 
(selected cases)
Hepatomegaly 
Increased 
aminotransferase 
enzymes 
Delayed motor 
milestones 
Hypotonia 
Short PR interval 
ECG criteria for extreme 
LVH
Screening: GAA activity in DBS or 
leucocytes/Glc4 dosing 
Diagnostic confirmation: acid 
alpha-glucosidase assay performed 
on skin fibroblasts (preferred 
method) or muscle biopsy
Type II glycogen storage 
disease (Pompe disease)
Cardiologist 
General Paediatrician/ 
neonatologist 
Gastroenterologist 
Neuromuscular 
disease specialist
Enzyme replacement therapy
Short PR interval 
Massive LVH 
Skeletal myopathy 
Increased serum CK 
enzyme 
Intellectual disability 
X-linked inheritance
NGS or target testing for LAMP-2 
variants
Danon disease
Cardiologist 
Neuromuscular 
disease specialist 
Pneumologist 
Advanced heart failure 
specialist
No treatment
Short PR interval 
Early-onset atrial 
fibrillation 
AV block 
Increased serum CK 
enzyme 
Autosomal dominant 
inheritance pattern
NGS or target testing for PRKAG2
PRKAG2 syndrome
Cardiologist 
Neuromuscular 
disease expert
No treatment
Continued 
ESC Guidelines                                                                                                                                                                                          3575


<!-- PAGE 74 -->

### Page 74

Progressive limb ataxia 
Diabetes mellitus 
Pes cavus 
Reduced native T1 at 
CMR imaging
NGS testing for bi-allelic expansion 
of GAA repeats in the FXN gene
Friedreich ataxia
Cardiologist 
Neurologist 
Endocrinologist 
Orthopaedic surgeon 
Neuromuscular 
disease expert
No specific treatment
Bilateral carpal tunnel 
syndrome 
Lumbar spinal stenosis 
Autonomic dysfunction 
Peripheral neuropathy 
Relative apical sparing 
pattern 
Ejection fraction/strain 
ratio >5 
Pseudonecrosis Q waves 
Low ECG voltages 
OR 
Positive serum or urine 
monoclonal chain at 
immunofixation
DPD/HMDP Tc99 scintigraphy 
Free light chain/serum and urine 
immunofixation 
Endomyocardial biopsy
Cardiac amyloidosis (AL 
or ATTR) (see Section 7.7)
Cardiologist 
Neurologist 
Nephrologist 
Haematologist (AL 
amyloidosis) 
Ophthalmologist
Tafamidis 
Patisirana 
Inotersena 
(ATTR-CA) 
OR 
Specific chemotherapy 
(AL amyloidosis)
Gastrointestinal 
symptoms 
Angiokeratoma 
Cornea verticillata 
Chronic kidney disease 
Proteinuria 
Sensorineural hypoacusia 
Stroke/TIA 
Neuropathic pain 
X-linked inheritance 
pattern 
Short PR interval 
Low native T1 at cardiac 
CMR
Screening in males: lyso-Gb3 
dosing 
Screening in females/diagnostic 
confirmation: genetic testing for 
GLA variants
Anderson–Fabry disease
Cardiologist 
Nephrologist 
Neurologist 
Ophthalmologist 
Audiologist 
Gastroenterologist 
Dermatologist
Enzyme replacement therapy 
(agalsidase alfa/beta) 
Migalastat
Skeletal myopathy 
Posterolateral 
pseudonecrosis pattern 
Posterolateral or 
inferolateral akinesia
Genetic testing for 
dystrophinopathies
DMD
Neurologist 
Cardiologist 
Pneumologist 
Neuromuscular 
disease expert
Steroids (prednisone or 
deflazacort)
Skeletal myopathy 
AV block 
Premature atrial 
fibrillation 
Malignant ventricular 
arrhythmias
NGS testing
LMNA cardiomyopathy 
Emery–Dreifuss muscular 
dystrophy
Cardiologist 
Neurologist
SCD risk prevention 
Pacing if indicated
Bilateral hilar 
lymphadenopathy 
Pulmonary infiltrates 
Uveitis 
Gastrointestinal 
involvement 
High-degree AV block 
Frequent VEs 
Thinned basal 
interventricular septum 
Extended LGE at CMR 
imaging
18F-FDG-PET 
Endomyocardial biopsy 
Lung biopsy
Sarcoidosis
Cardiologist 
Pneumologist 
Neurologist 
Gastroenterologist
Steroids 
Steroid-sparing 
immunosuppressant drugs
Continued


<!-- PAGE 75 -->

### Page 75

7.6.1.4. Management
Specific treatment strategies, including enzyme replacement or 
pharmacological chaperone, have limited efficacy in advanced cases 
with irreversible organ damage, so early initiation appears to be import­
ant. Enzyme replacement therapy is indicated in all symptomatic 
patients with classical disease, including children, at the earliest signs 
of organ involvement.974 Therapeutic strategies currently in develop­
ment include second-generation ERTs, substrate-reduction therapies, 
and gene and mRNA therapies.980
7.6.2. RASopathies
7.6.2.1. Definition
The RASopathies constitute a group of multisystemic syndromes caused 
by variants in the RAS-mitogen-activated kinase (RAS-MAPK) cas­
cade,984–986 including Noonan syndrome,987–989 Noonan syndrome 
with multiple lentigines;990,991 Costello syndrome,992,993 and cardiofa­
ciocutaneous syndrome.994–996
7.6.2.2. Diagnosis, clinical work-up, and differential diagnosis
The suspicion of an underlying RASopathy should be raised in infant- 
and childhood-onset HCM with coexisting CHD262,263,991,997–1000 or 
extracardiac abnormalities (see Table 22). Gene testing is recom­
mended for diagnosis when phenotypic features are present. 
Compared with sarcomeric HCM, RASopathy-associated HCM 
(RAS-HCM) shows earlier age at diagnosis,261,999 increased prevalence 
and severity of left or biventricular obstruction,258,262,1001 and higher 
rates of early hospitalizations for heart failure or need for interventional 
procedures or surgery.258
Pulmonary stenosis is the most 
commonly associated CHD, with a prevalence ranging between 25% 
and 70%, and unfavourable outcomes for pulmonary valvulo­
plasty.256,1002–1004
7.6.2.3. Clinical course, management, and sudden death risk 
stratification
Data from the North American Pediatric Cardiomyopathy Registry1005
cohort show poorer survival rates among patients with RAS-HCM 
compared with non-syndromic HCM, particularly in patients who 
have been diagnosed before 1 year of age. Disease-specific risk factors 
for SCD are currently an area of debate, and may include the degree of 
LV hypertrophy, prolonged QTc interval, ECG risk score for HCM,771
and the HCM Risk-Kids score >6%.81,826
7.6.2.4. Management
Non-vasodilating beta-blockers should be titrated to maximum toler­
ated dose in patients with RAS-HCM, particularly in cases of severe
Previous transfusions 
Chronic liver disease 
Skin pigmentation 
Diabetes 
Hypogonadotropic 
hypogonadism 
Elevated ferritin 
AV block
Iron status 
Complete blood count 
Increased T2* values at CMR 
imaging 
Genetic test for HFE, HJV, hepcidin 
receptor, ferroportin, HAMP gene 
Peripheral blood smear 
Haemoglobin electrophoresis 
Genetic testing for hereditary 
haemoglobinopathies
Iron overload 
cardiomyopathy
Cardiologist 
Haematologist 
Endocrinologist 
Paediatrician 
Gastroenterologist
Iron-chelating drugs 
Phlebotomy
© ESC 2023
18F-FDG-PET, 18F-fluorodeoxyglucose positron emission tomography; AL, amyloid light chain; ATTR, transthyretin amyloidosis; ATTR-CA: transthyretin cardiac amyloidosis; AV, 
atrioventricular; CCB, calcium channel blocker; CK, creatinine kinase; CMR, cardiac magnetic resonance; DBS, deep brain stimulation; DMD, Duchenne muscular dystrophy; DPD, 
3,3-diphosphono-1,2-propanodicarboxylic acid; ECG, electrocardiogram; Gb3, globotriaosylceramide; HCM, hypertrophic cardiomyopathy; HMDP, hydroxymethylene diphosphonate; 
LGE, late gadolinium enhancement; LMNA, lamin A/C; LVH, left ventricular hypertrophy; MELAS, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes 
(syndrome); MERRF, mitochondrial epilepsy with ragged-red fibres; MRI, magnetic resonance; mtDNA, mitochondrial DNA; NGS, next-generation sequencing; PRKAG2, protein kinase 
AMP-activated non-catalytic subunit gamma 2; RVOTO, right ventricular outflow tract obstruction; SCD, sudden cardiac death; TIA, transient ischaemic attack; VE, ventricular ectopic beats. 
aPatisiran and inotersen approved for treatment of familial polyneuropathy with/without cardiomyopathy.
Table 23 Anderson–Fabry disease red flags
Extracardiac red flags
No male-to-male transmission in pedigree
Renal involvement (dialysis, renal transplantation) or LVH in relatives
Neuropathic pain
Angiokeratomas
Albuminuria
Cornea verticillata
Hypohidrosis, heat/cold and exercise intolerance
Gastrointestinal symptoms (nausea, vomiting, non-specific abdominal pain, 
constipation, diarrhoea)
Hearing loss (either progressive or sudden), tinnitus, vertigo
Cardiac red flags
ECG
Short PQ interval in young patients
Atrioventricular blocks in adult patients
Bradycardia
Chronotropic incompetence
LVH
Echocardiogram
LVH with normal systolic function
Hypertrophy of papillary muscles
Mitral and aortic valve thickening with 
mild-to-moderate regurgitation
Reduced global longitudinal strain
CMR
Basal-inferolateral late gadolinium enhancement
Low native T1 (caution with ‘pseudonormalization’ in 
areas affected by fibrosis)
High focal/global T2
Laboratory
Elevated high-sensitivity troponin 
Elevated NT-proBNP
© ESC 2023
CMR, cardiac magnetic resonance; ECG, electrocardiogram; LVH, left ventricular 
hypertrophy; NT-proBNP, N-terminal pro-brain natriuretic peptide.
ESC Guidelines                                                                                                                                                                                          3577


<!-- PAGE 76 -->

### Page 76

biventricular obstruction.248,1002,1006–1008 Calcium channel blockers 
may be considered as a second-line option in patients >6 months of 
age when beta-blocker therapy is ineffective or not tolerated.267,639
Surgical myectomy and orthotopic heart transplantation may be con­
sidered in high-volume centres after multidisciplinary assessment by 
the heart team.265,266,1009–1011 Pulmonary valvuloplasty may be consid­
ered in children and infants with severe RV outflow tract obstruction 
(RVOTO).1012–1015
7.6.3. Friedreich ataxia
7.6.3.1. Definition
Friedreich ataxia is an autosomal recessive disorder caused by a 
homozygous GAA triplet repeat expansion in the frataxin (FTX) 
gene,1016–1019 leading to HCM, progressive neuromuscular symptoms, 
and extracardiac manifestations, including diabetes mellitus.1016,1020,1021
7.6.3.2. Diagnosis, clinical work-up, and differential diagnosis
Although several diagnostic criteria have been proposed to suspect 
Friedreich ataxia,1022,1023
genetic testing with identification of 
bi-co-allelic GAA expansion in the first intron of the FTX gene or com­
pound heterozygosis is required for diagnosis.1024,1025
Cardiovascular involvement usually manifests as hypertrophic non- 
obstructive cardiomyopathy, with hypokinetic end-stage disease pro­
gression and impaired perfusion reserve,1026 leading to advanced heart 
failure and death.248,1005,1027–1029 There appears to be no specific rela­
tionship between the extent of neurological involvement and cardiac 
If genetic study, include
GLA in HCM panel
N
Patient with suspected AFD
Red flags of AFDa
Results
VUS
Benign variant
P/LP variant
GLA genetic analysisb
Cardiac CMRc Lyso Gb3d Biopsye
Gender
Enzymatic activity
AFD unlikely
Diagnosis of AFD
Low index of suspicion
Female
Reduced
Normal
Normal
Abnormal
Y
Male
Figure 20 Anderson–Fabry disease diagnostic algorithm. α-Gal A, alpha-galactosidase A; AFD, Anderson–Fabry disease; CMR, cardiac magnetic resonance; 
Gb3, globotriaosylceramide; HCM, hypertrophic cardiomyopathy; LVH, left ventricular hypertrophy; lyso Gb3, globotriaosylsphingosine; P/LP, pathogenic/ 
likely pathogenic; VUS, variant of unknown significance. aSee Table 23. bGenetic analysis must include the study of possible large deletions or a copy number 
variation not detected by the Sanger method. cThe finding of increased plasma and/or urinary Gb3, or plasma lyso Gb3 and its analogues in the evaluation of 
male or female patients with a VUS and normal (in female patients) or lowered α-Gal A activity provides additional diagnostic information, but the role of 
biomarkers in such patients still requires validation. dLow native T1 values reinforce or generate suspicion of Fabry disease. Normal native T1 values do not 
exclude Fabry disease, as they are rarely observed in untreated patients with mild LVH (mostly females), or in advanced disease due to pseudonormalization. 
eAn endomyocardial biopsy is recommended, but could be done in other affected organs such as the kidneys and skin. It should be evaluated by expert 
pathologists and always include electron microscopy studies to detect lamellar bodies and intracellular inclusions. Of note, some drugs may produce 
drug-induced phospholipidosis with an intracellular accumulation of phospholipids in different organs that can mimic zebra bodies on electron 
microscopy.982,983


<!-- PAGE 77 -->

### Page 77

phenotype.248,1005,1027–1029,1005,1027–1030,1030 Mitochondrial iron stor­
age is the pathologic hallmark of the disease.1031
7.6.3.3. Clinical course, management, and risk stratification
Supraventricular arrhythmias, particularly AF, are commonly de­
tected.1027 Despite the lack of long-term follow-up longitudinal studies, 
the risk of ventricular arrhythmias and SCD seems low compared with 
sarcomeric HCM.1027,1032,1033 The Mitochondrial Protection with 
Idebenone in Cardiac or Neurological Outcome (MICONOS) study 
group1034 has proposed a staging of cardiac involvement based on 
LVEF and end-diastolic wall thickness. The extent of TWI at ECG, 
LVEF, LV end-diastolic posterior wall thickness, fibrosis on CMR, and 
hs-TnT have been proposed as negative prognostic factors.1035
7.6.3.4. Management
No specific treatment is currently available for Friedreich ataxia. 
Treatment with idebenone, a coenzyme Q10 analogue, showed the po­
tential to improve LV mass and cardiac outcomes in open-label stud­
ies;1036 nevertheless, four RCTs1037–1040 showed no significant 
benefit on cardiac or neurologic outcomes.
7.6.4. Glycogen storage disorders
7.6.4.1. Definition
Glycogen storage disorders (GSDs) represent a heterogeneous group 
of metabolic diseases, including infantile-onset Pompe disease (GSD, 
type IIa), Danon disease (GSD, type IIb), and PRKAG2 disease.272
7.6.4.2. Diagnosis, clinical work-up, and differential diagnosis
Despite wide clinical heterogeneity, a presentation within the first few 
months of life, hypotonia, failure to thrive, generalized muscle weak­
ness, and severe non-obstructive HCM with concentric pattern fol­
lowed by hypokinetic end-stage cardiomyopathy, usually within the 
first year of life, are typical of GSD IIa.259,268,1041,1042 Short PR interval 
and increased ECG voltages may represent useful diagnostic clues for 
GSDs.1042,1043 PRKAG2 syndrome should be suspected in the setting 
of autosomal dominant transmission and association with conduction 
system disease including ventricular pre-excitation, sick sinus syn­
drome, AF, AV block, intraventricular conduction delays or sinoatrial 
blocks.1043–1047 An X-linked pattern of inheritance is typical of 
Danon disease (GSD IIb). Skeletal myopathy, in association with learn­
ing disability, retinal involvement and ventricular pre-excitation, has 
been detected in males affected by Danon disease, while the cardiac 
phenotype can be isolated in affected females.1048–1052
7.6.4.3. Clinical course, management, and risk stratification
In the absence of therapeutic intervention, Pompe disease has a poor 
prognosis, mainly due to end-stage heart failure.268,1041 Recently, data 
from a large multicentre European registry have shown that Danon dis­
ease runs a malignant phenotype, but there are insufficient data to iden­
tify candidate risk factors for sudden death.1049 Sudden cardiac death 
occurs in almost 10% of patients with PRKAG2 syndrome, mainly as 
a consequence of advanced AV block, supraventricular tachycardia de­
generated to VF, or massive hypertrophy.1044,1053,1054
7.6.4.4. Management
Enzyme replacement therapy is recommended in patients with GSD 
IIa.269,274,275,1055,1056 To date, there are no approved aetiological ther­
apies for PRKAG2 syndrome and Danon disease. Heart failure therapy, 
antiarrhythmic therapy, and indications for the implantation of devices 
are included in Section 6.10.
7.7. Amyloidosis
It is beyond the scope of this document to provide specific recommen­
dations for the assessment and management of cardiac amyloidosis. 
Instead, the Task Force refers the reader to the 2021 position state­
ment of the ESC Working Group on Myocardial and Pericardial 
Diseases on Diagnosis and Treatment of Cardiac Amyloidosis.375
This section highlights only the key diagnostic and management issues.
7.7.1. Definition
Cardiac amyloidosis is characterized by the extracellular deposition of 
misfolded proteins in the ventricular myocardium with the pathogno­
monic histological property of green birefringence when viewed under 
cross-polarized light after staining with Congo Red.375
Although once considered a rare disease, data obtained in the last 
decade suggest that cardiac amyloidosis is underappreciated as a cause 
of common cardiac diseases or syndromes such as HFpEF, aortic sten­
osis, or unexplained LVH, particularly in the elderly.1057–1059 Although 
nine different types of cardiac amyloidosis have been described, most 
cases correspond to monoclonal immunoglobulin light chain amyloid­
osis (AL) or transthyretin amyloidosis (ATTR), either in its hereditary 
(ATTRv) or acquired (ATTRwt) form.375 The ATTRwt form, which 
is associated with ageing, is currently considered the most frequent 
form of cardiac amyloidosis worldwide.
7.7.2. Diagnosis, clinical work-up, and differential 
diagnosis
Cardiac amyloidosis should be suspected in patients with increased LV 
wall thickness in the presence of cardiac or extracardiac red flags and/or 
in specific clinical situations, as detailed in Figure 21, particularly in pa­
tients >65 years of age.375
Cardiac amyloidosis can be diagnosed using both invasive and non- 
invasive diagnostic criteria.375 Invasive diagnostic criteria apply to all 
forms of cardiac amyloidosis, whereas non-invasive criteria are ac­
cepted only for ATTR. Invasive criteria include demonstration of amyl­
oid fibrils within cardiac tissue or, alternatively, demonstration of 
amyloid deposits in an extracardiac biopsy accompanied either by char­
acteristic features of cardiac amyloidosis on echocardiography or 
CMR.375 Non-invasive criteria include typical echocardiographic/CMR 
findings combined with planar and single-photon emission computed 
tomography (SPECT) grade 2 or 3 myocardial radiotracer uptake in 
99mtechnetium-pyrophosphate (99mTc-PYP) or 3,3-diphosphono-1,2- 
propanodicarboxylic acid (DPD) or hydroxymethylene diphosphonate 
(HMDP) scintigraphy and exclusion of a clonal dyscrasia by all the fol­
lowing tests: serum free light chain assay, serum and urine protein elec­
trophoresis with immunofixation.168 Tomographic scintigraphy should 
be considered in order to reduce the number of misclassifications.1060
False negative scans may rarely occur in certain ATTRv genotypes; false 
positives may be due to AL, recent myocardial infarction, or long-term 
chloroquine use.370 Therefore, planar and SPECT scintigraphy coupled 
with assessment for monoclonal proteins followed by CMR and/or car­
diac/extracardiac biopsy if necessary allows appropriate diagnosis in pa­
tients with suggestive signs/symptoms, as described in Figure 22.375
However, the DPD/PYP/HMDP scan cannot distinguish between wild- 
type and mutated ATTR, and therefore TTR genetic testing is required. 
Of note, TTR genetic testing is recommended in all transthyretin amyl­
oid cardiomyopathy (ATTR-CM) patients regardless of age, as 5% of
ESC Guidelines                                                                                                                                                                                          3579


<!-- PAGE 78 -->

### Page 78

ATTR-CM patients ≥70 years (and 10% among females) have 
ATTRv.375,1061
7.7.3. Clinical course and risk stratification
Cardiac amyloidosis is a progressive disease with poor outcomes if left 
untreated. Amyloid light chain cardiac amyloidosis is associated with 
more rapid progression of heart failure and worse prognosis than 
ATTR.1058,1062,1063 Fortunately, the prognosis of AL amyloidosis has 
significantly improved with the introduction of very effective therapies 
capable of dramatically reducing the production of the cardiotoxic light 
chains.1064 Prognosis in ATTR depends on the variant, degree of cardiac 
involvement, and neurologic phenotype.1065–1068 Several multipara­
metric biomarker-based staging systems have been developed for 
AL1069,1070
and 
ATTR 
cardiac 
amyloidosis1066–1068
(see 
Supplementary data online, Table S5).
7.7.4. Management
The treatment of cardiac amyloidosis includes treating and preventing 
complications and stopping or delaying amyloid deposition by specific 
treatment.375,1071 There is no evidence to support the use of standard
Heart failure in 65 years
Aortic stenosis in 65 years
Hypotension or normotensive if previously hypertensive
Sensory involvement, autonomic dysfunction
Peripheral polyneuropathy
Proteinuria
Skin bruising
Bilateral carpal tunnel syndrome
Ruptured biceps tendon
Subendocardial/transmural LGE or increased ECV
Reduced longitudinal strain with apical sparing
Decreased QRS voltage to mass ratio
Pseudo Q waves on ECG
AV conduction disease
Possible family history of ATTR
Chronically increased troponin levels
Known multiple myeloma or MGUS
Left ventricular wall thickness 12 mm
1 of
Figure 21 Screening for cardiac amyloidosis. ATTR, transthyretin amyloidosis; AV, atrioventricular; ECG, electrocardiogram; ECV, extracellular volume; 
LGE, late gadolinium enhancement; MGUS, monoclonal gammopathy of undetermined significance.


<!-- PAGE 79 -->

### Page 79

heart failure therapy, which often is not well tolerated, apart from 
diuretics (see Section 6.10.2).1072,1073
The natural history of cardiac amyloidosis associates electrical con­
duction disease of the heart with symptomatic bradycardia and ad­
vanced AV block.375,1074,1075 The clinical threshold for pacemaker 
indication should be low, as the disease progresses and implantation 
of the device allows rate response to exercise and medication adjust­
ment.375,1074 The role of ICD in cardiac amyloidosis for SCD preven­
tion is not clearly known, but available data do not support their use 
in primary prevention.1076,1077
7.7.4.1. Specific therapies
Therapy for AL cardiac amyloidosis is based on treatment of the under­
lying haematological problem with chemotherapy or autologous stem- 
cell transplant.1064
Transthyretin stabilization and reduction of its production are the 
basis of TTR cardiac amyloidosis treatment. Tafamidis reduced all-cause 
mortality and cardiovascular hospitalizations in ATTR, with the largest 
effect achieved in patients at NYHA functional class I and II.1078
Additional studies are being conducted with other stabilizing agents 
and other molecules that reduce TTR production.1078a
8. Other recommendations
8.1. Sports
8.1.1. Cardiovascular benefits of exercise
Regular physical activity and systematic exercise confer several cardio­
vascular, psychological, and QoL benefits. Through curbing risk factors 
for atherosclerosis, such as obesity and insulin resistance,1079 hyperten­
sion,1080 and hyperlipidaemia,1081 regular physical activity is associated 
with an up to 50% risk reduction in an adverse event from CAD in 
middle-aged and older individuals.1082,1083 Individuals who exercise 
regularly live 5–7 years longer than their sedentary counterparts,1084
Scintigraphy grade
Haematologic tests
AL/ATTR cardiac amyloidosis unlikely
If suspicion 
persists consider repeat
CMR followed by biopsy
Scintigraphy grade
Haematologic tests
Grade
Cardiac ATTR
amyloidosis
TTR genetic testing
ATTRwt/ATTRv
Grade
Histological confirmation
(cardiac/
extracardiac)
to diagnose
Scintigraphy grade
Haematologic tests
Histological confirmation
(usually cardiac)
to subtype 
Scintigraphy grade
Haematologic tests
AL amyloidosis?
CMR
Amyloidosis unlikely
Histological confirmation
(cardiac/
extracardiac)
to diagnose
CMR       or inconclusive
Signs and symptoms, ECG, ECHO, or CMR suggestive of cardiac amyloidosis
99mTc-DPD/PYP/HMDP
scintigraphy with SPECT
Haematologic tests
(serum free light chain quantification and serum and urine immunofixation) 
0
-
1–3
-
0
+
1–3
+
I
2–3
-
+
Figure 22 Diagnosis of cardiac amyloidosis. AL, amyloid light chain; ATTR, transthyretin amyloidosis; ATTRv, variant transthyretin amyloidosis; ATTRwt, 
wild-type transthyretin amyloidosis; CMR, cardiac magnetic resonance; DPD, 3,3-diphosphono-1,2-propanodicarboxylic acid; ECG, electrocardiogram; 
ECHO, echocardiogram; HMDP, hydroxymethylene diphosphonate; PYP, pyrophosphate; TTR, transthyretin.
ESC Guidelines                                                                                                                                                                                          3581


<!-- PAGE 80 -->

### Page 80

and have a lower risk of cerebrovascular accidents1085 and certain ma­
lignancies.1085–1087 These benefits that can be derived later in life also 
apply to individuals with established cardiovascular disease. For a defin­
ition of exercise intensity levels, please refer to Supplementary data 
online, Table S6.
8.1.2. Exercise-related sudden cardiac death and 
historical exercise recommendations for patients 
with cardiomyopathy
Rigorous exercise may trigger myocardial infarction and fatal arrhyth­
mias among individuals with an underlying cardiovascular disease.1088– 
1091 Superimposed on the pathological substrate of the disease entity 
itself, exercise may induce sudden cardiac arrest through mechanical 
shearing forces within the coronary arteries, effects of high concentra­
tions of circulating catecholamines, increased cardiac loading condi­
tions, raised core temperature, electrolyte shifts, and acid-base 
disturbance.
Cardiomyopathies are the leading cause of exercise-related SCD in 
young people in the Western world.40,1092–1095 The established link be­
tween exercise and SCD from cardiomyopathy, and the finding that, in 
some cardiomyopathy phenotypes, exercise may accelerate progres­
sion of the underlying cardiomyopathic disease process, has historically 
resulted in restrictive exercise recommendations in all affected patients 
regardless of pathology, disease severity, symptomatic status, general 
risk profile, or prior therapeutic interventions, including an ICD.1096– 
1098 As a result, individuals with cardiomyopathy often confine them­
selves to a relatively sedentary lifestyle through fear of potential SCD 
and accrue risk factors for atherosclerotic CAD, which confer a worse 
prognosis.1099–1102,1096,1097
8.1.3. Exercise recommendations in hypertrophic 
cardiomyopathy
Recent pre-clinical1103 and clinical data suggest that moderate exercise 
may be beneficial and safe in patients with HCM.1098–1102 Information 
on a safe dose of vigorous exercise is still limited, but the heteroge­
neous morphology and pathophysiology of HCM means that some in­
dividuals are capable of participating in vigorous exercise, including 
high-intensity competitive sports.760 Most athletes capable of exercis­
ing intensively have mild LV hypertrophy, normal-sized or enlarged 
LV, normal diastolic function, and no evidence of LVOTO.1104,1105
Currently available data indicate that participation in vigorous exercise 
and competitive sport may be considered in a select group of predom­
inantly adult patients who have mild morphology and a low-risk pro­
file.1106–1108 However, studies examining the effect of vigorous 
exercise or moderate-to-high-intensity competitive sport on the nat­
ural history of HCM were not designed or powered adequately to ad­
dress the question and there are potential issues of selection bias. 
Nevertheless, based on emerging evidence, the Task Force agreed to 
adopt a comparatively liberal approach, advocating that, after appropri­
ate selection, some individuals with a low-risk profile may participate in 
high-intensity exercise and competitive sport after comprehensive ex­
pert evaluation and shared discussion, which highlights the unpredict­
able nature of exercise-related SCD in HCM. Sporting disciplines in 
which syncope may result in fatal accidental injury or danger to others 
are not recommended.
Genotype-positive/phenotype-negative patients may engage in all 
competitive sport; however, annual assessment is recommended to 
check for developing phenotypic features of disease.1109
8.1.4. Exercise recommendations in arrhythmogenic 
right ventricular cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy is a recognized cause of 
exercise-related SCD in young asymptomatic individuals,40,890 postulated 
to result from ventricular stretch leading to myocyte detachment with 
subsequent inflammation and fibro-fatty replacement of the ventricular 
myocardium. Fatal arrhythmias may occur during the inflammatory pro­
cess or because of myocardial scar. In addition, there are data to suggest 
that high-intensity exercise is associated with acceleration of disease 
phenotype in individuals with ARVC, including those who are genotype 
positive/phenotype negative, and particularly those with PKP2 var­
iants.181,1110–1114 Furthermore, exercise restriction has been shown to 
improve clinical outcomes in patients with ARVC.40,1111,1115–1117 Based 
on these data, the Task Force recommends against intensive exercise 
or competitive sports in individuals with ARVC as part of a shared 
decision-making process. The evidence on the impact of exercise in 
genotype-positive/phenotype-negative individuals is more limited. In these 
cases, the Task Force recommends a cautious approach in the context of 
shared decision-making when discussing competitive sports participation. 
Mild-to-moderate physical activity for up to 150 min per week is consid­
ered safe and is recommended in able phenotype-negative individuals.1118
8.1.5. Exercise recommendations in dilated 
cardiomyopathy and non-dilated left ventricular 
cardiomyopathy
There is evidence that moderate exercise in optimally treated patients 
with DCM improves functional capacity, ventricular function, and 
QoL;1119 however, intensive exercise and competitive sports may 
also trigger fatal arrhythmias in DCM and NDLVC.1093,1120–1122
In general, symptomatic individuals with DCM and NDLVC should 
abstain from most competitive and leisure sports, or recreational exer­
cise associated with moderate or high exercise intensity. A select group 
of asymptomatic individuals with DCM and NDLVC who have mildly 
impaired LV function without exercise-induced arrhythmias or signifi­
cant myocardial fibrosis may participate in most competitive sports.
Although the natural history of most pathogenic variants capable of 
causing DCM and NDLVC is unknown, it would be reasonable to permit 
intensive exercise and competitive sports in most individuals with patho­
genic variants in the absence of overt features of DCM or NDLVC. 
Special consideration, however, should be given to individuals with 
pathogenic variants in genes that are associated with an increased risk 
of life-threatening arrhythmias, such as lamin A/C181,1123 or TMEM43 
variants, for which there is emerging evidence that exercise may have 
an adverse effect on cardiac function and risk of potentially fatal arrhyth­
mias. The impact of vigorous exercise in patients with pathogenic variants 
in other high-risk genes, such as filamin C variants1112 exhibiting DCM or 
NDLVC phenotypes, is not fully understood; however, extrapolating our 
understanding of the effect of exercise on some ARVC and DCM phe­
notypes necessitates a cautious approach.
Recommendation Table 31 — Exercise recommenda­
tions for patients with cardiomyopathy
Recommendations
Classa
Levelb
All cardiomyopathies
Regular low- to moderate-intensity exercise is 
recommended in all able individuals with 
cardiomyopathy.
I
C
Continued


<!-- PAGE 81 -->

### Page 81

8.2. Reproductive issues
Pregnancy and the post-partum period constitute periods of increased 
risk of cardiovascular complications in women with cardiomyop­
athy.1127–1130 Cardiomyopathy can also be first diagnosed in pregnancy 
or arise during pregnancy as PPCM.1131
The risk associated with pregnancy in a patient with a cardiomyop­
athy is estimated using the modified World Health Organization 
(mWHO) classification.1130 Pregnancy is contraindicated in women 
with WHO class IV, including patients with EF <30% or NYHA 
class III–IV or previous PPCM with persisting impairment of the LV 
function.
8.2.1. Contraception, in vitro fertilization, and 
hormonal treatment
Counselling on safe and effective contraception is indicated in all wo­
men of fertile age. Ethinyloestradiol-containing contraceptives have 
the greatest risk of thrombosis1132 and are not advised in women 
with a high risk of thrombo-embolic disease. Progestin-only contracep­
tives are an alternative, as they have little or no effect on coagulation 
factors, blood pressure, and lipid levels. Levonorgestrel-based long- 
acting reversible contraception implants or intrauterine devices are 
the safest and most effective contraceptives and have few side effects 
affecting cardiomyopathies.
Medically assisted procreation adds risks beyond those of pregnancy 
alone; superovulation is pro-thrombotic and can be complicated by 
ovarian hyperstimulation syndrome, with marked fluid shifts and an 
even greater risk of thrombosis. Hormonal stimulation should be care­
fully considered in women who have WHO class III disease (VT or 
HCM) or who are anticoagulated.
8.2.2. Pregnancy management
8.2.2.1. Pre-pregnancy
Patients with a known cardiomyopathy and at risk of developing cardio­
myopathy should receive pre-pregnancy counselling by a multidisciplin­
ary team: the pregnancy heart team. The individual risk of the woman 
by pregnancy should be discussed using the WHO classification, in add­
ition to discussing the likelihood of transmission of the disease to the 
offspring and how to reduce the transgenerational risk of transmitting 
the disorder.
For individual risk estimation, at a minimum, an ECG, echocardiog­
raphy, and exercise test should be performed. Several aspects must 
be discussed with the woman, including long-term prognosis, drug ther­
apy, estimated maternal risk and outcome, and plans for pregnancy care 
and delivery.
8.2.2.2. Pregnancy
In women with mWHO class II–III, III, and IV (including women with 
HCM, VTs, and EF <35%), management during pregnancy and around 
delivery should be conducted in an expert centre by a multidisciplinary 
team: the pregnancy heart team, including cardiologists with expertise 
in cardiomyopathies and arrhythmias; obstetricians; and anaesthetists. 
Depending on the individual case, other specialists may be included 
(geneticist, cardio-thoracic surgeon, paediatric cardiologist, foetal medi­
cine specialist, neonatologist, etc.). A delivery plan should be created 
that includes the details of induction; the management of labour and de­
livery; and post-partum surveillance.
An individualized risk assessment for exercise 
prescription is recommended in all patients with 
cardiomyopathy.
I
C
HCM
High-intensity exercise and competitive sport should 
be considered in genotype-positive/ 
phenotype-negative individuals who seek to do 
so.1124
IIa
C
High-intensity exercise and competitive sport may be 
considered in asymptomatic low-riskc individuals 
with morphologically mild hypertrophic 
cardiomyopathy in the absence of resting or 
inducible left ventricular outflow obstruction and 
exercise-induced complex ventricular 
arrhythmias.1107,1113,1125,1126
IIb
B
High-intensity exercise, including competitive sport, 
is not recommended in high-risk individuals and in 
individuals with left ventricular outflow tract 
obstruction and exercise-induced complex 
ventricular arrhythmias.
III
C
ARVC
Avoidance of high-intensity exercise, including 
competitive sport, may be considered in 
genotype-positive/phenotype-negative individuals in 
families with ARVC.1111,1116,1117
IIb
C
Moderate- and/or high-intensity exercise, including 
competitive sport, is not recommended in individuals 
with ARVC.181,1111–1114
III
B
DCM and NDLVC
Moderate- and high-intensity exercise should be 
considered in individuals who are gene positive and 
phenotype negative (with the exception of 
pathogenic variants in LMNA and TMEM43) who seek 
to do so.1123
IIa
C
High-intensity exercise and competitive sport may be 
considered in a select group of asymptomatic and 
optimally treated individuals with a left ventricular 
ejection fraction ≥50% in the absence of 
exercise-induced complex arrhythmias.
IIb
C
Moderate-intensity exercise may be considered 
in asymptomatic and optimally treated individuals 
with a left ventricular ejection fraction of 40–49% in 
the absence of exercise-induced complex 
arrhythmias.
IIb
C
High-intensity exercise, including competitive sport, 
is not recommended in symptomatic individuals, 
those with a left ventricular ejection fraction ≤40%, 
exercise-induced arrhythmias or pathogenic variants 
in LMNA or TMEM43.
III
C
© ESC 2023
ARVC, arrhythmogenic right ventricular cardiomyopathy; DCM, dilated cardiomyopathy; 
HCM, hypertrophic cardiomyopathy; LMNA, lamin A/C; NDLVC, non-dilated left 
ventricular cardiomyopathy; TMEM43, transmembrane protein 43. 
aClass of recommendation. 
bLevel of evidence. 
cSee Section 7.1.5 for risk assessment in HCM.
ESC Guidelines                                                                                                                                                                                          3583


<!-- PAGE 82 -->

### Page 82

8.2.2.3. Timing and mode of delivery
The timing and mode of delivery should be personalized according to 
the type of cardiomyopathy, ventricular function, NYHA class, arrhyth­
mic risk, and thrombo-embolic risk. Vaginal delivery is associated with 
less blood loss and lower risk of infection, venous thrombosis, and em­
bolism than caesarean section and should be advised for most women. 
Caesarean section should be considered for obstetric indications, pa­
tients with severe outflow tract obstruction, or in cases of severe 
acute/intractable heart failure, or in cases at high risk of threatening ar­
rhythmia and for patients presenting in labour on oral anticoagu­
lants.1130 During delivery, patients with cardiomyopathy should be 
circulatory and heart rhythm monitored on an individualized basis.
8.2.2.4. Post-partum
The post-partum period is associated with significant haemodynamic 
changes and fluid shifts, particularly in the first 24–48 h after delivery, 
which may precipitate heart failure. Haemodynamic monitoring should 
therefore be continued for at least 24–48 h in patients at risk. Most 
drugs enter the milk and could thus contraindicate breastfeeding (see 
Section 8.2.2.5).
8.2.2.5. Pharmacological treatment: general aspects
Pharmacological treatment in pregnant women should be the same as 
in non-pregnant patients, with an avoidance of drugs contraindicated in 
pregnancy, such as ACE-Is, ARBs, and renin inhibitors.1130 The first tri­
mester is associated with the greatest teratogenic risk. Pharmacologic 
therapy is advised to begin as late as possible in pregnancy and at the 
lowest effective dose. Drug exposure later in pregnancy may confer ad­
verse effects on foetal growth and development. It is recommended to 
check drug and safety data before initiation of a new drug in pregnancy; 
see Table 7 in the 2018 ESC Guidelines for the management of cardiovas­
cular diseases during pregnancy.1130 From this list, antiarrhythmics can be 
summarized as follows: 
• Well tolerated: sotalol, oral verapamil.
• While the benefits and risks should be evaluated in each case, the fol­
lowing drugs can often be continued if there is a clear indication for 
use during pregnancy: bisoprolol, carvedilol, digoxin, diltiazem (pos­
sible teratogenic effects), disopyramide (uterine contractions), flecai­
nide, lidocaine, metoprolol, nadolol, propranolol, verapamil, 
quinidine.
• Insufficient data: ivabradine, mexiletine, propafenone, vernakalant.
• Contraindicated: amiodarone, atenolol, dronedarone, ACE-Is, ARBs, 
renin inhibitors, and spironolactone.1130
Ongoing beta-blocker treatment in cardiomyopathies should be con­
tinued during pregnancy, with close monitoring of foetal growth. After 
delivery, it is advised to heart rhythm monitor the infant for 48 h. The 
use of beta-blockers and anticoagulation during pregnancy is described 
in the 2018 ESC Guidelines for the management of cardiovascular diseases 
during pregnancy.1130
Vitamin K antagonist use in the first trimester results in embryopathy 
(limb defects, nasal hypoplasia) in 0.6–10% of cases.1133,1134 In contrast, 
unfractionated heparin (UFH) and low-molecular-weight heparin 
(LMWH) do not cross the placenta; therefore, substitution of VKA 
with UFH or LMWH in weeks 6–12 almost eliminates the risk of em­
bryopathy. This risk is also dose dependent (0.45–0.9% with low-dose 
warfarin). Vaginal delivery while the mother is on VKAs is 
contraindicated because of the risk of foetal intracranial bleeding. 
Haemorrhagic complications in the mother occur with all regimens, 
but the incidence is lower with VKA than with LMWH/UFH through­
out pregnancy.1130
VKA should be continued until pregnancy is achieved. Continuation 
of VKAs throughout pregnancy should be considered when the dose is 
low (see Table 7 in the 2018 ESC Guidelines for the management of car­
diovascular diseases during pregnancy1130). The target international nor­
malized ratio (INR) should be chosen according to current guidelines, 
with INR monitoring weekly or every 2 weeks. Self-monitoring of 
INR in suitable patients is recommended. Alternatively, depending on 
the indication, a switch to LMWH from weeks 6–12 under strict mon­
itoring may be considered in patients with a low dose requirement. 
When a higher dose of VKAs is required, discontinuation of VKAs be­
tween weeks 6 and 12 and replacement with adjusted-dose i.v. UFH or 
LMWH twice daily with dose adjustment according to peak anti-Xa (for 
LMWH) levels should be considered.
In case of delivery in anticoagulated women (not including mechan­
ical valves) with a planned caesarean section, therapeutic LMWH dosing 
can be simply omitted for 24 h prior to surgery. If delivery has to be 
performed earlier, anti-Xa activity can guide the timing of the 
procedure.
Antiarrhythmic therapy in pregnancy other than medication. 
Implantation of an ICD and catheter ablation should ideally be consid­
ered prior to pregnancy in patients with a high risk of ventricular ar­
rhythmias 
to 
avoid implantations 
and 
interventions during 
pregnancy.1135 If an ICD is indicated in pregnancy, ICD implantation 
should be performed beyond 8 weeks of gestation with radiation pro­
tection1136 and the indication should be weighed against the limited ex­
perience available. In pregnant patients with existing ICD, routine ICD 
interrogation and advice are recommended prior to delivery.
8.2.2.6. Specific cardiomyopathies
Most women with HCM tolerate pregnancy well.1137 Complications 
during pregnancy most often occur in women who have symptoms, ar­
rhythmias, or impaired LV function before pregnancy. Left ventricular 
outflow tract gradients may increase slightly during pregnancy and 
high gradients before pregnancy are associated with more complica­
tions.1137 Women should be assessed according to WHO risk class, in­
dicating at trimester for low-risk patients (class II) and monthly or 
bi-monthly for higher-risk patients (class III). Therapeutic anticoagula­
tion with LMWH or VKAs according to the stage of pregnancy is re­
commended for patients with AF. Cardioversion in pregnancy should 
be considered for poorly tolerated persistent AF. Hypovolaemia is 
poorly tolerated. Caesarean section should be considered in patients 
with severe LVOTO, pre-term labour while on oral anticoagulants, 
or severe heart failure.1130 Epidural and spinal anaesthesia must be ap­
plied cautiously, especially with severe LVOTO, due to potential hypo­
volaemia, and single-shot spinal anaesthesia should be avoided.
Pregnancy in ARVC seems to be relatively tolerable, as shown in sev­
eral studies, with no excess mortality and no clear negative long-term 
outcome.1138–1141 Previous VTs represent a WHO risk class III, indicat­
ing bi-monthly or monthly follow-up at an expert centre.
Women with DCM are at risk of further deterioration of LV function 
in pregnancy. Data suggest that pregnancy might not be associated with 
long-term adverse disease progression or event-free survival in LMNA 
genotype-positive women.1142 Predictors of maternal mortality are 
NYHA class III/IV and EF <40%. Highly adverse risk factors include


<!-- PAGE 83 -->

### Page 83

EF <20%, severe mitral regurgitation, RV failure, AF, and/or 
hypotension.1143
8.2.2.7. Peripartum cardiomyopathy
Genetic studies in patients with PPCM have revealed genetic similarity 
between PPCM and DCM. Specifically, an overrepresentation of trun­
cating variants has been demonstrated in TTN, FLNC, BAG3, and DSP, 
with TTN truncating variants most commonly involved (found in 
∼10% of patients).44,45 It has been suggested that approaches to genetic 
testing in PPCM should mirror those taken in DCM.45 Medications used 
to treat heart failure during pregnancy require special considerations as 
discussed above. In the presence of persistant cardiac dysfunction, 
medication should be continued. Use of bromocriptine as disease- 
specific therapy in patients with PPCM as an addition to standard heart 
failure therapy has shown promising results in two clinical trials.1144,1145
In severe cases of PPCM, temporary MCS has been used successfully 
and should be considered in patients with haemodynamic instability 
despite inotropic support.1146 In patients with PPCM, thresholds for 
early ICD implantations should be higher than in other conditions be­
cause of a high rate of spontaneous recovery after delivery.1147
8.3. Recommendations for non-cardiac 
surgery
Cardiomyopathies, in general, are associated with an increased inci­
dence of peri-operative heart failure and arrhythmias, although the sig­
nificant variability in the phenotypic expression of cardiomyopathies 
must be considered. Special attention should be given to the clinical sta­
tus, LVEF, volume overload, and increased levels of natriuretic peptides. 
In the period after non-cardiac surgery (NCS), fluids given during the 
operation may be mobilized, causing hypervolaemia and pulmonary 
congestion. Careful attention to fluid balance is therefore essen­
tial.1148,1149 Obstructive HCM deserves specific consideration due to 
its peculiar pathophysiology, with adequate intra-operative vigilance, 
avoiding factors and medication that may increase LVOTO and prompt 
pharmacological treatment and intravascular fluid therapy if needed 
(see Supplementary data online, Table S7).1150,1151
Natriuretic peptide concentrations are quantitative plasma biomar­
kers for the presence and severity of haemodynamic cardiac stress 
and heart failure, and elevated NT-proBNP concentrations may facili­
tate detection of heart failure, optimal intra-operative monitoring, 
and initiation or optimization of heart failure therapy after surgery.1152
Moreover, in cardiomyopathy patients elevated NT-proBNP values are 
strong predictors of overall prognosis.1153–1156
Patients with a first-degree relative with a genetic cardiomyopathy 
should be evaluated with an ECG and an echocardiographic examination 
to rule out the presence of the disease, irrespective of age (see Section 
6.11). There are no specific data on risks of NCS in phenotype-negative 
family members; however, they are at risk of developing the disease, which 
may be subclinical at the time of the NCS.1157 Data in children with HCM 
undergoing general anaesthesia for cardiac and non-cardiac procedures 
show that, in a specialist setting with multidisciplinary involvement, peri- 
operative morbidity and mortality are extremely low.1158
Recommendation Table 32 — Recommendations for 
reproductive issues in patients with cardiomyopathy
Recommendations
Classa
Levelb
Pre-pregnancy risk assessment and counselling are 
recommended in all women using the mWHO 
classification of maternal risk.
I
C
Counselling on safe and effective contraception is 
recommended in all women of fertile age and their 
partners.
I
C
Counselling on the risk of disease inheritance is 
recommended for all men and women before 
conception.
I
C
Vaginal delivery is recommended in most women 
with cardiomyopathies, unless there are obstetric 
indications for caesarean section, severe heart failure 
(EF <30% or NYHA class III–IV), or severe outflow 
tract obstructions, or in women presenting in labour 
on oral anticoagulants.
I
C
It is recommended that medication be carefully 
reviewed for safety in advance of pregnancy and 
adjusted according to tolerability in pregnancy.
I
C
Therapeutic anticoagulation with LMWH or VKAs 
according to the stage of pregnancy is recommended 
for patients with AF.
I
C
Continuation of beta-blockers should be considered 
during pregnancy in women with cardiomyopathies, 
with close follow-up of foetal growth and of the 
condition of the neonate, and if benefits outweigh 
risks.
IIa
C
Genetic counselling and testing should be considered 
in patients with peripartum cardiomyopathy.
IIa
C
© ESC 2023
AF, atrial fibrillation; EF, ejection fraction; LMWH, low-molecular-weight heparin; mWHO, 
modified World Health Organization; NYHA, New York Heart Association; VKA, vitamin 
K antagonist. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 33 — Recommendations for 
non-cardiac surgery in patients with cardiomyopathy
Recommendations
Classa
Levelb
Peri-operative ECG monitoring is recommended for 
all patients with cardiomyopathy undergoing surgery.
I
C
In patients with cardiomyopathy and suspected or 
known HF scheduled for intermediate or high-risk 
NCS, it is recommended to re-evaluate LV function 
with echocardiography (assessing LVOTO in HCM 
patients) and measurement of NT-proBNP/BNP 
levels, unless this has recently been 
performed.1151,1153–1156,1158–1165
I
B
It is recommended that cardiomyopathy patients 
with high-risk genotypes or associated factors for 
arrhythmic or heart failure complications or severe 
LVOTO be referred for additional specialized 
investigations to a cardiomyopathy unit before 
undergoing elective NCS.
I
C
In patients aged <65 years with a first-degree relative 
with a cardiomyopathy, it is recommended to perform 
an ECG and TTE before NCS, regardless of symptoms.
I
C
© ESC 2023
ECG, electrocardiogram; HCM, hypertrophic cardiomyopathy; HF, heart failure; LV, left 
ventricular; LVOTO, left ventricular outflow tract obstruction; NCS, non-cardiac 
surgery; NT-proBNP, N-terminal pro-brain natriuretic peptide; TTE, transthoracic 
echocardiography. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3585


<!-- PAGE 84 -->

### Page 84

### 9 Requirements for specialized

cardiomyopathy units
As genomic tests and information are incorporated into strategies for 
the routine diagnosis and management of cardiomyopathies and the es­
timation of disease risk, cardiologists need to familiarize themselves 
with the general principles underlying the interpretation of test results 
and must be able to convey the implications to patients. They also need 
to be able to make informed judgments about which tests are appropri­
ate for different patients and clinical situations. The risk of SCD and the 
possibility that family members could inherit the condition makes multi­
disciplinary expertise, including genetic counselling, psychological care, 
and patient support associations, a critical aspect of care.1166 As a re­
sult, there is a growing need for clinicians to develop their understand­
ing of the basic principles of clinical genetics and the diverse clinical 
manifestations of individual genetic disorders.54,964,1166,1167
Cardiomyopathies have a highly heterogeneous clinical presentation 
and an evolution that sometimes is difficult to predict. Disease phenotype 
can be the result of various acquired factors or genetic backgrounds. 
Mixed phenotypes or two conditions within the same patient or among 
a family can coexist. Genetic diagnosis raises common logistical and eth­
ical problems in its execution, as well as in the interpretation and com­
munication of the results.1166 Diagnostic process, the management of 
symptoms, and risk stratification often require comprehensive evaluation 
of the patient and their family, with the participation of multidisciplinary 
teams. On the other hand, interventional procedures (septal ablation, 
myectomies, etc.) require an expertise that only centres that treat 
many patients can achieve. Specialization in this area also requires per­
manent updating to accurately characterize the disease prognosis, ensure 
the choice of the best therapeutic option in each case, and guarantee the 
implementation of that choice by a team with experience in the field.
These characteristics imply that the adequate management of these 
diseases requires specific tools, extensive experience, and a multidiscip­
linary basic-clinical approach that are difficult to achieve.
The cardiomyopathy unit is usually integrated into a general cardioge­
netic (or inherited cardiac conditions) unit, where other professionals in­
volved in hereditary cardiac and vascular conditions, such as 
channelopathies, genetic aortopathies, familial dyslipidaemias, and a num­
ber of genetic metabolic and syndromic diseases with cardiac involve­
ment, are co-ordinated. They represent an organizational model aimed 
at providing comprehensive cardiovascular and genetic assessment and 
personalized management in patients with inherited cardiovascular dis­
eases. Specialized multidisciplinary clinics have long been advocated as 
the ideal model for the management of patients and families with inher­
ited cardiac conditions.4,53,559,1166 Such a model of care supports the hol­
istic care of patients and their at-risk family members, taking a 
patient-centred approach and valuing clinical, genetic, and psychosocial 
outcomes. The benefit of a specialized clinic for management of HCM 
has been previously reported, with patients showing better adjustment 
and less worry than those who did not attend.53,224 Besides expertise 
in the field of inherited cardiac conditions, the presence of a multidiscip­
linary team, access to good technical resources, participation in dedicated 
research projects, availability of genetic counselling, and family screening 
are all pre-requisites for organizing a cardiogenetic clinic. The ability to 
provide education and training for medical professionals and collabor­
ation with patients’ associations is of utmost importance.
Supplementary data online, Table S8 synthesizes the requirements 
and skills and recommendations for professional education/training 
needed for a cardiogenetic clinic as proposed by international expert 
associations.
10. Living with cardiomyopathy: 
advice for patients
Most people with cardiomyopathy lead normal and productive 
lives, but a small number experience significant symptoms and are at 
risk of disease-related complications. Regardless of the severity of their 
disease, it is important that individuals receive support and accurate 
advice from cardiomyopathy specialists and other healthcare 
professionals, and that they are encouraged to understand and 
manage the disease themselves (see the Supplemental Data online, 
Table S9, for a description of the patient education process).
Table 24 General guidance for daily activity for pa­
tients with cardiomyopathies
Topic
General guidance
Exercise
• See earlier section on exercise 
recommendations.
Diet, alcohol use, and 
weight
• Patients should be encouraged to maintain a 
recommended body mass index.
• Avoid dehydration, excess alcohol intake, and 
drugs consumption.
Smoking
• There are no data that show an interaction 
between tobacco smoking and 
cardiomyopathy, but patients should be 
provided with general advice on the health risks 
associated with smoking, including 
pro-arrhythmic and pro-inflammatory effects 
and, when available, information on smoking 
cessation.1168–1171
Reproductive issues
• Patients should be given the opportunity to 
discuss their concerns about reproductive 
issues. Anxiety and depression following a 
diagnosis are frequent, and some patients may 
express guilt or fear about their genetic 
diagnosis and the risk of transmission to 
offspring.
Sexual activity
• Patients should be counselled on the potential 
effect of their medication on sexual 
performance.
• Most people with cardiomyopathy will be able 
to undertake normal sexual activity. 
Individualized advice should be provided 
regarding its safety and the possible impact of 
sexual activity on the risk of disease 
progression, ventricular arrhythmias, and/or 
ICD shocks.
Medication
• Patients should be provided with information 
about their medication, including potential side 
and teratogenic effects and interactions with 
prescribed medications, over-the-counter 
remedies, and other complementary therapies.
Vaccination
• In the absence of contraindications, patients 
should be advised to have regular 
recommended vaccinations (e.g. yearly 
influenza and SARS-CoV-2 vaccination).
Continued


<!-- PAGE 85 -->

### Page 85

Table 24 summarizes some of the key issues that should be discussed 
with patients, relatives, and carers. When appropriate (e.g. when con­
sidering pregnancy, see Section 8.2), patients should be referred to 
other specialist services.
11. Sex differences in 
cardiomyopathies
Sex differences in phenotypic expression and outcomes are well docu­
mented across cardiovascular medicine. Differences in clinical presenta­
tion, progression, and outcome in cardiomyopathies between females 
and males can be attributable to genetic and hormonal differences, 
but also to variations in management, access to healthcare, or response 
to specific therapies.546,1173 Eliminating these variations represents a 
major unmet need in the care of cardiomyopathies.
Cardiomyopathies are typically inherited as an autosomal dominant 
trait. Therefore, the prevalence would be expected to be equal among 
the sexes. Women are consistently less represented than men in clinical 
studies across different cardiomyopathies (30–40%). Despite this, the 
difference may be explained by bias in interaction with healthcare facil­
ities or by diagnosis criteria based on unadjusted cardiac imaging mea­
surements; data from large pedigrees seem to support the hypothesis 
that there is a real delay in the age of phenotypic expression in female 
carriers (at least for HCM).178,1174–1176
Females with HCM are diagnosed later than males (8–13 years later), 
are more severely affected, more often have LVOTO, have more severe 
symptoms at baseline, and more commonly develop advanced heart failure 
during follow-up.1177,1178Women with LVOTO and indication for invasive 
procedures are often older and more symptomatic than males.1179–1181
Females and males appear to show similar survival benefit from invasive 
SRT.705,1181 Cardiomyopathy-related death has shown to be increased 
in middle-aged females with HCM compared with men and the general 
population; this is due to a higher rate of death from heart failure. No dif­
ference in SCD has been demonstrated in HCM regarding sex.1182,1183
Females with DCM may have a better response to therapy and seem 
to have a more favourable clinical course than males.186,1184 Male sex 
has been reported to be consistently associated with an increased 
SCD rate in DCM (general cohorts and particular genotypes ser­
ies),186,541,872,878,1185–1187 and death from heart failure or transplant 
in general DCM cohorts.1188,1189
Male sex and sports have been traditionally identified as variables as­
sociated with an earlier phenotypic penetrance and a more severe dis­
ease expression in genetic carriers, and are independent predictors of 
malignant ventricular arrhythmic events in ARVC.522,950,1190–1195 As in 
HCM, females with ARVC may have an increased risk of developing 
heart failure.1193
Reports on sex differences in familial or genetic RCM are 
scarce.331,546 Compared with other types of cardiomyopathies, females 
seem to be as equally represented as males in RCM series.331
12. Comorbidities and 
cardiovascular risk factors in 
cardiomyopathies
12.1. Cardiovascular risk factors
The 
penetrance 
of 
the 
disease 
in 
genetic 
carriers 
of 
cardiomyopathy-associated variants is incomplete. Gene–environment 
Driving
• Most patients should be eligible for an ordinary 
driving licence and can continue driving unless 
they experience distracting or disabling 
symptoms.
• Advice on driving licences for heavy goods or 
passenger-carrying vehicles should be in line 
with local legislation.
• For further information on driving with ICDs, 
see local rules.
Occupation
• Most people with cardiomyopathy will be able 
to accomplish their normal jobs. The 
implications of heavily manual jobs that involve 
strenuous activity should be discussed with the 
appropriate specialist.
• For some occupations, such as pilots, military 
personnel, and emergency services personnel, 
there are strict guidelines or rules on eligibility.
• The social and financial implications of a 
diagnosis of cardiomyopathy should be included 
in the counselling of relatives before clinical or 
genetic screening.
Holidays and travel 
insurance
• Most asymptomatic or mildly symptomatic 
patients can fly safely. For further information 
on flying with ICD, see ‘Fitness to fly for 
passengers with cardiovascular disease’.1172
• Insurance companies may charge more for 
travel insurance. In some countries, patient 
support organizations can provide advice about 
obtaining reasonable insurance.
Life insurance
• The diagnosis of cardiomyopathy will result in 
difficulty obtaining life insurance or mortgages. 
Advice on the rules that apply in different 
countries should be provided to patients at 
diagnosis.
Pregnancy and 
childbirth
See Section 8.2
Education/schooling
• Teachers and other carers should be provided 
with advice and written information relevant to 
the care of children with cardiomyopathy.
• In the absence of symptoms and risk factors, 
children should be allowed to perform low- to 
moderate-level aerobic physical activity, in 
accordance with advice from their paediatric 
cardiologist. Advice on high-intensity exercise in 
children should be guided by cardiomyopathy 
phenotype and the presence of symptoms and 
risk factors within a specialist paediatric 
cardiomyopathy setting.
• Provision should be made for children with 
learning difficulties and other special needs.
• Parents, teachers, and staff at sports facilities 
should be trained in CPR and in the use of 
AEDs.
© ESC 2023
AED, automated external defibrillator; CPR, cardio-pulmonary resuscitation; ICD, 
implantable cardioverter defibrillator; SARS-CoV-2, severe acute respiratory syndrome 
coronavirus 2.
ESC Guidelines                                                                                                                                                                                          3587


<!-- PAGE 86 -->

### Page 86

interactions can explain part of the heterogeneity of the phenotypic 
expression of all cardiomyopathy phenotypes, although published 
data focus primarily on HCM, DCM, and ARVC.
12.2. Dilated cardiomyopathy
Individual genetic predisposition favours a dilated phenotype in the 
presence of trigger factors, such as inflammation, infection, toxic insults 
from alcohol or drugs, and tachyarrhythmias.
12.3. Hypertrophic cardiomyopathy
Hypertension and obesity have been associated with penetrance and 
phenotypic expression of HCM.1196
Results from the EORP 
Cardiomyopathy/Mycarditis Registry showed that patients with HCM 
had a high prevalence of cardiovascular risk factors, comparable with 
data from the general population.1196 Hypertension, diabetes, and 
obesity were associated with older age at presentation, a lower preva­
lence of family history of HCM and SCD, more symptoms, frequent AF, 
and worse LV diastolic function.1197 Hypertension and obesity were 
also associated with higher provocable LVOT gradients and LVH.1198
12.4. Arrhythmogenic right ventricular 
cardiomyopathy
The role of intense exercise in disease expression and outcomes has 
been studied in HCM and DCM, but the impact has shown to be par­
ticularly relevant in ARVC (Table 25). Despite significant research, the 
pathophysiology of ARVC is complex and not well understood. The 
search for genetic or environmental triggers, such as viruses and im­
mune response, has failed to identify actionable factors. The role of in­
flammation on the pathophysiology is thought to be key.1199
13. Coronavirus disease 
(COVID-19) and cardiomyopathies
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infec­
tion, known as COVID-19, is characterized by a high variability of clin­
ical presentation and outcomes with an adverse association between 
underlying 
cardiac 
disease, 
including 
heart 
failure, 
and 
SARS-CoV-2-related mortality.1200–1202 However, examination of 
SARS-CoV-2 infection in underlying causes of heart failure, particularly 
cardiomyopathies, has been limited.
Analyses of international registries on cardiomyopathies and 
SARS-CoV-2 from the pre-vaccine period have identified several mar­
kers of adverse outcomes.1203 Prior history of heart failure and particu­
lar phenotypes (amyloidosis and DCM) were significantly associated 
with intensive care unit admission and death compared with HCM, 
ARVC, and the general population. For HCM, age, baseline functional 
class, LVOTO, and systolic impairment were independent predictors 
of death.1204
SARS-CoV-2 vaccination has been demonstrated to be safe in large 
population studies and reports on complications related to the vaccin­
ation in patients with cardiomyopathy are anecdotal. Given this, and the 
potential for worse outcomes in cardiomyopathy patients who con­
tract COVID-19, vaccination is encouraged in all cardiomyopathy pa­
tients and, in particular, in those with signs or symptoms of heart failure.
14. Key messages
(1) Cardiomyopathies are more common than previously thought 
and they typically require nuanced management that may differ 
from the conventional approach to patients with arrhythmia or 
heart failure.
(2) Aetiology is fundamental to the management of patients with 
heart muscle disease and careful and systematic description of 
the morphological and functional phenotype is a crucial first 
step in the diagnostic pathway.
(3) An approach to nomenclature and diagnosis of cardiomyopathies 
that is based on the predominant phenotype at presentation is 
recommended.
(4) Patients with cardiomyopathy may seek medical attention due to 
symptoms onset (HF or arrhythmia related), incidental abnormal 
findings, or as a result of family screening following the diagnosis in 
a relative.
Recommendation Table 34 — Recommendation for 
management of cardiovascular risk factors in patients 
with cardiomyopathy
Recommendation
Classa
Levelb
Identification and management of risk factors and 
concomitant diseases is recommended as an integral 
part of the management of cardiomyopathy patients.
I
C
© ESC 2023
aClass of recommendation. 
bLevel of evidence.
Table 25 Modulators of the phenotypic expression of cardiomyopathies
Condition
HCM
DCM
ARVC
Expression
Hypertension
+++
++
?
Hypertrophy, dilatation, dysfunction, AF
Diabetes
++
+
?
Hypertrophy, dysfunction, AF
Obesity
++
+
?
Hypertrophy, LVOTO, AF
Toxic
−
+++
?
Dilatation, dysfunction
Sports
+
+
+++
Dilatation, dysfunction, ventricular arrhythmia
Virus
−
++
+
Dilatation, dysfunction, ventricular arrhythmia
Pregnancy
−
++
−
Dilatation, dysfunction
© ESC 2023
AF, atrial fibrillation; ARVC, arrhythmogenic right ventricular cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LVOTO, left ventricular outflow tract 
obstruction. 
+, degree of positive association; −, absence of definitive association; ?, unknown association.


<!-- PAGE 87 -->

### Page 87

(5) Multimodality imaging to characterize the cardiac phenotype 
(morphology and function)—including tissue characterization 
for non-ischaemic myocardial scar detection—is necessary, 
in combination with a detailed personal and family history, 
clinical examination, electrocardiography, and laboratory 
investigations.
(6) Imaging results should always be interpreted in the overall clinical 
context, including genetic testing results, rather than in isolation.
(7) Tissue characterization by CMR is of value in diagnosis, monitor­
ing of disease progression and risk stratification in each of the 
main cardiomyopathy phenotypes.
(8) DPD/PYP/HMDP bone-tracer scintigraphy or SPECT represent 
the gold standard for the diagnosis of ATTR-related cardiac 
amyloidosis.
(9) The presence of non-ischaemic ventricular scar or fatty replace­
ment on cardiac CMR and/or pathological examination, which 
can occur with or without ventricular dilatation and/or systolic 
dysfunction, can be the sole clue to the diagnosis of a cardiomy­
opathy and can have prognostic significance that varies with 
aetiology.
(10) The aim of this multiparametric and systemic approach is to gen­
erate a phenotype-based aetiological diagnosis, interpreting avail­
able data with a cardiomyopathy-oriented mindset that combines 
cardiological assessment with non-cardiac parameters.
(11) A multidisciplinary approach to patient care and appropriate tran­
sition of care from paediatric to adult cardiomyopathy services is 
needed.
(12) Genetic testing should be performed in patients with cardiomy­
opathy and may influence risk stratification and management.
(13) Genetic counselling, including pre- and post-test counselling, and 
psychological support are an essential aspect of the multidisciplin­
ary care of patients with cardiomyopathy and their relatives.
(14) Paediatric cardiomyopathies largely represent part of the same 
clinical spectrum as those seen in older adolescents and adults, 
but infant-onset (in the first year of life) cardiomyopathies are of­
ten associated with severe phenotypes and a high rate of heart 
failure-related morbidity and mortality.
(15) Beyond the first year of life, genetic causes of childhood-onset 
cardiomyopathies are similar to those in adults.
(16) Symptom management, identification, and prevention of 
disease-related complications (including SCD, heart failure, and 
stroke) 
are 
the 
cornerstone 
of 
management 
of 
all 
cardiomyopathies.
(17) Cardiac myosin inhibitors (Mavacamten) should be considered in 
patients with HCM and LVOTO who remain symptomatic des­
pite optimal medical therapy.
(18) Validated SCD risk-prediction tools (HCM Risk-SCD and HCM 
Risk-Kids) are the first step in sudden death prevention in patients 
with HCM.
(19) Additional risk markers may be of use in patients with low or 
intermediate risk, but there is a lack of robust data on the impact 
of these parameters on the personalized risk estimates generated 
by the risk-prediction tools.
(20) Pharmacological treatment of DCM patients does not differ from 
those recommended in chronic heart failure.
(21) SCD risk of DCM and NDLVC patients varies depending on the 
underlying cause and genetic subtype.
(22) CMR findings play an important role in guiding ICD implantation 
for patients with DCM and NDLVC.
(23) In DCM and NDLVC patients, ICD should be considered for cer­
tain genetic forms even if LVEF is >35%.
(24) It is of importance to define aetiology for a tailored management 
in patients with syndromic and metabolic cardiomyopathies (i.e. 
ERT/chaperone in lysosomal storage disease; tafamidis in 
ATTRwt, etc.).
(25) Pregnancy and the post-partum period are associated with in­
creased cardiovascular risk in women with known cardiomyopathy.
(26) A multidisciplinary team should evaluate the patient with cardio­
myopathy to assess the risk associated with pregnancy.
(27) Beta-blocker therapy on arrhythmic indication can safely be con­
tinued during pregnancy; safety data should be checked before ini­
tiation of new drugs in pregnancy.
(28) Healthy adults of all ages and individuals with known cardiac dis­
ease should exercise with moderate intensity, totalling at least 
150 min per week.
(29) All patients with cardiomyopathy should have an individualized 
risk assessment for exercise prescription. Evaluation should be 
guided by three principles: (i) preventing life-threatening arrhyth­
mias during exercise; (ii) symptom management to allow sports; 
and (iii) preventing sports-induced progression of the arrhythmo­
genic condition.
(30) Individuals who are genotype positive/phenotype negative or have 
a mild cardiomyopathy phenotype and absence of symptoms or 
any risk factors, may be able to participate in competitive sports. 
In some high-risk patients with HCM, ARVC, and NDLVC, high- 
intensity exercise and competitive sports should be discouraged.
(31) Patients with high-risk genotypes or associated factors for ar­
rhythmic or heart failure complications or severe LVOTO should 
be referred for specialized investigations before undergoing elect­
ive NCS.
(32) Identification and management of risk factors and concomitant 
diseases is recommended as an integral part of the management 
of cardiomyopathy patients.
15. Gaps in evidence
Although there have been major advances in the genetics, diagnosis, and 
treatments of patients with cardiomyopathy over the last few years, 
there are a number of areas where robust evidence is still lacking and 
deserve to be addressed in future clinical research. 
(1) Cardiomyopathy phenotypes.
(2) Epidemiology: 
(a) Prevalence of NDLVC phenotype (children and adults).
(b) Systematic assessment of prevalence of cardiomyopathy phe­
notypes in childhood.
(3) Integrated patient management: 
(a) Embedding of telemedicine into cardiomyopathy networks.
(4) Patient pathway: 
(a) Laboratory tests: 
(i) Studies on novel ‘omic’ biomarkers (proteomics, metabo­
lomics, and transcriptomics) are needed to assess their 
potential value for diagnostic and prognostic purposes in 
cardiomyopathies.
(b) Multimodality imaging: 
(i) Advanced echocardiographic techniques, including speckle 
tracking deformation imaging, are promising but lack ro­
bust validation in the setting of cardiomyopathies.
ESC Guidelines                                                                                                                                                                                          3589


<!-- PAGE 88 -->

### Page 88

(ii) A universally accepted, standardized method for the 
quantification of myocardial fibrosis by CMR is lacking.
(iii) CMR scans may be performed in patients with compat­
ible implantable devices, but the quality is limited by 
artefacts.
(iv) Artificial intelligence enhanced electrocardiography and 
imaging for cardiomyopathy evaluation has been proving 
a novel tool to dramatically improve diagnosis and prog­
nosis; further studies are needed for routine introduction 
in clinical practice.
(v) Impact of CMR on screening in genotype-positive rela­
tives of individuals with cardiomyopathy and in 
gene-elusive families.
(c) Genetics: 
(i) Penetrance is poorly characterized for most pathogenic 
variants. This is true both for variants found through cas­
cade screening of relatives of a patient with cardiomyop­
athy, and also for variants found in the wider population 
who may have clinical sequencing for another indication 
or may choose to have genome sequencing as a screening 
test.
(ii) The benefits, harm, and costs of screening of 
cardiomyopathy-associated genes in individuals without 
a personal or family history of cardiomyopathy is not 
known.
(d) General principles in management: 
(i) Management 
of 
RV 
failure 
remains 
largely 
non-evidence-based.
(ii) Large-scale studies are required to guide ventricular ar­
rhythmia management in patients with genetic 
cardiomyopathies.
(iii) Optimal rate control and AADs per subtype of 
cardiomyopathy.
(iv) The role of ICDs in patients with well tolerated VT.
(v) All risk calculators are developed using baseline data. 
Therefore, the utility of their application during follow- 
up visits of patients remains unclear and needs to be 
studied.
(vi) Risk prediction in childhood cardiomyopathies other 
than HCM remains empirical—multicentre approach 
required to understand and develop SCD risk models 
in childhood.
(vii) Lack of controlled studies on the effect of ablation in pa­
tients with AF and cardiomyopathy.
(viii) Models to predict AF recurrence have not been vali­
dated in cardiomyopathy patients.
(ix) Lack of randomized studies assessing the efficacy of car­
diac sympathetic denervation for the prevention of VT/ 
VF recurrences.
(e) Approach to paediatric cardiomyopathies: 
(i) Lack of randomized studies or large registries addressing 
the benefit and optimal dosing of drug therapy in paediat­
ric population.
(5) Hypertrophic cardiomyopathy: 
(a) Epidemiology: 
(i) Imaging and genotype studies suggest a population preva­
lence of up to 1 in 200 of the population. However, 
HER-based studies suggest a much lower number of 3– 
4/10 000. Further studies into the prevalence of clinically 
important diseases are necessary.
(b) Aetiology: 
(i) Aetiology of gene-elusive disease.
(ii) The role of polygenic risk.
(iii) Interaction between comorbidity and disease outcomes.
(iv) Genetic and environmental determinants of disease ex­
pression in variant carriers.
(c) Symptom management: 
(i) Optimal timing of LVOTO management and its impact on 
disease progression.
(ii) Prevention of AF and heart failure.
(d) Sudden death prevention: 
(i) Impact of genetics (Mendelian and complex) on risk of 
disease-related outcomes.
(ii) Improved prediction models that reduce residual risk and 
prevent unnecessary ICD implantation.
(iii) Refinement of risk-prediction models to include serial 
data.
(iv) Role of LVOTO in risk prediction in children (apparent 
discrepancy compared with adults).
(e) New therapies: 
(i) Clinical utility of myosin inhibitors, other small molecules, 
and emerging genetic therapies.
(6) Dilated cardiomyopathy: 
(a) Genetic basis of familial DCM is still unknown in a high num­
ber of cases.
(b) Detailed data about the specific clinical course in diverse gen­
etic and non-genetic DCM forms are not available.
(c) It is unknown if patients with DCM respond differently to 
pharmacological treatment according to underlying aetiology.
(d) Optimized SCD prevention strategy remains unsolved. There 
are not data from prospective clinical trials in modern 
cohorts with contemporary medical treatment. This gap is 
knowledge is particularly relevant for DCM patients with 
LVEF > 35%.
(e) Sport recommendations and utility of prophylactic pharma­
cological therapy to prevent DCM onset in genetic carriers.
(7) Non-dilated left ventricular cardiomyopathy: 
(a) Prevalence of disease.
(b) Natural history and response to treatment.
(c) SCD prevention.
(d) Sports recommendations.
(8) Arrhythmogenic right ventricular cardiomyopathy: 
(a) RCTs for therapies for the management of arrhythmias and 
heart failure are lacking.
(b) Studies on the effect of exercise remain largely retrospective.
(c) Studies on the incidence and prognostication of heart failure 
remain limited.
(d) Studies on the frequency and mode of clinical screening for 
asymptomatic family members are lacking.
(9) Restrictive cardiomyopathy: 
(a) SCD prevention.
(10) Syndromic and metabolic cardiomyopathies: 
(a) Lack of randomized trials or large observational cohort stud­
ies assessing the role of new target therapies addressing the 
RAS/MAPK pathway (i.e trametinib).
(b) There are few long-term outcome studies addressing ven­
tricular remodelling in RAS-HCM.
(c) HCM Risk-Kids has not been validated in paediatric patients 
with RAS-HCM. Data regarding SCD risk stratification are 
lacking, although candidate risk factors have been identified.


<!-- PAGE 89 -->

### Page 89

(d) Lack of studies addressing the optimal timing to start ERT in 
adolescents and adults with late-onset Pompe disease.
(e) Lack of standardized protocols to treat cross-reactive im­
munologic material-negative patients.
(f) Lack of standardization of clinical endpoints in ERT/chaper­
one therapy trials.
(g) Lack of head-to-head comparisons between agalsidase alpha 
and beta.
(h) Optimal time to begin treatment in asymptomatic female pa­
tients with non-classic disease.
(11) Amyloid: 
(a) Further studies are needed to assess the efficacy and safety of 
tafamidis in NYHA class III patients.
(b) SCD risk stratification and indications for ICD implantation 
should be carefully defined, taking into account the estimated 
life expectancy, competitive non-cardiovascular mortality, 
and the high rate of pulseless electrical activity.
(c) The need for drug therapy in patients with cardiac amyloid­
osis and subclinical cardiac involvement (i.e asymptomatic pa­
tients, positive scintigraphy with negative ECHO) has not 
been clearly defined.
(12) Sports: 
(a) ‘Return to play’ for patients with low-risk cardiomyopathies 
(and how to define low risk in relation to exercise).
(b) SCD risk and exercise recommendations in phenotype- 
negative gene carriers.
(c) Role of exercise in disease expression and progression.
(d) Large, adequately powered randomized prospective studies are 
necessary to provide evidence-based recommendations for op­
timal exercise prescription without compromising safety.
(13) Reproductive issues: 
(a) Several cardiomyopathies lack specific outcome data regard­
ing pregnancy.
(b) There is a lack of randomized trials on the use of AADs, heart 
failure drugs, and interventions during pregnancy.
(14) Non-cardiac interventions: 
(a) There is a lack specific outcome data regarding risks of non- 
cardiac interventions.
(15) Management of cardiovascular risk factors in patients with 
cardiomyopathies: 
(a) There is a lack of data on the impact of comorbidities on 
penetrance, severity, and outcome of cardiomyopathies.
16. ‘What to do’ and ‘What not to do’ messages from the Guidelines
Recommendations
Classa
Levelb
Recommendations for the provision of service of multidisciplinary cardiomyopathy teams
It is recommended that all patients with cardiomyopathy and their relatives have access to multidisciplinary teams with expertise in the 
diagnosis and management of cardiomyopathies.
I
C
Timely and adequate preparation for transition of care from paediatric to adult services, including joint consultations, is recommended in all 
adolescents with cardiomyopathy.
I
C
Recommendations for diagnostic work-up in cardiomyopathies
It is recommended that all patients with suspected or established cardiomyopathy undergo systematic evaluation using a multiparametric 
approach that includes clinical evaluation, pedigree analysis, ECG, Holter monitoring, laboratory tests, and multimodality imaging.
I
C
It is recommended that all patients with suspected cardiomyopathy undergo evaluation of family history and that a three- to four-generation 
family tree is created to aid in diagnosis, provide clues to underlying aetiology, determine inheritance pattern, and identify at-risk relatives.
I
C
Recommendations for laboratory tests in the diagnosis of cardiomyopathies
Routine (first-level) laboratory tests are recommended in all patients with suspected or confirmed cardiomyopathy to evaluate aetiology, 
assess disease severity, and aid in detection of extracardiac manifestations and assessment of secondary organ dysfunction.
I
C
Recommendation for echocardiographic evaluation in patients with cardiomyopathy
A comprehensive evaluation of cardiac dimensions and LV and RV systolic (global and regional) and LV diastolic function is recommended in all 
patients with cardiomyopathy at initial evaluation, and during follow-up, to monitor disease progression and aid risk stratification and management.
I
B
Recommendations for cardiac magnetic resonance indication in patients with cardiomyopathy
Contrast-enhanced CMR is recommended in patients with cardiomyopathy at initial evaluation.
I
B
Recommendations for computed tomography and nuclear imaging
DPD/PYP/HMDP bone-tracer scintigraphy is recommended in patients with suspected ATTR-related cardiac amyloidosis to aid diagnosis.
I
B
Recommendations for genetic counselling and testing in cardiomyopathies
Genetic counselling
Genetic counselling, provided by an appropriately trained healthcare professional and including genetic education to inform decision-making 
and psychosocial support, is recommended for families with an inherited or suspected inherited cardiomyopathy, regardless of whether 
genetic testing is being considered.
I
B
Continued 
ESC Guidelines                                                                                                                                                                                          3591


<!-- PAGE 90 -->

### Page 90

It is recommended that genetic testing for cardiomyopathy is performed with access to a multidisciplinary team, including those with 
expertise in genetic testing methodology, sequence variant interpretation, and clinical application of genetic testing, typically in a specialized 
cardiomyopathy service or in a network model with access to equivalent expertise.
I
B
Pre- and post-test genetic counselling is recommended in all individuals undergoing genetic testing for cardiomyopathy.
I
B
If pre-natal diagnostic testing is to be pursued by the family, it is recommended that this is performed early in pregnancy, to allow decisions 
regarding continuation or co-ordination of pregnancy to be made.
I
C
Index patients
Genetic testing is recommended in patients fulfilling diagnostic criteria for cardiomyopathy in cases where it enables diagnosis, 
prognostication, therapeutic stratification, or reproductive management of the patient, or where it enables cascade genetic evaluation of 
their relatives who would otherwise be enrolled into long-term surveillance.
I
B
Genetic testing is recommended for a deceased individual identified to have cardiomyopathy at post-mortem if a genetic diagnosis would 
facilitate management of surviving relatives.
I
C
Family members
It is recommended that cascade genetic testing, with pre- and post-test counselling, is offered to adult at-risk relatives if a confident genetic 
diagnosis (i.e. a P/LP variant) has been established in an individual with cardiomyopathy in the family (starting with first-degree relatives if available, 
and cascading out sequentially).
I
B
Diagnostic genetic testing is not recommended in a phenotype-negative relative of a patient with cardiomyopathy in the absence of a 
confident genetic diagnosis (i.e. a P/LP variant) in the family.
III
C
Recommendations for cardiac transplantation in patients with cardiomyopathy
Orthotopic cardiac transplantation is recommended for eligible cardiomyopathy patients with advanced heart failure (NYHA class III–IV) or 
intractable ventricular arrhythmia refractory to medical/invasive/device therapy, and who do not have absolute contraindications.
I
C
Recommendations for management of atrial fibrillation and atrial flutter in patients with cardiomyopathy
Anticoagulation
Oral anticoagulation in order to reduce the risk of stroke and thromboembolic events is recommended in all patients with HCM or cardiac 
amyloidosis and AF or atrial flutter (unless contraindicated).
I
B
Oral anticoagulation to reduce the risk of stroke and thrombo-embolic events is recommended in patients with DCM, NDLVC, or ARVC, 
and AF or atrial flutter with a CHA2DS2-VASc score ≥2 in men or ≥3 in women.
I
B
Control of symptoms and heart failure
Atrial fibrillation catheter ablation is recommended for rhythm control after one failed or intolerant class I or III AAD to improve symptoms 
of AF recurrences in patients with paroxysmal or persistent AF and cardiomyopathy.
I
B
Atrial fibrillation catheter ablation is recommended to reverse LV dysfunction in AF patients with cardiomyopathy when a 
tachycardia-induced component is highly probable, independent of their symptom status.
I
B
Comorbidities and associated risk factor management
Modification of an unhealthy lifestyle and targeted therapy of intercurrent conditions is recommended to reduce AF burden and symptom 
severity in patients with cardiomyopathy.
I
B
Recommendations for implantable cardioverter defibrillator in patients with cardiomyopathy
General recommendations
Implantation of a cardioverter defibrillator is only recommended in patients who have an expectation of good quality survival >1 year.
I
C
It is recommended that ICD implantation be guided by shared decision-making that: 
• is evidence-based;
• considers a person’s individual preferences, beliefs, circumstances, and values; and
• ensures that the person understands the benefits, harm, and possible consequences of different treatment options.
I
C
It is recommended that prior to ICD implantation, patients are counselled on the risk of inappropriate shocks, implant complications, and 
the social, occupational, and driving implications of the device.
I
C
It is not recommended to implant an ICD in patients with incessant ventricular arrhythmias until the ventricular arrhythmia is controlled.
III
C
Secondary prevention
Implantation of an ICD is recommended:
• in patients with HCM, DCM, and ARVC who have survived a cardiac arrest due to VT or VF, or who have spontaneous sustained 
ventricular arrhythmia causing syncope or haemodynamic compromise in the absence of reversible causes.
I
B
• in patients with NDLVC and RCM who have survived a cardiac arrest due to VT or VF, or who have spontaneous sustained ventricular 
arrhythmia causing syncope or haemodynamic compromise in the absence of reversible causes.
I
C
Continued


<!-- PAGE 91 -->

### Page 91

Primary prevention
Comprehensive SCD risk stratification is recommended in all cardiomyopathy patients who have not suffered a previous cardiac arrest/ 
sustained ventricular arrhythmia at initial evaluation and at 1–2 year intervals, or whenever there is a change in clinical status.
I
C
The use of validated SCD algorithms/scores as aids to the shared decision-making when offering ICD implantation, where available is 
recommended in patients with HCM.
I
B
Choice of ICD
When an ICD is indicated, it is recommended to evaluate whether the patient could benefit from CRT.
I
A
Recommendations for routine follow-up of patients with cardiomyopathy
It is recommended that all clinically stable patients with cardiomyopathy undergo routine follow-up using a multiparametric approach that 
includes ECG and echocardiography every 1–2 years.
I
C
Clinical evaluation with ECG and multimodality imaging is recommended in patients with cardiomyopathy whenever there is a substantial or 
unexpected change in symptoms.
I
C
Recommendations for family screening and follow-up evaluation of relatives
Following cascade genetic testing, clinical evaluation using a multiparametric approach that includes ECG and cardiac imaging and long-term 
follow-up is recommended in first-degree relatives who have the same disease-causing variant as the proband.
I
B
Following cascade genetic testing, it is recommended that first-degree relatives without a phenotype who do not have the same 
disease-causing variant as the proband are discharged from further follow-up but advised to seek re-assessment if they develop symptoms 
or when new clinically relevant data emerge in the family.
I
C
It is recommended that when no P/LP variant is identified in the proband or genetic testing is not performed, an initial clinical evaluation 
using a multiparametric approach that includes ECG and cardiac imaging is performed in first-degree relatives.
I
C
Recommendations for psychological support in patients and family members with cardiomyopathies
It is recommended that psychological support by an appropriately trained health professional be offered to all individuals who have 
experienced the premature sudden cardiac death of a family member with cardiomyopathy.
I
B
It is recommended that psychological support by an appropriately trained health professional be offered to all individuals with an inherited 
cardiomyopathy who receive an implantable cardioverter defibrillator.
I
B
Recommendation for evaluation of left ventricular outflow tract obstruction
In all patients with HCM, at initial evaluation, transthoracic 2D and Doppler echocardiography are recommended, at rest and during Valsalva 
manoeuvre in the sitting and semi-supine positions—and then on standing if no gradient is provoked—to detect LVOTO.
I
B
In symptomatic patients with HCM and a resting or provoked peak instantaneous LV outflow tract gradient <50 mmHg, 2D and Doppler 
echocardiography during exercise in the standing, sitting (when possible), or semi-supine position are recommended to detect provocable 
LVOTO and exercise-induced mitral regurgitation.
I
B
Recommendations for medical treatment of left ventricular outflow tract obstruction
Non-vasodilating beta-blockers, titrated to maximum tolerated dose, are recommended as first-line therapy to improve symptoms in 
patients with resting or provoked LVOTO.
I
B
Verapamil or diltiazem, titrated to maximum tolerated dose, are recommended to improve symptoms in symptomatic patients with resting 
or provoked LVOTO who are intolerant or have contraindications to beta-blockers.
I
B
Disopyramide, titrated to maximum tolerated dose, is recommended in addition to a beta-blocker (or, if this is not possible, with verapamil 
or diltiazem) to improve symptoms in patients with resting or provoked LVOTO.
I
B
Recommendations for septal reduction therapy
It is recommended that SRT be performed by experienced operators working as part of a multidisciplinary team expert in the management 
of HCM.
I
C
SRT to improve symptoms is recommended in patients with a resting or maximum provoked LVOT gradient of ≥50 mmHg who are in 
NYHA/Ross functional class III–IV, despite maximum tolerated medical therapy.
I
B
Septal myectomy, rather than ASA, is recommended in children with an indication for SRT, as well as in adult patients with an indication for 
SRT and other lesions requiring surgical intervention (e.g. mitral valve abnormalities).
I
C
Additional recommendations for prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy
Secondary prevention
Implantation of an ICD is recommended in patients who have survived a cardiac arrest due to VT or VF, or who have spontaneous sustained 
VT with haemodynamic compromise.
I
B
Continued 
ESC Guidelines                                                                                                                                                                                          3593


<!-- PAGE 92 -->

### Page 92

Primary prevention
The HCM Risk-SCD calculator is recommended as a method of estimating risk of sudden death at 5 years in patients aged ≥16 years for 
primary prevention.
I
B
Validated paediatric-specific risk-prediction models (e.g. HCM Risk-Kids) are recommended as a method of estimating risk of sudden death 
at 5 years in patients aged <16 years for primary prevention.
I
B
It is recommended that the 5-year risk of SCD be assessed at first evaluation and re-evaluated at 1–2 year intervals or whenever there is a 
change in clinical status.
I
B
Recommendations for an implantable cardioverter defibrillator in patients with dilated cardiomyopathy
Secondary prevention
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with DCM who have survived a cardiac arrest 
or have recovered from a ventricular arrhythmia causing haemodynamic instability.
I
B
Recommendation for resting and ambulatory electrocardiogram monitoring in patients with non-dilated left ventricular 
cardiomyopathy
Ambulatory ECG monitoring is recommended in patients with NDLVC annually or when there is a change in clinical status, to aid in 
management and risk stratification.
I
C
Recommendations for an implantable cardioverter defibrillator in patients with non-dilated left ventricular cardiomyopathy
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with NDLVC who have survived a cardiac 
arrest or have recovered from a ventricular arrhythmia causing haemodynamic instability.
I
C
Recommendation for resting and ambulatory electrocardiogram monitoring in patients with arrhythmogenic right ventricular 
cardiomyopathy
Annual ambulatory ECG monitoring is recommended in patients with ARVC to aid in diagnosis, management, and risk stratification.
I
C
Recommendations for the antiarrhythmic management of patients with arrhythmogenic right ventricular cardiomyopathy
Beta-blocker therapy is recommended in ARVC patients with VE, NSVT, and VT.
I
C
Recommendations for sudden cardiac death prevention in patients with arrhythmogenic right ventricular cardiomyopathy
Secondary prevention
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with ARVC who have survived a cardiac 
arrest or have recovered from a ventricular arrhythmia causing haemodynamic instability.
I
A
Recommendations for the management of patients with restrictive cardiomyopathy
It is recommended that multimodality imaging be used to differentiate RCM from HCM or DCM with restrictive physiology.
I
C
It is recommended that baseline cardiac and non-cardiac investigations are performed to assess involvement of the neuromuscular system 
or other syndromic disorders.
I
C
Cardiac catheterization is recommended in all children with RCM to measure pulmonary artery pressures and PVR at diagnosis and at 6–12 
monthly intervals to assess change in PVR.
I
B
ICD implantation is recommended to reduce the risk of sudden death and all-cause mortality in patients with RCM who have survived a 
cardiac arrest or have recovered from a ventricular arrhythmia causing haemodynamic instability.
I
C
Exercise recommendations for cardiomyopathy patients
All cardiomyopathies
Regular low- to moderate-intensity exercise is recommended in all able individuals with cardiomyopathy.
I
C
An individualized risk assessment for exercise prescription is recommended in all patients with cardiomyopathy.
I
C
HCM
High-intensity exercise, including competitive sport, is not recommended in high-risk individuals and in individuals with left ventricular 
outflow tract obstruction and exercise-induced complex ventricular arrhythmias.
III
C
ARVC
Moderate- and/or high-intensity exercise, including competitive sport, is not recommended in individuals with ARVC.
III
B
DCM and NDLVC
High-intensity exercise, including competitive sport, is not recommended in symptomatic individuals, those with a left ventricular ejection 
fraction ≤40%, exercise-induced arrhythmias, or pathogenic variants in LMNA or TMEM43.
III
C
Recommendations for reproductive issues in patients with cardiomyopathy
Pre-pregnancy risk assessment and counselling are recommended in all women using the mWHO classification of maternal risk.
I
C
Continued


<!-- PAGE 93 -->

### Page 93

### 17 Supplementary data

Supplementary material is available at European Heart Journal online.
18. Data availability statement
No new data were generated or analysed in support of this research.
19. Author information
Author/Task Force Member Affiliations: Alexandros 
Protonotarios, Centre for Heart Muscle Disease, UCL Institute of 
Cardiovascular 
Science, 
London, 
United 
Kingdom, 
Inherited 
Cardiovascular Disease Unit, St Bartholomew’s Hospital, London, 
United Kingdom; Juan R. Gimeno, Inherited Heart Diseases Unit 
(CSUR /ERN), Hospital Universitario Virgen de la Arrixaca- IMIB- 
Universidad de Murcia, Murcia, Spain, European Reference Networks 
for rare, low prevalence and complex diseases of the heart, ERN 
GUARD-Heart, European Commission 6, Amsterdam, Netherlands; 
Eloisa Arbustini, Centre For Inherited Cardiovascular Diseases, 
IRCCS Foundation Policlinico San Matteo, Piazzale Golgi, 27100 
Pavia, Italy; Roberto Barriales-Villa, Inherited Cardiovascular 
Diseases 
Unit, 
Cardiology 
Service, 
Complexo 
Hospitalario 
Universitario A Coruña (CHUAC), A Coruña, Spain, Instituto de 
Investigación Biomédica de A Coruña (INIBIC), Servizo Galego de 
Saúde (SERGAS), Universidade da Coruña, A Coruña, Spain, Centro 
de 
Investigación 
Biomédica 
en 
Red 
de 
Enfermedades 
Cardiovasculares, Instituto de Salud Carlos III, A Coruña, Spain; 
Cristina Basso, Department of Cardiac, Thoracic, Vascular 
Sciences and Public Health-University of Padua, Cardiovascular 
Pathology 
Unit-Azienda 
Ospedaliera, 
Padua, 
Italy; 
Connie 
R. Bezzina, Amsterdam UMC location University of Amsterdam, 
Department of experimental cardiology, Heart centre, Meibergdreef 
9, Amsterdam, Netherlands, Amsterdam cardiovascular sciences, 
Heart failure and arrhythmias, Amsterdam, Netherlands, European 
Reference Networks for rare, low prevalence and complex diseases 
of the heart, ERN GUARD-Heart; Elena Biagini, Cardiology, 
IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, 
Cardiology, Centro di riferimento europeo delle malattie cardiovasco­
lari, ERN GUARD-Heart, Bologna, Italy; Nico A. Blom, Paediatric 
Cardiology, Leiden University Medical Center, Leiden, Netherlands, 
Paediatric Cardiology, Amsterdam University Medical Center, 
Amsterdam, Netherlands; Rudolf A. de Boer, Erasmus Medical 
Counselling on safe and effective contraception is recommended in all women of fertile age and their partners.
I
C
Counselling on the risk of disease inheritance is recommended for all men and women before conception.
I
C
Vaginal delivery is recommended in most women with cardiomyopathies, unless there are obstetric indications for caesarean section, severe 
heart failure (EF <30% or NYHA class III–IV), or severe outflow tract obstructions, or in women presenting in labour on oral anticoagulants.
I
C
It is recommended that medication be carefully reviewed for safety in advance of pregnancy and adjusted according to tolerability in 
pregnancy.
I
C
Therapeutic anticoagulation with LMWH or VKAs according to the stage of pregnancy is recommended for patients with AF.
I
C
Recommendations for non-cardiac surgery in patients with cardiomyopathy
Peri-operative ECG monitoring is recommended for all patients with cardiomyopathy undergoing surgery.
I
C
In patients with cardiomyopathy and suspected or known HF scheduled for intermediate or high-risk NCS, it is recommended to 
re-evaluate LV function with echocardiography (assessing LVOTO in HCM patients) and measurement of NT-proBNP/BNP levels, unless 
this has recently been performed.
I
B
It is recommended that cardiomyopathy patients with high-risk genotypes or associated factors for arrhythmic or heart failure 
complications or severe LVOTO be referred for additional specialized investigations to a cardiomyopathy unit before undergoing elective 
NCS.
I
C
In patients aged <65 years with a first-degree relative with a cardiomyopathy, it is recommended to perform an ECG and TTE before NCS, 
regardless of symptoms.
I
C
Recommendation for management of cardiovascular risk factors in patients with cardiomyopathy
Identification and management of risk factors and concomitant diseases is recommended as an integral part of the management of 
cardiomyopathy patients.
I
C
© ESC 2023
2D, two-dimensional; AAD, antiarrhythmic drug; AF, atrial fibrillation; ARVC, arrhythmogenic right ventricular cardiomyopathy; ASA, alcohol septal ablation; ATTR, transthyretin amyloidosis; 
BNP, brain natriuretic peptide; CHA2DS2-VASc, congestive heart failure or left ventricular dysfunction, hypertension, age ≥75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65– 
74, 
sex 
category 
(female) 
(score); 
CMR, 
cardiac 
magnetic 
resonance; 
CRT, 
cardiac 
resynchronization 
therapy; 
DCM, 
dilated 
cardiomyopathy; 
DPD, 
3,3-diphosphono-1,2-propanodicarboxylic acid; ECG, electrocardiogram; EF, ejection fraction; HCM, hypertrophic cardiomyopathy; HMDP, hydroxymethylene diphosphonate; ICD, 
implantable cardioverter defibrillator; LMWH, low-molecular-weight heparin; LV, left ventricular; LVOT, left ventricular outflow tract; LVOTO, left ventricular outflow tract obstruction; 
mWHO, modified World Health Organization; NCS, non-cardiac surgery; NDLVC, non-dilated left ventricular cardiomyopathy; NSVT, non-sustained ventricular tachycardia; 
NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; P/LP, pathogenic/likely pathogenic; PVR, pulmonary vascular resistance; PYP, 
pyrophosphate; RCM, restrictive cardiomyopathy; RV, right ventricular; SCD, sudden cardiac death; SRT, septal reduction therapy; TTE, transthorasic echocardiogram; VE, ventricular 
ectopic beats; VF, ventricular fibrillation; VKA, vitamin K antagonist; VT, ventricular tachycardia. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3595


<!-- PAGE 94 -->

### Page 94

Center, Department of Cardiology, Rotterdam, Netherlands; Tim De 
Winter (Belgium), ESC Patient Forum, Sophia Antipolis, France; 
Perry M. Elliott, UCL Institute of Cardiovascular Science 
University 
College 
London, 
London, 
United 
Kingdom, 
St. Bartholomew’s Hospital, London, United Kingdom; Marcus 
Flather, Norwich Medical School, University of East Anglia, 
Norwich, United Kingdom, Department of Cardiology, Norfolk and 
Norwich University Hospital, Norwich, United Kingdom; Pablo 
Garcia-Pavia, Department of cardiology, Hospital Universitario 
Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, Madrid, Spain, 
Centro Nacional de Invstigaciones Cardiovasculares (CNIC), Madrid, 
Spain, European Reference Networks for rare, low prevalence and 
complex diseases of the heart, ERN GUARD-Heart, Madrid, Spain; 
Kristina H. Haugaa, Cardiology, Karolinska University Hospital, 
Stockholm, Sweden, Cardiology, Oslo University Hospital, Oslo, 
Norway; Jodie Ingles, Centre for Population Genomics, Garvan 
Institute of Medical Research, and UNSW Sydney, Sydney, Australia; 
Ruxandra Oana Jurcut, Expert Center for Rare Genetic 
Cardiovascular Diseases, Department of Cardiology, Emergency 
Institute of Cardiovascular Diseases “Prof.dr.C.C.Iliescu”, Bucharest, 
Romania, Cardiology, University of Medicine and Pharmacy “Carol 
Davila”, Bucharest, Romania; Sabine Klaassen, Experimental and 
Clinical Research Center, A Cooperation Between the Max Delbrück 
Center and Charité - Universitätsmedizin Berlin, Charité - 
Universitätsmedizin Berlin, Corporate Member of Freie Universität 
Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 
Congenital Heart Disease - Pediatric Cardiology, Deutsches 
Herzzentrum der Charité (DHZC), Berlin, Germany, DZHK 
(German Centre for Cardiovascular Research) partner site Berlin, 
Berlin, Germany; Giuseppe Limongelli, Translational Medical 
Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy, 
Cardiology, Monaldi Hospital - AORN Colli, Naples, Italy, European 
Reference Network for Rare, Low Prevalence, or Complex Diseases 
of the Heart (ERN GUARD-Heart); Bart Loeys, Center for medical 
genetics, Antwerp university hospital/university of Antwerp, 
Antwerp, Belgium, Department of human genetics, Radboud university 
medical 
center, 
Nijmegen, 
Netherlands; 
Jens 
Mogensen, 
Department of Cardiology, Aalborg University Hospital, Aalborg, 
Denmark; Iacopo Olivotto, Meyer Children’s Hospital IRCCS, 
University of Florence, Florence, Italy; Antonis Pantazis, Royal 
Brompton, and Harefield Hospitals, London, United Kingdom; 
Sanjay Sharma, St George’s, University of London, London, United 
Kingdom, St George’s University Hospital NHS Foundation Trust, 
London, United Kingdom; J. Peter van Tintelen, Department of 
Genetics, University Medical Center Utrecht, Utrecht, Netherlands; 
and James S. Ware, National Heart & Lung Institute, Imperial 
College London, London, United Kingdom, MRC London Institute of 
Medical Sciences, Imperial College London, London, United Kingdom, 
Royal Brompton & Harefield Hospitals, Guy’s and St. Thomas’ NHS 
Foundation Trust, London, United Kingdom.
20. Appendix
ESC Scientific Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
Document Reviewers: Philippe Charron (CPG Review 
Co-ordinator) (France), Massimo Imazio (CPG Review Co-ordinator) 
(Italy), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Michael 
Arad (Israel), Folkert W. Asselbergs (Netherlands), Riccardo 
Asteggiano (Italy), Zofia Bilinska (Poland), Damien Bonnet (France), 
Henning Bundgaard (Denmark), Nuno Miguel Cardim (Portugal), 
Jelena Čelutkienė (Lithuania), Maja Cikes (Croatia), Gaetano Maria 
De Ferrari (Italy), Veronica Dusi (Italy), Volkmar Falk (Germany), 
Laurent Fauchier (France), Estelle Gandjbakhch (France), Tiina Heliö 
(Finland), Konstantinos Koskinas (Switzerland), Dipak Kotecha 
(United Kingdom), Ulf Landmesser (Germany), George Lazaros 
(Greece), Basil S. Lewis (Israel), Ales Linhart (Czechia), Maja-Lisa 
Løchen (Norway), Benjamin Meder (Germany), Richard Mindham 
(United Kingdom), James Moon (United Kingdom), Jens Cosedis 
Nielsen (Denmark), Steffen Petersen (United Kingdom), Eva Prescott 
(Denmark), Mary N. Sheppard (United Kingdom), Gianfranco Sinagra 
(Italy), Marta Sitges (Spain), Jacob Tfelt-Hansen (Denmark), Rhian 
Touyz (Canada), Rogier Veltrop (Netherlands), Josef Veselka 
(Czechia), Karim Wahbi (France), Arthur Wilde (Netherlands), and 
Katja Zeppenfeld (Netherlands).
ESC National Cardiac Societies actively involved in the review 
process of the 2023 ESC Guidelines for the management of 
cardiomyopathies:
Algeria: Algerian Society of Cardiology, Brahim Kichou; Armenia: 
Armenian Cardiologists Association, Hamayak Sisakian; Austria: 
Austrian Society of Cardiology, Daniel Scherr; Belgium: Belgian 
Society 
of 
Cardiology, 
Bernhard 
Gerber; 
Bosnia 
and 
Herzegovina: Association of Cardiologists of Bosnia and 
Herzegovina, Alen Džubur; Bulgaria: Bulgarian Society of 
Cardiology, Mariana Gospodinova; Croatia: Croatian Cardiac 
Society, Ivo Planinc; Cyprus: Cyprus Society of Cardiology, Hera 
Heracleous Moustra; Czechia: Czech Society of Cardiology, David 
Zemánek; Denmark: Danish Society of Cardiology, Morten Steen 
Kvistholm Jensen; Egypt: Egyptian Society of Cardiology, Ahmad 
Samir; Estonia: Estonian Society of Cardiology, Kairit Palm; 
Finland: Finnish Cardiac Society, Tiina Heliö; France: French 
Society of Cardiology, Karim,Wahbi; Germany: German Cardiac 
Society, Eric Schulze-Bahr; Greece: Hellenic Society of Cardiology, 
Vlachopoulos Haralambos; Hungary: Hungarian 
Society of 
Cardiology Róbert Sepp; Iceland: Icelandic Society of Cardiology, 
Berglind Aðalsteinsdóttir; Ireland: Irish Cardiac Society, Deirdre 
Ward; Israel: Israel Heart Society, Miry Blich; Italy: Italian 
Federation of Cardiology, Gianfranco Sinagra; Kosovo (Republic 
of): Kosovo Society of Cardiology, Afrim Poniku; Kyrgyzstan: 
Kyrgyz Society of Cardiology, Olga Lunegova, Latvia: Latvian Society 
of Cardiology, Ainars Rudzitis; Lebanon: Lebanese Society 
of Cardiology, Roland Kassab; Lithuania: Lithuanian Society of 
Cardiology, Jūratė Barysienė; Luxembourg: Luxembourg Society of 
Cardiology, Steve Huijnen; Malta: Maltese Cardiac Society, Tiziana 
Felice; Moldova (Republic of): Moldavian Society of Cardiology, 
Eleonora 
Vataman; 
Montenegro: 
Montenegro 
Society 
of 
Cardiology, 
Nikola 
Pavlovic; 
Morocco: 
Moroccan 
Society 
of Cardiology, Nawal Doghmi; Netherlands: Netherlands Society 
of Cardiology, Folkert W. Asselbergs; North Macedonia: The 
National Society of Cardiology of North Macedonia, Elizabeta 
Srbinovska Kostovska; Norway: Norwegian Society of Cardiology, 
Vibeke Marie Almaas; Poland: Polish Cardiac Society, Elżbieta 
Katarzyna Biernacka; Portugal: Portuguese Society of Cardiology, 
Dulce Brito; Romania: Romanian Society of Cardiology, Monica 
Rosca; San Marino: San Marino Society of Cardiology, Marco 
Zavatta; Serbia: Cardiology Society of Serbia, Arsen Ristic; 
Slovakia: Slovak Society of Cardiology, Eva Goncalvesová; 
Slovenia: Slovenian Society of Cardiology, Matjaž Šinkovec; Spain: 
Spanish Society of Cardiology, Victoria Cañadas-Godoy; Sweden:


<!-- PAGE 95 -->

### Page 95

Swedish Society of Cardiology, Pyotr G. Platonov; Switzerland: Swiss 
Society of Cardiology, Ardan M. Saguner; Syrian Arab Republic: 
Syrian Cardiovascular Association, Ahmad Rasheed Al Saadi; 
Tunisia: Tunisian Society of Cardiology and Cardiovascular Surgery, 
Ikram Kammoun; Türkiye: Turkish Society of Cardiology, Ahmet 
Celik; Ukraine: Ukrainian Association of Cardiology, Elena Nesukay; 
and Uzbekistan: Association of Cardiologists of Uzbekistan, Timur 
Abdullaev.
ESC Clinical Practice Guidelines (CPG) Committee: Eva 
Prescott (Chairperson) (Denmark), Stefan James (Co-Chairperson) 
(Sweden), Elena Arbelo (Spain), Colin Baigent (United Kingdom), 
Michael A. Borger (Germany), Sergio Buccheri (Sweden), Borja 
Ibanez (Spain), Lars Køber (Denmark), Konstantinos C. Koskinas 
(Switzerland), John William McEvoy (Ireland), Borislava Mihaylova 
(United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck 
(United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes Pasquet 
(Belgium), Amina Rakisheva (Kazakhstan), Bianca Rocca (Italy), Xavier 
Rossello (Spain), Ilonca Vaartjes (Netherlands), Christiaan Vrints 
(Belgium), Adam Witkowski (Poland), and Katja Zeppenfeld 
(Netherlands).
21. Acknowledgements
The Task Force Chairs thank Sebastian Onciul for providing cardiac 
magnetic resonance images in Figure 7.
